variant_id_str	chr	ap1_pos	gwas_pos	distance	snp_id	disease_trait	pvalue	mapped_genes	pubmed_id	ap1_max_score	ap1_max_raw_score	ap1_best_tf	gnomad_AF	quadrant	hamming_distance
chr15:51210647:A>C	chr15	51210647	51210647	0	rs4646	Height	4.0000000000000005e-49	CYP19A1, MIR4713HG	36224396	0.94468737	505.0	FOSL2	0.70161	Accessible, Low Impact	2
chr1:66588311:C>A	chr1	66588311	66588311	0	rs72676198	Decaffeinated coffee consumption or major depression disorder	9e-09	SGIP1	35898629	0.9782654	519.5	JUND	0.122909	Accessible, Low Impact	3
chr7:55327697:C>G	chr7	55327697	55327697	0	rs1997103	QRS interval (sulfonylurea treatment interaction)	6e-08	CALM1P2 - LANCL2	27958378	0.9131995	491.0	FOSL2	0.815981	Accessible, Low Impact	2
chr19:40864433:C>G	chr19	40864433	40864433	0	rs12461383	Post bronchodilator FEV1	1e-07	CYP2A6 - CYP2A7	26634245	0.9982064	2178.0	ATF3	0.423847	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293237	0	rs7751028	Vaginal microbiome MetaCyc pathway (PWY-5415|catechol degradation I (meta-cleavage pathway))	2e-06	TSBP1, TSBP1-AS1	34282934	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr19:40864433:C>G	chr19	40864433	40864433	0	rs12461383	Post bronchodilator FEV1/FVC ratio	3e-06	CYP2A6 - CYP2A7	26634245	0.9982064	2178.0	ATF3	0.423847	HIGH PRIORITY: Accessible + High Impact	3
chr5:85334140:C>G	chr5	85334140	85334140	0	rs452618	Maleate levels in elite athletes	5e-06	RBBP4P6 - RPL5P17	31882771	0.98739034	483.0	JUND	0.0	Low Priority	3
chr6:33156314:A>C	chr6	33156314	33156315	1	rs113845903	Whole body water mass (UKB data field 23102)	1e-12	HCG24 - COL11A2	39789286	0.9990577	554.0	FOS	0.0	Low Priority	2
chr6:169049918:C>A	chr6	169049918	169049920	2	rs389234	SMOC2 protein levels	7e-14	SMOC2 - LINC01615	39789286	0.9584504	360.0	FOSL1	6.95565e-06	Accessible, Low Impact	3
chr16:12723907:C>A	chr16	12723907	12723905	2	rs147619057	CPPED1 protein levels	3e-13	CPPED1	39789286	0.9239011	711.0	ATF3	6.57298e-06	High Impact, Hard to Access	3
chr18:31242999:C>A	chr18	31242999	31243001	2	rs539806826	DSC2 protein levels	1e-12	DSCAS	39789286	0.9855452	679.0	FOSL1	6.57419e-06	High Impact, Hard to Access	3
chr2:38082741:G>C	chr2	38082741	38082744	3	rs234561	Height (baseline)	5e-11	CYP1B1, CYP1B1-AS1	40374629	0.99197406	331.0	JUN	8.55106e-05	Accessible, Low Impact	3
chr8:7001781:A>C	chr8	7001781	7001777	4	rs143291774	Blood cell traits latent factor 25 (white cell)	5e-18	DEFA1B - DEFT1P2	40220762	0.95134485	67.1875	MAFK	4.71876e-05	Accessible, Low Impact	2
chr16:26155734:C>G	chr16	26155734	26155738	4	rs12928216	Educational attainment	1e-12	HS3ST4 - LINC02195	35361970	0.9036088	479.5	FOSL2	6.56607e-06	Low Priority	3
chr4:94084952:G>T	chr4	94084952	94084948	4	rs1848793	Brain morphology (MOSTest)	2e-08	ATOH1 - SMARCAD1-DT	32665545	0.92880905	445.75	JUN	5.25534e-05	Accessible, Low Impact	3
chr16:65231804:G>C	chr16	65231804	65231799	5	rs56249585	Pulse pressure	6e-14	LINC02126 - LINC00922	27841878	0.99641275	767.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr20:24892922:C>A	chr20	24892922	24892917	5	rs6050091	Cystatin-F levels	7e-12	SYNDIG1 - LINC02967	28240269	0.84946334	671.0	JUND	6.57099e-06	High Impact, Hard to Access	3
chr16:65231804:G>C	chr16	65231804	65231799	5	rs56249585	Systolic blood pressure	5e-09	LINC02126 - LINC00922	27841878	0.99641275	767.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr9:131334906:C>A	chr9	131334906	131334901	5	rs7850041	Electrocardiogram morphology (amplitude at temporal datapoints)	6e-09	PLPP7	32916098	0.9988404	1707.0	FOS	6.57384e-06	High Impact, Hard to Access	3
chr5:122083570:A>C	chr5	122083570	122083564	6	rs840461	Height	9e-76	LOX - ZNF474	36224396	0.9801434	650.0	ATF2	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	2
chr5:122083570:A>C	chr5	122083570	122083564	6	rs840461	Corneal resistance factor (MTAG)	3e-13	LOX - ZNF474	35446358	0.9801434	650.0	ATF2	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	2
chr5:122083570:A>C	chr5	122083570	122083564	6	rs840461	Central corneal thickness (MTAG)	9e-13	LOX - ZNF474	35446358	0.9801434	650.0	ATF2	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	2
chr5:109554000:T>A	chr5	109554000	109553994	6	rs7737074	Sinonasal disease	4e-08	PJA2 - KRT18P42	36653354	0.9910462	1274.5	JUNB	0.0	High Impact, Hard to Access	3
chr5:109554000:T>A	chr5	109554000	109553994	6	rs7737074	Chronic inflammatory sinonasal disease	5e-07	PJA2 - KRT18P42	36653354	0.9910462	1274.5	JUNB	0.0	High Impact, Hard to Access	3
chr5:122083570:A>C	chr5	122083570	122083564	6	rs840461	1-stearoyl-GPC (18:0) levels in elite athletes	3e-06	LOX - ZNF474	31882771	0.9801434	650.0	ATF2	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	2
chr16:1242245:G>C	chr16	1242245	1242253	8	rs1060314	Tryptase beta-2 levels	1e-103	TPSAB1	34648354	0.9993018	406.25	FOS	6.59083e-06	Low Priority	3
chr13:57742469:C>A	chr13	57742469	57742478	9	rs9569733	Cigarettes smoked per day (MTAG)	3e-09	PCDH17 - RNA5SP30	36376304	0.9810219	620.0	FOS	6.57886e-06	High Impact, Hard to Access	3
chr16:8246922:C>A	chr16	8246922	8246932	10	rs1868979	Body mass index	5e-09	RBFOX1 - LINC02152	40436827	0.9930392	1187.0	MAFG	7.92466e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:118268717:G>T	chr8	118268717	118268727	10	rs28505920	Ceramide (d40:1) levels	4e-08	SAMD12	37907536	0.92045027	459.5	FOSL1	6.5703e-06	Low Priority	3
chr9:130382074:G>T	chr9	130382074	130382085	11	rs576559505	HMCN2 protein levels	3e-18	HMCN2	39789286	0.9894933	929.0	BATF2	0.0	High Impact, Hard to Access	3
chr5:79644095:C>G	chr5	79644095	79644084	11	rs114878198	Post bronchodilator FEV1/FVC ratio in COPD	3e-06	TENT2	26634245	0.973383	695.0	JUND	1.31695e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:56642524:G>T	chr4	56642524	56642536	12	rs4576073	Diastolic blood pressure	9e-09	SPMAP2L - HOPX	38689001	0.8862913	533.5	FOS	3.94742e-05	Accessible, Low Impact	3
chr4:124862453:C>A	chr4	124862453	124862465	12	rs10222899	Baseline memory in normal cognition	3e-06	ANKRD50 - FAT4	37984853	0.97511876	603.5	FOSL2	6.57834e-06	High Impact, Hard to Access	3
chr4:56642524:G>T	chr4	56642524	56642536	12	rs4576073	Systolic blood pressure	3e-06	SPMAP2L - HOPX	38689001	0.8862913	533.5	FOS	3.94742e-05	Accessible, Low Impact	3
chr10:22105927:C>G	chr10	22105927	22105914	13	rs3011642	Calcium levels	1e-12	DNAJC1 - ADIPOR1P1	33887147	0.9514912	494.0	JUND	0.00101792	Accessible, Low Impact	3
chr3:148628063:C>G	chr3	148628063	148628076	13	rs11924272	Dementia	8e-06	LINC02046 - RPL38P1	39046104	0.9131995	435.25	ATF3	2.65168e-05	Accessible, Low Impact	3
chr11:6247302:C>A	chr11	6247302	6247316	14	rs12792379	Peptic ulcer disease	5e-09	CNGA4 - CCKBR	38036781	0.96905065	492.0	MAFG	6.57739e-06	Low Priority	3
chr11:6247302:C>A	chr11	6247302	6247316	14	rs12792379	Gastroesophageal reflux disease	2e-08	CNGA4 - CCKBR	31527586	0.96905065	492.0	MAFG	6.57739e-06	Low Priority	3
chr2:124609452:G>C	chr2	124609452	124609438	14	rs6750396	COVID-19 death (death vs tested and survived)	9e-07	CNTNAP5	35224516	0.8974094	488.5	FOSL2	0.00022339	Accessible, Low Impact	3
chr2:124609452:G>C	chr2	124609452	124609438	14	rs6750396	COVID-19 death (death vs population)	1e-06	CNTNAP5	35224516	0.8974094	488.5	FOSL2	0.00022339	Accessible, Low Impact	3
chr2:124609452:G>C	chr2	124609452	124609438	14	rs6750396	COVID-19 (severe vs tested, not severe)	7e-06	CNTNAP5	35224516	0.8974094	488.5	FOSL2	0.00022339	Accessible, Low Impact	3
chr2:124609452:G>C	chr2	124609452	124609438	14	rs6750396	COVID-19 (severe vs population)	8e-06	CNTNAP5	35224516	0.8974094	488.5	FOSL2	0.00022339	Accessible, Low Impact	3
chr2:124609452:G>C	chr2	124609452	124609438	14	rs6750396	Mortality in COVID-19	8e-06	CNTNAP5	35224516	0.8974094	488.5	FOSL2	0.00022339	Accessible, Low Impact	3
chr17:36002761:G>C	chr17	36002761	36002776	15	rs854628	C-C motif chemokine 15 levels	0.0	CCL15-CCL14 - CCL23	34648354	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:33392374:C>G	chr1	33392374	33392359	15	rs2763038	Weight	7.000000000000001e-23	PHC2	40436827	0.9756724	618.0	FOSL1	1.31453e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:36002761:G>C	chr17	36002761	36002776	15	rs854628	Hsp90alpha protein levels (SomaScan ID:14109-15)	4e-19	CCL15-CCL14 - CCL23	40883583	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr12:118694626:C>G	chr12	118694626	118694610	16	rs66992698	Weight	6e-09	LINC02460 - RPL17P37	40436827	0.9868027	724.0	JUNB	6.58449e-06	High Impact, Hard to Access	3
chr4:8969177:G>T	chr4	8969177	8969193	16	rs186090691	CD38 on IgD+ CD38+ B cell	1e-08	UNC93B8 - OR7E111FP	32929287	0.635053	266.25	MAFF	6.59857e-06	Low Priority	3
chr6:89720622:C>A	chr6	89720622	89720606	16	rs72915912	Endometrial cancer	4e-06	MDN1	31488892	0.94588065	501.5	FOSL1	6.57488e-06	Low Priority	3
chr16:31270672:C>A	chr16	31270672	31270689	17	rs200125675	PYDC1 protein levels	2e-58	ITGAM	39789286	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr16:31270672:C>A	chr16	31270672	31270689	17	rs200125675	Triglycerides to total lipids ratio in large VLDL	1e-08	ITGAM	35213538	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr8:4306474:C>G	chr8	4306474	4306491	17	rs4875320	HDL cholesterol	6e-06	CSMD1	21347282	0.92356306	403.0	JUN	6.57142e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31295274	18	rs2853926	neutrophil (absolute count, minimum, inv-norm transformed)	1.9999999999999998e-54	LINC02571	39024449	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31295274	18	rs2853926	DLL1/EFEMP1 protein level ratio	6e-30	LINC02571	38412862	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr11:77806748:C>A	chr11	77806748	77806766	18	rs4469913	Platelet count	2e-27	RSF1	40436827	0.99347407	1120.0	FOS	6.60816e-06	High Impact, Hard to Access	3
chr10:101987363:G>C	chr10	101987363	101987381	18	rs10883701	Heel bone mineral density	2e-11	ARMH3	30595370	0.99588126	825.0	FOS	6.57263e-06	High Impact, Hard to Access	3
chr12:82032669:A>C	chr12	82032669	82032687	18	rs11115162	Metabolic syndrome	7e-09	LINC02426 - CCDC59	39349817	0.9992518	822.0	FOS	6.57333e-06	HIGH PRIORITY: Accessible + High Impact	2
chr12:82032669:A>C	chr12	82032669	82032687	18	rs11115162	Gut microbiota relative abundance (Ruminococcus belonging to family Lachnospiraceae)	6e-06	LINC02426 - CCDC59	33208821	0.9992518	822.0	FOS	6.57333e-06	HIGH PRIORITY: Accessible + High Impact	2
chr6:160156692:C>A	chr6	160156692	160156711	19	rs7764927	Lipoprotein A levels (UKB data field 30790)	7e-46	SLC22A1	39789286	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr19:15643936:C>A	chr19	15643936	15643917	19	rs549862015	CD25++ CD45RA+ CD4 not regulatory T cell Absolute Count	4e-08	CYP4F3	32929287	0.9810219	1030.0	ATF3	1.3148e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:160156692:C>A	chr6	160156692	160156711	19	rs7764927	Color vision defects (Tritan)	7e-06	SLC22A1	37359372	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr9:12677999:C>A	chr9	12677999	12677979	20	rs10116013	Eye color	2e-08	LURAP1L-AS1	36672889	0.83089256	428.0	FOS	3.56014e-05	Accessible, Low Impact	3
chr2:18557258:C>G	chr2	18557258	18557279	21	rs2346136	Hippocampal volume	4e-06	NT5C1B-RDH14, RDH14	35386118	0.9976844	598.0	ATF2	1.31506e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:18557258:C>G	chr2	18557258	18557279	21	rs2346136	Right hippocampal volume	9e-06	NT5C1B-RDH14, RDH14	35386118	0.9976844	598.0	ATF2	1.31506e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:49680990:C>A	chr2	49680990	49681013	23	rs6744040	Educational attainment (MTAG)	4e-09	MIR548BAHG - RPL7P13	30038396	0.95933455	487.0	FOS	6.57696e-06	Low Priority	3
chr2:49680990:C>A	chr2	49680990	49681013	23	rs6744040	Educational attainment (years of education)	1e-08	MIR548BAHG - RPL7P13	30038396	0.95933455	487.0	FOS	6.57696e-06	Low Priority	3
chr6:80512292:G>C	chr6	80512292	80512268	24	rs9443788	Height (baseline)	4e-40	RPSAP72 - TENT5A	40374629	0.98639375	494.5	MAFK	0.000289314	Accessible, Low Impact	3
chr1:65364638:C>G	chr1	65364638	65364614	24	rs2296478	C-reactive protein levels (UKB data field 30710)	7e-21	DNAJC6	39789286	0.9545879	626.0	JUND	0.0	High Impact, Hard to Access	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Mean sphered cell volume	1e-55	SPTA1	34226706	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Hemoglobin A1c levels	1.0000000000000001e-45	SPTA1	34226706	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Reticulocyte fraction of red cells	3e-37	SPTA1	32888494	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Mean reticulocyte volume	9.999999999999999e-27	SPTA1	34226706	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Glycated hemoglobin levels	9.999999999999999e-27	SPTA1	33462484	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Mean corpuscular hemoglobin concentration	2e-19	SPTA1	32888494	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Reticulocyte count	2e-16	SPTA1	27863252	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	High light scatter reticulocyte count	2e-10	SPTA1	27863252	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	High light scatter reticulocyte percentage of red cells	3e-10	SPTA1	27863252	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:176411773:C>A	chr5	176411773	176411748	25	rs72807224	Albumin levels	5e-10	CLTB	40436827	0.99807435	895.5	FOSL1	1.31442e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:176411773:C>A	chr5	176411773	176411748	25	rs72807224	Serum albumin levels	1e-09	CLTB	34594039	0.99807435	895.5	FOSL1	1.31442e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613814	25	rs201514157	Bilirubin levels	3e-09	SPTA1	34226706	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:226447325:C>A	chr1	226447325	226447299	26	rs563532848	LEFTY2 protein levels	4e-58	RN7SKP165 - CDKN2AIPNLP1	39789286	0.972161	610.5	ATF3	0.0	High Impact, Hard to Access	3
chr8:125618697:C>A	chr8	125618697	125618723	26	rs114443260	Triglyceride levels	1e-36	TRIB1AL - LINC02964	32203549	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125618723	26	rs114443260	Triglyceride levels (UKB data field 30870)	1e-33	TRIB1AL - LINC02964	39789286	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125618723	26	rs114443260	Polyunsaturated fatty acids to monounsaturated fatty acids ratio	8e-09	TRIB1AL - LINC02964	40545721	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:63827693:G>C	chr17	63827693	63827667	26	rs60005475	Memory decline in normal cognition	1e-05	PSMC5, FTSJ3	37984853	0.9996589	5228.0	MAFF	1.97047e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:85496024:C>A	chr11	85496024	85496051	27	rs56256184	Bone mineral density variability	8e-09	DLG2	37500982	0.9780051	575.0	ATF3	6.57298e-06	High Impact, Hard to Access	3
chr4:7435002:C>A	chr4	7435002	7434974	28	rs77191210	Proactivator polypeptide-like 1 levels (PSAPL1.8814.33.3)	2e-58	SORCS2	29875488	0.99560076	2678.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr3:186365850:G>C	chr3	186365850	186365822	28	rs7618021	Lung function (FEV1/FVC)	1e-12	DGKG - LINC02020	36914875	0.9987857	2557.0	FOSL2	6.56935e-06	High Impact, Hard to Access	3
chr7:26543142:G>C	chr7	26543142	26543114	28	rs2158712	Heart rate response to recovery post exercise (10 sec)	1e-12	KIAA0087 - LINC03095	29497042	0.9991795	833.0	MAFG	6.57168e-06	High Impact, Hard to Access	3
chr12:106066096:C>G	chr12	106066096	106066124	28	rs6539247	Attention function in attention deficit hyperactive disorder	3e-06	NUAK1	26174813	0.9914465	628.5	FOS	6.56521e-06	High Impact, Hard to Access	3
chr6:6615625:G>T	chr6	6615625	6615596	29	rs147462252	Endometrial cancer (MTAG)	8e-08	LY86-AS1, LY86	31488892	0.95023745	523.0	MAFK	6.60493e-06	Low Priority	3
chr6:6615625:G>T	chr6	6615625	6615596	29	rs147462252	Endometrial cancer	9e-08	LY86-AS1, LY86	31488892	0.95023745	523.0	MAFK	6.60493e-06	Low Priority	3
chr10:104525579:C>G	chr10	104525579	104525550	29	rs975145	Cis-4-decenoylcarnitine (C10:1) levels in elite athletes	2e-06	LINC02620 - SORCS3	31882771	0.8766539	612.5	JUND	0.0261502	HIGH PRIORITY: Accessible + High Impact	2
chr21:14682271:C>A	chr21	14682271	14682242	29	rs2822831	CCL28 levels	4e-06	SAMSN1 - POLR2CP1	38326779	0.9715297	662.5	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:126854830:G>T	chr6	126854830	126854800	30	rs62436821	Systolic blood pressure	4.0000000000000005e-49	RPS4XP9 - RSPO3	40436827	0.94931644	459.0	JUND	2.62667e-05	Accessible, Low Impact	3
chr16:1767426:G>C	chr16	1767426	1767396	30	rs2575368	HAGH protein levels	1.9999999999999998e-42	MAPK8IP3	39789286	0.9979365	1430.0	FOS	6.56883e-06	High Impact, Hard to Access	3
chr6:126854830:G>T	chr6	126854830	126854800	30	rs62436821	Medication use (beta blocking agents)	3e-13	RPS4XP9 - RSPO3	31015401	0.94931644	459.0	JUND	2.62667e-05	Accessible, Low Impact	3
chr16:50107976:G>T	chr16	50107976	50107946	30	rs12934889	Atrial fibrillation	8e-09	HEATR3 - RPL10P14	40645996	0.9830546	1010.0	JUND	0.0	High Impact, Hard to Access	3
chr12:74276218:C>A	chr12	74276218	74276187	31	rs181181503	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	3e-07	LINC02882	28112199	0.850352	319.5	ATF2	0.0818755	Accessible, Low Impact	3
chr7:28354594:C>A	chr7	28354594	28354561	33	rs75174753	CRYBB2 protein levels	8e-18	CREB5	39789286	0.99919933	2567.5	FOSL2	6.57471e-06	High Impact, Hard to Access	3
chr2:62341119:C>A	chr2	62341119	62341086	33	rs13001372	Ankylosing spondylitis (PheCode 715.2)	2e-12	RN7SL51P - RN7SL18P	39024449	0.99812186	3287.0	BATF	6.57341e-06	High Impact, Hard to Access	3
chr2:62341119:C>A	chr2	62341119	62341086	33	rs13001372	Ankylosing spondylitis	7e-09	RN7SL51P - RN7SL18P	30946743	0.99812186	3287.0	BATF	6.57341e-06	High Impact, Hard to Access	3
chr15:38189837:C>A	chr15	38189837	38189803	34	rs970498	Height	4e-22	LINC02895	30595370	0.9944655	896.0	JUND	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:57742469:C>A	chr13	57742469	57742503	34	rs9563529	Diastolic blood pressure	4e-10	PCDH17 - RNA5SP30	30224653	0.9810219	620.0	FOS	6.57886e-06	High Impact, Hard to Access	3
chr13:57742469:C>A	chr13	57742469	57742503	34	rs9563529	Diastolic blood pressure (MTAG)	4e-08	PCDH17 - RNA5SP30	39537608	0.9810219	620.0	FOS	6.57886e-06	High Impact, Hard to Access	3
chr13:57742469:C>A	chr13	57742469	57742503	34	rs9563529	Systolic blood pressure	8e-07	PCDH17 - RNA5SP30	38689001	0.9810219	620.0	FOS	6.57886e-06	High Impact, Hard to Access	3
chr14:98137477:G>T	chr14	98137477	98137514	37	rs1461587	Lymphocyte count	4e-11	LINC02295	34594039	0.925176	524.5	JUND	1.31615e-05	Accessible, Low Impact	3
chr12:103061819:G>T	chr12	103061819	103061782	37	rs10778212	Body mass index (MTAG)	4e-08	ASCL1 - C12orf42-AS1	36376304	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr14:64743229:G>T	chr14	64743229	64743191	38	rs17180132	Mean spheric corpuscular volume	4e-14	PLEKHG3	32888494	0.95041513	745.0	FOSL2	6.56478e-06	High Impact, Hard to Access	3
chr20:48673816:G>T	chr20	48673816	48673855	39	rs6063304	Diastolic blood pressure	2e-10	PREX1	39134668	0.999539	1079.0	JUNB	6.57384e-06	High Impact, Hard to Access	3
chr15:73060795:C>G	chr15	73060795	73060834	39	rs6495046	Number of decayed, missing and filled tooth surfaces or use of dentures	3e-10	NEO1	31235808	0.9036088	509.5	ATF3	6.59057e-06	Low Priority	3
chr5:52870937:C>A	chr5	52870937	52870898	39	rs2456220	Gamma glutamyl transferase levels	7e-10	ITGA1	33462484	0.9939336	725.0	FOS	6.57047e-06	High Impact, Hard to Access	3
chr15:73060795:C>G	chr15	73060795	73060834	39	rs6495046	Dentures	9e-09	NEO1	31235808	0.9036088	509.5	ATF3	6.59057e-06	Low Priority	3
chr6:34432502:G>C	chr6	34432502	34432541	39	rs4713781	Obstructive sleep apnea	2e-07	RPS10 - PACSIN1	35819321	0.9949331	661.0	MAFG	6.58796e-06	High Impact, Hard to Access	3
chr7:93043880:G>C	chr7	93043880	93043840	40	rs6960056	Educational attainment	4.0000000000000006e-34	RN7SL7P - SAMD9	35361970	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr6:127177979:T>A	chr6	127177979	127177939	40	rs75699605	Heel bone mineral density	8e-14	RSPO3	30595370	0.99658346	1425.0	JUNB	6.59144e-06	High Impact, Hard to Access	3
chr7:93043880:G>C	chr7	93043880	93043840	40	rs6960056	Dorsomedial frontal area	1e-08	RN7SL7P - SAMD9	35113692	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr2:197633632:T>A	chr2	197633632	197633592	40	rs1979239	Motor premotor area (unadjusted for global measures)	4e-08	RFTN2	36893272	0.99658346	1520.0	JUNB	6.56953e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:93043880:G>C	chr7	93043880	93043840	40	rs6960056	Self-reported math ability	4e-08	RN7SL7P - SAMD9	30038396	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr2:197633632:T>A	chr2	197633632	197633592	40	rs1979239	Cortical surface area	6e-08	RFTN2	36893272	0.99658346	1520.0	JUNB	6.56953e-06	HIGH PRIORITY: Accessible + High Impact	2
chr1:26999082:G>C	chr1	26999082	26999041	41	rs6658653	White blood cell count	3e-10	TRNP1	32888494	0.9999636	14136.0	MAFK	6.57428e-06	High Impact, Hard to Access	3
chr16:81105537:G>T	chr16	81105537	81105578	41	rs560886290	X-16570 levels	4e-07	PKD1L2	36357675	0.88937473	424.0	JUN	0.0	Low Priority	3
chr3:157775316:C>G	chr3	157775316	157775357	41	rs703174	Essential tremor	4e-07	SLC66A1LP - RN7SKP46	34982113	0.925176	481.0	JUND	0.0	Low Priority	3
chrX:149380501:G>T	chrX	149380501	149380542	41	rs17325431	Survival in colon cancer	3e-06	AFF2 - IDS	25866641	0.8791271	415.5	JUND	1.78976e-05	Accessible, Low Impact	3
chr4:96995344:G>T	chr4	96995344	96995385	41	rs114795211	Calcific aortic valve stenosis	4e-06	COX7A2P2 - STPG2	32141789	0.93699247	506.5	FOS	0.000176274	Accessible, Low Impact	3
chr1:101251174:C>A	chr1	101251174	101251132	42	rs765344	Vertex-wise cortical surface area	2e-09	S1PR1 - PPIAP7	34910505	0.9981611	1042.0	FOS	6.57073e-06	High Impact, Hard to Access	3
chr1:101251174:C>A	chr1	101251174	101251132	42	rs765344	Vertex-wise sulcal depth	3e-09	S1PR1 - PPIAP7	34910505	0.9981611	1042.0	FOS	6.57073e-06	High Impact, Hard to Access	3
chr1:101251174:C>A	chr1	101251174	101251132	42	rs765344	Cortical surface area	9e-09	S1PR1 - PPIAP7	34560273	0.9981611	1042.0	FOS	6.57073e-06	High Impact, Hard to Access	3
chr3:128660481:A>C	chr3	128660481	128660438	43	rs141800474	Lymphocyte-to-monocyte ratio	9e-17	RPN1	34469753	0.99975276	1180.5	FOSL2	2.69836e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:504842:G>C	chr17	504842	504885	43	rs11654589	Hip circumference adjusted for BMI	1e-14	RFLNB - VPS53	34021172	0.99886686	437.5	FOSL2	1.56331e-05	Accessible, Low Impact	3
chr15:92401188:G>C	chr15	92401188	92401231	43	rs67607760	Femur bone mineral density x serum urate levels interaction	3e-09	ST8SIA2	34046847	0.99971604	6156.0	ATF3	6.57151e-06	High Impact, Hard to Access	3
chr16:58673185:C>G	chr16	58673185	58673228	43	rs11639682	Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer	8e-07	SLC38A7	30648747	0.7921896	510.5	ATF2	6.97866e-06	Accessible, Low Impact	3
chr9:7953296:C>G	chr9	7953296	7953253	43	rs10815728	Ferritin levels	8e-07	DMAC1 - PTPRD	33491795	0.9327804	453.0	JUN	6.57748e-06	Low Priority	3
chr2:77368534:G>T	chr2	77368534	77368577	43	rs71420994	Polycystic ovary syndrome in lean individuals (BMI <= 25 kg/m2)	1e-06	LRRTM4	38408933	0.9470497	462.0	JUN	6.59144e-06	Low Priority	3
chr6:169221461:G>C	chr6	169221461	169221505	44	rs140852957	THBS2 protein levels	1e-48	THBS2, THBS2-AS1	39789286	0.9894933	952.5	MAFG	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:1902089:C>A	chr19	1902089	1902045	44	rs145995246	FEV1 x serum 25-hydroxyvitamin D interaction in ever smokers (2df test)	1e-08	ABHD17A - SCAMP4	38484975	0.9992855	2304.0	JUND	6.57851e-06	High Impact, Hard to Access	3
chr15:47783401:T>A	chr15	47783401	47783356	45	rs607289	Restless legs syndrome	3e-28	LINC01491	38839884	0.89951414	461.5	JUND	3.28416e-05	Accessible, Low Impact	2
chr16:77263416:G>C	chr16	77263416	77263461	45	rs34375971	Insomnia	7e-09	ADAMTS18	35835914	0.9972157	721.0	BATF	6.64302e-06	HIGH PRIORITY: Accessible + High Impact	3
chr20:24736404:G>C	chr20	24736404	24736449	45	rs2424635	Bipolar disorder and schizophrenia	7e-06	SYNDIG1 - LINC02967	20889312	0.9996663	2055.0	MAFG	1.97073e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:64699311:G>C	chr3	64699311	64699265	46	rs4688504	Waist-hip index	5e-15	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr3:64699311:G>C	chr3	64699311	64699265	46	rs4688504	Waist-to-hip ratio adjusted for BMI	8e-15	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr3:64699311:G>C	chr3	64699311	64699265	46	rs4688504	A body shape index	9e-12	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr3:64699311:G>C	chr3	64699311	64699265	46	rs4688504	Waist circumference adjusted for body mass index	8e-11	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr2:41105677:C>G	chr2	41105677	41105631	46	rs7595121	Glioblastoma	3e-06	LINC01794 - HNRNPA1P57	36810956	0.98266596	510.5	JUND	1.31449e-05	Accessible, Low Impact	3
chr3:183477970:C>A	chr3	183477970	183478017	47	rs13062589	SAPHO syndrome	4e-10	TVP23CP3 - KLHL6	33816493	0.9695515	1041.0	MAFG	6.57237e-06	High Impact, Hard to Access	3
chr15:57085386:C>A	chr15	57085386	57085338	48	rs59854182	Putamen iron levels (quantitative susceptibility mapping)	3e-16	TCF12	38789058	0.9964227	1585.0	FOS	6.57194e-06	High Impact, Hard to Access	3
chr6:34035511:G>T	chr6	34035511	34035559	48	rs2451381	Educational attainment	1e-12	GRM4	35361970	0.9715297	668.5	ATF7	6.57428e-06	High Impact, Hard to Access	3
chr6:34035511:G>T	chr6	34035511	34035559	48	rs2451381	Cigarettes smoked per day	2e-09	GRM4	36477530	0.9715297	668.5	ATF7	6.57428e-06	High Impact, Hard to Access	3
chr7:6299240:G>C	chr7	6299240	6299288	48	rs10258415	RBC levels of Pyruvate (uM)	2e-08	CYTH3 - FAM220A	36395887	0.9896673	858.5	BATF	6.58892e-06	High Impact, Hard to Access	3
chr7:6299240:G>C	chr7	6299240	6299288	48	rs10258415	S-6-hydroxywarfarin levels	1e-06	CYTH3 - FAM220A	36210801	0.9896673	858.5	BATF	6.58892e-06	High Impact, Hard to Access	3
chr3:27359707:A>C	chr3	27359707	27359756	49	rs11715126	Postmenopausal breast cancer	5e-13	NEK10	38538606	0.9958938	1448.0	FOS	1.31397e-05	HIGH PRIORITY: Accessible + High Impact	2
chr3:27359707:A>C	chr3	27359707	27359756	49	rs11715126	Breast cancer	2e-12	NEK10	32808324	0.9958938	1448.0	FOS	1.31397e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:103816706:C>A	chr2	103816706	103816657	49	rs2375932	Attention deficit hyperactivity disorder	1e-07	CAPZBP1 - LINC01965	40962958	0.9695515	470.5	FOSL2	7.22648e-05	Accessible, Low Impact	3
chr8:8855544:C>A	chr8	8855544	8855493	51	rs13268671	Risk-taking behavior (multivariate analysis)	2e-10	MFHAS1	36324656	0.84946334	565.5	JUND	6.5735e-06	Low Priority	3
chr1:76205428:C>A	chr1	76205428	76205377	51	rs72675916	Cognitive performance (language ability) (longitudinal)	6e-06	ST6GALNAC3	35386118	0.92880905	447.0	FOS	1.31565e-05	Accessible, Low Impact	3
chr11:116450437:C>G	chr11	116450437	116450493	56	rs2851406	Triglyceride levels	7e-06	LINC02151	35884923	0.9514912	661.0	ATF2	0.943671	HIGH PRIORITY: Accessible + High Impact	3
chr15:80621186:G>T	chr15	80621186	80621243	57	rs78142448	Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)	4e-08	ARNT2 - RNU6-380P	34594039	0.9991806	3032.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr13:49551803:G>T	chr13	49551803	49551861	58	rs193054544	Height (baseline)	2e-43	RCBTB1	40374629	0.98327994	431.5	FOSL1	0.0	Low Priority	3
chr13:49551803:G>T	chr13	49551803	49551861	58	rs193054544	Physical function (baseline)	1e-22	RCBTB1	40374629	0.98327994	431.5	FOSL1	0.0	Low Priority	3
chr2:24715132:T>A	chr2	24715132	24715190	58	rs766746706	GLIPR1 protein levels	4e-17	NCOA1	39789286	0.98649883	838.0	ATF3	6.57912e-06	High Impact, Hard to Access	3
chr13:49551803:G>T	chr13	49551803	49551861	58	rs193054544	Forced expiratory volume (baseline)	2e-14	RCBTB1	40374629	0.98327994	431.5	FOSL1	0.0	Low Priority	3
chr17:74256762:C>G	chr17	74256762	74256820	58	rs555042436	Retinal vascular fractal dimension	2e-06	TTYH2	34743558	0.91866904	613.0	MAFK	3.28472e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:62067960:T>A	chr11	62067960	62068020	60	rs113461726	Bone mineral density mean	2e-183	LINC02733	37500982	0.8243095	469.5	FOSL2	6.57263e-06	Low Priority	3
chr6:33156314:A>C	chr6	33156314	33156254	60	rs3116961	Osteoarthritis (with total knee replacement)	2e-09	HCG24 - COL11A2	40205036	0.9990577	554.0	FOS	0.0	Low Priority	2
chr20:24779663:G>T	chr20	24779663	24779602	61	rs145341686	CST7 protein levels	3.9999999999999996e-50	SYNDIG1 - LINC02967	39789286	0.8663228	584.0	JUND	6.5684e-06	High Impact, Hard to Access	3
chr4:54682248:C>A	chr4	54682248	54682309	61	rs2855772	Systemic lupus erythematosus	1e-15	KIT	29494758	0.97237617	425.25	MAFG	6.60371e-06	Low Priority	3
chr1:219467486:C>A	chr1	219467486	219467425	61	rs12126911	Umbilical hernia	2e-08	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr2:32896498:C>G	chr2	32896498	32896437	61	rs6728021	Immune response to smallpox vaccine (IL-6)	4e-08	LINC00486	22610502	0.9975752	1743.5	MAFK	6.57583e-06	HIGH PRIORITY: Accessible + High Impact	2
chr1:120109635:G>C	chr1	120109635	120109572	63	rs2793925	Eosinophil percentage of white cells	4e-12	NOTCH2 - RNU6-465P	32888494	0.9780051	204.25	FOSL1	6.589e-06	Low Priority	3
chr1:120109635:G>C	chr1	120109635	120109572	63	rs2793925	Eosinophil count	3e-11	NOTCH2 - RNU6-465P	32888494	0.9780051	204.25	FOSL1	6.589e-06	Low Priority	3
chr4:26977138:G>C	chr4	26977138	26977201	63	rs192673813	Age at take-off	6e-07	STIM2	38483351	0.9970844	579.0	FOS	1.3142e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:50252784:A>C	chr8	50252784	50252848	64	rs35857674	Obstructive sleep apnea trait (apnea hypopnea index)	8e-07	SNTG1	29077507	0.99894255	622.0	FOS	1.31297e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:219467486:C>A	chr1	219467486	219467421	65	rs2605094	Umbilical hernia	4e-15	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr20:8871746:A>C	chr20	8871746	8871681	65	rs4502502	Height	3e-12	PLCB1	36224396	0.9990358	669.5	FOSL2	6.56987e-06	High Impact, Hard to Access	3
chr9:75571304:C>A	chr9	75571304	75571239	65	rs7862078	Apolipoprotein B levels	2e-09	CDCA7P2 - OTX2P1	33462484	0.94588065	457.0	JUN	0.0177219	Accessible, Low Impact	3
chr1:219467486:C>A	chr1	219467486	219467421	65	rs2605094	Inguinal hernia	4e-09	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr12:66030789:A>C	chr12	66030789	66030724	65	rs7137538	Waist-hip index	6e-09	LINC02425	34021172	0.9989667	913.75	FOS	1.97125e-05	HIGH PRIORITY: Accessible + High Impact	2
chr12:66030789:A>C	chr12	66030789	66030724	65	rs7137538	Waist-to-hip ratio adjusted for BMI	1e-08	LINC02425	34021172	0.9989667	913.75	FOS	1.97125e-05	HIGH PRIORITY: Accessible + High Impact	2
chr3:127826308:C>G	chr3	127826308	127826243	65	rs62270491	Gut microbial network clusters (BlueViolet (at 3 months) x Household furry pet dog (3 Months) interaction	2e-07	MGLL	40187613	0.9479486	549.0	MAFK	6.68619e-06	Accessible, Low Impact	3
chr9:96519921:A>C	chr9	96519921	96519987	66	rs10820757	FVC	1e-14	CDC14B	36641522	0.9999305	1672.0	FOS	1.31384e-05	HIGH PRIORITY: Accessible + High Impact	2
chr9:96519921:A>C	chr9	96519921	96519987	66	rs10820757	Waist circumference adjusted for body mass index	6e-12	CDC14B	34021172	0.9999305	1672.0	FOS	1.31384e-05	HIGH PRIORITY: Accessible + High Impact	2
chr20:24736404:G>C	chr20	24736404	24736472	68	rs2424637	Educational attainment	1e-11	SYNDIG1 - LINC02967	35361970	0.9996663	2055.0	MAFG	1.97073e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:64699311:G>C	chr3	64699311	64699243	68	rs28546794	Waist-hip index	5e-11	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr3:64699311:G>C	chr3	64699311	64699243	68	rs28546794	Waist-to-hip ratio adjusted for BMI	6e-11	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr6:8871411:A>C	chr6	8871411	8871480	69	rs4566922	Melanoma (in situ vs invasive)	5e-08	HULC	39141363	0.99936336	910.0	JUN	1.29079e-05	HIGH PRIORITY: Accessible + High Impact	3
chr21:44817564:G>C	chr21	44817564	44817494	70	rs7282882	Small ubiquitin-related modifier 2 levels	2e-12	SUMO3	34648354	0.9981611	3396.0	FOS	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:151588114:G>C	chr6	151588114	151588043	71	rs9478224	Bone mineral density mean	4e-09	CCDC170	37500982	0.9981182	656.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr20:36916341:C>G	chr20	36916341	36916270	71	rs4812586	Height	3e-08	SAMHD1	35399580	0.84946334	478.5	ATF3	3.97346e-05	Accessible, Low Impact	3
chr5:121915956:T>A	chr5	121915956	121916027	71	rs79880417	Gut microbial network clusters (Aquamarine (at 1 year) x Older Siblings interaction	2e-07	FTMT - SRFBP1	40187613	0.96886295	506.0	JUND	0.0667665	Accessible, Low Impact	3
chr2:156651081:C>A	chr2	156651081	156651153	72	rs68052276	Educational attainment (years of education)	3e-08	GPD2 - LINC01958	30595370	0.9875858	990.0	FOSL1	0.0	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27950722	73	rs11994699	Tenascin levels (TNC.4155.3.2)	2.0000000000000002e-39	SCARA5	29875488	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr11:60640096:C>A	chr11	60640096	60640023	73	rs188108038	Bone mineral density mean	2e-27	LINC00301, LINC00301	37500982	0.92045027	386.5	FOS	1.31874e-05	Accessible, Low Impact	3
chr17:4009522:G>T	chr17	4009522	4009449	73	rs117464936	Alkenylphosphatidylethanolamine (P-18:0/18:3) levels	4e-07	ZZEF1	35668104	0.9872979	756.5	MAFG	6.57687e-06	High Impact, Hard to Access	3
chr5:121356306:G>T	chr5	121356306	121356379	73	rs10078239	Baseline memory in impaired cognition	4e-06	RNU4-69P - RPL23AP44	37984853	0.9963395	566.0	JUND	6.59474e-06	Low Priority	3
chr10:25074125:G>C	chr10	25074125	25074199	74	rs11014382	Height	7.999999999999999e-63	ENKUR - LINC01516	36224396	0.99899024	2863.0	FOS	2.63116e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	Vertex-wise cortical thickness	8.000000000000001e-45	GNA12	34910505	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	Superior parietal thickness	2e-18	GNA12	35113692	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	Cortical surface area	1e-17	GNA12	34560273	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	Cortical thickness	1e-17	GNA12	34560273	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	White matter microstructure (mode of anisotropy)	6e-16	GNA12	31666681	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr10:25074125:G>C	chr10	25074125	25074199	74	rs11014382	Body size or adipose distribution (multivariate analysis)	9e-12	ENKUR - LINC01516	40796553	0.99899024	2863.0	FOS	2.63116e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	White matter microstructure (fractional anisotropy)	1e-10	GNA12	31666681	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	Ventral frontal thickness	2e-10	GNA12	35113692	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr7:2780167:G>C	chr7	2780167	2780093	74	rs7784066	Regional cortical thickness (superiorparietal)	7e-10	GNA12	38890310	0.96833974	380.0	FOSL2	2.01708e-05	Accessible, Low Impact	3
chr9:136210910:C>G	chr9	136210910	136210985	75	rs10858246	Appendicular lean mass	2e-20	QSOX2	33097823	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr9:136210910:C>G	chr9	136210910	136210985	75	rs10858246	Lung function (FVC)	4e-08	QSOX2	28166213	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr14:72172864:A>C	chr14	72172864	72172788	76	rs149662	Educational attainment	6e-14	RGS6	35361970	0.9422262	467.5	JUND	1.31404e-05	Accessible, Low Impact	2
chr3:70747621:A>C	chr3	70747621	70747545	76	rs13091518	Prostate cancer	3e-08	SAMMSON - COX6CP6	33398198	0.9978391	739.0	FOS	6.57082e-06	High Impact, Hard to Access	3
chr20:14986357:C>G	chr20	14986357	14986433	76	rs430086	Percentage gas trapping	3e-07	MACROD2	26030696	0.9999582	6644.0	ATF3	1.31563e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:119886294:C>A	chr12	119886294	119886217	77	rs7960673	NADK/PXN protein level ratio	6e-88	CIT - RPL35AP30	38412862	0.9824973	552.0	FOS	1.97228e-05	Accessible, Low Impact	3
chr4:15833989:A>C	chr4	15833989	15833912	77	rs188213195	CD38 protein levels	5.9999999999999996e-55	CD38	39789286	0.9999255	2038.0	JUND	6.57013e-06	High Impact, Hard to Access	3
chr3:67834368:C>A	chr3	67834368	67834445	77	rs80338391	Corpus callosum volume (MOSTest)	2e-08	SUCLG2-DT	37164063	0.80697334	361.0	ATF3	1.31468e-05	Accessible, Low Impact	3
chr7:110399588:G>C	chr7	110399588	110399666	78	rs7787637	Alanine aminotransferase level after methotrexate initiation in rheumatoid arthritis	3e-07	RPL3P8 - IMMP2L	36070248	0.99773717	743.0	FOS	1.31387e-05	HIGH PRIORITY: Accessible + High Impact	3
chr21:31127181:G>C	chr21	31127181	31127259	78	rs2833286	Vaginal microbiome MetaCyc pathway (PWY-5022|4-aminobutanoate degradation V)	5e-06	TIAM1	34282934	0.9565308	435.5	FOS	6.56935e-06	Low Priority	3
chr6:32121157:G>C	chr6	32121157	32121077	80	rs2228628	Serum levels of protein ATF6	4e-19	ATF6B	35078996	0.95348793	658.0	FOSL2	1.31373e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:75679725:G>T	chr8	75679725	75679645	80	rs1449544	Pulse pressure	3e-15	HNF4G - RNU2-54P	27841878	0.98266596	646.0	FOS	6.59953e-06	High Impact, Hard to Access	3
chr8:75679725:G>T	chr8	75679725	75679645	80	rs1449544	Descending aorta distensibility	6e-12	HNF4G - RNU2-54P	37019578	0.98266596	646.0	FOS	6.59953e-06	High Impact, Hard to Access	3
chr6:32121157:G>C	chr6	32121157	32121077	80	rs2228628	Platelet distribution width (UKB data field 30110)	1e-11	ATF6B	39789286	0.95348793	658.0	FOSL2	1.31373e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:105577175:C>A	chr2	105577175	105577095	80	rs3943516	Platelet count	1e-10	FHL2 - LINC02946	32888494	0.998203	1470.0	FOS	6.57134e-06	High Impact, Hard to Access	3
chr4:87245969:G>C	chr4	87245969	87245889	80	rs13151329	Saturated fatty acids levels	2e-10	KLHL8 - MIR5705	40545721	0.98438936	545.75	ATF3	1.97649e-05	Accessible, Low Impact	3
chr10:122418443:G>T	chr10	122418443	122418363	80	rs17103522	Age-related macular degeneration	6e-10	PLEKHA1	38542204	0.96744037	499.5	JUNB	1.9707e-05	Accessible, Low Impact	3
chr8:75679725:G>T	chr8	75679725	75679645	80	rs1449544	Descending aorta strain	3e-08	HNF4G - RNU2-54P	37019578	0.98266596	646.0	FOS	6.59953e-06	High Impact, Hard to Access	3
chr8:75679725:G>T	chr8	75679725	75679645	80	rs1449544	Systolic blood pressure	7e-06	HNF4G - RNU2-54P	27841878	0.98266596	646.0	FOS	6.59953e-06	High Impact, Hard to Access	3
chr3:49771266:G>T	chr3	49771266	49771185	81	rs7652179	Biological sex	3e-12	IP6K1	33888908	0.98739034	700.5	ATF2	0.0	High Impact, Hard to Access	3
chr1:231761380:C>A	chr1	231761380	231761461	81	rs17749164	Whole brain free water diffusion (multivariate analysis)	5e-11	TSNAX-DISC1, DISC1	35505052	0.9327804	465.0	JUND	6.57186e-06	Low Priority	3
chr1:231761380:C>A	chr1	231761380	231761461	81	rs17749164	Whole brain restricted isotropic diffusion (multivariate analysis)	3e-10	TSNAX-DISC1, DISC1	35505052	0.9327804	465.0	JUND	6.57186e-06	Low Priority	3
chr1:231761380:C>A	chr1	231761380	231761461	81	rs17749164	Whole brain restricted directional diffusion (multivariate analysis)	3e-10	TSNAX-DISC1, DISC1	35505052	0.9327804	465.0	JUND	6.57186e-06	Low Priority	3
chr16:9416712:G>C	chr16	9416712	9416631	81	rs148851398	Bone mineral density variability	5e-09	LINC02177	37500982	0.9950484	580.5	FOS	0.00236363	HIGH PRIORITY: Accessible + High Impact	3
chr11:134882271:C>A	chr11	134882271	134882352	81	rs4937972	Hospitalization rate in serious mental illnesses	7e-06	LINC02714 - LINC02697	38469033	0.97237617	494.0	JUN	0.0881669	Accessible, Low Impact	3
chr5:164437191:G>C	chr5	164437191	164437273	82	rs57542984	Uterine fibroid size (maximum dimension)	2e-09	LINC03000	30196971	0.9584504	448.0	JUN	1.98463e-05	Accessible, Low Impact	3
chr1:219467486:C>A	chr1	219467486	219467404	82	rs115328987	Waist-to-hip ratio adjusted for BMI	5e-09	LYPLAL1-AS1	34021172	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467404	82	rs115328987	Waist-hip index	6e-09	LYPLAL1-AS1	34021172	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr2:213064644:C>G	chr2	213064644	213064562	82	rs10186029	Systemic sclerosis	1e-06	IKZF2	29293537	0.99164	541.0	JUND	6.57938e-06	Low Priority	3
chr2:15736376:C>G	chr2	15736376	15736293	83	rs191185851	Post bronchodilator FEV1/FVC ratio	3e-07	LINC01804	26634245	0.9150109	491.5	FOS	7.04146e-06	Accessible, Low Impact	3
chr1:29794712:C>A	chr1	29794712	29794629	83	rs146919335	Bisoprolol clearance in non-ST elevation acute coronary syndrome	2e-06	LINC01756 - LINC01648	35356681	0.80316085	291.25	MAFK	0.000763263	Accessible, Low Impact	3
chr3:153301978:A>C	chr3	153301978	153302061	83	rs182456566	Vaginal microbiome relative abundance (s_Prevotella timonensis)	3e-06	RN7SL300P - LINC03109	34282934	0.9868027	879.0	ATF2	1.31806e-05	HIGH PRIORITY: Accessible + High Impact	2
chr14:24232477:G>T	chr14	24232477	24232393	84	rs532687339	Platelet count	3e-09	GMPR2	38116116	0.99926984	5000.0	MAFF	6.82342e-06	HIGH PRIORITY: Accessible + High Impact	3
chrX:121716383:G>C	chrX	121716383	121716468	85	rs2429676	Bone mineral density (hip) and age at menarche	4e-06	MIR3672 - TPT1P13	26312577	0.9982439	531.0	FOSL2	8.934e-06	Accessible, Low Impact	3
chr6:47430922:C>A	chr6	47430922	47431007	85	rs1931827	Memory decline	8e-06	B3GNTL1P2 - CD2AP-DT	37984853	0.9910462	764.0	FOSL1	6.5678e-06	High Impact, Hard to Access	3
chr17:36116332:C>A	chr17	36116332	36116418	86	rs4796154	C-C motif chemokine 18 levels	2e-14	RN7SL301P - TBC1D3B	36168886	0.9283083	550.5	JUND	6.57289e-06	Low Priority	3
chr11:86160258:T>A	chr11	86160258	86160172	86	rs61904266	Alzheimer's disease or family history of Alzheimer's disease	5e-08	RNU6-560P - LINC02695	29777097	0.9940711	1406.0	FOS	1.31627e-05	HIGH PRIORITY: Accessible + High Impact	2
chr7:17595096:G>C	chr7	17595096	17595010	86	rs1230423	High-sensitivity C-reactive protein (log-transformed) x plasma omega-3 fatty acids (% of total FA) from NMR interaction	4e-06	LINC02889 - SNX13	40038624	0.9997991	1576.5	ATF7	1.97179e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:96598525:G>C	chr8	96598525	96598612	87	rs2575725	Refractive error	4e-09	SDC2	32231278	0.9808213	659.0	FOSL2	0.000111767	HIGH PRIORITY: Accessible + High Impact	3
chr8:135415237:C>A	chr8	135415237	135415324	87	rs75045186	Protein quantitative trait loci (liver)	6e-09	LINC01591 - KHDRBS3	32778093	0.86362827	428.0	JUN	6.57635e-06	Low Priority	3
chr7:23434618:C>G	chr7	23434618	23434706	88	rs7808836	Height	1e-300	IGF2BP3	36224396	0.9884892	793.0	JUND	6.57004e-06	High Impact, Hard to Access	3
chr11:113032961:G>C	chr11	113032961	113032873	88	rs7945073	Smoking initiation	2e-179	NCAM1	36477530	0.961097	567.0	FOSL1	6.5697e-06	Low Priority	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	IDP dMRI ProbtrackX ISOVF unc r	9e-28	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr3:49364830:G>C	chr3	49364830	49364918	88	rs9812360	Substance use disorder	1e-27	RHOA	41057643	0.98289305	638.0	BATF	7.24896e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	IDP dMRI ProbtrackX ISOVF unc l	3e-24	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	IDP dMRI ProbtrackX L1 unc l	1e-22	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	IDP dMRI ProbtrackX L3 unc r	1e-21	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	IDP dMRI TBSS ISOVF External capsule L	3e-19	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	IDP dMRI TBSS ISOVF Anterior corona radiata L	2e-13	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51415849	88	rs7196814	Ventral frontal thickness	5e-12	UNGP1 - HNRNPA1L3	35113692	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr10:30820485:C>A	chr10	30820485	30820574	89	rs1538955	Height	2e-12	ZNF438	40436827	0.99987054	2617.0	JUND	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:43177592:C>A	chr2	43177592	43177681	89	rs934229	Medication use (agents acting on the renin-angiotensin system)	3e-10	LINC02580	34594039	0.9884892	1278.0	FOSL1	1.31804e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:104550062:C>G	chr11	104550062	104549972	90	rs60064090	Highest math class taken (MTAG)	4e-08	LINC02552	30038396	0.95134485	426.5	FOSL1	6.58415e-06	Low Priority	3
chr2:60250562:G>T	chr2	60250562	60250653	91	rs145678577	Age at first birth	2e-11	RNA5SP94 - MIR4432HG	34211149	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr2:103816706:C>A	chr2	103816706	103816798	92	rs62151809	Genetic generalized epilepsy	1e-11	CAPZBP1 - LINC01965	37653029	0.9695515	470.5	FOSL2	7.22648e-05	Accessible, Low Impact	3
chr2:103816706:C>A	chr2	103816706	103816798	92	rs62151809	Leisure screen time	4e-09	CAPZBP1 - LINC01965	36071172	0.9695515	470.5	FOSL2	7.22648e-05	Accessible, Low Impact	3
chr11:73012966:G>T	chr11	73012966	73013058	92	rs7105776	Height	1e-06	FCHSD2	36224396	0.9914465	544.0	JUND	6.56996e-06	Low Priority	3
chr2:226405659:T>A	chr2	226405659	226405752	93	rs34873302	STC2 protein levels	7e-17	NYAP2 - MIR5702	39789286	0.9940711	774.5	JUND	6.56582e-06	High Impact, Hard to Access	3
chr7:73563135:C>A	chr7	73563135	73563228	93	rs201887154	Waist-to-hip ratio adjusted for BMI	2e-08	BCL7B - TBL2	34021172	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr7:17972728:C>A	chr7	17972728	17972634	94	rs12699929	Albumin levels	7.999999999999999e-25	MRM3P2 - PRPS1L1	41044249	0.8908594	415.5	JUNB	6.57298e-06	Low Priority	3
chr7:17972728:C>A	chr7	17972728	17972634	94	rs12699929	Mean platelet volume	1e-17	MRM3P2 - PRPS1L1	32888494	0.8908594	415.5	JUNB	6.57298e-06	Low Priority	3
chr7:17972728:C>A	chr7	17972728	17972634	94	rs12699929	ROBO1 protein levels	3e-13	MRM3P2 - PRPS1L1	39789286	0.8908594	415.5	JUNB	6.57298e-06	Low Priority	3
chr19:38234799:G>C	chr19	38234799	38234704	95	rs10408973	PPP1R14A protein levels	6e-22	DPF1 - SPINT2	39789286	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:38234799:G>C	chr19	38234799	38234704	95	rs10408973	Kunitz-type protease inhibitor 2 levels	1e-15	DPF1 - SPINT2	36168886	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:80301382:C>A	chr13	80301382	80301287	95	rs1755255	Depression (broad)	8e-07	LINC01080 - SPRY2	29662059	0.96905065	511.5	BATF	6.57973e-06	Low Priority	3
chr17:31610652:G>T	chr17	31610652	31610747	95	rs147209203	COVID-19 (covid pneumonia vs population)	8e-06	MIR365BHG - RNU6-1134P	33888907	0.97511876	732.0	FOSL1	0.0	High Impact, Hard to Access	3
chr11:86594871:A>C	chr11	86594871	86594775	96	rs17149197	Adolescent idiopathic scoliosis	1e-10	ME3	30019117	0.9985754	1365.0	FOSL1	6.83826e-06	HIGH PRIORITY: Accessible + High Impact	2
chr15:27995971:C>A	chr15	27995971	27995874	97	rs4778224	Blond vs. brown/black hair color	3e-29	OCA2	30531825	0.9729977	447.75	BATF	1.31598e-05	Accessible, Low Impact	3
chrX:1464647:G>C	chrX	1464647	1464550	97	rs4933152	Eosinophil count	7e-10	P2RY8, P2RY8, P2RY8, P2RY8	32888494	0.9602251	651.5	MAFK	0.777783	HIGH PRIORITY: Accessible + High Impact	3
chrX:1464647:G>C	chrX	1464647	1464550	97	rs4933152	Eosinophil percentage of white cells	8e-09	P2RY8, P2RY8, P2RY8, P2RY8	32888494	0.9602251	651.5	MAFK	0.777783	HIGH PRIORITY: Accessible + High Impact	3
chr15:27995971:C>A	chr15	27995971	27995874	97	rs4778224	Brown vs. black hair color	3e-08	OCA2	30531825	0.9729977	447.75	BATF	1.31598e-05	Accessible, Low Impact	3
chr12:61856736:T>A	chr12	61856736	61856639	97	rs17605016	Asthma and hay fever	2e-06	TAFA2	24388013	0.9845253	686.0	FOS	6.58181e-06	High Impact, Hard to Access	3
chr3:128660481:A>C	chr3	128660481	128660579	98	rs9838579	Blood cell traits latent factor 8 (white cell)	2e-12	RPN1	40220762	0.99975276	1180.5	FOSL2	2.69836e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:3230824:G>T	chr1	3230824	3230726	98	rs6424070	Brain region volumes	1e-09	PRDM16	31676860	0.925176	777.0	JUND	6.56858e-06	High Impact, Hard to Access	3
chr9:113627109:T>A	chr9	113627109	113627009	100	rs479766	Heel bone mineral density	5e-08	RGS3 - C14orf119P1	30595370	0.9814467	719.0	FOS	6.57108e-06	HIGH PRIORITY: Accessible + High Impact	2
chr2:221937082:C>A	chr2	221937082	221936980	102	rs824931	Height	4e-31	RPL23P5 - LLPHP3	36224396	0.97697836	516.0	FOS	0.0	Low Priority	3
chr2:221937082:C>A	chr2	221937082	221936980	102	rs824931	Body mass index	3e-06	RPL23P5 - LLPHP3	19851299	0.97697836	516.0	FOS	0.0	Low Priority	3
chr15:89819146:G>C	chr15	89819146	89819043	103	rs8030349	Aminopeptidase N levels	3e-15	ANPEP - AP3S2	36349687	0.99159664	683.0	ATF3	6.57696e-06	High Impact, Hard to Access	3
chr7:2408755:G>T	chr7	2408755	2408858	103	rs6952809	Multiple sclerosis	4e-06	CHST12	21833088	0.96518815	742.0	BATF	6.57142e-06	High Impact, Hard to Access	3
chr20:1150373:T>A	chr20	1150373	1150476	103	rs6040155	Memory decline in normal cognition	1e-05	PSMF1	37984853	0.99956036	5693.5	ATF3	1.97143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:114526734:G>C	chr1	114526734	114526630	104	rs139846391	Platelet distribution width	1e-13	TRIM33 - PKMP1	32888494	0.9799247	671.0	JUN	6.56832e-06	High Impact, Hard to Access	3
chr16:88974025:C>A	chr16	88974025	88973921	104	rs13330216	Mean corpuscular hemoglobin	7e-11	CBFA2T3	32888494	0.95749575	851.0	MAFK	1.97088e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:123224048:C>G	chr12	123224048	123223943	105	rs10744149	Vertex-wise sulcal depth	2.0000000000000002e-23	MPHOSPH9	34910505	0.9785014	388.5	FOSL1	6.62901e-06	Low Priority	3
chr17:65964046:G>T	chr17	65964046	65964151	105	rs76731691	Occipital area	3e-17	CEP112	35113692	0.97674394	474.0	JUND	6.56996e-06	Low Priority	3
chr5:8219140:C>G	chr5	8219140	8219246	106	rs16880092	Adolescent idiopathic scoliosis	8e-06	LINC02226	30019117	0.93561655	414.0	FOS	6.57505e-06	Low Priority	3
chr10:116997950:G>C	chr10	116997950	116997843	107	rs11593277	Subcortical volume (MOSTest)	8e-12	SHTN1	32665545	0.98575574	590.0	ATF2	6.57177e-06	High Impact, Hard to Access	3
chr1:33323176:C>G	chr1	33323176	33323283	107	rs7542777	Cerebral white matter volume	3e-06	A3GALT2 - PHC2	31530798	0.996504	1992.0	FOSL2	6.5697e-06	HIGH PRIORITY: Accessible + High Impact	2
chr12:85000471:C>G	chr12	85000471	85000578	107	rs56889024	Letter-number span reordering	6e-06	SLC6A15 - TSPAN19	31596458	0.94588065	472.5	JUND	1.31492e-05	Accessible, Low Impact	3
chr8:27629291:C>A	chr8	27629291	27629399	108	rs576748	Alzheimer's disease or family history of Alzheimer's disease	5e-08	CLU - SCARA3	29777097	0.9834347	575.5	JUND	6.57921e-06	High Impact, Hard to Access	3
chr2:77881974:C>G	chr2	77881974	77881866	108	rs184205168	Plasma anti-thyroid peroxidase levels	5e-06	RPL38P2 - LINC01851	29678681	0.8940993	398.5	MAFK	6.65814e-06	Accessible, Low Impact	3
chr20:14486632:C>G	chr20	14486632	14486741	109	rs13038351	Blood protein levels	1e-43	MACROD2	30072576	0.8986329	426.5	FOSL1	1.33715e-05	Accessible, Low Impact	3
chr3:73151038:G>C	chr3	73151038	73151147	109	rs761486125	Alzheimer's disease or family history of Alzheimer's disease	1e-08	RNU2-64P - GPATCH11P1	39998322	0.9972791	610.5	FOS	6.595e-06	High Impact, Hard to Access	3
chr3:49845026:C>A	chr3	49845026	49844916	110	rs2247036	Pain intensity (NRS pain scale 0-11)	2e-20	TRAIP	38429522	0.994571	2438.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr3:49845026:C>A	chr3	49845026	49844916	110	rs2247036	Pain intensity (without opioid use disorder)	4e-19	TRAIP	38429522	0.994571	2438.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr3:49845026:C>A	chr3	49845026	49844916	110	rs2247036	Inflammatory bowel disease (MTAG)	3e-12	TRAIP	39792054	0.994571	2438.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr3:49845026:C>A	chr3	49845026	49844916	110	rs2247036	Pain intensity (NRS pain scale 1-11)	6e-11	TRAIP	38429522	0.994571	2438.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr3:23599902:G>C	chr3	23599902	23600012	110	rs73049452	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (3 Months) interaction	7e-07	UBE2E2 - RNU6-922P	40187613	0.9976305	920.5	FOS	0.000124842	HIGH PRIORITY: Accessible + High Impact	3
chr20:46101494:G>C	chr20	46101494	46101606	112	rs6032660	CD40LG protein levels	1e-55	RPL13P2 - CD40	39789286	0.95134485	594.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr6:37365908:C>A	chr6	37365908	37366020	112	rs195385	Height	7.999999999999999e-30	RNF8	36224396	0.99364895	899.0	JUND	2.62743e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:82379109:G>C	chr17	82379109	82379221	112	rs777693834	P4HB protein levels	2e-12	UTS2R - OGFOD3	39789286	0.9981182	1205.0	FOS	9.1919e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:28986902:G>C	chr16	28986902	28986790	112	rs4788115	Sarcoidosis	8e-11	LAT	40075078	0.99548393	659.0	FOS	6.57255e-06	High Impact, Hard to Access	3
chr16:28986902:G>C	chr16	28986902	28986790	112	rs4788115	Body mass index	2e-10	LAT	36581621	0.99548393	659.0	FOS	6.57255e-06	High Impact, Hard to Access	3
chr16:28986902:G>C	chr16	28986902	28986790	112	rs4788115	Educational attainment (MTAG)	1e-09	LAT	30038396	0.99548393	659.0	FOS	6.57255e-06	High Impact, Hard to Access	3
chr16:28986902:G>C	chr16	28986902	28986790	112	rs4788115	Educational attainment (years of education)	2e-09	LAT	30038396	0.99548393	659.0	FOS	6.57255e-06	High Impact, Hard to Access	3
chr20:46101494:G>C	chr20	46101494	46101606	112	rs6032660	Unswitched memory B cell %lymphocyte	7e-09	RPL13P2 - CD40	32929287	0.95134485	594.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr20:46101494:G>C	chr20	46101494	46101606	112	rs6032660	Post-traumatic stress disorder	1e-08	RPL13P2 - CD40	38637617	0.95134485	594.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr16:28986902:G>C	chr16	28986902	28986790	112	rs4788115	Educational attainment	2e-08	LAT	35361970	0.99548393	659.0	FOS	6.57255e-06	High Impact, Hard to Access	3
chr4:38721231:T>A	chr4	38721231	38721343	112	rs11096954	Asthma (childhood onset)	3e-08	KLF3 - RNA5SP158	31669095	0.8741373	537.0	ATF3	6.59378e-06	Low Priority	3
chr4:52875121:G>C	chr4	52875121	52875008	113	rs59649036	Whole brain restricted directional diffusion (multivariate analysis)	6e-17	SCFD2	35505052	0.99615616	553.5	FOS	6.57065e-06	Low Priority	3
chr22:50432230:C>A	chr22	50432230	50432117	113	rs34841112	High light scatter reticulocyte count (UKB data field 30300)	2e-13	PPP6R2	39789286	0.9996078	1064.0	FOS	1.31449e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:52875121:G>C	chr4	52875121	52875008	113	rs59649036	T1 FreeSurfer pial rh lateraloccipital area	1e-09	SCFD2	38811844	0.99615616	553.5	FOS	6.57065e-06	Low Priority	3
chr4:52875121:G>C	chr4	52875121	52875008	113	rs59649036	T1 FreeSurfer DK rh lateraloccipital area	5e-09	SCFD2	38811844	0.99615616	553.5	FOS	6.57065e-06	Low Priority	3
chr4:52875121:G>C	chr4	52875121	52875008	113	rs59649036	T1 FreeSurfer DKT rh lateraloccipital area	6e-09	SCFD2	38811844	0.99615616	553.5	FOS	6.57065e-06	Low Priority	3
chr4:52875121:G>C	chr4	52875121	52875008	113	rs59649036	T1 FreeSurfer a2009s rh Pole occipital area	8e-08	SCFD2	38811844	0.99615616	553.5	FOS	6.57065e-06	Low Priority	3
chr4:52875121:G>C	chr4	52875121	52875008	113	rs59649036	T1 FreeSurfer BA rh V2 exvivo area	5e-06	SCFD2	38811844	0.99615616	553.5	FOS	6.57065e-06	Low Priority	3
chr12:119308808:C>A	chr12	119308808	119308695	113	rs73404331	Oligodendroglioma	8e-06	LINC00934 - CCDC60	36810956	0.994183	783.0	FOS	0.0	High Impact, Hard to Access	3
chr18:74506902:G>T	chr18	74506902	74506788	114	rs12971120	Serum metabolite levels	1e-11	CNDP2	33031748	0.9808213	644.0	FOSL1	6.57065e-06	High Impact, Hard to Access	3
chr3:85365255:G>T	chr3	85365255	85365141	114	rs7627971	Regular attendance at a gym or sports club	6e-10	CADM2	29970889	0.95254505	526.0	FOS	7.33945e-06	Accessible, Low Impact	3
chr20:35660326:C>G	chr20	35660326	35660212	114	rs11698796	Phospholipid levels in very small VLDL	5e-09	RBM12, CPNE1	35213538	0.98618805	896.0	ATF3	6.57237e-06	High Impact, Hard to Access	3
chr20:35660326:C>G	chr20	35660326	35660212	114	rs11698796	Total lipid levels in very small VLDL	1e-08	RBM12, CPNE1	35213538	0.98618805	896.0	ATF3	6.57237e-06	High Impact, Hard to Access	3
chr2:159633853:C>G	chr2	159633853	159633739	114	rs755121215	Hypothyroidism	2e-08	BAZ2B-AS1 - RPS3AP13	34594039	0.93037623	443.0	ATF3	0.000125457	Accessible, Low Impact	3
chr20:35660326:C>G	chr20	35660326	35660212	114	rs11698796	Triglyceride levels in IDL	3e-08	RBM12, CPNE1	35213538	0.98618805	896.0	ATF3	6.57237e-06	High Impact, Hard to Access	3
chr18:74506902:G>T	chr18	74506902	74506788	114	rs12971120	Refractive error	2e-07	CNDP2	23396134	0.9808213	644.0	FOSL1	6.57065e-06	High Impact, Hard to Access	3
chr2:85230447:C>G	chr2	85230447	85230332	115	rs74642841	TGOLN2 protein levels	6e-20	TCF7L1	39789286	0.96533185	489.75	ATF3	1.31473e-05	Accessible, Low Impact	3
chr8:81073329:C>A	chr8	81073329	81073214	115	rs377205419	Heart transplant/surgery (PheCode 429.1)	3e-11	PAG1	39024449	0.9881423	555.5	FOS	6.57307e-06	Low Priority	3
chr2:44328144:G>C	chr2	44328144	44328260	116	rs111427001	Smoking initiation	5e-20	PREPL	36477530	0.8712331	586.0	FOS	6.58883e-06	High Impact, Hard to Access	3
chr5:71724918:C>A	chr5	71724918	71725034	116	rs4703660	Gut microbiome abundance (class Clostridium sensu stricto sp. 17 (at 1 year) x Any Breastfeeding (3 Months) interaction	5e-09	CARTPT - MAP1B	40187613	0.9094714	441.125	JUND	0.000102432	Accessible, Low Impact	3
chr11:86160258:T>A	chr11	86160258	86160142	116	rs7129687	Alzheimer's disease or family history of Alzheimer's disease	5e-08	RNU6-560P - LINC02695	29777097	0.9940711	1406.0	FOS	1.31627e-05	HIGH PRIORITY: Accessible + High Impact	2
chr14:58905781:A>C	chr14	58905781	58905897	116	rs562161427	Electrocardiogram morphology (amplitude at temporal datapoints)	5e-08	LINC01500	32916098	0.9708846	648.0	FOS	0.000978499	HIGH PRIORITY: Accessible + High Impact	2
chr14:72321981:A>C	chr14	72321981	72321865	116	rs847347	Severe COVID-19 infection	1e-06	RGS6	36662838	0.9970844	629.0	FOS	6.57774e-06	HIGH PRIORITY: Accessible + High Impact	2
chr16:20470233:A>C	chr16	20470233	20470350	117	rs1505100	Indolebutyrate levels	1e-18	ACSM2A	36635386	0.9995699	890.5	FOS	0.000623777	HIGH PRIORITY: Accessible + High Impact	3
chr7:46216695:C>A	chr7	46216695	46216578	117	rs35645744	Physical function (baseline)	3e-16	ZNF619P1 - HMGN1P19	40374629	0.94819474	811.0	JUN	1.97037e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144569997	118	rs190135380	Height (baseline)	9.000000000000001e-29	GUSBP5 - KRT18P51	40374629	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:94215479:G>C	chr4	94215479	94215361	118	rs11943926	Vertex-wise sulcal depth	3e-18	SMARCAD1	34910505	0.9708846	555.5	ATF2	0.298747	Accessible, Low Impact	3
chr4:144569879:C>G	chr4	144569879	144569997	118	rs190135380	Physical function (baseline)	9e-15	GUSBP5 - KRT18P51	40374629	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144569997	118	rs190135380	Whole body water mass (UKB data field 23102)	4e-13	GUSBP5 - KRT18P51	39789286	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:112209203:C>A	chr10	112209203	112209321	118	rs7079286	Metabolite peak levels (QI9680)	2e-12	GPAM	35995766	0.9907879	803.0	FOS	0.000144613	HIGH PRIORITY: Accessible + High Impact	3
chr10:112209203:C>A	chr10	112209203	112209321	118	rs7079286	N6-methyllysine levels	5e-12	GPAM	35995766	0.9907879	803.0	FOS	0.000144613	HIGH PRIORITY: Accessible + High Impact	3
chr16:57938135:C>G	chr16	57938135	57938017	118	rs16959567	Gut microbiome abundance (class Hungatella sp. 1 (at 1 year) x Household furry pet dog (3 Months) interaction	9e-09	CNGB1	40187613	0.98289305	657.0	MAFG	6.57091e-06	High Impact, Hard to Access	3
chr1:65418981:G>C	chr1	65418981	65419100	119	rs75148473	C-reactive protein levels	9e-11	RNU2-15P - LEPROT	33462484	0.99962544	1313.5	FOS	6.57004e-06	High Impact, Hard to Access	3
chr1:111404455:C>G	chr1	111404455	111404336	119	rs1539581	Cerebrospinal fluid t-tau:AB1-42 ratio	2e-08	PGBP - OVGP1	28641921	0.9327804	485.5	ATF3	1.31413e-05	Accessible, Low Impact	3
chr16:57938135:C>G	chr16	57938135	57938254	119	rs75999538	Alzheimer's disease, proxy Alzheimer's disease or related dementias	5e-06	CNGB1	40708016	0.98289305	657.0	MAFG	6.57091e-06	High Impact, Hard to Access	3
chr7:65719593:A>C	chr7	65719593	65719713	120	rs4473913	Glycated haemoglobin HbA1c levels (UKB data field 30750)	2e-16	LINC03006	39789286	0.99991244	2422.0	FOSL1	0.0	High Impact, Hard to Access	2
chr7:65719593:A>C	chr7	65719593	65719713	120	rs4473913	Hemoglobin A1c levels	4e-13	LINC03006	34594039	0.99991244	2422.0	FOSL1	0.0	High Impact, Hard to Access	2
chr16:77263416:G>C	chr16	77263416	77263296	120	rs2162957	Insomnia	3e-12	ADAMTS18	35835914	0.9972157	721.0	BATF	6.64302e-06	HIGH PRIORITY: Accessible + High Impact	3
chr15:88019862:G>C	chr15	88019862	88019982	120	rs536922999	Stomatitis and mucositis (PheCode 528.1)	3e-11	NTRK3	39024449	0.9978391	694.5	FOS	6.57091e-06	High Impact, Hard to Access	3
chr7:65719593:A>C	chr7	65719593	65719713	120	rs4473913	Prostate-specific antigen levels	5e-10	LINC03006	39930085	0.99991244	2422.0	FOSL1	0.0	High Impact, Hard to Access	2
chr12:121670712:G>T	chr12	121670712	121670591	121	rs1408180684	Alzheimer's disease or family history of Alzheimer's disease	2e-40	MORN3	39998322	0.9803781	597.0	MAFK	6.57999e-06	High Impact, Hard to Access	3
chr1:219604005:G>T	chr1	219604005	219604126	121	rs10863469	Body surface area	4e-13	LYPLAL1-AS1 - ZC3H11B	36502284	0.8072176	291.75	FOSL2	6.57212e-06	Low Priority	3
chr1:219604005:G>T	chr1	219604005	219604126	121	rs10863469	Umbilical hernia	1e-09	LYPLAL1-AS1 - ZC3H11B	34382107	0.8072176	291.75	FOSL2	6.57212e-06	Low Priority	3
chr3:3234114:C>A	chr3	3234114	3233993	121	rs11928098	Cortex volume change rate	2e-06	CRBN - SUMF1	35383335	0.7643487	380.25	ATF3	0.0	Low Priority	3
chr7:38027054:C>A	chr7	38027054	38026932	122	rs1717739	Bone mineral density mean	6e-16	SFRP4 - STARD3NL	37500982	0.988674	411.0	BATF	3.28934e-05	Accessible, Low Impact	3
chr3:195151389:G>C	chr3	195151389	195151266	123	rs13315459	OTU99_19 (Bacteria) prevalence	5e-06	XXYLT1, XXYLT1-AS2	33462482	0.9872979	864.25	FOS	0.000256262	HIGH PRIORITY: Accessible + High Impact	3
chr3:195151389:G>C	chr3	195151389	195151266	123	rs13315459	OTU97_19 (Bacteria) prevalence	5e-06	XXYLT1, XXYLT1-AS2	33462482	0.9872979	864.25	FOS	0.000256262	HIGH PRIORITY: Accessible + High Impact	3
chr16:53422873:A>C	chr16	53422873	53422749	124	rs9932007	Serum alkaline phosphatase levels	1e-15	MPHOSPH10P1 - RBL2	34594039	0.99843514	675.0	FOS	6.57237e-06	High Impact, Hard to Access	3
chr16:53422873:A>C	chr16	53422873	53422749	124	rs9932007	Liver enzyme levels (alkaline phosphatase)	4e-15	MPHOSPH10P1 - RBL2	33972514	0.99843514	675.0	FOS	6.57237e-06	High Impact, Hard to Access	3
chr6:157835526:C>G	chr6	157835526	157835650	124	rs7775039	mean platelet volume (MPV, minimum, inv-norm transformed)	3e-12	SNX9	39024449	0.925176	627.0	FOSL1	1.31834e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:137040579:G>C	chr9	137040579	137040455	124	rs9411298	Monocyte percentage of white cells	1e-10	NPDC1	27863252	0.9704257	682.0	FOS	1.31456e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:41901852:A>C	chr12	41901852	41901977	125	rs138017112	Parkinson's disease or first degree relation to individual with Parkinson's disease	7e-12	LINC02400 - GXYLT1	31701892	0.94346935	435.5	FOS	6.56892e-06	Low Priority	3
chr6:151507048:C>A	chr6	151507048	151506923	125	rs141252918	Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia	6e-07	CCDC170	31164008	0.98327994	564.0	BATF	6.57203e-06	Low Priority	3
chr6:151507048:C>A	chr6	151507048	151506923	125	rs141252918	Suicide behaviour in schizophrenia or bipolar 1 disorder or mood disorder	7e-07	CCDC170	38491344	0.98327994	564.0	BATF	6.57203e-06	Low Priority	3
chr3:149404770:C>A	chr3	149404770	149404644	126	rs934295	Alanine aminotransferase levels	7.000000000000001e-60	TM4SF1-AS1 - RPL32P8	40436827	0.9904106	1184.0	FOSL1	2.63082e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:149404770:C>A	chr3	149404770	149404644	126	rs934295	Alanine transaminase (ALT, minimum, inv-norm transformed)	1e-20	TM4SF1-AS1 - RPL32P8	39024449	0.9904106	1184.0	FOSL1	2.63082e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:149404770:C>A	chr3	149404770	149404644	126	rs934295	Alanine transaminase (ALT, maximum, inv-norm transformed)	4e-17	TM4SF1-AS1 - RPL32P8	39024449	0.9904106	1184.0	FOSL1	2.63082e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:149404770:C>A	chr3	149404770	149404644	126	rs934295	Chronic elevation of alanine aminotransferase (cALT) levels	3e-16	TM4SF1-AS1 - RPL32P8	35654975	0.9904106	1184.0	FOSL1	2.63082e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:205788823:C>A	chr1	205788823	205788696	127	rs1775148	Albumin levels	7e-14	RAB29 - SLC41A1	40436827	0.99197406	1005.5	BATF	6.57514e-06	High Impact, Hard to Access	3
chr1:205788823:C>A	chr1	205788823	205788696	127	rs1775148	Serum uric acid levels	2e-09	RAB29 - SLC41A1	34594039	0.99197406	1005.5	BATF	6.57514e-06	High Impact, Hard to Access	3
chr1:205788823:C>A	chr1	205788823	205788696	127	rs1775148	Prostate cancer	4e-08	RAB29 - SLC41A1	25217961	0.99197406	1005.5	BATF	6.57514e-06	High Impact, Hard to Access	3
chr9:126697989:C>G	chr9	126697989	126698117	128	rs10987416	Vertex-wise sulcal depth	3e-24	LMX1B	34910505	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr1:190337814:C>A	chr1	190337814	190337942	128	rs718609	Gout	3e-09	BRINP3	39406924	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr9:4298409:A>C	chr9	4298409	4298537	128	rs12340657	Osteoarthritis	2e-08	GLIS3	36411363	0.98996234	2186.0	JUN	0.000111678	HIGH PRIORITY: Accessible + High Impact	2
chr21:35376070:C>G	chr21	35376070	35376199	129	rs4507181	Waist-to-hip ratio adjusted for BMI	5e-10	RUNX1	31669095	0.9131995	482.0	JUND	6.57462e-06	Low Priority	3
chr16:51415937:C>A	chr16	51415937	51416067	130	rs7197215	IDP dMRI ProbtrackX MD unc r	8.000000000000001e-24	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51416067	130	rs7197215	IDP dMRI ProbtrackX ISOVF slf l	8e-22	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51416067	130	rs7197215	IDP dMRI ProbtrackX L1 unc r	1e-20	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51416067	130	rs7197215	IDP dMRI ProbtrackX L2 unc r	3e-18	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr17:67095570:C>G	chr17	67095570	67095440	130	rs7212076	Total cholesterol levels	3e-14	HELZ	34887591	0.99999	11604.0	JUNB	6.57808e-06	High Impact, Hard to Access	3
chr8:92054295:G>T	chr8	92054295	92054425	130	rs7833370	Smoking initiation (ever regular vs never regular) (MTAG)	4e-14	RUNX1T1	30643251	0.9739743	552.5	JUND	3.28455e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51416067	130	rs7197215	IDP dMRI TBSS ISOVF Superior longitudinal fasciculus L	5e-14	UNGP1 - HNRNPA1L3	33875891	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr11:32802866:C>G	chr11	32802866	32802996	130	rs11032001	Inguinal hernia	2e-13	CCDC73 - PRRG4	34382107	0.93561655	523.5	ATF7	2.63598e-05	Accessible, Low Impact	3
chr1:197209201:C>G	chr1	197209201	197209331	130	rs369166561	CFP protein levels	2e-12	ZBTB41 - CRB1	39789286	0.9702253	658.0	JUNB	0.00324292	HIGH PRIORITY: Accessible + High Impact	3
chr16:51415937:C>A	chr16	51415937	51416067	130	rs7197215	Cortical thickness	6e-12	UNGP1 - HNRNPA1L3	32963231	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31395249	131	rs2523466	Platelet-to-lymphocyte ratio	8e-68	MICA-AS1	34469753	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31395249	131	rs2523466	SFTPD protein levels	2e-53	MICA-AS1	39789286	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr1:8931417:A>C	chr1	8931417	8931286	131	rs140675884	CA6 protein levels	2e-15	HMGN2P17 - CA6	39789286	0.9727787	684.0	ATF7	9.84665e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:20782169:C>A	chr8	20782169	20782300	131	rs4366093	Body mass index	2e-11	LZTS1 - TMEM97P2	31669095	0.9912486	1418.5	BATF	0.0001117	HIGH PRIORITY: Accessible + High Impact	3
chr8:18014241:A>C	chr8	18014241	18014110	131	rs28551649	Chronic obstructive pulmonary disease liability (machine learning-based score)	2e-10	PCM1	37069358	0.97511876	584.0	FOS	1.97163e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:20782169:C>A	chr8	20782169	20782300	131	rs4366093	Adiposity (multivariate analysis)	2e-10	LZTS1 - TMEM97P2	40796553	0.9912486	1418.5	BATF	0.0001117	HIGH PRIORITY: Accessible + High Impact	3
chr11:134882271:C>A	chr11	134882271	134882140	131	rs10894895	Response to paliperidone in schizophrenia (CGI-S score)	9e-06	LINC02714 - LINC02697	27846195	0.97237617	494.0	JUN	0.0881669	Accessible, Low Impact	3
chr2:53854810:G>C	chr2	53854810	53854678	132	rs80328470	Weight	2e-15	ASB3, GPR75	40436827	0.99807435	938.0	FOSL1	6.57402e-06	High Impact, Hard to Access	3
chr2:53854810:G>C	chr2	53854810	53854678	132	rs80328470	Waist circumference	1e-14	ASB3, GPR75	40436827	0.99807435	938.0	FOSL1	6.57402e-06	High Impact, Hard to Access	3
chr2:53854810:G>C	chr2	53854810	53854678	132	rs80328470	Body mass index	3e-13	ASB3, GPR75	40436827	0.99807435	938.0	FOSL1	6.57402e-06	High Impact, Hard to Access	3
chr2:51704694:C>G	chr2	51704694	51704826	132	rs1516179	Educational attainment (years of education)	1e-09	NRXN1-DT	30595370	0.9702253	521.0	FOS	6.57696e-06	Low Priority	3
chr2:51704694:C>G	chr2	51704694	51704826	132	rs1516179	CAMSIS occupational score	3e-08	NRXN1-DT	39715877	0.9702253	521.0	FOS	6.57696e-06	Low Priority	3
chr11:128319074:G>C	chr11	128319074	128319206	132	rs4937314	Alzheimer's disease (late onset)	7e-06	LINC02098 - ETS1	22881374	0.999976	9980.0	JUNB	6.57479e-06	High Impact, Hard to Access	3
chr21:15982596:T>A	chr21	15982596	15982729	133	rs12483653	Standing height (UKB data field 50)	1e-17	MIR99AHG	39789286	0.8209431	438.5	ATF7	1.31479e-05	Accessible, Low Impact	3
chr21:15982596:T>A	chr21	15982596	15982729	133	rs12483653	Height	2e-16	MIR99AHG	39134668	0.8209431	438.5	ATF7	1.31479e-05	Accessible, Low Impact	3
chr6:168359628:C>A	chr6	168359628	168359761	133	rs73791415	Height (baseline)	2e-16	DACT2 - SMOC2	40374629	0.9396624	607.0	ATF3	6.57108e-06	High Impact, Hard to Access	3
chr21:15982596:T>A	chr21	15982596	15982729	133	rs12483653	Height (standard GWA)	3e-11	MIR99AHG	37106081	0.8209431	438.5	ATF7	1.31479e-05	Accessible, Low Impact	3
chr17:71922718:C>G	chr17	71922718	71922851	133	rs34374422	Physical function (baseline)	6e-10	ROCR	40374629	0.996504	1861.5	FOSL2	1.31468e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:116578433:C>G	chr11	116578433	116578566	133	rs7122363	Metabolic syndrome	2e-09	LINC02151 - LINC02702	39349817	0.7156284	458.75	FOSL1	6.57039e-06	Low Priority	3
chr8:47892028:C>A	chr8	47892028	47892161	133	rs143662847	Adult body size	5e-08	PRKDC	32376654	0.9659551	616.5	ATF2	0.000815125	HIGH PRIORITY: Accessible + High Impact	3
chr2:43196174:C>A	chr2	43196174	43196040	134	rs35936219	Red blood cell count	8.000000000000001e-29	LINC02580	40436827	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196040	134	rs35936219	Estimated glomerular filtration rate (creatinine, cystatin c)	5e-27	LINC02580	39256582	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196040	134	rs35936219	Estimated glomerular filtration rate (creatinine)	9.999999999999999e-27	LINC02580	39256582	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr19:4069294:C>A	chr19	4069294	4069428	134	rs350832	Leg fat percentage right (UKB data field 23111)	2e-20	ZBTB7A - MAP2K2	39789286	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:4069294:C>A	chr19	4069294	4069428	134	rs350832	Leg fat percentage left (UKB data field 23115)	1e-19	ZBTB7A - MAP2K2	39789286	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:4069294:C>A	chr19	4069294	4069428	134	rs350832	Body mass index	1e-17	ZBTB7A - MAP2K2	39375568	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:4069294:C>A	chr19	4069294	4069428	134	rs350832	Body fat percentage (UKB data field 23099)	5e-15	ZBTB7A - MAP2K2	39789286	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:4069294:C>A	chr19	4069294	4069428	134	rs350832	Alkaline phosphatase (UKB data field 30610)	2e-14	ZBTB7A - MAP2K2	39789286	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:43196174:C>A	chr2	43196174	43196040	134	rs35936219	Estimated glomerular filtration rate (cystatin c)	8e-14	LINC02580	39256582	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr19:4069294:C>A	chr19	4069294	4069428	134	rs350832	Metabolic syndrome	2e-13	ZBTB7A - MAP2K2	39349817	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:26394847:C>A	chr6	26394847	26394982	135	rs373476294	BTN3A2 protein levels	3e-37	BTN2A2 - BTN3A1	39789286	0.972161	583.0	JUN	6.5773e-06	High Impact, Hard to Access	3
chr18:62348567:A>C	chr18	62348567	62348702	135	rs11877530	Type 2 diabetes	2e-21	TNFRSF11A	35893037	0.9990358	575.0	FOSL2	1.96894e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:15673574:G>T	chr7	15673574	15673439	135	rs10046550	Standing height (UKB data field 50)	3e-13	MEOX2	39789286	0.9980294	484.5	MAFK	0.0	Low Priority	3
chr6:90140876:C>A	chr6	90140876	90141011	135	rs79005509	Height	4e-06	BACH2	28552196	0.9997353	9756.0	MAFK	3.28563e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:40451691:C>A	chr19	40451691	40451827	136	rs34288924	Height	6e-35	BLVRB	36224396	0.91684973	694.0	JUN	6.57281e-06	High Impact, Hard to Access	3
chr7:92952169:C>A	chr7	92952169	92952033	136	rs28393421	Height (baseline)	1e-11	CDK6-AS1 - RN7SL7P	40374629	0.9872979	440.25	MAFK	0.000145918	Accessible, Low Impact	3
chr8:4173786:A>C	chr8	4173786	4173923	137	rs149587005	Glucagon-like peptide-1 levels in overweight individuals	5e-08	CSMD1	34620218	0.99548393	522.5	FOSL2	6.57531e-06	Low Priority	3
chr8:137689702:C>G	chr8	137689702	137689565	137	rs11166746	Skeletal muscle index	3e-06	ZYXP1 - FAM135B	35241739	0.9470497	443.5	FOSL2	6.57436e-06	Low Priority	3
chr7:7262525:G>C	chr7	7262525	7262662	137	rs1299548	Visceral adipose tissue adjusted for BMI	4e-06	LINC03016	22589738	0.9957853	588.5	FOS	1.31401e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:72271341:C>A	chr4	72271341	72271203	138	rs7679388	Height	4e-20	NPFFR2 - ADAMTS3	36224396	0.96204376	422.5	BATF	1.31529e-05	Accessible, Low Impact	3
chr22:19553745:G>T	chr22	19553745	19553883	138	rs5748282	Pediatric bone mineral density (femoral neck)	4e-06	LINC00895	28181694	0.9545879	502.5	JUNB	0.0	Low Priority	3
chr1:117546580:T>A	chr1	117546580	117546719	139	rs2622363	CEACAM19 protein levels	3e-12	MAN1A2 - VPS25P1	39789286	0.9990358	882.0	ATF2	6.57091e-06	HIGH PRIORITY: Accessible + High Impact	2
chr20:50138880:C>A	chr20	50138880	50139019	139	rs232738	TestASV_43 (Parasutterella) prevalence	5e-06	PEDS1-UBE2V1, PEDS1	33462482	0.9971508	2876.0	FOSL2	6.5653e-06	High Impact, Hard to Access	3
chr8:96598525:G>C	chr8	96598525	96598665	140	rs2582801	Height	3e-18	SDC2	36224396	0.9808213	659.0	FOSL2	0.000111767	HIGH PRIORITY: Accessible + High Impact	3
chr9:84630160:A>C	chr9	84630160	84630020	140	rs72737616	Drinks per week	4e-12	SLC28A3 - NTRK2	36477530	0.9990792	653.5	FOS	6.56909e-06	High Impact, Hard to Access	3
chr10:12703509:G>T	chr10	12703509	12703649	140	rs61847363	Age of smoking initiation	7e-10	CAMK1D	36477530	0.98521286	740.0	JUNB	6.57022e-06	High Impact, Hard to Access	3
chr4:63682260:A>C	chr4	63682260	63682120	140	rs142722457	Appendicular skeletal muscle mass	5e-06	LARP1BP1 - TECRL	35241739	0.99746084	492.0	FOS	6.56556e-06	Low Priority	3
chr3:25007960:C>A	chr3	25007960	25007819	141	rs11129176	Height	1.9999999999999998e-54	RARB	36224396	0.999142	4136.0	JUNB	6.58155e-06	High Impact, Hard to Access	3
chr3:71633895:A>C	chr3	71633895	71633754	141	rs35987099	FEV1	3e-19	FOXP1-DT - EIF4E3	36641522	0.9992518	711.5	FOS	6.5697e-06	HIGH PRIORITY: Accessible + High Impact	2
chr3:25007960:C>A	chr3	25007960	25007819	141	rs11129176	Retinal thickness (pixel 38_18)	2e-14	RARB	39904976	0.999142	4136.0	JUNB	6.58155e-06	High Impact, Hard to Access	3
chr3:25007960:C>A	chr3	25007960	25007819	141	rs11129176	Optic disc area	2e-08	RARB	25631615	0.999142	4136.0	JUNB	6.58155e-06	High Impact, Hard to Access	3
chr3:25007960:C>A	chr3	25007960	25007819	141	rs11129176	Photoreceptor cell layer thickness phenotypes (MTAG)	2e-08	RARB	36848389	0.999142	4136.0	JUNB	6.58155e-06	High Impact, Hard to Access	3
chr3:25007960:C>A	chr3	25007960	25007819	141	rs11129176	Optic nerve head parameters (multi-trait analysis)	4e-08	RARB	31798171	0.999142	4136.0	JUNB	6.58155e-06	High Impact, Hard to Access	3
chr13:39409136:C>A	chr13	39409136	39408995	141	rs9576793	Circulating odd-numbered chain saturated fatty acid levels (C17:0)	1e-06	LHFPL6	29738550	0.9872979	479.0	FOS	1.9728e-05	Accessible, Low Impact	3
chr19:95840:G>T	chr19	95840	95981	141	rs8110113	Urinary uromodulin levels (indexed to creatinine)	5e-06	OR4G3P - OR4G1P	35228297	0.8263989	104.875	ATF2	0.0	Low Priority	3
chr10:133326648:C>G	chr10	133326648	133326506	142	rs532482218	ADAM8 protein levels	2e-43	ZNF511-PRAP1, CALY	39789286	0.95842487	561.0	FOSL1	1.97132e-05	Accessible, Low Impact	3
chr22:39492627:C>G	chr22	39492627	39492769	142	rs1033415	CNTNAP2 protein levels	9.000000000000001e-23	MGAT3 - MIEF1	39789286	0.9298287	652.0	FOSL2	6.56978e-06	HIGH PRIORITY: Accessible + High Impact	2
chr22:39492627:C>G	chr22	39492627	39492769	142	rs1033415	CHL1 protein levels	1e-16	MGAT3 - MIEF1	39789286	0.9298287	652.0	FOSL2	6.56978e-06	HIGH PRIORITY: Accessible + High Impact	2
chr22:39492627:C>G	chr22	39492627	39492769	142	rs1033415	LY75 protein levels	6e-12	MGAT3 - MIEF1	39789286	0.9298287	652.0	FOSL2	6.56978e-06	HIGH PRIORITY: Accessible + High Impact	2
chr8:66744664:C>A	chr8	66744664	66744806	142	rs571690420	Electrocardiogram morphology (amplitude at temporal datapoints)	5e-09	SGK3, C8orf44-SGK3	32916098	0.8626385	386.5	MAFG	6.65974e-06	Accessible, Low Impact	3
chr7:115039791:C>G	chr7	115039791	115039649	142	rs12706006	Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis)	3e-08	LINC01393	33349686	0.973383	433.0	JUND	6.57973e-06	Low Priority	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Cholesteryl ester levels in chylomicrons and extremely large VLDL	2e-17	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Triglycerides in small LDL	5e-17	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Total lipids in very large VLDL	9e-17	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Phospholipids in very large VLDL	1e-16	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Free cholesterol in very large VLDL	3e-16	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Phospholipids in large VLDL	3e-15	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr16:19907808:G>T	chr16	19907808	19907665	143	rs12102869	Insomnia	3e-14	GPRC5B - GPR139	35835914	0.9972855	2187.0	ATF2	6.57125e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Polyunsaturated fatty acids to total fatty acids percentage	2e-13	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr3:69813160:C>A	chr3	69813160	69813303	143	rs62251027	QT interval	2e-13	MITF	36050321	0.9838064	630.5	JUND	6.5735e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Triglycerides in medium LDL	7e-12	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Triglycerides in LDL	1e-11	BMAL1	41044249	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	HDL cholesterol	1e-10	BMAL1	30275531	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Omega-6 fatty acids to total fatty acids percentage	3e-10	BMAL1	40545721	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Iron status biomarkers (transferrin levels)	4e-10	BMAL1	25352340	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Polyunsaturated fatty acids to monounsaturated fatty acids ratio	2e-09	BMAL1	40545721	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	Monounsaturated fatty acid levels	3e-09	BMAL1	40545721	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334223	143	rs6486121	High density lipoprotein cholesterol levels	1e-08	BMAL1	34887591	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr6:159828036:T>A	chr6	159828036	159828179	143	rs36065083	Omega-6 fatty acids to total fatty acids percentage	2e-08	PNLDC1 - MAS1	40545721	0.97922516	957.0	ATF3	0.0	High Impact, Hard to Access	3
chr12:7721108:G>C	chr12	7721108	7720964	144	rs541506146	CLEC4C protein levels	4e-19	DPPA3 - CLEC4C	39789286	0.9897305	1308.75	JUN	6.57843e-06	High Impact, Hard to Access	3
chr3:13093945:G>C	chr3	13093945	13093800	145	rs11128633	Educational attainment	1e-08	IQSEC1	35361970	0.9961673	1030.0	ATF3	1.31413e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:13435472:C>A	chr8	13435472	13435617	145	rs145099037	Switch to non-stimulant treatment in ADHD	4e-06	DLC1	34154395	0.94045055	453.0	ATF3	6.57333e-06	Low Priority	3
chr4:9573645:C>A	chr4	9573645	9573790	145	rs759806869	Vertigo	7e-06	RPS3AP19 - SNRPCP13	34620984	0.961175	181.75	FOSL1	7.90564e-06	Accessible, Low Impact	3
chr11:62081229:C>A	chr11	62081229	62081083	146	rs259869	Docosahexaenoic acid to total fatty acids percentage	6e-16	LINC02733	40545721	0.9383409	582.5	JUNB	1.31572e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:62081229:C>A	chr11	62081229	62081083	146	rs259869	Degree of unsaturation	1e-14	LINC02733	40545721	0.9383409	582.5	JUNB	1.31572e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:62081229:C>A	chr11	62081229	62081083	146	rs259869	Linoleic acid levels	1e-12	LINC02733	40545721	0.9383409	582.5	JUNB	1.31572e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:62081229:C>A	chr11	62081229	62081083	146	rs259869	Polyunsaturated fatty acids to monounsaturated fatty acids ratio	1e-09	LINC02733	40545721	0.9383409	582.5	JUNB	1.31572e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:62081229:C>A	chr11	62081229	62081083	146	rs259869	Monounsaturated fatty acids to total fatty acids percentage	2e-08	LINC02733	40545721	0.9383409	582.5	JUNB	1.31572e-05	HIGH PRIORITY: Accessible + High Impact	3
chr20:59460024:C>A	chr20	59460024	59459877	147	rs541204244	Nonrheumatic tricuspid valve disorders (PheCode 395.3)	8e-13	EDN3 - PIEZO1P1	39024449	0.9637244	640.0	FOS	0.000236609	HIGH PRIORITY: Accessible + High Impact	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Waist-to-hip ratio adjusted for body mass index	3e-27	LYPLAL1-AS1	28448500	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	6e-26	LYPLAL1-AS1	28448500	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Waist-to-hip ratio adjusted for BMI in active individuals	2e-21	LYPLAL1-AS1	28448500	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Body mass index or hip osteoarthritis (pleiotropy)	2e-15	LYPLAL1-AS1	36889626	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Umbilical hernia	3e-15	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Osteoarthritis (hospital diagnosed)	2e-09	LYPLAL1-AS1	29559693	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Fasting insulin	4e-09	LYPLAL1-AS1	33402679	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Inguinal hernia	5e-09	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Osteoarthritis (hip)	9e-09	LYPLAL1-AS1	30374069	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Osteoarthritis of the hip or knee (hospital diagnosed)	2e-08	LYPLAL1-AS1	29559693	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Body mass index	4e-08	LYPLAL1-AS1	29381148	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Waist-to-hip ratio adjusted for BMI in inactive individuals	5e-07	LYPLAL1-AS1	28448500	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Osteoarthritis	1e-06	LYPLAL1-AS1	30664745	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467338	148	rs2820436	Osteoarthritis of the hip (hospital diagnosed)	6e-06	LYPLAL1-AS1	29559693	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr6:127095181:C>G	chr6	127095181	127095330	149	rs2800732	Glucose levels (UKB data field 30740)	2e-14	RPS4XP9 - RSPO3	39789286	0.9756724	625.0	FOS	6.59118e-06	High Impact, Hard to Access	3
chr8:18014241:A>C	chr8	18014241	18014089	152	rs13266287	Educational attainment (years of education)	2e-08	PCM1	30038396	0.97511876	584.0	FOS	1.97163e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:135204412:C>G	chr6	135204412	135204258	154	rs3819409	Serum IgE levels	2e-12	MYB	38199299	0.96744037	767.0	ATF3	6.57436e-06	High Impact, Hard to Access	3
chr8:69031094:T>A	chr8	69031094	69031249	155	rs117052263	Gamma-glutamyl-alpha-lysine levels	4e-06	LINC01592	40360795	0.9715297	461.0	JUND	6.57696e-06	Low Priority	3
chr3:186365850:G>C	chr3	186365850	186365694	156	rs73182224	Chronic obstructive pulmonary disease liability (machine learning-based score)	5e-16	DGKG - LINC02020	37069358	0.9987857	2557.0	FOSL2	6.56935e-06	High Impact, Hard to Access	3
chr3:186365850:G>C	chr3	186365850	186365694	156	rs73182224	Lung function (FEV1/FVC)	8e-15	DGKG - LINC02020	30595370	0.9987857	2557.0	FOSL2	6.56935e-06	High Impact, Hard to Access	3
chr3:186365850:G>C	chr3	186365850	186365694	156	rs73182224	Forced expiratory volume in 1 second FEV1 Z score (UKB data field 20256)	3e-13	DGKG - LINC02020	39789286	0.9987857	2557.0	FOSL2	6.56935e-06	High Impact, Hard to Access	3
chr11:62067960:T>A	chr11	62067960	62067803	157	rs148047529	Omega-3 fatty acids to Omega-6 fatty acids ratio	1e-12	LINC02733	40545721	0.8243095	469.5	FOSL2	6.57263e-06	Low Priority	3
chr11:62067960:T>A	chr11	62067960	62067803	157	rs148047529	Omega-3 fatty acids to total fatty acids percentage	2e-12	LINC02733	40545721	0.8243095	469.5	FOSL2	6.57263e-06	Low Priority	3
chr7:153318564:C>G	chr7	153318564	153318407	157	rs540750275	Phobia (PheCode 300.13)	1e-11	ACTR3B - LINC01287	39024449	0.9430595	470.0	MAFK	1.31477e-05	Accessible, Low Impact	3
chr11:62067960:T>A	chr11	62067960	62067803	157	rs148047529	Omega-3 fatty acid levels	6e-11	LINC02733	40545721	0.8243095	469.5	FOSL2	6.57263e-06	Low Priority	3
chr6:149597849:A>C	chr6	149597849	149598007	158	rs9322193	Lung cancer	1e-07	KATNA1	27393504	0.99875736	675.0	FOS	0.00015765	HIGH PRIORITY: Accessible + High Impact	3
chr9:135486852:G>T	chr9	135486852	135487010	158	rs2078266	Schizophrenia	2e-07	PPP1R26	35396580	0.9396624	675.0	JUND	1.31432e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:90012108:G>T	chr15	90012108	90011949	159	rs187856913	Mean platelet thrombocyte volume (UKB data field 30100)	9.999999999999999e-26	ZNF710	39789286	0.96686935	726.5	ATF2	6.58077e-06	High Impact, Hard to Access	3
chr15:90012108:G>T	chr15	90012108	90011949	159	rs187856913	Lymphocyte count	3e-16	ZNF710	32888494	0.96686935	726.5	ATF2	6.58077e-06	High Impact, Hard to Access	3
chr12:103069021:C>A	chr12	103069021	103069180	159	rs147557133	STAB2 protein levels	7e-15	ASCL1 - C12orf42-AS1	39789286	0.68165225	269.125	FOS	0.0	Low Priority	3
chr3:46960340:C>A	chr3	46960340	46960500	160	rs7628747	White blood cell count	1e-09	CCDC12	29403010	0.9978927	2619.0	JUN	6.57091e-06	High Impact, Hard to Access	3
chr19:40864433:C>G	chr19	40864433	40864271	162	rs113029345	Nicotine metabolite ratio in current smokers	1e-41	CYP2A6 - CYP2A7	27488534	0.9982064	2178.0	ATF3	0.423847	HIGH PRIORITY: Accessible + High Impact	3
chr19:40864433:C>G	chr19	40864433	40864271	162	rs113029345	Post bronchodilator FEV1	8e-08	CYP2A6 - CYP2A7	26634245	0.9982064	2178.0	ATF3	0.423847	HIGH PRIORITY: Accessible + High Impact	3
chr19:40864433:C>G	chr19	40864433	40864271	162	rs113029345	Post bronchodilator FEV1/FVC ratio	2e-06	CYP2A6 - CYP2A7	26634245	0.9982064	2178.0	ATF3	0.423847	HIGH PRIORITY: Accessible + High Impact	3
chr8:95405120:C>G	chr8	95405120	95404957	163	rs7825742	Height	1e-15	CFAP418-AS1	30595370	0.9071543	404.25	MAFK	1.98547e-05	Accessible, Low Impact	3
chr9:123787333:G>C	chr9	123787333	123787170	163	rs5900587	Major depressive disorder (broad)	7e-11	DENND1A	38177345	0.994571	755.0	FOSL2	1.31506e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:207720600:C>A	chr1	207720600	207720437	163	rs2761424	Height	2e-08	CR1L	36224396	0.9854257	709.0	BATF	6.57393e-06	High Impact, Hard to Access	3
chr1:77771042:C>A	chr1	77771042	77771206	164	rs61777140	Total cholesterol levels	4e-13	USP33 - ACTG1P21	36333282	0.99364895	1343.0	JUNB	0.000262843	HIGH PRIORITY: Accessible + High Impact	3
chr1:77771042:C>A	chr1	77771042	77771206	164	rs61777140	Height (baseline)	4e-12	USP33 - ACTG1P21	40374629	0.99364895	1343.0	JUNB	0.000262843	HIGH PRIORITY: Accessible + High Impact	3
chr13:52984332:C>G	chr13	52984332	52984168	164	rs1323110	Educational attainment	3e-11	PCDH8 - OLFM4	35361970	0.9830546	637.0	JUND	1.97231e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:77771042:C>A	chr1	77771042	77771206	164	rs61777140	Platelet count during  third trimester of pregnancy	5e-08	USP33 - ACTG1P21	38064665	0.99364895	1343.0	JUNB	0.000262843	HIGH PRIORITY: Accessible + High Impact	3
chr3:73151038:G>C	chr3	73151038	73151202	164	rs145241697	Systolic blood pressure	4e-06	RNU2-64P - GPATCH11P1	38104120	0.9972791	610.5	FOS	6.595e-06	High Impact, Hard to Access	3
chr2:207258495:C>A	chr2	207258495	207258660	165	rs10804157	Uterine fibroids	7e-12	MYOSLID-AS1, LINC01802	40050615	0.99930274	2607.0	JUNB	6.57022e-06	High Impact, Hard to Access	3
chr2:207258495:C>A	chr2	207258495	207258660	165	rs10804157	Uterine leiomyomata	4e-09	MYOSLID-AS1, LINC01802	36726022	0.99930274	2607.0	JUNB	6.57022e-06	High Impact, Hard to Access	3
chr3:63064716:C>A	chr3	63064716	63064551	165	rs7644552	Body mass index	4e-08	LINC00698	31669095	0.97511876	582.0	JUN	0.0103491	HIGH PRIORITY: Accessible + High Impact	3
chr15:97698518:A>C	chr15	97698518	97698683	165	rs7166685	Vaginal microbiome MetaCyc pathway (PWY-6396|superpathway of 2,3-butanediol biosynthesis)	2e-06	LINC00923	34282934	0.99606663	572.0	FOS	6.57263e-06	HIGH PRIORITY: Accessible + High Impact	2
chr19:9075019:C>A	chr19	9075019	9074853	166	rs4581824	Stromal-cell-derived factor 1 alpha levels	3e-06	BOLA3P2 - OR1M4P	27989323	0.9998084	1166.5	FOS	6.57237e-06	High Impact, Hard to Access	3
chr11:111054155:C>A	chr11	111054155	111054321	166	rs61902591	Body mass index	9e-06	RNA5SP350 - LINC02550	35051171	0.9704257	368.0	FOS	6.5697e-06	Low Priority	3
chr8:10580191:G>C	chr8	10580191	10580358	167	rs13250449	Serum alkaline phosphatase levels	2e-18	PRSS55 - RP1L1	33462484	0.99939203	1206.0	FOS	6.57462e-06	High Impact, Hard to Access	3
chr9:4298409:A>C	chr9	4298409	4298576	167	rs12350099	Osteoarthritis of the hip or knee (with total joint replacement)	4e-13	GLIS3	40205036	0.98996234	2186.0	JUN	0.000111678	HIGH PRIORITY: Accessible + High Impact	2
chr16:88477810:G>C	chr16	88477810	88477643	167	rs12447514	QRS duration	1e-10	ZFPM1	36050321	0.99937785	1042.0	FOS	6.56676e-06	High Impact, Hard to Access	3
chr8:10580191:G>C	chr8	10580191	10580358	167	rs13250449	Pizza liking	9e-10	PRSS55 - RP1L1	35585065	0.99939203	1206.0	FOS	6.57462e-06	High Impact, Hard to Access	3
chr9:4298409:A>C	chr9	4298409	4298576	167	rs12350099	Osteoarthritis	6e-08	GLIS3	36411363	0.98996234	2186.0	JUN	0.000111678	HIGH PRIORITY: Accessible + High Impact	2
chr19:18276172:G>C	chr19	18276172	18276004	168	rs6146484	Impedance of arm right (UKB data field 23109)	1e-19	IQCN - JUND	39789286	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr19:18276172:G>C	chr19	18276172	18276004	168	rs6146484	Impedance of whole body (UKB data field 23106)	2e-17	IQCN - JUND	39789286	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr19:18276172:G>C	chr19	18276172	18276004	168	rs6146484	Impedance of arm left (UKB data field 23110)	2e-15	IQCN - JUND	39789286	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr19:18276172:G>C	chr19	18276172	18276004	168	rs6146484	FNDC1 protein levels	3e-13	IQCN - JUND	39789286	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr19:18276172:G>C	chr19	18276172	18276004	168	rs6146484	Creatinine levels (UKB data field 30700)	3e-13	IQCN - JUND	39789286	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr19:18276172:G>C	chr19	18276172	18276004	168	rs6146484	Appendicular lean mass	9e-10	IQCN - JUND	31761296	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr8:11590002:C>G	chr8	11590002	11590170	168	rs7823651	Sib-shared facial trait 976; Facial segment 60; 3D morphology of the eye sockets	2e-08	LINC00208 - GATA4	33983923	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr5:154442951:T>A	chr5	154442951	154442782	169	rs11167682	12-lead ECG morphology phenotype	5e-11	SAP30L-AS1	38180560	0.9946945	882.5	ATF3	6.57099e-06	High Impact, Hard to Access	3
chr9:117835973:A>C	chr9	117835973	117836142	169	rs10983813	Insomnia	5e-10	TLR4 - TPT1P9	35835914	0.99999	11832.0	JUNB	6.56927e-06	HIGH PRIORITY: Accessible + High Impact	2
chr5:165946374:G>C	chr5	165946374	165946205	169	rs26442	Self-reported math ability	6e-10	RPL21P59 - RPL7P20	30038396	0.99035496	355.0	FOSL2	6.58918e-06	Low Priority	3
chr17:7124123:C>A	chr17	7124123	7123954	169	rs1961524	IL10 levels	3e-06	ASGR2 - RPL7AP64	38326779	0.9479486	520.5	FOS	6.57125e-06	Low Priority	3
chr8:60794996:C>A	chr8	60794996	60795166	170	rs4540437	Free androgen index	6e-21	CHD7	36653534	0.98618805	613.0	JUND	1.31548e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:49348784:G>C	chr3	49348784	49348614	170	rs62259939	Whole body fat mass (UKB data field 23100)	2e-12	USP4 - GPX1	38538606	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr3:49348784:G>C	chr3	49348784	49348614	170	rs62259939	Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy)	5e-11	USP4 - GPX1	35764056	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr3:42866090:C>G	chr3	42866090	42865920	170	rs141413113	Blood cell traits latent factor 7 (white cell)	2e-10	ACKR2, CYP8B1	40220762	0.9584504	501.5	MAFK	6.57748e-06	Low Priority	3
chr3:42866090:C>G	chr3	42866090	42865920	170	rs141413113	Lymphocyte percentage of white cells	2e-09	ACKR2, CYP8B1	27863252	0.9584504	501.5	MAFK	6.57748e-06	Low Priority	3
chr7:48201161:C>A	chr7	48201161	48200991	170	rs35878068	Progression free survival in serous epithelial ovarian cancer	9e-06	ABCA13	34162658	0.9937929	970.0	MAFK	6.57117e-06	High Impact, Hard to Access	3
chr6:149597849:A>C	chr6	149597849	149598020	171	rs77261077	LRP11 protein levels	4.0000000000000004e-24	KATNA1	39789286	0.99875736	675.0	FOS	0.00015765	HIGH PRIORITY: Accessible + High Impact	3
chr18:27113430:C>G	chr18	27113430	27113257	173	rs12607664	Circulating plasma alpha-Klotho levels	2e-27	CHST9, AQP4-AS1	34542150	0.90755373	448.0	FOS	6.58129e-06	Low Priority	3
chr4:160809673:C>A	chr4	160809673	160809846	173	rs7439403	Educational attainment	3e-08	LINC02477 - RPS14P7	35361970	0.9430595	306.0	JUNB	6.65611e-06	Accessible, Low Impact	3
chr19:4069294:C>A	chr19	4069294	4069121	173	rs7254272	Chronic lymphocytic leukemia	5e-08	ZBTB7A - MAP2K2	28165464	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:155119779:C>G	chr5	155119779	155119605	174	rs139708138	Congenital anomalies of the eye (PheCode 753)	2e-11	RPL6P32 - RNA5SP199	39024449	0.92557216	475.0	FOSL1	1.97143e-05	Accessible, Low Impact	3
chr16:56978292:C>A	chr16	56978292	56978467	175	rs12708980	HDL cholesterol	2.0000000000000002e-28	CETP	21909109	0.90755373	693.5	FOSL1	2.63241e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:56978292:C>A	chr16	56978292	56978467	175	rs12708980	Height	5e-18	CETP	36224396	0.90755373	693.5	FOSL1	2.63241e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:109160576:C>A	chr1	109160576	109160401	175	rs1337247	Familial combined hyperlipidemia defined by Consensus criteria	6e-12	ELAPOR1	34906840	0.98266596	738.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:28279587:C>A	chr8	28279587	28279412	175	rs12680508	Weight (mean, inv-normal transformed)	1e-11	ELP3 - RPL5P22	39024449	0.8209431	354.5	ATF3	0.0	Low Priority	3
chr1:109160576:C>A	chr1	109160576	109160401	175	rs1337247	Familial combined hyperlipidemia defined by Mexico criteria	2e-08	ELAPOR1	34906840	0.98266596	738.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:4731490:G>T	chr4	4731490	4731665	175	rs4689926	Inguinal hernia	2e-08	STX18-AS1	34382107	0.8791271	473.0	JUND	3.94285e-05	Accessible, Low Impact	3
chr1:109160576:C>A	chr1	109160576	109160401	175	rs1337247	Familial combined hyperlipidemia defined by Dutch criteria	5e-08	ELAPOR1	34906840	0.98266596	738.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:56978292:C>A	chr16	56978292	56978467	175	rs12708980	High density lipoprotein cholesterol levels	1e-07	CETP	31217584	0.90755373	693.5	FOSL1	2.63241e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:56978292:C>A	chr16	56978292	56978467	175	rs12708980	Low HDL-cholesterol levels	2e-06	CETP	31910446	0.90755373	693.5	FOSL1	2.63241e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:56978292:C>A	chr16	56978292	56978467	175	rs12708980	Hypertriglyceridemia	3e-06	CETP	31910446	0.90755373	693.5	FOSL1	2.63241e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:22198187:T>A	chr1	22198187	22198362	175	rs145302900	Acute radiotoxicity in prostate cancer	4e-06	WNT4 - MIR4418	37862240	0.9986684	557.0	ATF2	0.000223203	Accessible, Low Impact	2
chr1:109160576:C>A	chr1	109160576	109160401	175	rs1337247	Familial combined hyperlipidemia defined by Brunzell criteria	5e-06	ELAPOR1	34906840	0.98266596	738.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:99304471:G>C	chr11	99304471	99304647	176	rs1461672	Contactin-5 levels	2e-18	CNTN5	28240269	0.9383409	523.0	FOSL1	6.57298e-06	Low Priority	3
chr4:102283377:G>T	chr4	102283377	102283201	176	rs233821	Central nucleus volume	7e-17	SLC39A8	37391117	0.97968936	476.0	JUND	6.57471e-06	Low Priority	3
chr4:102283377:G>T	chr4	102283377	102283201	176	rs233821	Anterior amygdaloid area volume	6e-12	SLC39A8	37391117	0.97968936	476.0	JUND	6.57471e-06	Low Priority	3
chr2:36602791:C>A	chr2	36602791	36602615	176	rs13026635	High-density lipoprotein levels	9e-11	FEZ2	40436827	0.9840279	363.5	FOS	1.31413e-05	Accessible, Low Impact	3
chr10:79350727:C>A	chr10	79350727	79350551	176	rs1316313	Hip circumference adjusted for BMI	2e-10	PPIF	34021172	0.9964944	1053.0	FOS	6.56978e-06	High Impact, Hard to Access	3
chr4:54502439:C>A	chr4	54502439	54502615	176	rs13151013	Gut microbial network clusters (Pink (at 1 year) x Homesmokers interaction	5e-10	LINC02283 - LINC02260	40187613	0.925176	455.0	JUND	6.57177e-06	Low Priority	3
chr1:231761380:C>A	chr1	231761380	231761557	177	rs1538977	General cognitive ability	3e-06	DISC1, TSNAX-DISC1	29844566	0.9327804	465.0	JUND	6.57186e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55783338	178	rs10496052	Inguinal hernia	3e-35	PNPT1 - EFEMP1	34382107	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr15:28315754:G>T	chr15	28315754	28315576	178	rs77572354	Blond vs. brown/black hair color	8e-12	HERC2	30531825	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr17:78382610:T>A	chr17	78382610	78382788	178	rs11656568	Severe COVID-19 infection	8e-06	PGS1	36662838	0.9986684	1528.0	FOSL1	6.58579e-06	High Impact, Hard to Access	3
chr4:139213684:C>G	chr4	139213684	139213505	179	rs6820313	Height	3.9999999999999997e-25	Y_RNA - RNU6-506P	36224396	0.9830546	827.0	JUNB	1.3195e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:69445867:A>C	chr8	69445867	69445688	179	rs555310482	Nontoxic nodular goiter (PheCode 241)	8e-21	LINC01603	39024449	0.9409573	501.0	FOSL2	6.56858e-06	Accessible, Low Impact	2
chr11:77806748:C>A	chr11	77806748	77806927	179	rs75713100	Sex hormone-binding globulin levels and heel estimated bone mineral density	7e-16	RSF1	37615194	0.99347407	1120.0	FOS	6.60816e-06	High Impact, Hard to Access	3
chr11:77806748:C>A	chr11	77806748	77806927	179	rs75713100	Sex hormone-binding globulin levels adjusted for BMI and heel estimated bone mineral density	3e-14	RSF1	37615194	0.99347407	1120.0	FOS	6.60816e-06	High Impact, Hard to Access	3
chr7:20399750:G>T	chr7	20399750	20399929	179	rs34436326	Vertex-wise sulcal depth	9e-11	ITGB8	34910505	0.9972157	1054.0	ATF2	6.57583e-06	High Impact, Hard to Access	3
chr11:77806748:C>A	chr11	77806748	77806927	179	rs75713100	Diastolic blood pressure	2e-10	RSF1	40436827	0.99347407	1120.0	FOS	6.60816e-06	High Impact, Hard to Access	3
chr11:77806748:C>A	chr11	77806748	77806927	179	rs75713100	Sex hormone-binding globulin levels	3e-10	RSF1	32042192	0.99347407	1120.0	FOS	6.60816e-06	High Impact, Hard to Access	3
chr11:77806748:C>A	chr11	77806748	77806927	179	rs75713100	Sex hormone-binding globulin levels adjusted for BMI	4e-09	RSF1	32042192	0.99347407	1120.0	FOS	6.60816e-06	High Impact, Hard to Access	3
chr7:20399750:G>T	chr7	20399750	20399929	179	rs34436326	Vertex-wise cortical surface area	4e-08	ITGB8	34910505	0.9972157	1054.0	ATF2	6.57583e-06	High Impact, Hard to Access	3
chr2:124683854:C>A	chr2	124683854	124683675	179	rs191947856	Post bronchodilator FEV1/FVC ratio	2e-06	CNTNAP5	26634245	0.9928779	1324.5	MAFK	2.62978e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:15035391:C>A	chr4	15035391	15035212	179	rs71648192	Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis	4e-06	CPEB2, C1QTNF7-AS1	32009195	0.99319685	980.0	JUNB	6.57583e-06	High Impact, Hard to Access	3
chr1:159538399:G>T	chr1	159538399	159538219	180	rs75285799	Monocyte chemoattractant protein-1 levels	1.9999999999999998e-26	LINC02819	33227023	0.94045055	548.5	JUN	6.57004e-06	Low Priority	3
chr9:4298409:A>C	chr9	4298409	4298589	180	rs35338539	UMOD protein levels	4e-17	GLIS3	39789286	0.98996234	2186.0	JUN	0.000111678	HIGH PRIORITY: Accessible + High Impact	2
chr17:48210360:G>T	chr17	48210360	48210179	181	rs12150533	Endometriosis	9e-12	SKAP1	37544299	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Waist-to-hip ratio adjusted for BMI	2e-15	PEMT	34021172	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Waist-hip index	2e-15	PEMT	34021172	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Total lipids in large HDL	1e-14	PEMT	41044249	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Phospholipids in large HDL	3e-14	PEMT	41044249	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Free cholesterol in large HDL	7e-14	PEMT	41044249	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Apolipoprotein A1 levels	2e-10	PEMT	32203549	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Gluteofemoral adipose tissue volumes (adjusted for BMI and height)	2e-10	PEMT	35773277	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr7:2709449:C>A	chr7	2709449	2709267	182	rs58748470	Hip circumference adjusted for BMI	2e-09	AMZ1	34021172	0.9978883	1251.0	JUNB	4.29332e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:75104650:G>C	chr15	75104650	75104468	182	rs12910558	Blood cell traits latent factor 20 (red cell)	2e-08	PPCDC	40220762	0.9944446	1816.0	FOS	6.5825e-06	High Impact, Hard to Access	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	A body shape index	4e-08	PEMT	34021172	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr17:17552060:G>C	chr17	17552060	17551878	182	rs8075019	Hip index	5e-08	PEMT	34021172	0.95348793	598.0	JUN	0.0292665	HIGH PRIORITY: Accessible + High Impact	3
chr9:79035549:G>T	chr9	79035549	79035732	183	rs7043998	Educational attainment	4e-11	MTND2P8 - KRT18P24	35361970	0.9820924	541.0	ATF7	6.56685e-06	Low Priority	3
chr2:77881974:C>G	chr2	77881974	77881791	183	rs10202675	Facial morphology	4e-08	RPL38P2 - LINC01851	31763980	0.8940993	398.5	MAFK	6.65814e-06	Accessible, Low Impact	3
chr7:38928723:G>C	chr7	38928723	38928540	183	rs1534417	Colorectal cancer x estrogen-progesterone hormone therapy interaction	2e-07	VPS41	35512400	0.98786724	482.0	ATF3	1.31378e-05	Accessible, Low Impact	3
chr14:52311078:G>C	chr14	52311078	52310895	183	rs1254603	Adolescent idiopathic scoliosis	1e-06	PTGDR - PTGER2	30019117	0.9820924	458.0	FOSL2	0.000236602	Accessible, Low Impact	3
chr7:38928723:G>C	chr7	38928723	38928540	183	rs1534417	Colorectal cancer x estrogen-progesterone hormone therapy interaction (2df test)	1e-06	VPS41	35512400	0.98786724	482.0	ATF3	1.31378e-05	Accessible, Low Impact	3
chr7:38928723:G>C	chr7	38928723	38928540	183	rs1534417	Colorectal cancer x estrogen-progesterone hormone therapy interaction (3df test)	3e-06	VPS41	35512400	0.98786724	482.0	ATF3	1.31378e-05	Accessible, Low Impact	3
chr2:218424360:G>C	chr2	218424360	218424176	184	rs3731866	Height	1e-22	VIL1	31562340	0.9990358	1076.0	FOSL1	6.57168e-06	High Impact, Hard to Access	3
chr3:73193440:T>A	chr3	73193440	73193256	184	rs186503563	Arthropathy associated with other disorders (PheCode 713)	3e-13	GPATCH11P1 - RNU6-1270P	39024449	0.9396624	531.5	ATF3	0.0	Low Priority	3
chr3:27359707:A>C	chr3	27359707	27359523	184	rs9870054	Diastolic blood pressure	3e-11	NEK10	40436827	0.9958938	1448.0	FOS	1.31397e-05	HIGH PRIORITY: Accessible + High Impact	2
chr17:18850741:C>A	chr17	18850741	18850557	184	rs4924935	Height	3e-10	PRPSAP2	36224396	0.97534883	607.0	BATF	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:18850741:C>A	chr17	18850741	18850557	184	rs4924935	Pancreatic cancer	8e-06	PRPSAP2	20686608	0.97534883	607.0	BATF	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:62133669:G>C	chr12	62133669	62133853	184	rs1245440	Solar lentigines (non-facial)	9e-06	TAFA2	38029837	0.9996424	1530.0	FOSL2	6.57808e-06	High Impact, Hard to Access	3
chr4:96995344:G>T	chr4	96995344	96995529	185	rs111877695	Alkenylphosphatidylethanolamine (P-19:0/20:4) (a) levels	4e-08	COX7A2P2 - STPG2	35668104	0.93699247	506.5	FOS	0.000176274	Accessible, Low Impact	3
chr12:101844165:G>T	chr12	101844165	101844351	186	rs11111055	Cathepsin F levels	4.999999999999999e-32	RNA5SP369 - RNU6-1183P	34648354	0.99944633	9277.5	ATF2	6.58224e-06	High Impact, Hard to Access	3
chr1:177960180:G>C	chr1	177960180	177960366	186	rs34246968	Body mass index	6e-16	CRYZL2P-SEC16B, SEC16B	36581621	0.9991015	5013.0	MAFK	6.57263e-06	High Impact, Hard to Access	3
chr11:74719243:C>A	chr11	74719243	74719057	186	rs11236228	Blood protein levels	1e-15	CHRDL2	30072576	0.9036088	566.5	FOSL1	1.31463e-05	Accessible, Low Impact	3
chr5:149992707:G>T	chr5	149992707	149992893	186	rs139840241	Monocyte percentage (UKB data field 30190)	7e-12	SLC26A2	39789286	0.9928779	662.0	JUND	1.97192e-05	HIGH PRIORITY: Accessible + High Impact	2
chr16:24151247:C>A	chr16	24151247	24151061	186	rs395897	Self-reported math ability (MTAG)	6e-09	PRKCB	30038396	0.9782654	576.5	JUN	1.97169e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:27042805:G>C	chr15	27042805	27042618	187	rs8031551	Kynurenate levels in elite athletes	3e-07	GABRG3-AS1, GABRG3	31882771	0.9983231	644.0	FOS	0.000603889	HIGH PRIORITY: Accessible + High Impact	3
chr16:89504699:C>G	chr16	89504699	89504511	188	rs113849132	Red vs non-red hair color	2e-09	SPG7	36672889	0.9593788	1160.0	MAFK	6.58631e-06	High Impact, Hard to Access	3
chr14:51360658:A>C	chr14	51360658	51360847	189	rs2356894	Height	3e-22	LINC00640	36224396	0.99954957	1561.0	JUNB	1.31432e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:134511454:C>A	chr2	134511454	134511265	189	rs60802178	Triglyceride to HDL cholesterol ratio	8e-06	TMEM163	38200128	0.9131995	675.0	BATF2	6.56996e-06	High Impact, Hard to Access	3
chr7:94392616:C>A	chr7	94392616	94392806	190	rs3763467	Appendicular lean mass	3e-18	BET1-AS1 - COL1A2	33097823	0.9992343	1133.0	BATF	6.57402e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93921599	190	rs143779661	Metabolonic lactone sulfate levels	5e-09	GNGT1 - GNG11	34563731	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome relative abundance (s_Dialister propionicifaciens)	5e-09	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome relative abundance (s_Peptoniphilus vaginalis)	2e-07	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome relative abundance (g_Peptoniphilus)	2e-07	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:9703553:C>A	chr12	9703553	9703362	191	rs11052552	Type 1 diabetes	7e-07	CLEC2D - LINC02390	17554300	0.9131995	397.75	FOS	6.57877e-06	Low Priority	3
chr2:62341119:C>A	chr2	62341119	62341310	191	rs6759298	Ankylosing spondylitis	2e-06	RN7SL51P - RN7SL18P	23749187	0.99812186	3287.0	BATF	6.57341e-06	High Impact, Hard to Access	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome MetaCyc pathway (PWY-7332|superpathway of UDP-N-acetylglucosamine-derived O-antigen building blocks biosynthesis)	3e-06	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:204083300:G>C	chr1	204083300	204083109	191	rs77930975	RS-10-hydroxywarfarin to RS-warfarin ratio	5e-06	SOX13	36210801	0.946766	670.0	FOS	6.57358e-06	High Impact, Hard to Access	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome MetaCyc pathway (PWY-6397|mycolyl-arabinogalactan-peptidoglycan complex biosynthesis)	5e-06	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:4414882:G>T	chr4	4414882	4414691	191	rs73199814	Bacterial meningitis	5e-06	NSG1	28928442	0.95842487	805.0	FOSL2	1.31622e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome relative abundance (s_Finegoldia magna)	7e-06	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome relative abundance (f_Peptostreptococcales-Tissierellales)	9e-06	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:109224985:C>A	chr4	109224985	109225176	191	rs117189532	Vaginal microbiome relative abundance (o_Campylobacterales)	9e-06	COL25A1	34282934	0.98521286	802.0	MAFG	1.31593e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:239934911:G>T	chr1	239934911	239934719	192	rs7523792	Memory decline in impaired cognition	1e-06	CHRM3-AS1	37984853	0.8930825	396.0	FOS	0.21642	Accessible, Low Impact	3
chr12:56004211:G>C	chr12	56004211	56004018	193	rs141735896	SUOX protein levels	3e-18	SUOX	39789286	0.9988404	1176.0	FOS	3.94265e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:26172512:C>A	chr9	26172512	26172705	193	rs2571511	Pursuit maintenance gain	5e-06	LINC03106 - CAAP1	29064472	0.99254405	570.5	JUND	6.57151e-06	High Impact, Hard to Access	3
chr5:179321131:C>A	chr5	179321131	179320938	193	rs163497	NK-cell telomere length	8e-06	ADAMTS2	35681050	0.80697334	486.0	FOSL1	6.57748e-06	Low Priority	3
chr2:213064644:C>G	chr2	213064644	213064450	194	rs116399861	DNA methylation variation (age effect)	4e-08	IKZF2	30348214	0.99164	541.0	JUND	6.57938e-06	Low Priority	3
chr1:91889794:C>G	chr1	91889794	91889599	195	rs12032588	Pulse pressure	2e-09	TGFBR3	35762941	0.9644045	652.25	JUNB	6.69478e-06	HIGH PRIORITY: Accessible + High Impact	3
chr2:24758891:G>T	chr2	24758891	24759086	195	rs56226330	Pregnenolone sulfate levels	5e-09	NCOA1	36357675	0.97898656	580.0	ATF3	6.5786e-06	High Impact, Hard to Access	3
chr5:14773405:G>T	chr5	14773405	14773208	197	rs116017108	Protein quantitative trait loci (liver)	8e-12	ANKH	32778093	0.9470497	520.5	MAFK	0.0	Low Priority	3
chr8:125618697:C>A	chr8	125618697	125618895	198	rs1551393	Metabolic syndrome	4e-18	TRIB1AL - LINC02964	39349817	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:85034114:C>G	chr7	85034114	85033916	198	rs11771699	Lung function (FVC)	2e-16	SEMA3D	30595370	0.9555776	463.0	JUND	6.58068e-06	Low Priority	3
chr1:1774704:G>C	chr1	1774704	1774506	198	rs11260629	Lung function (FVC)	3e-11	NADK	30595370	0.9994327	1320.0	FOS	6.57134e-06	High Impact, Hard to Access	3
chr17:63827693:G>C	chr17	63827693	63827891	198	rs186941288	Genu valgum or varum (acquired) (PheCode 736.4)	3e-11	PSMC5, FTSJ3	39024449	0.9996589	5228.0	MAFF	1.97047e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Omega-6 fatty acid levels	9.000000000000001e-23	POLR1HASP	40545721	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Linoleic acid levels	1e-22	POLR1HASP	40545721	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Polyunsaturated fatty acid levels	2e-13	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Monounsaturated fatty acids to total fatty acids percentage	1e-11	POLR1HASP	40545721	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Concentration of medium HDL particles	2e-11	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Cognitive function (baseline)	7e-11	POLR1HASP	40374629	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Apolipoprotein A1 levels	9e-11	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Phosphoglycerides levels	3e-10	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	A body shape index	4e-10	POLR1HASP	34021172	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Concentration of HDL particles	4e-10	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Free cholesterol levels in medium HDL	5e-10	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr13:59312845:G>C	chr13	59312845	59313044	199	rs1326098	Metabolic syndrome	7e-10	RPP40P2 - RNU7-88P	39349817	0.97922516	876.0	MAFK	6.56918e-06	High Impact, Hard to Access	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Cholesterol levels in medium HDL	2e-09	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Total concentration of lipoprotein particles	2e-09	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Phosphatidylcholine levels	3e-09	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Phospholipids to total lipids ratio in small LDL	1e-08	POLR1HASP	35213538	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Help-seeking from a GP (without major depressive disorder symptoms)	5e-08	POLR1HASP	32231276	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:30003382:G>T	chr6	30003382	30003183	199	rs3094146	Breast cancer	7e-07	POLR1HASP	29059683	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr6:26670063:C>A	chr6	26670063	26670263	200	rs6901225	Height (baseline)	2.9999999999999995e-54	ZNF322 - GUSBP2	40374629	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:152021444:C>A	chr6	152021444	152021644	200	rs9340995	Pulse pressure	6e-32	ESR1	30578418	0.9185313	443.0	JUND	6.57678e-06	Low Priority	3
chr4:166770149:C>G	chr4	166770149	166769949	200	rs2124456	Serum levels of protein SPOCK3	8e-17	SPOCK3	35078996	0.92024124	591.0	JUND	6.57315e-06	High Impact, Hard to Access	3
chr6:26670063:C>A	chr6	26670063	26670263	200	rs6901225	Physical function (baseline)	1e-14	ZNF322 - GUSBP2	40374629	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:26670063:C>A	chr6	26670063	26670263	200	rs6901225	Insomnia	1e-08	ZNF322 - GUSBP2	35835914	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:26670063:C>A	chr6	26670063	26670263	200	rs6901225	Height	5e-07	ZNF322 - GUSBP2	28552196	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:27857190:G>C	chr6	27857190	27856988	202	rs200986	Autism spectrum disorder or schizophrenia	2e-11	H2BC15 - H2BC16P	28540026	0.9989667	723.0	FOSL2	6.57272e-06	High Impact, Hard to Access	3
chr5:92897219:T>A	chr5	92897219	92897017	202	rs1988145	Body mass index	3e-10	LINC02058	39375568	0.99527115	1466.0	ATF2	6.57393e-06	HIGH PRIORITY: Accessible + High Impact	2
chr5:133109866:G>T	chr5	133109866	133110068	202	rs62374461	Systolic blood pressure	7e-10	HSPA4 - RPL6P15	30595370	0.8844523	409.75	ATF3	7.86411e-06	Accessible, Low Impact	3
chr6:27857190:G>C	chr6	27857190	27856988	202	rs200986	Inguinal hernia	4e-08	H2BC15 - H2BC16P	34382107	0.9989667	723.0	FOSL2	6.57272e-06	High Impact, Hard to Access	3
chr19:18522424:C>A	chr19	18522424	18522627	203	rs271620	Mean corpuscular hemoglobin	8.000000000000001e-49	ELL - FKBP8	32888494	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr19:18522424:C>A	chr19	18522424	18522627	203	rs271620	Mean corpuscular volume	4e-31	ELL - FKBP8	32888494	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196080	203	rs2412980	FEV1	7e-28	HORMAD2 - LIF-AS1	36641522	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr19:18522424:C>A	chr19	18522424	18522627	203	rs271620	mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed)	3e-16	ELL - FKBP8	39024449	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196080	203	rs2412980	Physical function (baseline)	3e-14	HORMAD2 - LIF-AS1	40374629	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196080	203	rs2412980	Glycated hemoglobin levels	5e-14	HORMAD2 - LIF-AS1	33462484	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr19:18522424:C>A	chr19	18522424	18522627	203	rs271620	red blood cell count (RBC, minimum, inv-norm transformed)	1e-13	ELL - FKBP8	39024449	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr19:18522424:C>A	chr19	18522424	18522627	203	rs271620	Red cell distribution width	1e-11	ELL - FKBP8	32888494	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr9:16792452:C>A	chr9	16792452	16792249	203	rs59983343	Inguinal hernia	2e-09	BNC2	34382107	0.9777694	481.0	JUND	6.57168e-06	Low Priority	3
chr22:30196283:G>C	chr22	30196283	30196080	203	rs2412980	Dialysis-related mortality	4e-06	HORMAD2 - LIF-AS1	21546767	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr1:4509172:T>A	chr1	4509172	4509376	204	rs780569	Alcohol consumption	5e-12	LINC01777 - LINC01646	31358974	0.99548393	540.5	FOS	5.95199e-05	Accessible, Low Impact	2
chr1:4509172:T>A	chr1	4509172	4509376	204	rs780569	Alcohol consumption (drinks per week)	4e-10	LINC01777 - LINC01646	30643258	0.99548393	540.5	FOS	5.95199e-05	Accessible, Low Impact	2
chr1:4509172:T>A	chr1	4509172	4509376	204	rs780569	Educational attainment (years of education)	5e-08	LINC01777 - LINC01646	30038396	0.99548393	540.5	FOS	5.95199e-05	Accessible, Low Impact	2
chr1:4509172:T>A	chr1	4509172	4509376	204	rs780569	Bitter alcoholic beverage consumption	8e-06	LINC01777 - LINC01646	31046077	0.99548393	540.5	FOS	5.95199e-05	Accessible, Low Impact	2
chr4:76504369:G>C	chr4	76504369	76504164	205	rs184081623	NAAA protein levels	1e-46	SHROOM3	39789286	0.9645371	459.5	FOS	1.97233e-05	Accessible, Low Impact	3
chr17:504680:G>C	chr17	504680	504885	205	rs11654589	Hip circumference adjusted for BMI	1e-14	RFLNB - VPS53	34021172	0.9983231	474.5	FOS	2.6588e-05	Accessible, Low Impact	3
chr4:27331147:C>G	chr4	27331147	27330942	205	rs7679282	Diastolic blood pressure	4e-08	LINC02261 - IGBP1P5	36329257	0.91678804	432.0	JUN	6.57722e-06	Accessible, Low Impact	2
chr9:4343200:G>C	chr9	4343200	4342995	205	rs2094785	Systolic blood pressure	5e-08	GLIS3	40436827	0.8793248	472.0	FOS	8.555e-05	Accessible, Low Impact	3
chr2:44112267:T>A	chr2	44112267	44112473	206	rs12622038	Isoeugenol sulfate levels in elite athletes	2e-06	LRPPRC - PPM1B-DT	31882771	0.9987876	1027.0	JUND	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:144689733:C>A	chr8	144689733	144689939	206	rs12216824	General cognitive ability	4e-06	ARHGAP39 - ZNF251	29844566	0.9584504	633.5	MAFK	6.65735e-06	HIGH PRIORITY: Accessible + High Impact	3
chr14:55201580:C>A	chr14	55201580	55201787	207	rs79485449	Mean platelet volume	2e-73	DLGAP5 - COX5AP1	32888494	0.9989667	1156.5	BATF	0.000322021	HIGH PRIORITY: Accessible + High Impact	3
chr19:12227129:C>A	chr19	12227129	12227336	207	rs2459023	Gut microbiota alpha diversity (Inverse Simpson index)	4e-06	ZNF44	33462485	0.9681593	505.5	FOSL2	6.57082e-06	Low Priority	3
chr6:32121157:G>C	chr6	32121157	32121365	208	rs204888	Complement C4 levels	2e-12	ATF6B	28240269	0.95348793	658.0	FOSL2	1.31373e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:46794047:G>T	chr2	46794047	46793837	210	rs36071056	Body mass index (MTAG)	4e-15	LINC01118	36376304	0.9756724	1030.5	FOSL1	3.28692e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:190337814:C>A	chr1	190337814	190337604	210	rs12145281	Impedance of whole body (UKB data field 23106)	4e-13	BRINP3	39789286	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr10:3629087:A>C	chr10	3629087	3629297	210	rs151165594	Oligodendroglioma	1e-07	LINC02669 - KLF6	36810956	0.95842487	518.0	ATF3	6.56987e-06	Low Priority	3
chr17:60578208:G>C	chr17	60578208	60577997	211	rs545164273	Heel bone mineral density	1e-22	LINC01999	30048462	0.9870033	710.0	FOSL2	6.65566e-06	HIGH PRIORITY: Accessible + High Impact	3
chr18:60053755:T>A	chr18	60053755	60053966	211	rs72989246	BMI (standard GWA)	8e-15	RNU6-567P - LINC03111	37106081	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr18:60053755:T>A	chr18	60053755	60053966	211	rs72989246	Multi-trait sex score	2e-11	RNU6-567P - LINC03111	37277458	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr2:226317592:C>A	chr2	226317592	226317803	211	rs79615915	Triglyceride levels	2e-11	NYAP2 - MIR5702	33462484	0.9818622	687.5	JUN	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:226317592:C>A	chr2	226317592	226317803	211	rs79615915	Sex hormone-binding globulin levels	7e-11	NYAP2 - MIR5702	33462484	0.9818622	687.5	JUN	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:60053755:T>A	chr18	60053755	60053966	211	rs72989246	High density lipoprotein cholesterol levels	6e-10	RNU6-567P - LINC03111	33462484	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr15:90461039:C>G	chr15	90461039	90461250	211	rs144954201	Heel bone mineral density x serum urate levels interaction	7e-10	IQGAP1	34046847	0.81405944	637.0	FOSL2	0.000301503	HIGH PRIORITY: Accessible + High Impact	3
chr18:60053755:T>A	chr18	60053755	60053966	211	rs72989246	Weight	2e-07	RNU6-567P - LINC03111	28552196	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr18:60053755:T>A	chr18	60053755	60053966	211	rs72989246	Body mass index	2e-06	RNU6-567P - LINC03111	28552196	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr10:37774929:C>A	chr10	37774929	37775141	212	rs10508861	DNA methylation Hannum age acceleration	7e-13	MTND1P18 - ZNF248	34187551	0.90917575	467.0	BATF	6.57713e-06	Low Priority	3
chr7:25572255:T>A	chr7	25572255	25572043	212	rs2521747	Atrial fibrillation	3e-09	LINC03007	40645996	0.94931644	452.5	JUND	6.56452e-06	Low Priority	3
chr8:26421870:C>A	chr8	26421870	26421657	213	rs73219806	Educational attainment	1e-18	BNIP3L	35361970	0.97174054	707.0	FOS	6.57289e-06	High Impact, Hard to Access	3
chr4:182085244:T>A	chr4	182085244	182085457	213	rs576189584	GLIPR1 protein levels	2e-14	TENM3-AS1	39789286	0.99921757	1676.0	ATF2	6.57177e-06	HIGH PRIORITY: Accessible + High Impact	2
chr8:26421870:C>A	chr8	26421870	26421657	213	rs73219806	Schizophrenia	5e-14	BNIP3L	35396580	0.97174054	707.0	FOS	6.57289e-06	High Impact, Hard to Access	3
chr11:35267709:C>A	chr11	35267709	35267496	213	rs11033048	Type 1 diabetes	2e-10	SLC1A2-AS1, SLC1A2	34127860	0.9977934	1401.0	JUND	6.57895e-06	High Impact, Hard to Access	3
chr8:26421870:C>A	chr8	26421870	26421657	213	rs73219806	Mean corpuscular volume	2e-09	BNIP3L	32888494	0.97174054	707.0	FOS	6.57289e-06	High Impact, Hard to Access	3
chr8:26421870:C>A	chr8	26421870	26421657	213	rs73219806	Educational attainment (MTAG)	4e-09	BNIP3L	30038396	0.97174054	707.0	FOS	6.57289e-06	High Impact, Hard to Access	3
chr8:26421870:C>A	chr8	26421870	26421657	213	rs73219806	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	7e-09	BNIP3L	31374203	0.97174054	707.0	FOS	6.57289e-06	High Impact, Hard to Access	3
chr8:26421870:C>A	chr8	26421870	26421657	213	rs73219806	Educational attainment (years of education)	2e-08	BNIP3L	30038396	0.97174054	707.0	FOS	6.57289e-06	High Impact, Hard to Access	3
chr3:100984493:A>C	chr3	100984493	100984280	213	rs1449311	Gut microbiota relative abundance (Faecalibacterium)	3e-06	ABI3BP	33208821	0.973383	457.0	JUND	4.6e-05	Accessible, Low Impact	2
chr4:86869866:C>G	chr4	86869866	86869652	214	rs13103212	Urate levels	4e-08	SLC10A6 - RPL6P13	33356394	0.8791271	428.25	FOSL1	6.56996e-06	Low Priority	3
chrX:58105297:C>A	chrX	58105297	58105512	215	rs139087387	Male-pattern baldness	3e-283	KRT8P17 - SSBL2P	30573740	0.92720795	392.5	FOSL2	8.93943e-06	Accessible, Low Impact	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Vertical cup-disc ratio	5e-24	HORMAD2 - LIF-AS1	34077760	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Standing height (UKB data field 50)	6e-24	HORMAD2 - LIF-AS1	39789286	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	FVC	2e-21	HORMAD2 - LIF-AS1	36641522	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Height (baseline)	6e-21	HORMAD2 - LIF-AS1	40374629	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Height	8e-21	HORMAD2 - LIF-AS1	39134668	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	ICD10 J35: Chronic diseases of tonsils and adenoids	2e-20	HORMAD2 - LIF-AS1	36653354	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Pharyngeal disease	7e-18	HORMAD2 - LIF-AS1	36653354	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Vertical cup-disc ratio (adjusted for vertical disc diameter)	9e-14	HORMAD2 - LIF-AS1	31959993	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Aspartate aminotransferase (AST, mean, inv-norm transformed)	7e-13	HORMAD2 - LIF-AS1	39024449	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Crohn's disease	7e-12	HORMAD2 - LIF-AS1	21102463	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Aspartate aminotransferase (AST, maximum, inv-norm transformed)	3e-11	HORMAD2 - LIF-AS1	39024449	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr8:23951954:C>G	chr8	23951954	23952169	215	rs28501371	Waist circumference adjusted for body mass index	5e-09	STC1 - RNU1-148P	31669095	0.86842537	463.0	FOSL2	6.57004e-06	Low Priority	3
chr10:1330163:G>C	chr10	1330163	1330378	215	rs904963	RBC levels of [Similar to: L-Glutathione (reduced); deltaMass: -0.0338 Da]	3e-08	ADARB2	36395887	0.9986987	571.0	MAFG	6.57505e-06	High Impact, Hard to Access	3
chr8:11959789:G>T	chr8	11959789	11959574	215	rs11775396	Number of sexual partners	5e-08	OR7E161P - DEFB136	30643258	0.95749575	553.0	FOSL2	1.97368e-05	Accessible, Low Impact	3
chr22:30196283:G>C	chr22	30196283	30196498	215	rs713875	Disease progression in age-related macular degeneration (adjusted for baseline)	7e-06	HORMAD2 - LIF-AS1	29346644	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr7:73563135:C>A	chr7	73563135	73562919	216	rs34594435	Ratio of polyunsaturated fatty acids to total fatty acids	2e-22	BCL7B - TBL2	38448586	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr11:78383807:G>C	chr11	78383807	78384023	216	rs11237477	Body mass index	3e-21	GAB2	40436827	0.99694693	665.5	FOS	6.57583e-06	High Impact, Hard to Access	3
chr7:73563135:C>A	chr7	73563135	73562919	216	rs34594435	B4GAT1 protein levels	2e-13	BCL7B - TBL2	39789286	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr7:73563135:C>A	chr7	73563135	73562919	216	rs34594435	Cholesterol in small HDL (UKB data field 23575)	1e-12	BCL7B - TBL2	36764567	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr12:122123188:C>A	chr12	122123188	122123404	216	rs12368309	Valine levels	2e-10	MLXIP	38448586	0.9923714	2062.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:73563135:C>A	chr7	73563135	73562919	216	rs34594435	Free cholesterol to total lipids ratio in very large VLDL	5e-10	BCL7B - TBL2	38448586	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr7:73563135:C>A	chr7	73563135	73562919	216	rs34594435	Red cell distribution width	6e-10	BCL7B - TBL2	32888494	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31395164	216	rs142973694	IgA levels	7e-10	MICA-AS1	28628107	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr7:73563135:C>A	chr7	73563135	73562919	216	rs34594435	Diastolic blood pressure	1e-09	BCL7B - TBL2	27841878	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr17:50912641:C>G	chr17	50912641	50912857	216	rs2215316	Metabolite levels	9e-06	TOB1-AS1	23823483	0.9710905	520.5	FOSL2	1.31506e-05	Accessible, Low Impact	3
chr8:51586043:C>A	chr8	51586043	51585825	218	rs16916544	Adolescent idiopathic scoliosis	5e-24	PXDNL	30019117	0.9659551	543.0	FOSL2	6.57445e-06	Low Priority	3
chr6:158684599:C>A	chr6	158684599	158684381	218	rs1979541	Lipoprotein (a) levels	2e-13	SYTL3	26377243	0.9836582	503.5	BATF	6.57644e-06	Low Priority	3
chr18:56056114:C>A	chr18	56056114	56056332	218	rs7240100	Educational attainment	1e-11	LINC01539, LINC01905	35361970	0.9239011	407.5	FOS	6.57333e-06	Low Priority	3
chr4:4731490:G>T	chr4	4731490	4731272	218	rs12503880	Inguinal hernia	4e-08	STX18-AS1	34382107	0.8791271	473.0	JUND	3.94285e-05	Accessible, Low Impact	3
chr17:7699848:C>G	chr17	7699848	7700066	218	rs183294622	R-6-hydroxywarfarin levels	8e-08	WRAP53	36210801	0.97174054	564.0	FOSL1	6.60476e-06	Low Priority	3
chr15:50682036:G>C	chr15	50682036	50682256	220	rs12595562	Monocyte count	7e-15	TRPM7	32888493	0.99901325	1584.0	BATF	0.137066	HIGH PRIORITY: Accessible + High Impact	3
chr7:55044496:C>A	chr7	55044496	55044717	221	rs11760406	White matter microstructure (fractional anisotropy)	4e-09	EGFR	31666681	0.9840279	642.0	FOS	1.31411e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:52870937:C>A	chr5	52870937	52871158	221	rs73106321	Protein quantitative trait loci (liver)	9e-09	ITGA1	32778093	0.9939336	725.0	FOS	6.57047e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19978572	222	rs10732279	Protein levels in obesity	3e-26	PLA2G2A	29234017	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:157438106:T>A	chr1	157438106	157438328	222	rs146001952	FCRL3 protein levels	2e-19	LINC02772 - FCRL5	39789286	0.95452464	462.0	ATF2	1.31437e-05	Accessible, Low Impact	3
chr11:78405779:C>G	chr11	78405779	78406001	222	rs6592775	Glycated haemoglobin HbA1c levels (UKB data field 30750)	9e-19	GAB2	39789286	0.93561655	650.0	JUND	6.57358e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17641390	222	rs12449964	Hip index	2e-16	PEMT - SMCR2	34021172	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17641390	222	rs12449964	Waist-hip index	3e-13	PEMT - SMCR2	34021172	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17641390	222	rs12449964	Waist-to-hip ratio adjusted for BMI	7e-13	PEMT - SMCR2	34021172	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17641390	222	rs12449964	Hip circumference adjusted for BMI	2e-09	PEMT - SMCR2	34021172	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17641390	222	rs12449964	Coronary artery disease or ischemic stroke	2e-08	PEMT - SMCR2	24262325	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr6:27303589:T>A	chr6	27303589	27303811	222	rs147121091	Asthma and major depressive disorder	3e-08	POM121L2	31619474	0.9912486	1005.5	FOSL2	6.57117e-06	HIGH PRIORITY: Accessible + High Impact	2
chr11:78405779:C>G	chr11	78405779	78406001	222	rs6592775	Smoking initiation (ever regular vs never regular) (MTAG)	4e-08	GAB2	30643251	0.93561655	650.0	JUND	6.57358e-06	High Impact, Hard to Access	3
chr2:19608116:C>A	chr2	19608116	19608338	222	rs4145607	Blood protein levels	4e-06	LINC01808 - CISD1P1	27532455	0.999696	3098.0	JUND	6.57298e-06	High Impact, Hard to Access	3
chr19:4925820:C>A	chr19	4925820	4926043	223	rs190520	Insomnia	1e-08	UHRF1	35835914	0.9896673	694.0	FOS	0.0	High Impact, Hard to Access	3
chr21:35081316:T>A	chr21	35081316	35081540	224	rs2242900	Asthma	2e-18	RUNX1	32296059	0.8862913	472.5	FOS	0.000289295	Accessible, Low Impact	2
chr2:82695295:G>C	chr2	82695295	82695071	224	rs58011745	Serum immune biomarker levels	2e-08	RBX1P1 - MTND4P25	32066700	0.9943153	449.0	MAFG	6.57748e-06	Low Priority	3
chr6:2187546:C>G	chr6	2187546	2187322	224	rs75749315	Iris heterochromicity	4e-06	GMDS	30895295	0.97511876	602.5	JUNB	6.57212e-06	High Impact, Hard to Access	3
chr4:21454479:C>A	chr4	21454479	21454254	225	rs1460485	Postburn scar height	9e-06	KCNIP4	30595539	0.9955867	558.5	FOSL1	6.57523e-06	Low Priority	3
chr2:37664548:C>A	chr2	37664548	37664322	226	rs6544100	Anteromedial temporal area	1e-10	CDC42EP3-AS1, CDC42EP3	35113692	0.992679	868.0	FOS	1.31551e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:28986902:G>C	chr16	28986902	28986676	226	rs1131543	Anti-SARS-CoV-2 spike protein IgG seronegativity after first dose of COVID-19 vaccine	3e-08	LAT	38181733	0.99548393	659.0	FOS	6.57255e-06	High Impact, Hard to Access	3
chr13:74819819:C>A	chr13	74819819	74819593	226	rs4310742	Baseline memory in impaired cognition	6e-06	LINC00347 - RIOK3P1	37984853	0.97534883	436.0	FOS	6.57618e-06	Low Priority	3
chr13:109868747:G>C	chr13	109868747	109868973	226	rs444033	Vaginal microbiome relative abundance (f_Lachnospiraceae)	9e-06	IRS2 - RN7SKP10	34282934	0.9990358	1025.5	FOSL2	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:141884816:C>A	chr3	141884816	141885045	229	rs6785570	Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG)	1e-19	ATP1B3	38858783	0.9845253	904.5	ATF2	0.000374409	HIGH PRIORITY: Accessible + High Impact	3
chr3:141884816:C>A	chr3	141884816	141885045	229	rs6785570	Blood pressure (pleiotropy model 1 DBP adjusted for estimated causal effects x SBP)	2e-11	ATP1B3	34989438	0.9845253	904.5	ATF2	0.000374409	HIGH PRIORITY: Accessible + High Impact	3
chr3:141884816:C>A	chr3	141884816	141885045	229	rs6785570	Blood pressure (pleiotropy model 2 SBP adjusted for estimated causal effects x DBP)	1e-10	ATP1B3	34989438	0.9845253	904.5	ATF2	0.000374409	HIGH PRIORITY: Accessible + High Impact	3
chr4:111863968:G>T	chr4	111863968	111864198	230	rs28544078	ODAM protein levels	3e-15	LINC02945	39789286	0.94819474	427.0	JUND	6.57263e-06	Low Priority	3
chr6:169221461:G>C	chr6	169221461	169221692	231	rs6605532	Blood pressure (pleiotropy model 1 DBP adjusted for estimated causal effects x SBP)	2e-10	THBS2-AS1, THBS2	34989438	0.9894933	952.5	MAFG	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:2695432:C>G	chr19	2695432	2695663	231	rs10402849	Chronotype	3e-09	GNG7	30696823	0.9946945	886.0	FOSL1	6.57013e-06	High Impact, Hard to Access	3
chr19:2695432:C>G	chr19	2695432	2695663	231	rs10402849	Morningness	7e-09	GNG7	30804565	0.9946945	886.0	FOSL1	6.57013e-06	High Impact, Hard to Access	3
chr6:169221461:G>C	chr6	169221461	169221692	231	rs6605532	Blood pressure (pleiotropy model 2 SBP adjusted for estimated causal effects x DBP)	1e-08	THBS2-AS1, THBS2	34989438	0.9894933	952.5	MAFG	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:47123105:G>T	chr15	47123105	47123337	232	rs62015803	Type 2 diabetes	2e-10	RN7SKP101 - SEMA6D	38374256	0.9739743	543.0	FOS	0.0	Low Priority	3
chr1:109160576:C>A	chr1	109160576	109160808	232	rs17641977	Docosahexaenoic acid levels	5e-09	ELAPOR1	40545721	0.98266596	738.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:109160576:C>A	chr1	109160576	109160808	232	rs17641977	Omega-3 fatty acid levels	7e-09	ELAPOR1	40545721	0.98266596	738.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:207720600:C>A	chr1	207720600	207720367	233	rs2761423	CD55 protein levels	5e-18	CR1L	39789286	0.9854257	709.0	BATF	6.57393e-06	High Impact, Hard to Access	3
chr14:60713706:C>A	chr14	60713706	60713939	233	rs3742636	Type 2 diabetes	9e-16	SIX4	38374256	0.9963292	1126.5	FOS	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:150416156:A>C	chr6	150416156	150416390	234	rs9478735	LRP11 protein levels	1e-11	IYD - PLEKHG1	39789286	0.97674394	690.5	JUN	3.28407e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:27950649:C>G	chr8	27950649	27950414	235	rs35039172	Pulmonary surfactant-associated protein C levels (SFTPC.5738.25.3)	4e-51	SCARA5	29875488	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr14:71588226:G>C	chr14	71588226	71587991	235	rs78621209	Body mass index	7e-10	SIPA1L1	36581621	0.99965847	2051.0	FOS	6.57004e-06	High Impact, Hard to Access	3
chr12:94407931:C>G	chr12	94407931	94408166	235	rs12368829	Femur bone mineral density x serum urate levels interaction	3e-08	CEP83	34046847	0.95041513	555.5	JUND	6.57108e-06	Low Priority	3
chr2:60250562:G>T	chr2	60250562	60250326	236	rs359248	Morning person	2e-16	RNA5SP94 - MIR4432HG	30696823	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr2:60250562:G>T	chr2	60250562	60250326	236	rs359248	Chronotype	2e-16	RNA5SP94 - MIR4432HG	30696823	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr13:56374362:G>C	chr13	56374362	56374126	236	rs71428218	Schizophrenia	6e-10	SPATA2P1 - RN7SKP6	31740837	0.9939092	582.0	FOS	6.60615e-06	High Impact, Hard to Access	3
chr2:96434372:C>G	chr2	96434372	96434608	236	rs139743432	Organic or persistent insomnia (PheCode 327.41)	4e-08	NCAPH - NEURL3	40465716	0.9185313	457.0	ATF3	6.78316e-06	Accessible, Low Impact	3
chr3:61992473:C>G	chr3	61992473	61992237	236	rs40409	Epithelial ovarian cancer	2e-06	PTPRG	30898391	0.7921896	490.25	FOSL2	1.97174e-05	Accessible, Low Impact	3
chr1:219604005:G>T	chr1	219604005	219603768	237	rs11118356	Umbilical hernia	2e-09	LYPLAL1-AS1 - ZC3H11B	34382107	0.8072176	291.75	FOSL2	6.57212e-06	Low Priority	3
chr15:48464576:G>T	chr15	48464576	48464339	237	rs34539187	Spherical equivalent or myopia (age of diagnosis)	6e-09	FBN1	29808027	0.8608881	453.0	JUND	6.58007e-06	Low Priority	3
chr18:44672680:A>C	chr18	44672680	44672443	237	rs138775024	Reaction time	3e-06	LINC01478 - SETBP1-DT	29844566	0.9997991	2127.0	FOSL2	3.28455e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:12378556:G>C	chr16	12378556	12378793	237	rs7191671	Response to esketamine (responder status) in treatment resistant depression	4e-06	SNX29	32724131	0.9983613	667.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr16:12378556:G>C	chr16	12378556	12378793	237	rs7191671	Response to esketamine in treatment resistant depression	9e-06	SNX29	32724131	0.9983613	667.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Idiopathic membranous nephropathy	5e-71	TSBP1-AS1, TSBP1	21323541	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr16:268237:C>G	chr16	268237	268475	238	rs3743879	Mean corpuscular hemoglobin	8e-69	RGS11, FAM234A	30595370	0.9975805	1037.0	BATF2	6.57117e-06	High Impact, Hard to Access	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Hemoglobin levels	1e-35	TSBP1-AS1, TSBP1	32327693	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_223208)	4e-21	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_229757)	3e-20	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for staphylococcus aureus peptide (agilent_222381)	3e-20	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for staphylococcaceae peptide (agilent_4825)	2e-18	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for staphylococcus aureus peptide (agilent_226247)	8e-17	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for staphylococcus aureus peptide (agilent_236333)	6e-16	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr16:268237:C>G	chr16	268237	268475	238	rs3743879	Mean corpuscular haemoglobin concentration (UKB data field 30060)	5e-15	RGS11, FAM234A	39789286	0.9975805	1037.0	BATF2	6.57117e-06	High Impact, Hard to Access	3
chr16:268237:C>G	chr16	268237	268475	238	rs3743879	Red blood cell count	2e-14	RGS11, FAM234A	30595370	0.9975805	1037.0	BATF2	6.57117e-06	High Impact, Hard to Access	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for staphylococcus aureus subsp. aureus MW2 peptide (agilent_235512)	5e-14	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_241214)	6e-14	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for blautia producta peptide (agilent_74695)	2e-13	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Chronic obstructive pulmonary disease	3e-13	TSBP1-AS1, TSBP1	33909500	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_223825)	3e-13	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_227833)	2e-11	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_223641)	4e-11	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_241401)	4e-10	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr3:61992473:C>G	chr3	61992473	61992711	238	rs251036	Smoking initiation	3e-09	PTPRG	36477530	0.7921896	490.25	FOSL2	1.97174e-05	Accessible, Low Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_220184)	8e-09	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Lung cancer in ever smokers	1e-08	TSBP1-AS1, TSBP1	37167549	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for dorea formicigenerans (agilent_198014)	2e-08	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_243229)	3e-08	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Seropositivity for streptococcus pneumoniae peptide (agilent_243228)	3e-08	TSBP1-AS1, TSBP1	37164013	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Inguinal hernia	4e-08	TSBP1-AS1, TSBP1	34382107	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32293475	238	rs7775397	Lung cancer	8e-07	TSBP1-AS1, TSBP1	37167549	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr8:61082461:G>C	chr8	61082461	61082222	239	rs6471915	Prudent dietary pattern	2e-06	CLVS1	28644415	0.97922516	704.0	ATF2	6.5917e-06	High Impact, Hard to Access	3
chr1:177960180:G>C	chr1	177960180	177960419	239	rs10913472	Epigenetic age acceleration in alcohol use disorder	9e-06	SEC16B, CRYZL2P-SEC16B	31466081	0.9991015	5013.0	MAFK	6.57263e-06	High Impact, Hard to Access	3
chr16:67191838:G>C	chr16	67191838	67191598	240	rs3729639	HDL cholesterol	2e-11	EXOC3L1 - E2F4	21347282	0.99319685	2471.0	JUN	6.57013e-06	High Impact, Hard to Access	3
chr10:56934022:C>A	chr10	56934022	56933782	240	rs34747361	Medication use (antimigraine preparations)	3e-08	ZWINT - MIR3924	34594039	0.8335761	309.75	MAFK	0.000704168	Accessible, Low Impact	3
chr12:101674766:G>T	chr12	101674766	101675007	241	rs142307641	SMPDL3A protein levels	7e-20	MYBPC1	39789286	0.96670574	715.0	MAFK	0.000540101	HIGH PRIORITY: Accessible + High Impact	3
chr12:101674766:G>T	chr12	101674766	101675007	241	rs142307641	MAN2B2 protein levels	3e-15	MYBPC1	39789286	0.96670574	715.0	MAFK	0.000540101	HIGH PRIORITY: Accessible + High Impact	3
chr12:101674766:G>T	chr12	101674766	101675007	241	rs142307641	CPQ protein levels	1e-12	MYBPC1	39789286	0.96670574	715.0	MAFK	0.000540101	HIGH PRIORITY: Accessible + High Impact	3
chr19:48649457:G>T	chr19	48649457	48649698	241	rs8111500	Elevated serum carcinoembryonic antigen levels	4e-09	SEC1P, SEC1P	24941225	0.9976844	1694.0	ATF3	1.97475e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:113027735:C>A	chr11	113027735	113027494	241	rs10891491	Gastroesophageal reflux disease	4e-08	NCAM1	33608531	0.97621405	822.0	MAFK	3.28554e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:82166740:C>G	chr16	82166740	82166498	242	rs2967355	Telomere length	4e-19	MPHOSPH6	35530816	0.9422262	519.0	JUNB	6.5659e-06	Low Priority	3
chr16:82166740:C>G	chr16	82166740	82166498	242	rs2967355	Height	4e-09	MPHOSPH6	40436827	0.9422262	519.0	JUNB	6.5659e-06	Low Priority	3
chr16:82166740:C>G	chr16	82166740	82166498	242	rs2967355	Leukocyte telomere length	4e-08	MPHOSPH6	37216007	0.9422262	519.0	JUNB	6.5659e-06	Low Priority	3
chr17:798124:G>C	chr17	798124	797882	242	rs910920	Taxane-induced peripheral neuropathy in breast cancer	5e-06	MRM3 - NXN	29278617	0.95749575	713.0	ATF2	1.31359e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:117901948:T>A	chr9	117901948	117902191	243	rs1877875	Body mass index	3e-10	TLR4 - TPT1P9	30239722	0.93699247	414.5	JUN	5.91545e-05	Accessible, Low Impact	2
chr6:8871411:A>C	chr6	8871411	8871655	244	rs76301696	Protein quantitative trait loci (liver)	4e-10	HULC	32778093	0.99936336	910.0	JUN	1.29079e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:41188377:C>G	chr17	41188377	41188621	244	rs56294834	Major depressive disorder in trauma-unexposed individuals	8e-06	KRTAP4-17P - KRTAP9-1	31969693	0.9094714	463.5	JUND	6.57047e-06	Low Priority	3
chr16:89841042:G>C	chr16	89841042	89840797	245	rs6500458	Mean reticulocyte volume	3e-27	SPIRE2	32888494	0.9759043	646.5	ATF3	6.57825e-06	High Impact, Hard to Access	3
chr7:26543142:G>C	chr7	26543142	26542897	245	rs10232785	heart rate (HR, minimum, inv-normal transformed)	2e-12	KIAA0087 - LINC03095	39024449	0.9991795	833.0	MAFG	6.57168e-06	High Impact, Hard to Access	3
chr16:89841042:G>C	chr16	89841042	89840797	245	rs6500458	Age-related hearing impairment (high frequency)	1e-08	SPIRE2	31645637	0.9759043	646.5	ATF3	6.57825e-06	High Impact, Hard to Access	3
chr1:154836057:C>A	chr1	154836057	154835811	246	rs4845394	Height (baseline)	4e-09	KCNN3	40374629	0.96686935	582.5	FOS	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:128671064:C>G	chr3	128671064	128670816	248	rs150918492	White blood cell count	1e-35	RPN1	32888493	0.946766	643.0	MAFK	1.40792e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:128671064:C>G	chr3	128671064	128670816	248	rs150918492	Neutrophil count	9e-17	RPN1	32888494	0.946766	643.0	MAFK	1.40792e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:128671064:C>G	chr3	128671064	128670816	248	rs150918492	CRISP3 protein levels	3e-15	RPN1	39789286	0.946766	643.0	MAFK	1.40792e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:128671064:C>G	chr3	128671064	128670816	248	rs150918492	Myeloperoxidase levels	4e-11	RPN1	33067605	0.946766	643.0	MAFK	1.40792e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:130882648:C>G	chr9	130882648	130882398	250	rs3808814	Height	1e-15	ABL1	36224396	0.96905065	588.0	JUND	6.57566e-06	High Impact, Hard to Access	3
chr4:144569879:C>G	chr4	144569879	144570129	250	rs1512288	Post bronchodilator FEV1/FVC ratio	8e-14	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:93043880:G>C	chr7	93043880	93044130	250	rs2374602	Body size or adipose distribution (multivariate analysis)	4e-10	RN7SL7P - SAMD9	40796553	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144570129	250	rs1512288	Post bronchodilator FEV1	2e-09	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144570129	250	rs1512288	Post bronchodilator FEV1/FVC ratio in COPD	1e-06	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:155959658:C>G	chr1	155959658	155959910	252	rs12080846	Testosterone levels	9e-10	ARHGEF2	40229599	0.9708846	747.0	FOSL1	1.31444e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:93659884:C>A	chr9	93659884	93660138	254	rs10992836	Educational attainment	6e-26	PHF2	35361970	0.9976844	2273.5	FOS	1.97114e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:28037958:G>T	chr9	28037958	28037704	254	rs548787624	GLIPR1 protein levels	4e-17	LINGO2	39789286	0.94346935	435.5	ATF3	2.62881e-05	Accessible, Low Impact	3
chr12:109968835:C>G	chr12	109968835	109968581	254	rs9634314	Systolic blood pressure (MTAG)	3e-11	GIT2, TCHP	39537608	0.9727787	764.0	FOSL1	6.57263e-06	High Impact, Hard to Access	3
chr12:109968835:C>G	chr12	109968835	109968581	254	rs9634314	Cardiovascular disease	4e-08	GIT2, TCHP	30595370	0.9727787	764.0	FOSL1	6.57263e-06	High Impact, Hard to Access	3
chr17:54337734:G>C	chr17	54337734	54337989	255	rs56040334	Pilocytic astrocytoma and optic pathway glioma	2e-06	KIF2B - ISCA1P3	36810956	0.96905065	439.0	FOS	1.3186e-05	Accessible, Low Impact	3
chr12:15267008:C>A	chr12	15267008	15267263	255	rs7954918	Vaginal microbiome MetaCyc pathway (PWY-5896|superpathway of menaquinol-10 biosynthesis)	9e-06	RERG	34282934	0.8263989	431.75	FOSL2	6.58059e-06	Low Priority	3
chr3:70467014:C>A	chr3	70467014	70467270	256	rs10510998	Height	4e-11	SAMMSON	36224396	0.94468737	445.5	FOS	6.57246e-06	Low Priority	3
chr3:65812212:C>A	chr3	65812212	65812468	256	rs145965284	Knee osteoarthritis	3e-07	MAGI1	28916551	0.9979406	1336.0	JUND	6.57445e-06	High Impact, Hard to Access	3
chr1:55033740:C>A	chr1	55033740	55033483	257	rs7525649	LDL cholesterol	3e-11	BSND - PCSK9	26582766	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr1:55033740:C>A	chr1	55033740	55033483	257	rs7525649	Cholesterol, total	2e-10	BSND - PCSK9	26582766	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr1:55033740:C>A	chr1	55033740	55033483	257	rs7525649	Total cholesterol levels	2e-07	BSND - PCSK9	31217584	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr1:55033740:C>A	chr1	55033740	55033483	257	rs7525649	Low density lipoprotein cholesterol levels	1e-06	BSND - PCSK9	31217584	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr2:62341119:C>A	chr2	62341119	62340861	258	rs112392179	N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 levels	1.9999999999999999e-56	RN7SL51P - RN7SL18P	34648354	0.99812186	3287.0	BATF	6.57341e-06	High Impact, Hard to Access	3
chr11:58003808:T>A	chr11	58003808	58004066	258	rs10526240	Height	1e-17	OR5BD1P - CYCSP26	31562340	0.9918291	870.0	JUN	6.57592e-06	HIGH PRIORITY: Accessible + High Impact	2
chr17:34726351:G>T	chr17	34726351	34726609	258	rs184814605	CCL15 protein levels	3e-12	TMEM132E - CCT6B	39789286	0.84946334	450.5	FOSL1	0.0	Low Priority	3
chr1:231761380:C>A	chr1	231761380	231761122	258	rs1538979	Internet addiction disorder	3e-08	DISC1, TSNAX-DISC1	36566681	0.9327804	465.0	JUND	6.57186e-06	Low Priority	3
chr12:11374124:C>G	chr12	11374124	11373865	259	rs73054820	PRSS53 protein levels	2e-21	PRB1 - PRB2	39789286	0.9810219	906.0	MAFK	2.68936e-05	HIGH PRIORITY: Accessible + High Impact	3
chr21:17562480:C>A	chr21	17562480	17562221	259	rs2739393	FEV1/FVC or gastro-oesophageal reflux disease (pleiotropy)	5e-09	CXADR	38102678	0.97697836	560.5	BATF	6.57047e-06	Low Priority	3
chr12:75849155:C>G	chr12	75849155	75848895	260	rs12230172	Non-glioblastoma glioma	8e-11	SNORA70 - RN7SL734P	26424050	0.99250877	777.0	FOS	7.23085e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:75849155:C>G	chr12	75849155	75848895	260	rs12230172	Glioma	2e-06	SNORA70 - RN7SL734P	26424050	0.99250877	777.0	FOS	7.23085e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:129503468:G>T	chr8	129503468	129503207	261	rs72714270	Adult diffuse glioma (IDH mutation)	9e-14	CCDC26	32386320	0.9704257	629.5	MAFK	5.25714e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:129503468:G>T	chr8	129503468	129503207	261	rs72714270	Adult diffuse glioma (IDH mutation, 1p/19q codeletion)	1e-10	CCDC26	32386320	0.9704257	629.5	MAFK	5.25714e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:129503468:G>T	chr8	129503468	129503207	261	rs72714270	Adult diffuse triple positive glioma (IDH and TERT mutations, 1p19q codeletion)	7e-10	CCDC26	32386320	0.9704257	629.5	MAFK	5.25714e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:124683854:C>A	chr2	124683854	124684116	262	rs17011859	Post bronchodilator FEV1/FVC ratio	2e-06	CNTNAP5	26634245	0.9928779	1324.5	MAFK	2.62978e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:55783160:G>T	chr2	55783160	55783423	263	rs11684367	Hip circumference adjusted for BMI	4e-11	PNPT1 - EFEMP1	34021172	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55783423	263	rs11684367	Multi-trait sex score	7e-11	PNPT1 - EFEMP1	37277458	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr8:110466355:C>G	chr8	110466355	110466092	263	rs13267290	Schizophrenia (MTAG)	2e-09	RPSAP48 - NDUFB9P3	33479212	0.9555776	434.0	JUND	6.58519e-06	Low Priority	3
chr8:110466355:C>G	chr8	110466355	110466092	263	rs13267290	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	2e-09	RPSAP48 - NDUFB9P3	31374203	0.9555776	434.0	JUND	6.58519e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55783423	263	rs11684367	Inguinal hernia	6e-09	PNPT1 - EFEMP1	34382107	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr5:26015991:C>A	chr5	26015991	26016254	263	rs10067113	Adventurousness	1e-08	RNU4-43P - CCNB3P1	30643258	0.9055997	449.5	JUND	6.57575e-06	Low Priority	3
chr3:17833965:G>C	chr3	17833965	17833702	263	rs1004307	Estimated glomerular filtration rate based on creatinine and cystatin C in bottom 99% of individuals by creatinine levels	2e-08	TBC1D5	39927731	0.99945825	1688.0	JUND	1.97062e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Gremlin-1 levels	0.0	SCG5 - GREM1	34648354	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Colorectal cancer or advanced adenoma	6e-37	SCG5 - GREM1	30510241	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	UTP--glucose-1-phosphate uridylyltransferase protein levels (SomaScan ID:18878-15)	4e-27	SCG5 - GREM1	40883583	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	ICD10 C18, C19, C20: colorectal cancer	2e-16	SCG5 - GREM1	37965154	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Mean corpuscular hemoglobin	2e-14	SCG5 - GREM1	32888494	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Mean corpuscular volume	8e-14	SCG5 - GREM1	32888493	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Red cell distribution width	2e-11	SCG5 - GREM1	32888494	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Colorectal cancer (PheCode 153)	1e-10	SCG5 - GREM1	30104761	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Rectal cancer	1e-08	SCG5 - GREM1	32887889	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Colorectal cancer	3e-08	SCG5 - GREM1	37340002	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:32709797:C>G	chr15	32709797	32709533	264	rs58658771	Cancer (pleiotropy)	5e-08	SCG5 - GREM1	32887889	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:141227731:T>A	chr2	141227731	141227995	264	rs113030029	Aspartate aminotransferase levels (adjusted for BMI) x vegetarianism interaction	9e-06	LRP1B	38990837	0.961097	494.5	FOS	6.56996e-06	Accessible, Low Impact	2
chr11:132794020:C>G	chr11	132794020	132793755	265	rs4076157	Suicidal or self-harm ideation	3e-06	OPCML	31926482	0.93131924	530.5	JUNB	6.56953e-06	Accessible, Low Impact	2
chr2:240597417:C>A	chr2	240597417	240597684	267	rs12465143	Blood cell traits latent factor 16 (white cell)	1e-09	CAPN10	40220762	0.9939092	2021.0	FOSL2	1.97132e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:240597417:C>A	chr2	240597417	240597684	267	rs12465143	Blood cell traits latent factor 5 (platelet)	1e-09	CAPN10	40220762	0.9939092	2021.0	FOSL2	1.97132e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:123417755:C>A	chr9	123417755	123417488	267	rs113977954	Alcohol consumption x playing computer games interaction	2e-08	DENND1A	34877740	0.9422262	636.0	ATF2	6.56564e-06	High Impact, Hard to Access	3
chr10:25481363:A>C	chr10	25481363	25481096	267	rs72786268	QRS duration in Tripanosoma cruzi seropositivity	4e-07	GPR158	24324551	0.9993485	1349.0	FOSL1	6.5735e-06	HIGH PRIORITY: Accessible + High Impact	2
chr12:54776945:G>T	chr12	54776945	54776678	267	rs1378069	Dementia	9e-06	DCD - VDAC1P5	39046104	0.87398493	559.0	MAFK	6.57039e-06	Low Priority	3
chr4:7435002:C>A	chr4	7435002	7435270	268	rs4484302	Proactivator polypeptide-like 1 levels	7.000000000000001e-228	SORCS2	34648354	0.99560076	2678.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr1:62900720:A>C	chr1	62900720	62900452	268	rs2780876	Polyunsaturated fatty acid levels	6e-19	ATG4C - LINC01739	40545721	0.95933455	467.0	JUND	0.00825958	Accessible, Low Impact	2
chr3:110353116:A>C	chr3	110353116	110353384	268	rs7636367	Height	1e-09	ZFAND2AP1 - NECTIN3-AS1	36224396	0.9997797	2642.0	JUN	6.57142e-06	High Impact, Hard to Access	3
chr1:62900720:A>C	chr1	62900720	62900452	268	rs2780876	Omega-3 fatty acids to Omega-6 fatty acids ratio	2e-08	ATG4C - LINC01739	40545721	0.95933455	467.0	JUND	0.00825958	Accessible, Low Impact	2
chr15:77259372:C>A	chr15	77259372	77259103	269	rs12909924	Type 2 diabetes (PheCode 250.2)	1e-15	PEAK1	40465716	0.9681593	535.0	JUNB	6.57652e-06	Low Priority	3
chr14:60713706:C>A	chr14	60713706	60713975	269	rs77115877	Vaginal microbiome relative abundance (s_Lactobacillus reuteri)	9e-06	SIX4	34282934	0.9963292	1126.5	FOS	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:184359594:T>A	chr4	184359594	184359864	270	rs144271358	Depression	3e-06	LINC02363 - LINC02362	34586374	0.9772623	663.5	MAFG	0.0	High Impact, Hard to Access	2
chr3:110478565:T>A	chr3	110478565	110478294	271	rs13058952	Smoking initiation	2e-21	NECTIN3-AS1	36477530	0.99641275	1943.0	JUN	6.59248e-06	High Impact, Hard to Access	3
chr17:36002761:G>C	chr17	36002761	36002489	272	rs854626	C-C motif chemokine 15 levels	1e-288	CCL15-CCL14 - CCL23	36349687	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr17:36002761:G>C	chr17	36002761	36002489	272	rs854626	Butyrophilin subfamily 3 member A1 protein levels (SomaScan ID:18289-16)	6e-21	CCL15-CCL14 - CCL23	40883583	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr17:36002761:G>C	chr17	36002761	36002489	272	rs854626	Heat shock 70 kDa protein 6 protein levels (SomaScan ID:3509-1)	7e-18	CCL15-CCL14 - CCL23	40883583	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr20:63560395:C>A	chr20	63560395	63560122	273	rs3810478	Height	7e-10	HELZ2	30595370	0.98942745	820.0	FOS	6.57713e-06	High Impact, Hard to Access	3
chr20:63560395:C>A	chr20	63560395	63560122	273	rs3810478	Pneumonia	8e-07	HELZ2	34340725	0.98942745	820.0	FOS	6.57713e-06	High Impact, Hard to Access	3
chr16:88477810:G>C	chr16	88477810	88478085	275	rs188255148	Hair color	2e-18	ZFPM1	30595370	0.99937785	1042.0	FOS	6.56676e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31395105	275	rs183809241	Pneumonia	9e-16	MICA-AS1	34594039	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr4:73391800:C>A	chr4	73391800	73392076	276	rs553977556	AFM protein levels	1e-108	ANKRD17-DT - ALB	39789286	0.99364895	1314.0	JUNB	6.57661e-06	High Impact, Hard to Access	3
chr9:8712877:C>A	chr9	8712877	8712601	276	rs10815925	Gout	1e-07	PTPRD	22179738	0.96028686	390.5	BATF	6.57549e-06	Low Priority	3
chr3:16824069:A>C	chr3	16824069	16824346	277	rs9882532	Educational attainment (MTAG)	6e-21	PLCL2	30038396	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr8:128168021:G>C	chr8	128168021	128167744	277	rs2648846	Height	1e-19	PVT1	39134668	0.9996509	6948.0	JUNB	6.61472e-06	High Impact, Hard to Access	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	Educational attainment	1e-17	LINC01868 - NPAS2	35361970	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr3:16824069:A>C	chr3	16824069	16824346	277	rs9882532	Educational attainment (years of education)	2e-17	PLCL2	30038396	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	Educational attainment (MTAG)	2e-16	LINC01868 - NPAS2	30038396	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr3:16824069:A>C	chr3	16824069	16824346	277	rs9882532	CAMSIS occupational score (MTAG)	2e-14	PLCL2	39715877	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr3:16824069:A>C	chr3	16824069	16824346	277	rs9882532	SIOPS occupational score (MTAG)	5e-14	PLCL2	39715877	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr3:16824069:A>C	chr3	16824069	16824346	277	rs9882532	ISEI occupational score (MTAG)	6e-14	PLCL2	39715877	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	CAMSIS occupational score (MTAG)	4e-11	LINC01868 - NPAS2	39715877	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	SIOPS occupational score (MTAG)	4e-11	LINC01868 - NPAS2	39715877	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	ISEI occupational score (MTAG)	6e-11	LINC01868 - NPAS2	39715877	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr19:2695432:C>G	chr19	2695432	2695709	277	rs2159917	Metabolic syndrome	3e-10	GNG7	39349817	0.9946945	886.0	FOSL1	6.57013e-06	High Impact, Hard to Access	3
chr3:16824069:A>C	chr3	16824069	16824346	277	rs9882532	Income (MTAG)	1e-08	PLCL2	39875632	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	Household income (MTAG)	2e-08	LINC01868 - NPAS2	31844048	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr2:100712543:C>A	chr2	100712543	100712266	277	rs77702819	Educational attainment (years of education)	3e-08	LINC01868 - NPAS2	27225129	0.6281189	324.0	JUND	2.06455e-05	Accessible, Low Impact	3
chr6:44066314:G>C	chr6	44066314	44066037	277	rs71562790	Change in processing speed in pediatric CNS tumors treated with craniospinal irradiation	4e-07	SCIRT	37038335	0.99588126	747.0	FOSL2	0.0	High Impact, Hard to Access	3
chr2:144212330:G>T	chr2	144212330	144212051	279	rs16823583	2'-O-methyluridine levels in elite athletes	8e-06	GTDC1	31882771	0.97511876	744.0	JUNB	6.58224e-06	High Impact, Hard to Access	3
chr12:117974848:C>A	chr12	117974848	117974568	280	rs34965774	Type 2 diabetes	1e-14	KSR2 - RFC5	32541925	0.96886295	656.0	FOSL2	6.56909e-06	High Impact, Hard to Access	3
chr6:141151946:G>C	chr6	141151946	141152226	280	rs1452991	Body size at age 10	5e-12	RPS3AP24 - RN7SKP106	32376654	0.99847347	4104.0	MAFK	6.57557e-06	High Impact, Hard to Access	3
chr3:111781435:G>C	chr3	111781435	111781155	280	rs28675079	Diastolic blood pressure	8e-11	PHLDB2, PLCXD2	30224653	0.9951775	2504.0	ATF2	3.94778e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:111781435:G>C	chr3	111781435	111781155	280	rs28675079	Diastolic blood pressure (MTAG)	5e-10	PHLDB2, PLCXD2	39537608	0.9951775	2504.0	ATF2	3.94778e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:141151946:G>C	chr6	141151946	141152226	280	rs1452991	Height (standard GWA)	5e-08	RPS3AP24 - RN7SKP106	37106081	0.99847347	4104.0	MAFK	6.57557e-06	High Impact, Hard to Access	3
chr6:31295292:A>C	chr6	31295292	31295573	281	rs2524144	White blood cell count	2e-14	LINC02571	36329257	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr22:30606117:G>T	chr22	30606117	30605835	282	rs5749131	Holo-Transcobalamin-2 levels	5e-245	PES1, PES1-AS1	39528825	0.9838064	1132.0	FOSL1	6.56668e-06	High Impact, Hard to Access	3
chr2:18557258:C>G	chr2	18557258	18556976	282	rs78038889	Femur bone mineral density x serum urate levels interaction	1e-09	RDH14, NT5C1B-RDH14	34046847	0.9976844	598.0	ATF2	1.31506e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:44066314:G>C	chr6	44066314	44066032	282	rs71562789	Change in working memory in pediatric CNS tumors treated with craniospinal irradiation	1e-05	SCIRT	37038335	0.99588126	747.0	FOSL2	0.0	High Impact, Hard to Access	3
chr2:217112151:C>G	chr2	217112151	217111868	283	rs6723845	Cystatin C levels	3e-12	TESHL	33462484	0.9383409	487.0	JUNB	6.5716e-06	Low Priority	3
chr17:66150479:C>G	chr17	66150479	66150196	283	rs78606665	SOD3 protein levels	1e-11	CEP112	39789286	0.9644045	540.5	FOSL2	6.5703e-06	Low Priority	3
chr2:217112151:C>G	chr2	217112151	217111868	283	rs6723845	Estimated glomerular filtration rate (creatinine)	5e-10	TESHL	35710981	0.9383409	487.0	JUNB	6.5716e-06	Low Priority	3
chr2:217112151:C>G	chr2	217112151	217111868	283	rs6723845	Urate levels	6e-10	TESHL	33462484	0.9383409	487.0	JUNB	6.5716e-06	Low Priority	3
chr1:45297694:G>C	chr1	45297694	45297978	284	rs4233496	Height	9e-46	ZSWIM5	36224396	0.9967285	2908.0	FOS	6.56918e-06	High Impact, Hard to Access	3
chr17:28265636:C>A	chr17	28265636	28265920	284	rs241771	Serum levels of protein VEGFA	3e-13	PPY2P - KRT18P55	35078996	0.9999845	27328.0	MAFK	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:28265636:C>A	chr17	28265636	28265920	284	rs241771	Endophilin-B1 levels	1e-11	PPY2P - KRT18P55	34648354	0.9999845	27328.0	MAFK	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:28265636:C>A	chr17	28265636	28265920	284	rs241771	Blood protein levels in cardiovascular risk	3e-11	PPY2P - KRT18P55	28369058	0.9999845	27328.0	MAFK	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:16700555:C>A	chr9	16700555	16700839	284	rs10756785	Adolescent idiopathic scoliosis	7e-10	BNC2	30395268	0.99606663	609.0	FOS	6.56953e-06	High Impact, Hard to Access	3
chr15:81308454:C>G	chr15	81308454	81308169	285	rs11632978	IL16 protein levels	2.0000000000000002e-75	IL16	39789286	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:107465719:G>C	chr3	107465719	107466004	285	rs6778790	Height	2e-09	LINC01990 - BBX	31562340	0.989182	639.0	ATF2	0.000164497	HIGH PRIORITY: Accessible + High Impact	3
chr16:88736351:G>T	chr16	88736351	88736065	286	rs76354120	Osteoarthritis	5e-10	HSALR1, PIEZO1	40205036	0.98487294	805.0	BATF2	6.57056e-06	High Impact, Hard to Access	3
chr8:138668954:G>T	chr8	138668954	138669240	286	rs4909828	HDL cholesterol levels in HIV infection	4e-06	COL22A1	33109212	0.9627861	681.0	JUNB	1.31396e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:4265140:G>C	chr16	4265140	4265426	286	rs139475760	Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)	7e-06	TFAP4	40708016	0.994571	755.0	ATF3	0.0299422	HIGH PRIORITY: Accessible + High Impact	3
chr1:65364638:C>G	chr1	65364638	65364925	287	rs1570868	C-reactive protein levels	8.000000000000001e-23	DNAJC6	31900758	0.9545879	626.0	JUND	0.0	High Impact, Hard to Access	3
chr6:31295292:A>C	chr6	31295292	31295004	288	rs2524147	Lymphocyte count	8e-65	LINC02571	34469753	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr1:40693763:C>A	chr1	40693763	40694051	288	rs11419988	Body mass index	4e-09	NFYC	40436827	0.9772623	821.0	ATF3	0.000630401	HIGH PRIORITY: Accessible + High Impact	3
chr7:39681432:C>G	chr7	39681432	39681144	288	rs1034771	Type 1 diabetes	5e-06	RALA	39749473	0.9777694	665.5	MAFG	6.76425e-06	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Cobalt levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Chlorpyrifos levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	DDT metabolite (DDD p-p') levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Di-n-butyl phthalate levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	DDT metabolite (DDT o-p') levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	DDT metabolite (DDT p-p') levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Aldrin levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Cadmium chloride levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Azinphos methyl levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Disulfoton levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Endosulfan levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (AC50 high)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (AC50 low)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Dieldrin levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Dicofol levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Diazinon levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	4,6-dinitro-o-cresol levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	2,4,5-trichlorophenol levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	2,4,5-trichlorophenol-2 levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Potassium chromate levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (POD low)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Nickel levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (RfD high)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (RfD low)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Methoxychlor levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (Expo low)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Mercuric chloride-2 levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (Expo high)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Mercuric chloride levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Endrin levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Heptachlor epoxide levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Heptachlor levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Ethion levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Environmental pollutants exposure (POD high)	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Parathion levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:200081382:C>A	chr2	200081382	200081670	288	rs2347286	Pentachlorophenol levels	1e-05	MAIP1 - SPATS2L	36006120	0.9917875	634.5	MAFK	5.25389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:105110067:G>T	chr4	105110067	105109777	290	rs6835942	Height (baseline)	3.9999999999999997e-25	RNU6-351P - TET2	40374629	0.92720795	390.5	ATF2	6.58397e-06	Low Priority	3
chr4:105110067:G>T	chr4	105110067	105109777	290	rs6835942	Physical function (baseline)	2e-14	RNU6-351P - TET2	40374629	0.92720795	390.5	ATF2	6.58397e-06	Low Priority	3
chr4:105110067:G>T	chr4	105110067	105109777	290	rs6835942	Forced expiratory volume (baseline)	9e-10	RNU6-351P - TET2	40374629	0.92720795	390.5	ATF2	6.58397e-06	Low Priority	3
chr13:63445657:C>A	chr13	63445657	63445947	290	rs117204974	Granulocyte telomere length	9e-06	LINC00376 - LINC00395	35681050	0.9008302	274.75	ATF2	0.0	Low Priority	3
chr12:12277393:G>T	chr12	12277393	12277102	291	rs11054761	Height	3e-07	LRP6 - RNU6-318P	36224396	0.994183	552.0	MAFK	6.58042e-06	Low Priority	3
chr9:17684751:A>C	chr9	17684751	17684459	292	rs73422620	RBC levels of Pyruvate (uM)	4e-08	SH3GL2	36395887	0.9994327	980.5	FOS	7.87991e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:139849104:A>C	chr8	139849104	139849397	293	rs58662159	Ischemic stroke	8e-06	TRAPPC9	38317187	0.97621405	868.5	BATF	1.97068e-05	HIGH PRIORITY: Accessible + High Impact	2
chr9:70519642:C>A	chr9	70519642	70519936	294	rs117531342	Glioblastoma	5e-07	KLF9 - TRPM3	36810956	0.97511876	614.0	JUNB	6.57696e-06	High Impact, Hard to Access	3
chr17:31730095:T>A	chr17	31730095	31730390	295	rs9907690	Male-pattern baldness	4e-08	RNU6-1134P - GPR160P2	30573740	0.94588065	595.0	MAFK	6.57022e-06	High Impact, Hard to Access	3
chr6:155608372:T>A	chr6	155608372	155608667	295	rs35229355	Response to treatment for acute lymphoblastic leukemia	5e-06	NOX3 - RNU7-152P	19176441	0.9327804	433.5	FOS	1.31427e-05	Accessible, Low Impact	3
chr6:99474311:C>G	chr6	99474311	99474608	297	rs570183164	Hearing aid use	2e-07	USP45, PNISR-AS1	34847940	0.9298287	545.0	JUND	6.57134e-06	Low Priority	3
chr13:92082615:C>G	chr13	92082615	92082317	298	rs148929900	GPC5 protein levels	2e-15	GPC5	39789286	0.9957853	955.0	MAFK	2.62864e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:77259372:C>A	chr15	77259372	77259074	298	rs116902949	Height (baseline)	1e-11	PEAK1	40374629	0.9681593	535.0	JUNB	6.57652e-06	Low Priority	3
chr2:51704694:C>G	chr2	51704694	51704992	298	rs1516180	Noncognitive aspects of educational attainment	5e-10	NRXN1-DT	33414549	0.9702253	521.0	FOS	6.57696e-06	Low Priority	3
chr12:85000471:C>G	chr12	85000471	85000172	299	rs562763018	GLIPR1 protein levels	7e-13	SLC6A15 - TSPAN19	39789286	0.94588065	472.5	JUND	1.31492e-05	Accessible, Low Impact	3
chr9:16846412:T>A	chr9	16846412	16846113	299	rs10962638	Body fat distribution (leg fat ratio)	4e-10	BNC2	30664634	0.9185313	434.5	JUND	6.56452e-06	Low Priority	3
chr9:16846412:T>A	chr9	16846412	16846113	299	rs10962638	Body fat distribution (trunk fat ratio)	1e-09	BNC2	30664634	0.9185313	434.5	JUND	6.56452e-06	Low Priority	3
chr21:43046645:C>A	chr21	43046645	43046944	299	rs395256	Body mass index	2e-08	PKNOX1 - CBS	40436827	0.93191016	318.375	ATF7	0.00204188	Accessible, Low Impact	3
chr10:112933171:G>C	chr10	112933171	112933471	300	rs7912286	monocyte (fraction, maximum, inv-norm transformed)	2e-17	LINC02935	39024449	0.9908391	1420.5	ATF2	1.31534e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:159828036:T>A	chr6	159828036	159828336	300	rs11965350	Lipoprotein (a) levels	1e-11	PNLDC1 - MAS1	33462484	0.97922516	957.0	ATF3	0.0	High Impact, Hard to Access	3
chr10:112933171:G>C	chr10	112933171	112933471	300	rs7912286	Body mass index	5e-08	LINC02935	36581621	0.9908391	1420.5	ATF2	1.31534e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:52652420:G>C	chr10	52652420	52652721	301	rs17662822	Heel bone mineral density	3e-110	LNCAROD	30598549	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr2:60898016:C>G	chr2	60898016	60897715	301	rs34695944	Rheumatoid arthritis	4e-16	REL	24390342	0.9890026	616.0	ATF2	1.31353e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:60898016:C>G	chr2	60898016	60897715	301	rs34695944	Rheumatoid arthritis (ACPA-positive)	4e-13	REL	24532676	0.9890026	616.0	ATF2	1.31353e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:89504699:C>G	chr16	89504699	89505000	301	rs4785683	Hand grip strength (baseline)	1e-09	SPG7	40374629	0.9593788	1160.0	MAFK	6.58631e-06	High Impact, Hard to Access	3
chr10:53362807:C>A	chr10	53362807	53362506	301	rs41391044	Carotid Intima-media thickness (mean of the maximum cIMT)	5e-06	SNRPEP8 - RNA5SP318	35165267	0.9409573	481.5	FOS	0.000157749	Accessible, Low Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	Apolipoprotein L1 levels	1.0000000000000001e-305	DHX38	34648354	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	Serum levels of protein APOL1	2.0000000000000002e-162	DHX38	35078996	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	Apolipoprotein A-I levels	2e-135	DHX38	34648354	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	3-Hydroxybutyrate levels	1e-98	DHX38	41044249	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:133719916:C>A	chr9	133719916	133720218	302	rs142102138	DBH protein levels	4.0000000000000003e-81	SARDH	39789286	0.9955867	602.5	BATF	0.000152629	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	Serum levels of protein APOA1	5e-22	DHX38	35078996	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	LAMB1 protein levels	7e-21	DHX38	39789286	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	3-hydroxybutyrate levels (UKB data field 23474)	1e-19	DHX38	36764567	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	FSTL1 protein levels	8e-17	DHX38	39789286	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	CLSTN3 protein levels	5e-13	DHX38	39789286	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	Phospholipids to total lipids in IDL percentage (UKB data field 23609)	7e-11	DHX38	36764567	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:72097928:G>C	chr16	72097928	72098230	302	rs11075921	Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL	2e-10	DHX38	38448586	0.9881423	607.0	ATF3	1.31415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:111374174:A>C	chr6	111374174	111373870	304	rs455645	Smoking initiation	1.0000000000000001e-82	REV3L, MFSD4B	36477530	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr3:64699311:G>C	chr3	64699311	64699007	304	rs13084009	Waist-to-hip ratio adjusted for BMI	1e-09	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr3:64699311:G>C	chr3	64699311	64699007	304	rs13084009	Waist-hip index	2e-09	ADAMTS9-AS2	34021172	0.96204376	430.5	FOS	6.5716e-06	Low Priority	3
chr16:51415937:C>A	chr16	51415937	51415632	305	rs41318749	Primary open angle glaucoma (MTAG)	7e-22	UNGP1 - HNRNPA1L3	37386247	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr16:51415937:C>A	chr16	51415937	51415632	305	rs41318749	Primary open angle glaucoma (multi-trait analysis)	3e-21	UNGP1 - HNRNPA1L3	37386247	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr19:11114974:C>A	chr19	11114974	11114669	305	rs17248840	Total cholesterol levels	1e-12	LDLR	31217584	0.9879521	1266.0	JUN	6.57289e-06	High Impact, Hard to Access	3
chr16:51415937:C>A	chr16	51415937	51415632	305	rs41318749	Reaction time	3e-07	UNGP1 - HNRNPA1L3	29844566	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr15:28315754:G>T	chr15	28315754	28316060	306	rs11396433	Eye color	7.0000000000000006e-34	HERC2	36672889	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr15:28315754:G>T	chr15	28315754	28316060	306	rs11396433	Skin phototype score	2e-12	HERC2	36672889	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr15:28315754:G>T	chr15	28315754	28316060	306	rs11396433	Skin color (Fitzpatrick scale)	3e-11	HERC2	36672889	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr17:31576070:G>T	chr17	31576070	31576376	306	rs223144	Systolic blood pressure	5e-08	MIR365BHG - RNU6-1134P	40436827	0.91866904	519.0	ATF3	3.28567e-05	Accessible, Low Impact	3
chr4:156605244:C>A	chr4	156605244	156604937	307	rs13106454	prostate-specific antigen (PSA, maximum, inv-norm transformed)	4.0000000000000006e-34	FTH1P21 - LINC02272	39024449	0.98786724	343.25	FOS	6.70817e-06	Accessible, Low Impact	3
chr4:156605244:C>A	chr4	156605244	156604937	307	rs13106454	prostate-specific antigen (PSA, mean, inv-norm transformed)	7.999999999999999e-32	FTH1P21 - LINC02272	39024449	0.98786724	343.25	FOS	6.70817e-06	Accessible, Low Impact	3
chr1:219467486:C>A	chr1	219467486	219467179	307	rs2605093	Umbilical hernia	4e-15	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr4:156605244:C>A	chr4	156605244	156604937	307	rs13106454	Enlarged prostate (Benign prostatic hyperplasia)	9e-14	FTH1P21 - LINC02272	39024449	0.98786724	343.25	FOS	6.70817e-06	Accessible, Low Impact	3
chr3:16821677:C>G	chr3	16821677	16821370	307	rs9846711	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	4e-12	PLCL2	31374203	0.8952657	426.0	JUND	1.31422e-05	Accessible, Low Impact	3
chr1:219467486:C>A	chr1	219467486	219467179	307	rs2605093	Inguinal hernia	4e-09	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr11:62661784:G>C	chr11	62661784	62662091	307	rs71490396	FEV1 or irritable bowel syndrome (pleiotropy)	8e-09	INTS5 - C11orf98	38102678	0.94819474	652.0	JUN	1.97751e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:98404377:C>A	chr10	98404377	98404685	308	rs7901577	Serum metabolite levels	3e-89	PYROXD2	33031748	0.9985082	2006.0	JUNB	1.31544e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:89973987:C>A	chr2	89973987	89973679	308	rs184405696	Height (baseline)	1e-12	IGKV1D-27 - IGKV2D-26	40374629	0.9876744	999.0	MAFK	6.65035e-06	HIGH PRIORITY: Accessible + High Impact	3
chr15:25943350:C>A	chr15	25943350	25943658	308	rs78631113	Oligodendroglioma	1e-05	LINC02346	36810956	0.9917875	579.5	FOS	0.0	High Impact, Hard to Access	3
chr11:69359711:G>C	chr11	69359711	69359402	309	rs4326824	Height	6e-59	MYEOV - LINC02956	36224396	0.9870033	522.0	BATF	6.57022e-06	Low Priority	3
chr21:25335310:C>A	chr21	25335310	25335001	309	rs565440494	Abnormal posture (PheCode 781.2)	6e-18	RNA5SP489 - RPL13AP7	39024449	0.8189428	458.5	JUN	3.28891e-05	Accessible, Low Impact	3
chr17:63827693:G>C	chr17	63827693	63827384	309	rs141975038	Protein quantitative trait loci (liver)	2e-08	PSMC5, FTSJ3	32778093	0.9996589	5228.0	MAFF	1.97047e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:32207779:G>C	chr3	32207779	32207470	309	rs4955138	Overall survival in osteosarcoma	6e-06	RPSAP11 - CMTM8	29210060	0.998203	884.0	FOS	6.57134e-06	High Impact, Hard to Access	3
chr20:21890004:C>A	chr20	21890004	21890315	311	rs6047703	Adolescent idiopathic scoliosis	2e-11	RPL41P1 - LINC01432	30395268	0.9836582	411.0	MAFK	1.31525e-05	Accessible, Low Impact	3
chr2:33958228:C>A	chr2	33958228	33958539	311	rs12611527	IgA nephropathy	4e-07	LINC01320	37337107	0.7959622	429.5	ATF7	1.34407e-05	Accessible, Low Impact	3
chr4:102283377:G>T	chr4	102283377	102283688	311	rs233817	Sitting height ratio	4e-06	SLC39A8	25865494	0.97968936	476.0	JUND	6.57471e-06	Low Priority	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	Heel bone mineral density	3.9999999999999995e-182	LNCAROD	30048462	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	Dickkopf-related protein 1 levels	5e-65	LNCAROD	33067605	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	DKK1/SDC4 protein level ratio	9e-57	LNCAROD	38412862	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	DKK1 protein levels	1e-36	LNCAROD	39789286	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	Fracture of forearm	3e-21	LNCAROD	37919453	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	Total body bone mineral density	1e-09	LNCAROD	29304378	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr10:52652420:G>C	chr10	52652420	52652733	313	rs1159798	Bone stiffness index	3e-07	LNCAROD	36329257	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr5:110857950:G>C	chr5	110857950	110858263	313	rs4382205	alpha-Aminoadipic acid levels	6e-06	SLC25A46 - BCLAF1P1	35621206	0.9950484	551.5	FOS	0.021082	Accessible, Low Impact	3
chr3:41878709:C>A	chr3	41878709	41879023	314	rs9829586	COVID-19 (hospitalized vs tested, not hospitalized)	2e-06	ULK4	35224516	0.95749575	465.0	FOS	0.0	Low Priority	3
chr7:46645170:T>A	chr7	46645170	46644856	314	rs2195889	Endometriosis or asthma (pleiotropy)	5e-06	HMGN1P19 - EPS15P1	35472084	0.9702253	596.0	MAFG	6.56909e-06	HIGH PRIORITY: Accessible + High Impact	2
chr3:41878709:C>A	chr3	41878709	41879023	314	rs9829586	COVID-19 (hospitalized vs population)	7e-06	ULK4	35224516	0.95749575	465.0	FOS	0.0	Low Priority	3
chr8:135701209:G>T	chr8	135701209	135700894	315	rs4243849	Non-alcoholic fatty liver disease histology (other)	2e-06	KHDRBS3 - RNU1-35P	20708005	0.98618805	1110.0	FOS	6.57436e-06	HIGH PRIORITY: Accessible + High Impact	2
chr20:17848952:G>C	chr20	17848952	17848636	316	rs2745851	Percentage of FA2BG1 in total neutral plasma glycans (GPn) (GP63)	1e-08	BANF2 - RNU6-192P	40593539	0.96761274	878.0	ATF7	1.96902e-05	HIGH PRIORITY: Accessible + High Impact	3
chr14:97371116:T>A	chr14	97371116	97370800	316	rs17095293	Bread consumption (slices per week) (UKB data field 1438)	2e-08	LINC02304 - LINC02325	32193382	0.9470497	443.5	FOSL2	6.57237e-06	Low Priority	3
chr2:140582258:C>G	chr2	140582258	140581942	316	rs13425997	Vaginal microbiome beta diversity (Weighted Unifrac)	1e-06	LRP1B	34282934	0.9695515	527.5	JUND	6.57419e-06	Low Priority	3
chr20:17848952:G>C	chr20	17848952	17848636	316	rs2745851	IgG glycosylation	2e-06	BANF2 - RNU6-192P	23382691	0.96761274	878.0	ATF7	1.96902e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:117947009:C>A	chr11	117947009	117947326	317	rs2187639	TestASV_44 (Parasutterella) abundance	3e-06	TMPRSS13 - IL10RA	33462482	0.99972284	7888.0	ATF3	0.000341413	HIGH PRIORITY: Accessible + High Impact	3
chr1:198726542:A>C	chr1	198726542	198726860	318	rs552839429	PTPRC protein levels	1.0000000000000001e-186	PTPRC	39789286	0.9994202	3400.0	FOS	2.62608e-05	HIGH PRIORITY: Accessible + High Impact	2
chr7:50665937:G>C	chr7	50665937	50665619	318	rs2237467	Birth weight	5e-09	GRB10	31043758	0.9992518	1299.0	FOS	0.000118182	HIGH PRIORITY: Accessible + High Impact	3
chr1:14467652:C>A	chr1	14467652	14467333	319	rs181411722	Gram negative septicemia (PheCode 38.1)	3e-16	KAZN	39024449	0.961097	530.0	ATF3	0.0	Low Priority	3
chr17:69676908:C>G	chr17	69676908	69676589	319	rs2214207	Skull bone mineral density	2e-08	LINC01483	37402774	0.97455275	551.0	FOS	6.58025e-06	Low Priority	3
chr3:187880928:T>A	chr3	187880928	187880609	319	rs487575	Childhood steroid-sensitive nephrotic syndrome	1e-06	BCL6-AS1 - LINC01991	31263063	0.99254405	1204.0	FOSL1	6.57229e-06	HIGH PRIORITY: Accessible + High Impact	2
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Major depressive disorder	9.000000000000001e-29	LINC02796	34045744	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Depression	1e-27	LINC02796	37464041	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Drinks per week	2e-20	LINC02796	36477530	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy)	1e-17	LINC02796	35764056	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Obesity	2e-17	LINC02796	23563607	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Intelligence	1e-16	LINC02796	29942086	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Bipolar disorder or major depressive disorder	1e-16	LINC02796	31926635	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	1e-15	LINC02796	31835028	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr6:147271561:A>C	chr6	147271561	147271241	320	rs75993961	Protein Wnt-7a levels	1e-11	STXBP5	34814699	0.993008	908.0	FOSL2	6.57324e-06	HIGH PRIORITY: Accessible + High Impact	2
chr11:27584906:C>G	chr11	27584906	27584586	320	rs2029362	Total body bone mineral density	7e-11	BDNF-AS	29304378	0.93561655	470.5	JUND	3.944e-05	Accessible, Low Impact	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Waist circumference	2e-10	LINC02796	25673412	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Inflammatory bowel disease or major depressive disorder (pleiotropy)	3e-10	LINC02796	36753304	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Education attainment or major depressive disorder	4e-10	LINC02796	38250258	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Hip circumference	6e-10	LINC02796	25673412	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Major depressive disorder or urate levels (MTAG)	2e-09	LINC02796	38858783	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Major depressive disorder (MTAG)	1e-08	LINC02796	34159505	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Body mass index	4e-07	LINC02796	28552196	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Weight	7e-07	LINC02796	28552196	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371556	320	rs7531118	Body mass index in physically active individuals	1e-06	LINC02796	28448500	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr3:49348784:G>C	chr3	49348784	49349106	322	rs114918429	Bone mineral density mean	3e-11	USP4 - GPX1	37500982	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr3:117812119:G>C	chr3	117812119	117811797	322	rs13081204	Height	5e-08	LINC03051, LSAMP	40436827	0.973383	607.0	FOSL1	1.3447e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:27950649:C>G	chr8	27950649	27950972	323	rs2685416	Protein FAM163A levels (FAM163A.6260.14.3)	1.0000000000000001e-49	SCARA5	29875488	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr4:105110067:G>T	chr4	105110067	105110391	324	rs531713998	Height (baseline)	1e-14	RNU6-351P - TET2	40374629	0.92720795	390.5	ATF2	6.58397e-06	Low Priority	3
chr3:49771266:G>T	chr3	49771266	49770941	325	rs7431106	Post-traumatic stress disorder	2e-15	IP6K1	38637617	0.98739034	700.5	ATF2	0.0	High Impact, Hard to Access	3
chr2:173210708:C>A	chr2	173210708	173211033	325	rs1866631	High density lipoprotein cholesterol levels	2e-10	MAP3K20, MAP3K20-AS1	34887591	0.9994067	4500.0	ATF3	7.22335e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:11141598:C>A	chr16	11141598	11141273	325	rs6498168	Multiple sclerosis	1e-09	CLEC16A	27386562	0.9383409	779.0	BATF2	1.31382e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:83621561:A>C	chr11	83621561	83621886	325	rs12291033	Smoking initiation	2e-09	DLG2	36477530	0.9992518	717.0	FOS	1.31423e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:173210708:C>A	chr2	173210708	173211033	325	rs1866631	Lung cancer in ever smokers	2e-06	MAP3K20, MAP3K20-AS1	28604730	0.9994067	4500.0	ATF3	7.22335e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:136789874:G>T	chr3	136789874	136790199	325	rs13098800	Height	7e-06	STAG1-DT	28552196	0.9890026	1287.0	FOS	6.57315e-06	High Impact, Hard to Access	3
chr6:73979859:G>T	chr6	73979859	73979533	326	rs538647114	GLIPR1 protein levels	1e-22	CD109 - TXNP7	39789286	0.97511876	459.0	JUND	0.0	Low Priority	3
chr6:116956142:C>G	chr6	116956142	116956468	326	rs1741676	Fasting plasma glucose	1e-14	RFX6 - RPS29P13	36333282	0.9855452	553.0	JUND	6.57765e-06	Low Priority	3
chr11:113141325:G>C	chr11	113141325	113140999	326	rs1245133	Substance use disorder	1e-08	NCAM1	41057643	0.9964944	556.0	FOS	1.97202e-05	Accessible, Low Impact	3
chr10:5553625:C>G	chr10	5553625	5553299	326	rs77832400	Vaginal microbiome MetaCyc pathway (FUCCAT-PWY|fucose degradation)	3e-06	CALML3-AS1 - LASTR	34282934	0.9939336	718.0	FOS	4.59716e-05	HIGH PRIORITY: Accessible + High Impact	2
chr18:58243617:C>A	chr18	58243617	58243291	326	rs158856	Insomnia (caffeine-induced)	7e-06	NEDD4L	22754043	0.95842487	495.5	JUND	6.56728e-06	Low Priority	3
chr7:93921789:G>C	chr7	93921789	93922116	327	rs4262	heart rate (HR, mean, inv-normal transformed)	9e-42	GNG11	39024449	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93922116	327	rs4262	heart rate (HR, minimum, inv-normal transformed)	5.9999999999999996e-36	GNG11	39024449	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93922116	327	rs4262	Heart rate variability traits (SDNN)	4e-17	GNG11	28613276	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93922116	327	rs4262	Heart rate variability traits (pvRSA/HF)	2e-11	GNG11	28613276	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr6:50844865:G>T	chr6	50844865	50845193	328	rs2817419	Body mass index (MTAG)	4.0000000000000005e-49	TFAP2B	36376304	0.9739743	721.0	JUND	0.000236621	HIGH PRIORITY: Accessible + High Impact	3
chr6:50844865:G>T	chr6	50844865	50845193	328	rs2817419	Body mass index	6e-26	TFAP2B	35051171	0.9739743	721.0	JUND	0.000236621	HIGH PRIORITY: Accessible + High Impact	3
chr6:50844865:G>T	chr6	50844865	50845193	328	rs2817419	Gout	4e-16	TFAP2B	39406924	0.9739743	721.0	JUND	0.000236621	HIGH PRIORITY: Accessible + High Impact	3
chr6:50844865:G>T	chr6	50844865	50845193	328	rs2817419	Hemoglobin concentration	6e-13	TFAP2B	32888493	0.9739743	721.0	JUND	0.000236621	HIGH PRIORITY: Accessible + High Impact	3
chr6:50844865:G>T	chr6	50844865	50845193	328	rs2817419	Age at adiposity rebound	4e-11	TFAP2B	31840077	0.9739743	721.0	JUND	0.000236621	HIGH PRIORITY: Accessible + High Impact	3
chr6:50844865:G>T	chr6	50844865	50845193	328	rs2817419	Body fat percentage (adjusted for testosterone and SHBG)	3e-09	TFAP2B	37867527	0.9739743	721.0	JUND	0.000236621	HIGH PRIORITY: Accessible + High Impact	3
chr5:123184508:C>A	chr5	123184508	123184837	329	rs335196	Ascending aorta maximum area	2e-14	PRDM6	35922433	0.9409573	501.0	FOS	6.57203e-06	Low Priority	3
chr5:123184508:C>A	chr5	123184508	123184837	329	rs335196	Ascending aorta maximum area (MTAG)	1e-13	PRDM6	35922433	0.9409573	501.0	FOS	6.57203e-06	Low Priority	3
chr5:45586486:C>G	chr5	45586486	45586815	329	rs2580258	ECG cardiac MRI latent space	5e-09	HCN1	37105979	0.9094714	568.0	MAFK	6.57203e-06	Low Priority	3
chr10:25580741:T>A	chr10	25580741	25581070	329	rs71495469	Memory decline in impaired cognition	7e-06	GPR158	37984853	0.9283083	393.0	FOS	4.60375e-05	Accessible, Low Impact	3
chr1:119873816:A>C	chr1	119873816	119873486	330	rs185996554	ACP6 protein levels	9e-12	PFN1P9 - NOTCH2P1	39789286	0.9998704	3811.0	FOS	6.56832e-06	HIGH PRIORITY: Accessible + High Impact	2
chr6:157835526:C>G	chr6	157835526	157835196	330	rs6455847	Platelet count	3e-10	SNX9	32888493	0.925176	627.0	FOSL1	1.31834e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:70919313:G>C	chr17	70919313	70919644	331	rs55757227	4-hydroxychlorothalonil levels	6e-06	CALM2P1 - CASC17	40360795	0.994183	484.5	FOS	6.56961e-06	Low Priority	3
chr4:68446332:C>G	chr4	68446332	68446664	332	rs146674238	X-24947 levels	2e-22	MT2P1 - TMPRSS11E	36635386	0.9834347	467.0	JUND	6.57644e-06	Low Priority	3
chr4:68446332:C>G	chr4	68446332	68446664	332	rs146674238	Alkaline phosphatase (UKB data field 30610)	4e-15	MT2P1 - TMPRSS11E	39789286	0.9834347	467.0	JUND	6.57644e-06	Low Priority	3
chr17:28266252:C>A	chr17	28266252	28265920	332	rs241771	Serum levels of protein VEGFA	3e-13	PPY2P - KRT18P55	35078996	0.99999	33840.0	MAFK	6.57652e-06	High Impact, Hard to Access	3
chr4:68446332:C>G	chr4	68446332	68446664	332	rs146674238	Medication use for hyperlipidemia (number of purchases)	3e-13	MT2P1 - TMPRSS11E	36653479	0.9834347	467.0	JUND	6.57644e-06	Low Priority	3
chr4:68446332:C>G	chr4	68446332	68446664	332	rs146674238	IGF 1 (UKB data field 30770)	3e-13	MT2P1 - TMPRSS11E	39789286	0.9834347	467.0	JUND	6.57644e-06	Low Priority	3
chr6:32121157:G>C	chr6	32121157	32120825	332	rs144595899	Rheumatoid arthritis or inflammatory bowel disease	8e-13	ATF6B	37377963	0.95348793	658.0	FOSL2	1.31373e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:32121157:G>C	chr6	32121157	32120825	332	rs144595899	Rheumatoid arthritis or multiple sclerosis	1e-12	ATF6B	37377963	0.95348793	658.0	FOSL2	1.31373e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:28266252:C>A	chr17	28266252	28265920	332	rs241771	Endophilin-B1 levels	1e-11	PPY2P - KRT18P55	34648354	0.99999	33840.0	MAFK	6.57652e-06	High Impact, Hard to Access	3
chr17:28266252:C>A	chr17	28266252	28265920	332	rs241771	Blood protein levels in cardiovascular risk	3e-11	PPY2P - KRT18P55	28369058	0.99999	33840.0	MAFK	6.57652e-06	High Impact, Hard to Access	3
chr1:21283964:C>G	chr1	21283964	21283632	332	rs142311960	Prostate cancer	5e-07	ECE1	39358599	0.98327994	641.0	FOSL1	6.57272e-06	High Impact, Hard to Access	3
chr15:32224758:A>C	chr15	32224758	32224426	332	rs2651424	Liver fibrosis in non-alcoholic fatty liver disease	8e-06	Y_RNA - RNU6-18P	31311600	0.99993944	1400.5	FOS	1.31964e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119226408:G>T	chr11	119226408	119226075	333	rs12786104	platelet count (maximum, inv-norm transformed)	1.0000000000000001e-66	CBL	39024449	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:36116332:C>A	chr17	36116332	36115999	333	rs562262126	Serum levels of protein CCL4L1	2e-14	RN7SL301P - TBC1D3B	35078996	0.9283083	550.5	JUND	6.57289e-06	Low Priority	3
chr11:119226408:G>T	chr11	119226408	119226075	333	rs12786104	platelet count (minimum, inv-norm transformed)	3e-11	CBL	39024449	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119226408:G>T	chr11	119226408	119226075	333	rs12786104	potassium (mean, inv-norm transformed)	3e-11	CBL	39024449	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:45636379:G>C	chr18	45636379	45636045	334	rs12959849	Urate levels	5e-11	SLC14A2	33356394	0.9994327	1098.0	FOS	1.31422e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:124599165:C>G	chr6	124599165	124598830	335	rs629356	Memory decline	8e-06	NKAIN2	37984853	0.9342127	513.0	FOS	1.97704e-05	Accessible, Low Impact	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	TEK protein levels	4e-48	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	AOC3 protein levels	3e-45	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	AOC3/ITGB1 protein level ratio	2e-37	MMP14	38412862	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Heel bone mineral density	6e-30	MMP14	30048462	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Dupuytren's disease	2e-19	MMP14	28886342	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	CD276 protein levels	5e-19	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Contracture of palmar fascia [Dupuytren's disease] (PheCode 728.71)	4e-16	MMP14	39024449	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Plexin-A1 levels	9e-16	MMP14	34648354	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Impedance of arm right (UKB data field 23109)	7e-13	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Impedance of arm left (UKB data field 23110)	7e-13	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Frozen shoulder	1e-12	MMP14	34111113	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Adolescent idiopathic scoliosis	8e-09	MMP14	38277211	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22843385	336	rs1042704	Waist-to-hip ratio adjusted for BMI (additive genetic model)	1e-07	MMP14	30778226	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr10:103221073:C>G	chr10	103221073	103221410	337	rs10786747	Fasting blood glucose	3e-08	NT5C2	40436827	0.9814467	596.0	JUNB	6.58094e-06	High Impact, Hard to Access	3
chr16:51415937:C>A	chr16	51415937	51415600	337	rs61130724	Childhood body mass index	3e-08	UNGP1 - HNRNPA1L3	37280435	0.84346706	449.25	ATF3	5.25673e-05	Accessible, Low Impact	3
chr5:33396502:C>A	chr5	33396502	33396164	338	rs187381727	Height (baseline)	5e-09	LINC02160 - TARS1-DT	40374629	0.94468737	484.5	JUND	6.57151e-06	Low Priority	3
chr18:63083382:A>C	chr18	63083382	63083044	338	rs12970449	Global cognition (Mini Mental State Examination)	3e-06	PHLPP1 - BCL2	35386118	0.99958926	1771.0	JUN	6.57255e-06	HIGH PRIORITY: Accessible + High Impact	2
chr8:5726344:A>C	chr8	5726344	5726005	339	rs142560854	Male infertility and abnormal spermatozoa (PheCode 609)	1e-11	RPL23AP54 - RN7SKP159	40465716	0.98786724	316.375	FOS	6.57099e-06	Low Priority	3
chr8:5726344:A>C	chr8	5726344	5726005	339	rs142560854	Infertility, male (PheCode 609.1)	9e-11	RPL23AP54 - RN7SKP159	40465716	0.98786724	316.375	FOS	6.57099e-06	Low Priority	3
chr11:102700157:C>A	chr11	102700157	102699817	340	rs4121468	MMP8 protein levels	5e-14	MMP27	39789286	0.9756724	647.5	JUN	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:49523670:G>C	chr18	49523670	49523330	340	rs76290759	Cholesterol to total lipids ratio in IDL	2e-11	LINC02837	35213538	0.9875858	496.0	JUN	6.58215e-06	Low Priority	3
chr18:49523670:G>C	chr18	49523670	49523330	340	rs76290759	Fasting phospholipid levels in medium HDL	1e-08	LINC02837	34610981	0.9875858	496.0	JUN	6.58215e-06	Low Priority	3
chr4:144449854:C>A	chr4	144449854	144450194	340	rs749316	Waist-hip index	4e-08	GUSBP5 - KRT18P51	34021172	0.9957853	785.0	FOS	0.000197088	HIGH PRIORITY: Accessible + High Impact	3
chr15:56383275:G>C	chr15	56383275	56383616	341	rs35497167	Mean corpuscular hemoglobin	7.000000000000001e-31	TEX9	34594039	0.99961674	1435.5	FOSL1	1.97086e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:145694210:C>G	chr1	145694210	145694551	341	rs72704277	Urate levels	2e-10	PDZK1	33462484	0.8552694	512.0	FOSL2	6.56426e-06	Low Priority	3
chr1:247702130:G>T	chr1	247702130	247702471	341	rs3862188	Pre-treatment pain in head and neck squamous cell carcinoma	3e-08	OR13G1 - OR6F1	27670397	0.972161	588.0	FOS	1.31742e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:128168021:G>C	chr8	128168021	128167680	341	rs1499364	Red blood cell count	4e-08	PVT1	30595370	0.9996509	6948.0	JUNB	6.61472e-06	High Impact, Hard to Access	3
chr15:56383275:G>C	chr15	56383275	56383616	341	rs35497167	Mean corpuscular volume	5e-08	TEX9	34594039	0.99961674	1435.5	FOSL1	1.97086e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:31295292:A>C	chr6	31295292	31294950	342	rs76343304	MICA-MICB heterodimer protein levels	1e-10	LINC02571	38565889	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr9:74775207:C>A	chr9	74775207	74774865	342	rs78890952	Gut microbial network clusters (Salmon (at 1 year) x Household furry pet dog (3 Months) interaction	3e-09	TRPM6	40187613	0.9185313	453.5	ATF3	6.57125e-06	Low Priority	3
chr10:60030667:C>G	chr10	60030667	60030325	342	rs137898089	Venous thromboembolism adjusted for sickle cell variant rs77121243-T	4e-06	ANK3	28203683	0.9910462	1412.0	BATF	6.57099e-06	High Impact, Hard to Access	3
chr8:10580191:G>C	chr8	10580191	10580534	343	rs34092276	Waist-hip index	6e-10	PRSS55 - RP1L1	34021172	0.99939203	1206.0	FOS	6.57462e-06	High Impact, Hard to Access	3
chr8:10580191:G>C	chr8	10580191	10580534	343	rs34092276	Waist-to-hip ratio adjusted for BMI	2e-09	PRSS55 - RP1L1	34021172	0.99939203	1206.0	FOS	6.57462e-06	High Impact, Hard to Access	3
chr8:10580191:G>C	chr8	10580191	10580534	343	rs34092276	Waist circumference adjusted for body mass index	4e-09	PRSS55 - RP1L1	34021172	0.99939203	1206.0	FOS	6.57462e-06	High Impact, Hard to Access	3
chr9:123787333:G>C	chr9	123787333	123787676	343	rs10986105	Polycystic ovary syndrome	2e-06	DENND1A	26284813	0.994571	755.0	FOSL2	1.31506e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Pro-interleukin-16 levels	0.0	IL16	33067605	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	IL16/LSP1 protein level ratio	0.0	IL16	38412862	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Serum levels of protein IL16	2e-147	IL16	35078996	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Height	1e-70	IL16	36224396	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Interleukin-16 levels	2e-59	IL16	34814699	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Interleukin-16 levels (IL16.2774.10.3)	5e-59	IL16	29875488	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Protein quantitative trait loci	2e-38	IL16	32492067	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:57664409:G>T	chr18	57664409	57664753	344	rs12969748	Gamma glutamyl transferase levels	3e-25	ATP8B1, ATP8B1-AS1	33462484	0.97174054	568.5	ATF3	1.32473e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:57664409:G>T	chr18	57664409	57664753	344	rs12969748	Alanine aminotransferase levels	8e-19	ATP8B1, ATP8B1-AS1	33462484	0.97174054	568.5	ATF3	1.32473e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:57664409:G>T	chr18	57664409	57664753	344	rs12969748	Aspartate aminotransferase to alanine aminotransferase ratio	1e-17	ATP8B1, ATP8B1-AS1	33462484	0.97174054	568.5	ATF3	1.32473e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81308110	344	rs4778639	Platelet count	7e-14	IL16	40436827	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:7790523:G>C	chr16	7790523	7790179	344	rs4238884	Left ventricle wall thickness	6e-06	RBFOX1 - LINC02152	28394258	0.9645371	578.5	FOS	6.57687e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Lipoprotein (a) levels	2e-285	SLC22A1	33462484	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Low density lipoprotein cholesterol levels	1e-18	SLC22A1	33462484	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Total cholesterol levels	1e-16	SLC22A1	33462484	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Apolipoprotein B levels	2e-15	SLC22A1	33462484	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Direct low density lipoprotein levels (UKB data field 30780)	3e-14	SLC22A1	39789286	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	LDL cholesterol levels	9e-14	SLC22A1	32203549	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580)	6e-13	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487)	2e-12	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581)	7e-12	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Triglycerides to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23583)	5e-11	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr18:45396232:T>A	chr18	45396232	45396577	345	rs12965285	Height	1e-10	SLC14A2	36224396	0.963604	465.0	JUN	1.31399e-05	Accessible, Low Impact	2
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Cholesteryl esters to total lipids in large VLDL percentage (UKB data field 23591)	1e-10	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482)	3e-10	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586)	5e-10	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr6:160156692:C>A	chr6	160156692	160157037	345	rs146534110	Cholesterol to total lipids in large VLDL percentage (UKB data field 23590)	7e-10	SLC22A1	36764567	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr20:7378122:C>A	chr20	7378122	7377776	346	rs11908000	Systemic lupus erythematosus	2e-06	MIR8062 - RN7SL547P	26502338	0.9729977	452.5	BATF	1.31536e-05	Accessible, Low Impact	3
chr20:33928164:C>G	chr20	33928164	33928511	347	rs4911377	Height (baseline)	2e-19	TPM3P2 - PIGPP3	40374629	0.98058754	790.0	FOS	1.97096e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:76743952:G>T	chr5	76743952	76743605	347	rs457606	Platelet count	1e-09	F2R - F2RL1	34469753	0.9708846	591.5	ATF3	6.65274e-06	HIGH PRIORITY: Accessible + High Impact	3
chr13:91431033:C>A	chr13	91431033	91431381	348	rs118000667	Serum levels of protein GPC5	1.9999999999999999e-56	GPC5	35078996	0.8940993	460.0	MAFG	4.60199e-05	Accessible, Low Impact	3
chr16:82581788:G>C	chr16	82581788	82582136	348	rs9925015	Drinks per week	2e-09	MPHOSPH6-DT - CDH13	36477530	0.9928454	433.0	ATF3	6.57272e-06	Low Priority	3
chr19:18276172:G>C	chr19	18276172	18275824	348	rs2384991	Systemic lupus erythematosus	5e-08	IQCN - JUND	33536424	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr7:129557916:C>A	chr7	129557916	129557567	349	rs691184	Prudent dietary pattern	7e-07	SMKR1 - NRF1	28644415	0.99376744	540.5	MAFG	6.58025e-06	Low Priority	3
chr7:93043880:G>C	chr7	93043880	93043530	350	rs140176556	Height (baseline)	9e-16	RN7SL7P - SAMD9	40374629	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr7:93043880:G>C	chr7	93043880	93043530	350	rs140176556	Standing height (UKB data field 50)	2e-15	RN7SL7P - SAMD9	39789286	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr20:32022316:C>A	chr20	32022316	32022666	350	rs146973403	Cystatin C levels	9e-10	CCM2L	34226706	0.96195054	470.5	JUN	6.57367e-06	Low Priority	3
chr7:93043880:G>C	chr7	93043880	93043530	350	rs140176556	Schizophrenia	2e-06	RN7SL7P - SAMD9	35396580	0.99886686	2018.0	FOSL2	0.000105042	HIGH PRIORITY: Accessible + High Impact	3
chr10:118285270:T>A	chr10	118285270	118284920	350	rs55744556	High-sensitivity cardiac troponin T levels	1e-05	LINC02944 - FAM204A	34732054	0.7921896	440.5	JUNB	6.57903e-06	Low Priority	3
chr8:70259974:A>C	chr8	70259974	70259623	351	rs2977980	Uterine fibroids	3e-14	NCOA2	40050615	0.9999736	2393.0	FOSL2	6.56866e-06	HIGH PRIORITY: Accessible + High Impact	2
chr5:134576872:C>A	chr5	134576872	134577224	352	rs140711410	Height (baseline)	1e-10	JADE2	40374629	0.99035496	1151.0	FOS	6.56883e-06	High Impact, Hard to Access	3
chr15:100141111:T>A	chr15	100141111	100141463	352	rs56193483	Corneal resistance factor (MTAG)	3e-09	ADAMTS17	35446358	0.9860784	805.0	FOSL1	0.0	High Impact, Hard to Access	3
chr1:57353180:C>A	chr1	57353180	57353532	352	rs11588755	Insomnia	5e-09	DAB1	30804565	0.84039664	431.25	ATF3	1.32892e-05	Accessible, Low Impact	3
chr17:21107933:C>A	chr17	21107933	21107581	352	rs11658031	BMI (standard GWA)	2e-08	LINC01563	37106081	0.8819146	539.5	BATF	4.60139e-05	Accessible, Low Impact	3
chr5:134576872:C>A	chr5	134576872	134577224	352	rs140711410	Glioblastoma	2e-07	JADE2	36810956	0.99035496	1151.0	FOS	6.56883e-06	High Impact, Hard to Access	3
chr16:1322422:C>A	chr16	1322422	1322069	353	rs113690116	Tryptase beta-1 levels	6e-208	UBE2I	34648354	0.9645371	704.0	JUN	6.57774e-06	High Impact, Hard to Access	3
chr6:160831261:C>G	chr6	160831261	160830908	353	rs138491411	LPA protein levels	5e-31	PLG - MAP3K4-AS1	39789286	0.9810219	549.0	JUND	2.63033e-05	Accessible, Low Impact	3
chr17:80052125:C>G	chr17	80052125	80052478	353	rs186706847	SGSH protein levels	2e-15	CCDC40	39789286	0.9555776	707.0	FOSL1	6.56953e-06	High Impact, Hard to Access	3
chr4:59987542:G>C	chr4	59987542	59987895	353	rs10461286	Pyelonephritis (PheCode 590)	8e-07	RNU6-1325P - LINC02496	40465716	0.988674	488.5	ATF3	6.57696e-06	Low Priority	3
chr7:87438794:G>T	chr7	87438794	87439148	354	rs31674	Low density lipoprotein cholesterol levels	6e-09	ABCB4	32154731	0.9928779	1549.5	ATF2	6.57921e-06	High Impact, Hard to Access	3
chr6:126854830:G>T	chr6	126854830	126855185	355	rs77598707	Node-level brain connectivity (multivariate analysis)	2e-10	RPS4XP9 - RSPO3	36800424	0.94931644	459.0	JUND	2.62667e-05	Accessible, Low Impact	3
chr6:126854830:G>T	chr6	126854830	126855185	355	rs77598707	aparc-pial rh area TotalSurface	3e-09	RPS4XP9 - RSPO3	33875891	0.94931644	459.0	JUND	2.62667e-05	Accessible, Low Impact	3
chr6:126854830:G>T	chr6	126854830	126855185	355	rs77598707	Diastolic blood pressure (MTAG)	4e-09	RPS4XP9 - RSPO3	39537608	0.94931644	459.0	JUND	2.62667e-05	Accessible, Low Impact	3
chr3:25007960:C>A	chr3	25007960	25007605	355	rs9853280	Retinal vascular fractal dimension	9e-06	RARB	34743558	0.999142	4136.0	JUNB	6.58155e-06	High Impact, Hard to Access	3
chr11:55507674:C>A	chr11	55507674	55507318	356	rs11602661	Glycated hemoglobin levels	8e-10	OR4A21P - OR4C1P	33462484	0.8930825	368.0	FOS	1.97631e-05	Accessible, Low Impact	3
chr5:159488235:T>A	chr5	159488235	159488594	359	rs2421185	IL12B protein levels	3e-18	IL12B-AS1	39789286	0.96195054	456.0	JUND	3.28532e-05	Accessible, Low Impact	3
chr5:159488235:T>A	chr5	159488235	159488594	359	rs2421185	IL12A or IL12B protein levels	1e-14	IL12B-AS1	39789286	0.96195054	456.0	JUND	3.28532e-05	Accessible, Low Impact	3
chr3:78229951:C>A	chr3	78229951	78230311	360	rs7645322	Phoneme awareness	9e-06	RN7SKP61 - MRPS17P3	30741946	0.9872979	379.125	BATF	9.79259e-06	Accessible, Low Impact	3
chr1:19978794:A>C	chr1	19978794	19978433	361	rs4744	Blood protein levels	2e-111	PLA2G2A	30072576	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31395741	361	rs73728564	MHC class I polypeptide-related sequence A levels	5e-20	MICA-AS1	36168886	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr1:19978794:A>C	chr1	19978794	19978433	361	rs4744	Phospholipase A2, membrane associated levels	1e-15	PLA2G2A	39528825	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19978433	361	rs4744	PTN protein levels	5e-12	PLA2G2A	39789286	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr15:78532052:G>C	chr15	78532052	78531689	363	rs1847530	Cerebrospinal fluid 5-hydroxylysine levels	9e-13	HYKK	39528826	0.9943153	507.0	FOSL2	0.000368159	Accessible, Low Impact	3
chr4:151147575:C>G	chr4	151147575	151147938	363	rs78397848	Gamma glutamyl transferase levels	3e-09	SH3D19	40436827	0.9939092	980.0	ATF3	1.97094e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:57605689:A>C	chr5	57605689	57605326	363	rs112742515	Branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1) levels	2e-07	LNCBRM	40360795	0.9975752	576.0	FOS	6.58033e-06	High Impact, Hard to Access	3
chr16:82166740:C>G	chr16	82166740	82166375	365	rs7194734	Height	2.0000000000000002e-23	MPHOSPH6	34594039	0.9422262	519.0	JUNB	6.5659e-06	Low Priority	3
chr16:88736351:G>T	chr16	88736351	88736716	365	rs13333358	HDL cholesterol levels (UKB data field 30760)	5e-22	PIEZO1, HSALR1	39789286	0.98487294	805.0	BATF2	6.57056e-06	High Impact, Hard to Access	3
chr16:88736351:G>T	chr16	88736351	88736716	365	rs13333358	Red blood cell erythrocyte count (UKB data field 30010)	2e-16	PIEZO1, HSALR1	39789286	0.98487294	805.0	BATF2	6.57056e-06	High Impact, Hard to Access	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	Cognitive performance (MTAG)	9e-15	JUN-DT	30038396	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	Highest math class taken (MTAG)	5e-14	JUN-DT	30038396	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr16:82166740:C>G	chr16	82166740	82166375	365	rs7194734	Telomere length	3e-13	MPHOSPH6	35530816	0.9422262	519.0	JUNB	6.5659e-06	Low Priority	3
chr16:88736351:G>T	chr16	88736351	88736716	365	rs13333358	Haemoglobin concentration (UKB data field 30020)	6e-12	PIEZO1, HSALR1	39789286	0.98487294	805.0	BATF2	6.57056e-06	High Impact, Hard to Access	3
chr16:88736351:G>T	chr16	88736351	88736716	365	rs13333358	Reticulocyte count	6e-11	PIEZO1, HSALR1	32888494	0.98487294	805.0	BATF2	6.57056e-06	High Impact, Hard to Access	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	Cognitive performance	1e-10	JUN-DT	30038396	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	Cognitive aspects of educational attainment	2e-10	JUN-DT	33414549	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	Intelligence	5e-10	JUN-DT	29942086	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr16:82166740:C>G	chr16	82166740	82166375	365	rs7194734	Leukocyte telomere length	7e-10	MPHOSPH6	32109421	0.9422262	519.0	JUNB	6.5659e-06	Low Priority	3
chr6:151617233:G>T	chr6	151617233	151616868	365	rs12210699	Bone mineral density mean	4e-09	CCDC170	37500982	0.9814467	564.5	ATF3	6.57505e-06	Low Priority	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	Educational attainment (MTAG)	1e-08	JUN-DT	30038396	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr1:59094300:G>C	chr1	59094300	59094665	365	rs1831539	General cognitive ability	9e-08	JUN-DT	29844566	0.9949331	489.0	FOS	1.31453e-05	Accessible, Low Impact	3
chr2:240525864:G>T	chr2	240525864	240525498	366	rs4398270	PDGFA/SERPINE1 protein level ratio	1.9999999999999998e-25	ANKMY1	38412862	0.9818622	802.0	BATF2	6.57203e-06	High Impact, Hard to Access	3
chr2:240525864:G>T	chr2	240525864	240525498	366	rs4398270	PDGFA/PDGFB protein level ratio	5e-18	ANKMY1	38412862	0.9818622	802.0	BATF2	6.57203e-06	High Impact, Hard to Access	3
chr2:240525864:G>T	chr2	240525864	240525498	366	rs4398270	CASP8/DARS1 protein level ratio	2e-17	ANKMY1	38412862	0.9818622	802.0	BATF2	6.57203e-06	High Impact, Hard to Access	3
chr12:30666066:A>C	chr12	30666066	30665700	366	rs557290520	GLIPR1 protein levels	5e-15	IPO8	39789286	0.97511876	596.0	JUND	1.3133e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:34035511:G>T	chr6	34035511	34035145	366	rs902198	Height (standard GWA)	2e-14	GRM4	37106081	0.9715297	668.5	ATF7	6.57428e-06	High Impact, Hard to Access	3
chr6:34035511:G>T	chr6	34035511	34035145	366	rs902198	Biliverdin levels in elite athletes	1e-06	GRM4	31882771	0.9715297	668.5	ATF7	6.57428e-06	High Impact, Hard to Access	3
chr6:11394422:C>G	chr6	11394422	11394054	368	rs17507554	Retinal thickness (pixel 60_157)	9.999999999999999e-26	NEDD9 - RNU1-64P	39904976	0.9978391	1080.0	MAFK	1.31508e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:11394422:C>G	chr6	11394422	11394054	368	rs17507554	Macular thickness	3e-25	NEDD9 - RNU1-64P	30535121	0.9978391	1080.0	MAFK	1.31508e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:11394422:C>G	chr6	11394422	11394054	368	rs17507554	Photoreceptor cell layer thickness phenotypes (MTAG)	4e-09	NEDD9 - RNU1-64P	36848389	0.9978391	1080.0	MAFK	1.31508e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:18151864:C>G	chr3	18151864	18151496	368	rs6577621	Glasses or contact lenses use (age of onset) (UKB data field 2217)	8e-09	TBC1D5	35220419	0.96195054	506.0	JUND	6.57289e-06	Low Priority	3
chr17:18048756:C>G	chr17	18048756	18049125	369	rs11652894	Myocardial infarction	5e-09	GID4	33532862	0.97898656	469.0	ATF3	6.58623e-06	Low Priority	3
chr10:13494456:C>G	chr10	13494456	13494086	370	rs11258419	Neutrophil count	2e-18	BEND7	32888493	0.8885958	610.5	ATF7	0.000111758	HIGH PRIORITY: Accessible + High Impact	3
chr2:83305838:C>A	chr2	83305838	83305468	370	rs74867097	COVID-19	2e-06	DHFRP3 - LINC01809	35224516	0.9834347	996.5	FOS	6.57419e-06	High Impact, Hard to Access	3
chr2:83305838:C>A	chr2	83305838	83305468	370	rs74867097	COVID-19 (covid vs negative)	1e-05	DHFRP3 - LINC01809	35224516	0.9834347	996.5	FOS	6.57419e-06	High Impact, Hard to Access	3
chr1:26667900:C>A	chr1	26667900	26668271	371	rs34232231	Personality traits or cognitive traits (multivariate analysis)	9e-10	RNU7-29P - ARID1A	37365406	0.9575012	518.5	MAFF	1.31763e-05	Accessible, Low Impact	3
chr1:26667900:C>A	chr1	26667900	26668271	371	rs34232231	Plateletcrit	3e-09	RNU7-29P - ARID1A	32888494	0.9575012	518.5	MAFF	1.31763e-05	Accessible, Low Impact	3
chr1:213364816:G>C	chr1	213364816	213365187	371	rs7543981	Pulmonary embolism	4e-08	RPS6KC1 - RPL31P13	37076872	0.91499144	562.5	FOS	6.578e-06	Low Priority	3
chr21:23301400:C>A	chr21	23301400	23301772	372	rs73343199	Absolute neutrophil count	4e-07	RNU2-55P - EEF1A1P1	33848412	0.9327804	405.0	FOS	6.5741e-06	Low Priority	3
chr1:212246571:C>A	chr1	212246571	212246944	373	rs10863958	Smoking initiation	3e-10	LINC02608	36477530	0.9131995	585.5	FOS	6.57013e-06	High Impact, Hard to Access	3
chr8:125618697:C>A	chr8	125618697	125618324	373	rs72724622	Type 2 diabetes	2e-08	TRIB1AL - LINC02964	38685053	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125618324	373	rs72724622	Cholesterol to total lipids ratio in large LDL	4e-08	TRIB1AL - LINC02964	35213538	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:233926291:C>A	chr2	233926291	233926665	374	rs17863840	Total bilirubin levels	9.000000000000001e-29	TRPM8	33462484	0.92024124	694.0	JUNB	0.000124933	HIGH PRIORITY: Accessible + High Impact	3
chr2:233926291:C>A	chr2	233926291	233926665	374	rs17863840	Direct bilirubin levels	7e-18	TRPM8	33462484	0.92024124	694.0	JUNB	0.000124933	HIGH PRIORITY: Accessible + High Impact	3
chr1:219604005:G>T	chr1	219604005	219604379	374	rs11118357	Umbilical hernia	3e-09	LYPLAL1-AS1 - ZC3H11B	34382107	0.8072176	291.75	FOSL2	6.57212e-06	Low Priority	3
chr20:56535287:G>T	chr20	56535287	56534912	375	rs4630823	Neutral antibody levels in response to SARS-CoV-2 vaccination	9e-08	FAM209B	36451823	0.9836582	598.0	MAFK	1.31782e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:88558661:G>C	chr16	88558661	88559038	377	rs139767369	Hemoglobin A1c levels	5.999999999999999e-70	ZFPM1 - ZC3H18	39414775	0.9988404	823.0	FOSL2	0.00133841	HIGH PRIORITY: Accessible + High Impact	3
chr16:88558661:G>C	chr16	88558661	88559038	377	rs139767369	Red cell distribution width	5e-30	ZFPM1 - ZC3H18	39414775	0.9988404	823.0	FOSL2	0.00133841	HIGH PRIORITY: Accessible + High Impact	3
chr16:88558661:G>C	chr16	88558661	88559038	377	rs139767369	Red blood cell count	9.999999999999999e-27	ZFPM1 - ZC3H18	39414775	0.9988404	823.0	FOSL2	0.00133841	HIGH PRIORITY: Accessible + High Impact	3
chr16:88558661:G>C	chr16	88558661	88559038	377	rs139767369	Hemoglobin levels	3.9999999999999997e-25	ZFPM1 - ZC3H18	39414775	0.9988404	823.0	FOSL2	0.00133841	HIGH PRIORITY: Accessible + High Impact	3
chr16:88558661:G>C	chr16	88558661	88559038	377	rs139767369	Mean corpuscular volume	1e-20	ZFPM1 - ZC3H18	39414775	0.9988404	823.0	FOSL2	0.00133841	HIGH PRIORITY: Accessible + High Impact	3
chr6:37691964:C>A	chr6	37691964	37692341	377	rs6916856	Insomnia	9e-16	MDGA1	35835914	0.9921947	1598.5	FOSL1	6.56875e-06	High Impact, Hard to Access	3
chr3:57120218:A>C	chr3	57120218	57119841	377	rs747089	Height	9e-12	IL17RD	36224396	0.9998704	1599.0	FOSL1	1.31387e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:68785771:C>G	chr12	68785771	68786149	378	rs11177372	Blood pressure (pleiotropy model 1 DBP adjusted for estimated causal effects x SBP)	2e-16	SLC35E3	34989438	0.9975242	2167.0	ATF3	6.56745e-06	HIGH PRIORITY: Accessible + High Impact	2
chr12:68785771:C>G	chr12	68785771	68786149	378	rs11177372	Blood pressure (pleiotropy model 2 SBP adjusted for estimated causal effects x DBP)	4e-13	SLC35E3	34989438	0.9975242	2167.0	ATF3	6.56745e-06	HIGH PRIORITY: Accessible + High Impact	2
chr12:68785771:C>G	chr12	68785771	68786149	378	rs11177372	Mean reticulocyte volume (UKB data field 30260)	7e-12	SLC35E3	39789286	0.9975242	2167.0	ATF3	6.56745e-06	HIGH PRIORITY: Accessible + High Impact	2
chr12:68785771:C>G	chr12	68785771	68786149	378	rs11177372	Mean reticulocyte volume	5e-09	SLC35E3	32888494	0.9975242	2167.0	ATF3	6.56745e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:12756984:T>A	chr7	12756984	12757363	379	rs545164356	GLIPR1 protein levels	1e-15	ARL4A - RN7SKP228	39789286	0.9879521	677.0	FOSL1	7.22914e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:120081240:C>G	chr11	120081240	120080861	379	rs10892532	Interleukin-25 levels	5e-13	LINC02744 - TRIM29	36168886	0.93191016	561.5	FOS	0.0	Low Priority	3
chr5:180911270:C>A	chr5	180911270	180911649	379	rs148293230	Colorectal cancer x estrogen hormone therapy interaction (2df test)	2e-06	BTNL8	35512400	0.9981182	977.0	FOS	1.31325e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:180911270:C>A	chr5	180911270	180911649	379	rs148293230	Colorectal cancer x estrogen hormone therapy interaction (3df test)	3e-06	BTNL8	35512400	0.9981182	977.0	FOS	1.31325e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:83561711:A>G	chr9	83561711	83562090	379	rs148334987	Aerodigestive squamous cell cancer (pleiotropy)	8e-06	FRMD3 - RNU4-15P	33667223	0.9999062	2888.0	MAFK	6.56883e-06	High Impact, Hard to Access	3
chr7:99502602:T>A	chr7	99502602	99502222	380	rs141579238	Gamma glutamyl transferase levels	3e-12	ZNF789, ZKSCAN5, ZNF394	40436827	0.90298235	414.75	FOS	1.31465e-05	Accessible, Low Impact	2
chr6:149891655:G>T	chr6	149891655	149892036	381	rs567051977	LRP11 protein levels	2e-21	RAET1E, RAET1E-AS1	39789286	0.9417692	448.5	JUND	6.57229e-06	Low Priority	3
chr1:75801597:G>T	chr1	75801597	75801979	382	rs182408933	Nonsyndromic cleft palate	2e-06	MSH4	39500877	0.9697459	661.0	MAFF	6.60939e-06	High Impact, Hard to Access	3
chr7:17943291:A>C	chr7	17943291	17943674	383	rs4543441	Body size or adipose distribution (multivariate analysis)	5e-08	SNX13 - MRM3P2	40796553	0.9995699	927.0	FOS	6.57367e-05	HIGH PRIORITY: Accessible + High Impact	2
chr10:93585926:C>A	chr10	93585926	93586310	384	rs10882271	Waist-hip index	1e-14	FFAR4	34021172	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:3514228:C>G	chr19	3514228	3513844	384	rs10417686	Free cholesterol in medium HDL	5e-11	FZR1	41044249	0.9545879	762.0	JUND	6.56918e-06	High Impact, Hard to Access	3
chr19:3514228:C>G	chr19	3514228	3513844	384	rs10417686	Apolipoprotein A1 levels	5e-11	FZR1	41044249	0.9545879	762.0	JUND	6.56918e-06	High Impact, Hard to Access	3
chr19:3514228:C>G	chr19	3514228	3513844	384	rs10417686	Concentration of medium HDL particles	1e-10	FZR1	41044249	0.9545879	762.0	JUND	6.56918e-06	High Impact, Hard to Access	3
chr19:3514228:C>G	chr19	3514228	3513844	384	rs10417686	Phospholipids in HDL	1e-10	FZR1	41044249	0.9545879	762.0	JUND	6.56918e-06	High Impact, Hard to Access	3
chr10:103182872:C>G	chr10	103182872	103182487	385	rs34747231	systolic blood pressure (SBP, mean, inv-normal transformed)	3e-41	NT5C2	39024449	0.9868027	797.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:16722308:G>C	chr9	16722308	16721923	385	rs146494938	Body mass index	1e-21	BNC2	34594039	0.99746656	2526.0	MAFK	6.56996e-06	High Impact, Hard to Access	3
chr7:33465301:G>T	chr7	33465301	33465686	385	rs1362228	Primary open angle glaucoma (multi-trait analysis)	1e-08	BBS9	37386247	0.9787506	584.75	JUND	0.0	High Impact, Hard to Access	3
chr18:58267065:T>A	chr18	58267065	58266680	385	rs62094545	Depression (age of onset)	8e-06	NEDD4L	35330412	0.9470497	489.5	FOS	6.57575e-06	Low Priority	3
chr6:31395380:G>T	chr6	31395380	31394993	387	rs2523469	NCAN protein levels	4e-13	MICA-AS1	39789286	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr1:45297694:G>C	chr1	45297694	45298081	387	rs4233497	Height	9e-09	ZSWIM5	36224396	0.9967285	2908.0	FOS	6.56918e-06	High Impact, Hard to Access	3
chr12:106132981:G>C	chr12	106132981	106132593	388	rs115095912	Serum levels of protein SMIM13	5e-13	NUAK1	35078996	0.9970844	1862.0	FOS	0.000111744	HIGH PRIORITY: Accessible + High Impact	3
chr17:36497698:C>G	chr17	36497698	36497309	389	rs72818336	C-C motif chemokine 4-like levels	7e-18	ZNHIT3, MYO19	36168886	0.96670574	695.0	JUND	6.57367e-06	High Impact, Hard to Access	3
chr15:60799325:G>T	chr15	60799325	60798936	389	rs35043218	Phosphatidylethanolamine (38:6) levels	7e-10	RORA	35393526	0.9834347	956.0	JUNB	6.57168e-06	High Impact, Hard to Access	3
chr2:44057396:G>C	chr2	44057396	44057785	389	rs10202948	Smoking x traumatic event in childhood (sexually molested) interaction	3e-08	LRPPRC - PPM1B-DT	34417442	0.9923346	1003.0	FOS	0.000210299	HIGH PRIORITY: Accessible + High Impact	3
chr8:131460245:C>A	chr8	131460245	131459855	390	rs10505574	Visceral adipose tissue	3e-07	SNORA72 - EFR3A	26480920	0.79481876	338.5	ATF2	6.57315e-06	Low Priority	3
chr1:248188641:G>T	chr1	248188641	248189032	391	rs4475789	Coffee consumption	1e-07	OR2M2 - OR2M3	31046077	0.9803781	105.53125	MAFK	0.0	Low Priority	3
chr3:20589414:G>C	chr3	20589414	20589806	392	rs9866123	Educational attainment (years of education)	1e-09	SGO1-AS1	30038396	0.9983986	1350.0	FOSL2	6.57462e-06	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61903684	393	rs1151139	Mean corpuscular hemoglobin	9e-11	RAB3IL1	32888493	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr9:101650995:G>C	chr9	101650995	101651388	393	rs12380816	Educational attainment (MTAG)	2e-09	GRIN3A	30038396	0.9896673	449.0	FOS	0.00751083	Accessible, Low Impact	3
chr9:101650995:G>C	chr9	101650995	101651388	393	rs12380816	Highest math class taken (MTAG)	1e-08	GRIN3A	30038396	0.9896673	449.0	FOS	0.00751083	Accessible, Low Impact	3
chr16:53422873:A>C	chr16	53422873	53422479	394	rs62048491	Waist-to-hip ratio adjusted for BMI	2e-12	MPHOSPH10P1 - RBL2	31669095	0.99843514	675.0	FOS	6.57237e-06	High Impact, Hard to Access	3
chr9:82071500:C>A	chr9	82071500	82071894	394	rs192693579	Spondin-1 levels	8e-07	SPATA31B1P - DDX10P2	33067605	0.85351515	283.75	FOS	0.0	Low Priority	3
chr17:39867887:C>G	chr17	39867887	39867492	395	rs4795397	Lymphocyte count	4e-57	IKZF3 - ZPBP2	32888493	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr17:39867887:C>G	chr17	39867887	39867492	395	rs4795397	Inflammatory bowel disease	8e-44	IKZF3 - ZPBP2	26192919	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr17:39867887:C>G	chr17	39867887	39867492	395	rs4795397	Lymphocyte count (UKB data field 30120)	2.9999999999999998e-36	IKZF3 - ZPBP2	39789286	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr17:39867887:C>G	chr17	39867887	39867492	395	rs4795397	Platelet-to-lymphocyte ratio	3.9999999999999996e-30	IKZF3 - ZPBP2	34469753	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr17:39867887:C>G	chr17	39867887	39867492	395	rs4795397	Asthma and cardiovascular disease	9e-28	IKZF3 - ZPBP2	35126453	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr17:39867887:C>G	chr17	39867887	39867492	395	rs4795397	Asthma	4e-12	IKZF3 - ZPBP2	28461288	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr12:117657044:C>A	chr12	117657044	117657440	396	rs142960195	Protein quantitative trait loci (liver)	2e-08	KSR2	32778093	0.9785014	359.375	BATF	0.000347813	Accessible, Low Impact	3
chr14:96609148:C>A	chr14	96609148	96608752	396	rs74089505	Oligodendroglioma	3e-06	PAPOLA - RN7SKP108	36810956	0.9055997	657.0	JUND	6.57039e-06	High Impact, Hard to Access	3
chr6:6170596:C>G	chr6	6170596	6170992	396	rs13362686	COVID-19 (hospitalized covid vs population)	7e-06	F13A1	39361370	0.90755373	454.5	JUND	6.5672e-06	Low Priority	3
chr20:24736404:G>C	chr20	24736404	24736007	397	rs138244010	CST5 protein levels	2e-13	SYNDIG1 - LINC02967	39789286	0.9996663	2055.0	MAFG	1.97073e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:91199836:G>T	chr15	91199836	91199439	397	rs2285528	Low myopia	6e-06	SV2B	33830181	0.9977887	627.0	MAFG	1.31316e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:39409136:C>A	chr13	39409136	39409534	398	rs9315681	Circulating odd-numbered chain saturated fatty acid levels (C17:0)	1e-06	LHFPL6	29738550	0.9872979	479.0	FOS	1.9728e-05	Accessible, Low Impact	3
chr11:95122336:C>G	chr11	95122336	95121937	399	rs55688751	Reticulocyte count	1e-13	ENDOD1	32888494	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:95122336:C>G	chr11	95122336	95121937	399	rs55688751	High light scatter reticulocyte count	2e-10	ENDOD1	32888494	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:95122336:C>G	chr11	95122336	95121937	399	rs55688751	High light scatter reticulocyte percentage of red cells	3e-10	ENDOD1	32888494	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:20399750:G>T	chr7	20399750	20399351	399	rs17365498	Lung function (FVC)	9e-09	ITGB8	30595370	0.9972157	1054.0	ATF2	6.57583e-06	High Impact, Hard to Access	3
chr8:102907262:C>G	chr8	102907262	102906862	400	rs11993347	Skull bone mineral density	2e-12	MAILR	37402774	0.9555776	580.5	JUNB	6.58311e-06	High Impact, Hard to Access	3
chr17:67940464:A>C	chr17	67940464	67940064	400	rs781830044	Saturated fatty acids levels	2e-11	BPTF	41044249	0.9996813	1477.0	FOS	1.31325e-05	HIGH PRIORITY: Accessible + High Impact	3
chr14:63697510:C>G	chr14	63697510	63697110	400	rs7148755	Sphingomyelin(32:1)_[M+H]1+ levels	2e-10	SGPP1	34503513	0.972161	497.0	JUND	3.28735e-05	Accessible, Low Impact	3
chr11:133479411:C>A	chr11	133479411	133479811	400	rs6590712	Substance use disorder	1e-08	OPCML	41057643	0.9036088	583.0	FOSL1	6.57065e-06	High Impact, Hard to Access	3
chr17:67940464:A>C	chr17	67940464	67940064	400	rs781830044	Total fatty acid levels	5e-08	BPTF	40545721	0.9996813	1477.0	FOS	1.31325e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:110110063:G>C	chr13	110110063	110109663	400	rs191527530	X-11787 levels	5e-06	LINC03082	40360795	0.99985456	2946.0	JUN	6.57212e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334483	403	rs7947951	Total bilirubin levels	6e-20	BMAL1	34594039	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334483	403	rs7947951	Gamma glutamyl transferase levels	5e-16	BMAL1	40436827	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334483	403	rs7947951	MEP1B protein levels	5e-14	BMAL1	39789286	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334483	403	rs7947951	Triglyceride levels	6e-14	BMAL1	31928498	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr2:207617434:G>T	chr2	207617434	207617031	403	rs2551944	Estimated glomerular filtration rate (creatinine)	4e-12	METTL21A	35710981	0.9992865	2594.0	JUN	6.56616e-06	HIGH PRIORITY: Accessible + High Impact	2
chr9:93682031:G>C	chr9	93682031	93681628	403	rs7040340	Educational attainment (years of education)	1e-11	PHF2 - MIR4291	30038396	0.9727787	1047.0	JUND	6.56866e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334483	403	rs7947951	Sex hormone-binding globulin levels	8e-10	BMAL1	34321204	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr9:93682031:G>C	chr9	93682031	93681628	403	rs7040340	Educational attainment	2e-08	PHF2 - MIR4291	34855049	0.9727787	1047.0	JUND	6.56866e-06	High Impact, Hard to Access	3
chr11:119701011:G>C	chr11	119701011	119701414	403	rs73004983	Gut microbial network clusters (Salmon (at 1 year) x Any Breastfeeding (Duration) interaction	6e-08	NECTIN1	40187613	0.9998168	5210.0	JUNB	6.57168e-06	High Impact, Hard to Access	3
chr11:13334080:A>C	chr11	13334080	13334483	403	rs7947951	Systolic blood pressure	1e-07	BMAL1	31928498	0.99931777	1287.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr5:34753421:A>C	chr5	34753421	34753017	404	rs6893700	DSG4 protein levels	1e-12	RAI14	39789286	0.9998405	1820.0	JUND	1.31434e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:34753421:A>C	chr5	34753421	34753017	404	rs6893700	Hair color	8e-10	RAI14	30595370	0.9998405	1820.0	JUND	1.31434e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:78606918:G>C	chr6	78606918	78606513	405	rs10806133	Educational attainment (years of education)	3e-08	MEI4 - IRAK1BP1	30038396	0.9868027	742.0	FOS	2.63387e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:139806376:C>G	chr7	139806376	139806781	405	rs10277664	Gray matter volume (schizophrenia interaction)	1e-07	TBXAS1	24086445	0.9764474	522.5	MAFK	2.63227e-05	Accessible, Low Impact	3
chr3:49364830:G>C	chr3	49364830	49365236	406	rs193100523	Fluid intelligence score (baseline)	4e-08	RHOA, RHOA-IT1	40374629	0.98289305	638.0	BATF	7.24896e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:4069294:C>A	chr19	4069294	4068887	407	rs60722909	White blood cell count	2e-09	ZBTB7A - MAP2K2	40436827	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:109591828:G>A	chr10	109591828	109592235	407	rs61881849	Protein quantitative trait loci (liver)	1e-08	BTF3P15 - XIAPP1	32778093	0.9944655	1146.5	MAFK	0.000302043	HIGH PRIORITY: Accessible + High Impact	3
chr17:39395327:G>T	chr17	39395327	39395735	408	rs10491128	Estimated glomerular filtration rate (creatinine)	1e-106	FBXL20	35710981	0.97898656	736.0	FOSL1	6.57056e-06	High Impact, Hard to Access	3
chr4:145776319:G>C	chr4	145776319	145775911	408	rs6818581	Height	3.0000000000000003e-31	ZNF827	36224396	0.9970844	1467.0	JUN	1.97329e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:39395327:G>T	chr17	39395327	39395735	408	rs10491128	Estimated glomerular filtration rate in non-diabetics	4e-15	FBXL20	31451708	0.97898656	736.0	FOSL1	6.57056e-06	High Impact, Hard to Access	3
chr18:24822769:C>A	chr18	24822769	24822361	408	rs72887889	Educational attainment	2e-12	LINC01915 - LINC01894	35361970	0.8209431	568.5	JUND	6.57652e-06	High Impact, Hard to Access	3
chr18:24822769:C>A	chr18	24822769	24822361	408	rs72887889	Whole body fat mass (UKB data field 23100)	7e-09	LINC01915 - LINC01894	38538606	0.8209431	568.5	JUND	6.57652e-06	High Impact, Hard to Access	3
chr3:191283427:T>A	chr3	191283427	191283019	408	rs10937470	Total ventricular volume (Alzheimer's disease interaction)	9e-06	UTS2B	21116278	0.9988686	2849.5	JUNB	6.57203e-06	High Impact, Hard to Access	3
chr4:145776319:G>C	chr4	145776319	145775911	408	rs6818581	Breast cancer	9e-06	ZNF827	29059683	0.9970844	1467.0	JUN	1.97329e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:38234799:G>C	chr19	38234799	38234390	409	rs8103692	PSAPL1 protein levels	6e-12	DPF1 - SPINT2	39789286	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:44112267:T>A	chr2	44112267	44112677	410	rs72800950	Cholelithiasis (UKB data field 20002_1162)	2e-51	LRPPRC - PPM1B-DT	37965154	0.9987876	1027.0	JUND	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	2
chr15:60489724:G>C	chr15	60489724	60489314	410	rs3743266	Height	2e-17	RORA, RORA-AS1	30595370	0.9921564	616.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr15:60489724:G>C	chr15	60489724	60489314	410	rs3743266	Standing height (UKB data field 50)	4e-16	RORA, RORA-AS1	39789286	0.9921564	616.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr15:60489724:G>C	chr15	60489724	60489314	410	rs3743266	Menarche (age at onset)	2e-13	RORA, RORA-AS1	25231870	0.9921564	616.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr15:60489724:G>C	chr15	60489724	60489314	410	rs3743266	Height (baseline)	2e-13	RORA, RORA-AS1	40374629	0.9921564	616.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr15:60489724:G>C	chr15	60489724	60489314	410	rs3743266	Male puberty timing (age at voice breaking MTAG)	2e-12	RORA, RORA-AS1	32210231	0.9921564	616.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr15:60489724:G>C	chr15	60489724	60489314	410	rs3743266	Male puberty timing (late vs. average onset facial hair)	2e-07	RORA, RORA-AS1	32210231	0.9921564	616.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr2:241605958:C>A	chr2	241605958	241605547	411	rs6414219	Hypothyroidism (PheCode 244)	1e-13	THAP4	39024449	0.9710905	540.5	FOS	6.56987e-06	Low Priority	3
chr4:7435002:C>A	chr4	7435002	7435413	411	rs140402034	PSAPL1 protein levels	1e-13	SORCS2	39789286	0.99560076	2678.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr9:106290641:A>C	chr9	106290641	106291053	412	rs56057588	L1-L4 bone mineral density x serum urate levels interaction	8e-06	LINC01505	34046847	0.9545879	482.0	JUN	6.57142e-06	Low Priority	3
chr1:65910899:G>T	chr1	65910899	65910486	413	rs116008365	C-reactive protein levels (UKB data field 30710)	1e-13	PDE4B	39789286	0.94819474	467.5	JUND	1.3148e-05	Accessible, Low Impact	3
chr2:88112497:T>A	chr2	88112497	88112912	415	rs115495247	Bone mineral density mean	1e-300	SMYD1	37500982	0.9627861	532.5	JUNB	2.62854e-05	Accessible, Low Impact	3
chr9:84630160:A>C	chr9	84630160	84629745	415	rs72737615	Drinks per week	3e-12	SLC28A3 - NTRK2	36477530	0.9990792	653.5	FOS	6.56909e-06	High Impact, Hard to Access	3
chr17:70408512:A>C	chr17	70408512	70408927	415	rs11870969	C-reactive protein levels (MTAG)	2e-09	CALM2P1 - CASC17	36376304	0.9994327	974.0	FOS	0.0	High Impact, Hard to Access	3
chr4:30826599:C>G	chr4	30826599	30826183	416	rs4619848	Attention deficit hyperactivity disorder	4e-06	PCDH7	40962958	0.95041513	468.5	JUND	0.0	Low Priority	2
chr10:114887101:T>A	chr10	114887101	114887518	417	rs113721756	Complement factor H-related protein 3 levels	2e-08	FHIP2A	34260948	0.989182	486.0	FOS	0.533905	Accessible, Low Impact	3
chr5:54117207:G>C	chr5	54117207	54116790	417	rs279744	Type 2 diabetes	3e-08	ARL15	30297969	0.9840279	543.5	FOS	0.000124918	Accessible, Low Impact	3
chr12:63847653:G>C	chr12	63847653	63848070	417	rs7960838	CXCL6 levels	2e-06	SRGAP1	38326779	0.9978883	879.0	FOS	1.31537e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:11590002:C>G	chr8	11590002	11589584	418	rs55896564	Adult body size	3e-17	LINC00208 - GATA4	32376654	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr8:11590002:C>G	chr8	11590002	11589584	418	rs55896564	Medication use (diuretics)	5e-15	LINC00208 - GATA4	34594039	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr2:226317592:C>A	chr2	226317592	226318010	418	rs58335745	Glutamine levels	8e-15	NYAP2 - MIR5702	41044249	0.9818622	687.5	JUN	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:27241867:T>A	chr11	27241867	27242285	418	rs11604730	Diastolic blood pressure	6e-10	BBOX1-AS1 - CCDC34	40436827	0.9984708	1516.5	JUNB	1.31389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:11590002:C>G	chr8	11590002	11589584	418	rs55896564	Accumbens iron levels (quantitative susceptibility mapping)	2e-08	LINC00208 - GATA4	38789058	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr10:103182872:C>G	chr10	103182872	103183291	419	rs11191595	Body mass index	6e-11	NT5C2	31669095	0.9868027	797.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:103182872:C>G	chr10	103182872	103183291	419	rs11191595	Insomnia symptoms (never/rarely vs. usually)	1e-09	NT5C2	30804566	0.9868027	797.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:103182872:C>G	chr10	103182872	103183291	419	rs11191595	Insomnia symptoms (never/rarely vs. sometimes/usually)	2e-09	NT5C2	30804566	0.9868027	797.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:103182872:C>G	chr10	103182872	103183291	419	rs11191595	Whole body fat mass (UKB data field 23100)	9e-09	NT5C2	38538606	0.9868027	797.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:26670063:C>A	chr6	26670063	26669643	420	rs3956845	Body mass index	4e-11	ZNF322 - GUSBP2	38538606	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:41202361:G>C	chr6	41202361	41201941	420	rs17643398	Waist circumference	5e-06	TREML2 - TREML3P	28552196	0.9918291	1406.5	ATF3	6.5741e-06	High Impact, Hard to Access	3
chr7:92547747:C>A	chr7	92547747	92547326	421	rs11772579	Hip circumference adjusted for BMI	1e-10	RBM48 - FAM133B	34021172	0.9882237	1096.0	BATF2	1.97127e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:64813048:C>G	chr15	64813048	64812627	421	rs4777602	Platelet distribution width	4e-09	RBPMS2 - PIF1	32888494	0.9772623	1997.0	FOSL2	1.31444e-05	HIGH PRIORITY: Accessible + High Impact	3
chr14:51360658:A>C	chr14	51360658	51361080	422	rs139706713	Ischemic stroke in hypertension	3e-06	LINC00640	33632238	0.99954957	1561.0	JUNB	1.31432e-05	HIGH PRIORITY: Accessible + High Impact	2
chr6:31295292:A>C	chr6	31295292	31295715	423	rs28732114	Lifetime major depressive disorder (AutoComplete Impute)	3e-08	LINC02571	37985818	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr2:54673339:C>G	chr2	54673339	54673762	423	rs142874192	Urate levels	7e-07	SPTBN1-AS2	31578528	0.99746656	2064.0	ATF2	6.57272e-06	High Impact, Hard to Access	3
chr10:100289645:G>C	chr10	100289645	100289222	423	rs12765052	Squamous cell lung carcinoma	1e-06	PKD2L1	28604730	0.9840279	1636.625	FOS	6.5703e-06	High Impact, Hard to Access	3
chr2:29058318:G>C	chr2	29058318	29057895	423	rs882632	Major depressive disorder	2e-06	TOGARAM2 - PCARE	20125088	0.9899018	623.0	FOSL1	6.56607e-06	High Impact, Hard to Access	3
chr9:114232689:C>A	chr9	114232689	114232265	424	rs747771422	Spinal cord injury without evidence of spinal bone injury (PheCode 952)	1e-13	COL27A1	39024449	0.96533185	733.0	FOS	0.000991243	HIGH PRIORITY: Accessible + High Impact	3
chr2:221437260:C>G	chr2	221437260	221437685	425	rs56099808	Weight	3e-09	EPHA4	34594039	0.98487294	590.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr11:62081229:C>A	chr11	62081229	62080804	425	rs12420131	Docosahexaenoic acid levels	1e-08	LINC02733	40545721	0.9383409	582.5	JUNB	1.31572e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:51028649:C>A	chr18	51028649	51028224	425	rs150912768	Hippocampal volume	7e-07	ELAC1 - SMAD4	34785643	0.97922516	768.25	FOSL1	6.57022e-06	High Impact, Hard to Access	3
chr13:83399642:C>A	chr13	83399642	83400067	425	rs4414368	Acute kidney injury	2e-06	RNU6-67P - SLITRK1	37273234	0.9131995	369.5	FOS	0.0	Low Priority	3
chr8:5658231:C>A	chr8	5658231	5657806	425	rs7001733	Vascular dementia	9e-06	RPL23AP54 - RN7SKP159	39046104	0.97360545	454.5	FOS	6.57333e-06	Low Priority	3
chr9:23379022:C>A	chr9	23379022	23379448	426	rs11999669	Intelligence	2e-08	LINC03142	29942086	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr2:37664548:C>A	chr2	37664548	37664975	427	rs7586641	Cortical surface area (MOSTest)	8e-15	CDC42EP3-AS1, CDC42EP3	32665545	0.992679	868.0	FOS	1.31551e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:37664548:C>A	chr2	37664548	37664975	427	rs7586641	Brain morphology (MOSTest)	2e-11	CDC42EP3-AS1, CDC42EP3	32665545	0.992679	868.0	FOS	1.31551e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:19978794:A>C	chr1	19978794	19978364	430	rs2307246	Group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP	0.0	PLA2G2A	31070471	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19978364	430	rs2307246	Phospholipase A2, membrane associated levels (PLA2G2A.2692.74.2)	0.0	PLA2G2A	29875488	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr6:39779881:C>A	chr6	39779881	39779451	430	rs1504329	Height	2e-13	KIF6 - DAAM2	34594039	0.9847427	431.0	ATF3	0.000144744	Accessible, Low Impact	3
chr6:39779881:C>A	chr6	39779881	39779451	430	rs1504329	Platelet count	6e-13	KIF6 - DAAM2	40436827	0.9847427	431.0	ATF3	0.000144744	Accessible, Low Impact	3
chr4:144449854:C>A	chr4	144449854	144450284	430	rs13142439	Post bronchodilator FEV1/FVC ratio	1e-11	GUSBP5 - KRT18P51	26634245	0.9957853	785.0	FOS	0.000197088	HIGH PRIORITY: Accessible + High Impact	3
chr4:144449854:C>A	chr4	144449854	144450284	430	rs13142439	Post bronchodilator FEV1	4e-09	GUSBP5 - KRT18P51	26634245	0.9957853	785.0	FOS	0.000197088	HIGH PRIORITY: Accessible + High Impact	3
chr5:116176225:C>G	chr5	116176225	116176655	430	rs1396485	Inflammatory biomarkers	7e-07	COMMD10	22228203	0.9930392	666.0	JUND	1.97148e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:15952781:C>A	chr3	15952781	15953212	431	rs76121506	BTD protein levels	1e-40	IMPDH1P8 - GALNT15	39789286	0.9982472	3806.0	MAFK	0.0	High Impact, Hard to Access	3
chr6:90140876:C>A	chr6	90140876	90140445	431	rs2325259	CD80 on myeloid Dendritic Cell	1e-12	BACH2	32929287	0.9997353	9756.0	MAFK	3.28563e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:89958995:C>A	chr16	89958995	89958562	433	rs74800773	Melanoma	2.0000000000000002e-39	DEF8	34813871	0.97455275	842.0	ATF3	1.31416e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:95122336:C>G	chr11	95122336	95122769	433	rs10831307	Reticulocyte percentage (UKB data field 30240)	4e-17	ENDOD1	39789286	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:95122336:C>G	chr11	95122336	95122769	433	rs10831307	Reticulocyte count (UKB data field 30250)	2e-16	ENDOD1	39789286	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:42153356:G>T	chr15	42153356	42153789	433	rs1624183	creatinine (minimum, inv-norm transformed)	2e-14	PLA2G4F	39024449	0.9409573	723.0	JUND	0.138197	HIGH PRIORITY: Accessible + High Impact	3
chr16:89958995:C>A	chr16	89958995	89958562	433	rs74800773	Blond vs. brown/black hair color	4e-14	DEF8	34737440	0.97455275	842.0	ATF3	1.31416e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:95122336:C>G	chr11	95122336	95122769	433	rs10831307	High light scatter reticulocyte count (UKB data field 30300)	1e-13	ENDOD1	39789286	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:95122336:C>G	chr11	95122336	95122769	433	rs10831307	High light scatter reticulocyte percentage (UKB data field 30290)	1e-13	ENDOD1	39789286	0.9787506	612.0	ATF2	1.97288e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:42153356:G>T	chr15	42153356	42153789	433	rs1624183	estimated glomerular filtration rate (eGFR, mean, inv-norm transformed)	1e-12	PLA2G4F	39024449	0.9409573	723.0	JUND	0.138197	HIGH PRIORITY: Accessible + High Impact	3
chr15:42153356:G>T	chr15	42153356	42153789	433	rs1624183	estimated glomerular filtration rate (eGFR, maximum, inv-norm transformed)	2e-11	PLA2G4F	39024449	0.9409573	723.0	JUND	0.138197	HIGH PRIORITY: Accessible + High Impact	3
chr7:73563135:C>A	chr7	73563135	73563568	433	rs12539316	Gamma glutamyl transpeptidase	6e-10	BCL7B - TBL2	21909109	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr18:62348567:A>C	chr18	62348567	62349000	433	rs4263037	Myasthenia gravis	1e-08	TNFRSF11A	25643325	0.9990358	575.0	FOSL2	1.96894e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:30826599:C>G	chr4	30826599	30826165	434	rs6815248	Adolescent idiopathic scoliosis	1.0000000000000001e-24	PCDH7	30019117	0.95041513	468.5	JUND	0.0	Low Priority	2
chr6:125657280:G>T	chr6	125657280	125657714	434	rs3898124	3-hydroxydodecanedioate levels	4e-06	HEY2-AS1	40360795	0.9113531	484.0	ATF3	0.0	Low Priority	3
chr6:125657280:G>T	chr6	125657280	125657714	434	rs3898124	Tetradecadienedioate (C14:2-DC) levels	5e-06	HEY2-AS1	40360795	0.9113531	484.0	ATF3	0.0	Low Priority	3
chr20:21236903:G>T	chr20	21236903	21237338	435	rs6082354	Height	2e-58	KIZ	40436827	0.9645371	608.0	MAFK	0.000289706	HIGH PRIORITY: Accessible + High Impact	3
chr20:21236903:G>T	chr20	21236903	21237338	435	rs6082354	Appendicular lean mass	9.999999999999999e-33	KIZ	33097823	0.9645371	608.0	MAFK	0.000289706	HIGH PRIORITY: Accessible + High Impact	3
chr20:21236903:G>T	chr20	21236903	21237338	435	rs6082354	Height (baseline)	1e-19	KIZ	40374629	0.9645371	608.0	MAFK	0.000289706	HIGH PRIORITY: Accessible + High Impact	3
chr20:21236903:G>T	chr20	21236903	21237338	435	rs6082354	Physical function (baseline)	9e-18	KIZ	40374629	0.9645371	608.0	MAFK	0.000289706	HIGH PRIORITY: Accessible + High Impact	3
chr20:36136744:C>A	chr20	36136744	36137179	435	rs6142517	Body mass index	1e-13	EPB41L1	40436827	0.973383	692.5	FOSL2	7.21834e-06	HIGH PRIORITY: Accessible + High Impact	3
chr20:21236903:G>T	chr20	21236903	21237338	435	rs6082354	Hip circumference adjusted for BMI	1e-10	KIZ	34021172	0.9645371	608.0	MAFK	0.000289706	HIGH PRIORITY: Accessible + High Impact	3
chr5:97815757:C>G	chr5	97815757	97815321	436	rs554299823	Bone mineral density mean	1e-300	LINC01340	37500982	0.9565308	460.5	JUND	1.96969e-05	Accessible, Low Impact	3
chr1:7933924:G>C	chr1	7933924	7934360	436	rs2493214	TNFRSF9 protein levels	1.0000000000000001e-124	TNFRSF9	39789286	0.9907879	547.5	FOSL1	6.57549e-06	Low Priority	3
chr12:26239584:C>A	chr12	26239584	26239147	437	rs16930371	Vertical cup-disc ratio	5e-09	SSPN, SSPN-AS1	34077760	0.999696	5086.0	JUND	0.00030893	HIGH PRIORITY: Accessible + High Impact	3
chr2:21916688:G>T	chr2	21916688	21917125	437	rs147323247	LDL cholesterol levels	1e-08	LINC01822 - RN7SL117P	35884923	0.91866904	428.0	JUND	8.55308e-05	Accessible, Low Impact	3
chr12:26239584:C>A	chr12	26239584	26239147	437	rs16930371	Vertical cup-disc ratio (multi-trait analysis)	2e-08	SSPN, SSPN-AS1	31959993	0.999696	5086.0	JUND	0.00030893	HIGH PRIORITY: Accessible + High Impact	3
chr2:21916688:G>T	chr2	21916688	21917125	437	rs147323247	Total cholesterol levels	5e-06	LINC01822 - RN7SL117P	35884923	0.91866904	428.0	JUND	8.55308e-05	Accessible, Low Impact	3
chr12:26239584:C>A	chr12	26239584	26239147	437	rs16930371	Vertical cup-disc ratio (adjusted for vertical disc diameter)	7e-06	SSPN, SSPN-AS1	31959993	0.999696	5086.0	JUND	0.00030893	HIGH PRIORITY: Accessible + High Impact	3
chr11:64143363:C>A	chr11	64143363	64143801	438	rs190528931	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	7e-16	MACROD1	30698716	0.91678804	582.25	FOSL1	0.000413924	HIGH PRIORITY: Accessible + High Impact	3
chr20:41156767:C>A	chr20	41156767	41157205	438	rs370692925	Phospholipids to Total Lipids in Small HDL percentage	2e-15	PLCG1	41044249	0.9708846	718.0	MAFK	6.56944e-06	High Impact, Hard to Access	3
chr11:64143363:C>A	chr11	64143363	64143801	438	rs190528931	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1e-12	MACROD1	30698716	0.91678804	582.25	FOSL1	0.000413924	HIGH PRIORITY: Accessible + High Impact	3
chr11:64143363:C>A	chr11	64143363	64143801	438	rs190528931	HDL cholesterol x physical activity interaction (2df test)	2e-12	MACROD1	30670697	0.91678804	582.25	FOSL1	0.000413924	HIGH PRIORITY: Accessible + High Impact	3
chr11:64143363:C>A	chr11	64143363	64143801	438	rs190528931	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	6e-09	MACROD1	30698716	0.91678804	582.25	FOSL1	0.000413924	HIGH PRIORITY: Accessible + High Impact	3
chr20:41156767:C>A	chr20	41156767	41157205	438	rs370692925	Glycoprotein acetyls levels	3e-08	PLCG1	35213538	0.9708846	718.0	MAFK	6.56944e-06	High Impact, Hard to Access	3
chr20:41156767:C>A	chr20	41156767	41157205	438	rs370692925	Omega-6 fatty acid levels	4e-08	PLCG1	40545721	0.9708846	718.0	MAFK	6.56944e-06	High Impact, Hard to Access	3
chr11:64143363:C>A	chr11	64143363	64143801	438	rs190528931	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	6e-08	MACROD1	30698716	0.91678804	582.25	FOSL1	0.000413924	HIGH PRIORITY: Accessible + High Impact	3
chr11:64143363:C>A	chr11	64143363	64143801	438	rs190528931	Triglyceride levels in current drinkers	2e-07	MACROD1	30698716	0.91678804	582.25	FOSL1	0.000413924	HIGH PRIORITY: Accessible + High Impact	3
chr2:114006917:G>T	chr2	114006917	114007355	438	rs66648140	Acute graft-versus-host disease (gut) (donor effect)	4e-07	LINC01191	34996099	0.9838064	1543.0	FOSL1	6.57177e-06	High Impact, Hard to Access	3
chr11:83521817:C>A	chr11	83521817	83522255	438	rs6592119	Schizophrenia	5e-07	DLG2	35396580	0.9881423	860.5	FOS	1.97371e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:136210910:C>G	chr9	136210910	136210471	439	rs61482805	Estimated glomerular filtration rate (creatinine)	8e-16	QSOX2	34272381	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr1:219467486:C>A	chr1	219467486	219467047	439	rs2605092	Umbilical hernia	4e-15	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr9:136210910:C>G	chr9	136210910	136210471	439	rs61482805	Insomnia	3e-11	QSOX2	35835914	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr11:92998751:C>A	chr11	92998751	92998312	439	rs271035	Type 2 diabetes	3e-10	MTNR1B - RPL26P31	38374256	0.9875858	471.25	MAFG	6.58683e-06	Low Priority	3
chr1:219467486:C>A	chr1	219467486	219467047	439	rs2605092	Inguinal hernia	4e-09	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr9:136210910:C>G	chr9	136210910	136210471	439	rs61482805	Diastolic blood pressure	1e-08	QSOX2	40436827	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr9:75249004:C>A	chr9	75249004	75249443	439	rs113417742	Color vision defects (Tritan)	9e-07	RNU6-1228P - CDCA7P2	37359372	0.9914013	493.0	FOSL1	1.97151e-05	Accessible, Low Impact	3
chr9:136210910:C>G	chr9	136210910	136210471	439	rs61482805	CCL19 levels	5e-06	QSOX2	38326779	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr14:54972600:G>T	chr14	54972600	54973040	440	rs3074190	Mean spheric corpuscular volume	3e-12	WDHD1	32888494	0.99164	1348.5	MAFK	0.0	High Impact, Hard to Access	3
chr7:41732792:G>T	chr7	41732792	41732352	440	rs188851454	Allergy/adverse effect of penicillin (PheCode 960.2)	1e-11	INHBA-AS1	39024449	0.9884892	667.0	FOS	6.56789e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:73134177:C>G	chr10	73134177	73134617	440	rs2271904	Systolic blood pressure	3e-10	ECD	33230300	0.9894933	652.0	JUND	1.31712e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:73134177:C>G	chr10	73134177	73134617	440	rs2271904	Diastolic blood pressure	8e-09	ECD	33230300	0.9894933	652.0	JUND	1.31712e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:37691964:C>A	chr6	37691964	37691524	440	rs3901254	Conotruncal heart defects with normally related great vessels (without 22q.11.2 deletion syndrome)	2e-06	MDGA1	34356046	0.9921947	1598.5	FOSL1	6.56875e-06	High Impact, Hard to Access	3
chr6:31295292:A>C	chr6	31295292	31295733	441	rs2524143	Total cholesterol levels	1.9999999999999998e-54	LINC02571	34887591	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31295733	441	rs2524143	Killer cell immunoglobulin-like receptor 2DS2 levels (KIR2DS2.10428.1.3)	2e-52	LINC02571	29875488	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr10:17560262:C>G	chr10	17560262	17560703	441	rs12259191	Aspartate aminotransferase levels	5e-43	ST8SIA6 - PRPF38AP2	33462484	0.95749575	746.0	ATF7	6.64646e-06	HIGH PRIORITY: Accessible + High Impact	3
chr10:17560262:C>G	chr10	17560262	17560703	441	rs12259191	Aspartate aminotransferase to alanine aminotransferase ratio	6e-27	ST8SIA6 - PRPF38AP2	33462484	0.95749575	746.0	ATF7	6.64646e-06	HIGH PRIORITY: Accessible + High Impact	3
chr7:117939716:C>G	chr7	117939716	117939275	441	rs1024432	Bipolar disorder vs major depressive disorder (ordinary least squares (OLS))	7e-09	CTTNBP2 - LSM8	33686288	0.9342127	446.0	JUND	5.25693e-05	Accessible, Low Impact	3
chr1:162756736:C>A	chr1	162756736	162757178	442	rs147711199	SLAM family member 7 levels	2e-11	DDR2	36168886	0.9955867	1255.0	FOS	1.3147e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:72661005:C>A	chr4	72661005	72660562	443	rs28608630	Appendicular lean mass	9e-19	ADAMTS3 - HNRNPA1P67	31761296	0.97621405	433.0	JUND	2.62978e-05	Accessible, Low Impact	3
chr5:154664710:C>G	chr5	154664710	154665154	444	rs59296790	Mean corpuscular haemoglobin (UKB data field 30050)	3e-33	MIR3141 - LARP1	39789286	0.96905065	545.0	ATF3	6.65788e-06	Accessible, Low Impact	3
chr7:22829214:T>A	chr7	22829214	22828770	444	rs113424631	C-reactive protein levels (MTAG)	5e-09	TOMM7 - SNHG26	36376304	0.9747807	492.0	ATF2	0.0	Low Priority	2
chr15:85175541:C>G	chr15	85175541	85175097	444	rs145893358	COVID-19 (hospitalized vs population)	9e-06	PDE8A - NIFKP8	35224516	0.99615616	800.0	FOSL2	6.57056e-06	High Impact, Hard to Access	3
chr1:21507945:T>A	chr1	21507945	21507500	445	rs181473281	Alkaline phosphatase (UKB data field 30610)	9.999999999999999e-33	NBPF3 - ALPL	39789286	0.98942745	547.0	FOS	6.57047e-06	Low Priority	3
chr1:21507945:T>A	chr1	21507945	21507500	445	rs181473281	Phosphate levels (UKB data field 30810)	5e-21	NBPF3 - ALPL	39789286	0.98942745	547.0	FOS	6.57047e-06	Low Priority	3
chr16:88736351:G>T	chr16	88736351	88736797	446	rs142484519	Glycated hemoglobin levels	1e-19	HSALR1, PIEZO1	34059833	0.98487294	805.0	BATF2	6.57056e-06	High Impact, Hard to Access	3
chr7:148486948:C>G	chr7	148486948	148486502	446	rs6464906	Protein quantitative trait loci (liver)	2e-08	RN7SL72P - RPL32P17	32778093	0.9727787	776.0	BATF2	6.56961e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:149251955:A>C	chr4	149251955	149252401	446	rs138249847	Oligodendroglioma	5e-07	LINC02355	36810956	0.99916035	1279.5	FOS	1.97415e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:72520925:G>C	chr18	72520925	72521371	446	rs1432073	Homeostasis model assessment of insulin resistance in overweight or obesity	2e-06	LINC01899 - CBLN2	40699860	0.99894255	632.5	FOSL2	1.3137e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:20761935:T>G	chr9	20761935	20761489	446	rs13291925	IL18 levels	5e-06	FOCAD	38326779	0.9983986	797.0	FOS	3.9383e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:7001781:A>C	chr8	7001781	7002229	448	rs140493188	Blood cell traits latent factor 22 (white cell)	4.0000000000000006e-34	DEFA1B - DEFT1P2	40220762	0.95134485	67.1875	MAFK	4.71876e-05	Accessible, Low Impact	2
chr17:79756075:C>A	chr17	79756075	79756523	448	rs74559650	ENPP7 protein levels	7e-22	ENPP7 - CBX2	39789286	0.96833974	887.0	BATF	1.3584e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:16036936:C>A	chr7	16036936	16036488	448	rs6980254	Alanine aminotransferase levels	1e-08	LINC02587 - CRPPA	40436827	0.9841699	794.5	JUND	1.97117e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:7001781:A>C	chr8	7001781	7002229	448	rs140493188	Blood cell traits latent factor 25 (white cell)	2e-08	DEFA1B - DEFT1P2	40220762	0.95134485	67.1875	MAFK	4.71876e-05	Accessible, Low Impact	2
chr1:59169851:C>A	chr1	59169851	59170299	448	rs11207415	Spontaneous coronary artery dissection	3e-06	JUN-DT, FGGY-DT	32887874	0.98618805	833.0	MAFG	0.0	High Impact, Hard to Access	3
chr6:78716672:C>A	chr6	78716672	78717121	449	rs9341741	Diastolic blood pressure (UKB data field 4079)	3e-12	MEI4 - IRAK1BP1	39789286	0.9185313	401.5	JUNB	0.208484	Accessible, Low Impact	3
chr12:65762547:C>G	chr12	65762547	65762996	449	rs58811733	Waist circumference adjusted for body mass index	1e-10	RPSAP52, RPSAP52	31669095	0.95041513	504.0	FOSL1	1.98185e-05	Accessible, Low Impact	3
chr11:119226408:G>T	chr11	119226408	119226858	450	rs11217194	Platelet count	4e-73	CBL	38116116	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119226408:G>T	chr11	119226408	119226858	450	rs11217194	platelet count (maximum, inv-norm transformed)	7.999999999999999e-56	CBL	39024449	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119226408:G>T	chr11	119226408	119226858	450	rs11217194	platelet count (mean, inv-norm transformed)	2.0000000000000002e-29	CBL	39024449	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119226408:G>T	chr11	119226408	119226858	450	rs11217194	platelet count (minimum, inv-norm transformed)	9e-21	CBL	39024449	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119226408:G>T	chr11	119226408	119226858	450	rs11217194	Blood cell traits latent factor 10 (platelet)	3e-14	CBL	40220762	0.961097	578.5	ATF2	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:112635971:T>A	chr3	112635971	112636422	451	rs75755325	Height	1e-15	CCDC80	31562340	0.9992528	4260.0	JUNB	6.56392e-06	High Impact, Hard to Access	3
chr12:45873026:T>A	chr12	45873026	45873477	451	rs80127816	Sex hormone-binding globulin levels	2e-09	ARID2	36653534	0.9841699	631.0	JUND	6.56383e-06	High Impact, Hard to Access	3
chr16:8453671:G>C	chr16	8453671	8453220	451	rs8045405	QT interval	9e-06	LINC02152 - TMEM114	23534349	0.9644045	458.5	FOSL2	6.5754e-06	Low Priority	3
chr7:94392616:C>A	chr7	94392616	94392163	453	rs3763469	TFPI2 protein levels	1.9999999999999998e-25	BET1-AS1 - COL1A2	39789286	0.9992343	1133.0	BATF	6.57402e-06	High Impact, Hard to Access	3
chr6:31295292:A>C	chr6	31295292	31295745	453	rs2524142	cAMP-specific 3',5'-cyclic phosphodiesterase 4D levels (PDE4D.5255.22.3)	3e-22	LINC02571	29875488	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr7:94392616:C>A	chr7	94392616	94392163	453	rs3763469	Impedance of whole body (UKB data field 23106)	4e-14	BET1-AS1 - COL1A2	39789286	0.9992343	1133.0	BATF	6.57402e-06	High Impact, Hard to Access	3
chr7:94392616:C>A	chr7	94392616	94392163	453	rs3763469	Impedance of arm right (UKB data field 23109)	4e-14	BET1-AS1 - COL1A2	39789286	0.9992343	1133.0	BATF	6.57402e-06	High Impact, Hard to Access	3
chr7:94392616:C>A	chr7	94392616	94392163	453	rs3763469	Impedance of arm left (UKB data field 23110)	5e-12	BET1-AS1 - COL1A2	39789286	0.9992343	1133.0	BATF	6.57402e-06	High Impact, Hard to Access	3
chr8:94237877:C>G	chr8	94237877	94238330	453	rs2607068	Pulse pressure	6e-12	CDH17 - GEM	35762941	0.972161	615.0	MAFG	7.34182e-06	HIGH PRIORITY: Accessible + High Impact	3
chr9:99162342:T>A	chr9	99162342	99162795	453	rs401186	Age-related macular degeneration or COVID-19 infection (MTAG)	1e-10	TGFBR1 - RN7SL794P	36614910	0.9470497	556.0	FOSL2	6.5634e-06	Low Priority	3
chr9:99162342:T>A	chr9	99162342	99162795	453	rs401186	Age-related macular degeneration or COVID-19 hospitalization (MTAG)	1e-10	TGFBR1 - RN7SL794P	36614910	0.9470497	556.0	FOSL2	6.5634e-06	Low Priority	3
chr9:99162342:T>A	chr9	99162342	99162795	453	rs401186	Age-related macular degeneration or COVID-19 critical illness (MTAG)	1e-10	TGFBR1 - RN7SL794P	36614910	0.9470497	556.0	FOSL2	6.5634e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31295745	453	rs2524142	Cholesteryl esters to total lipids ratio in medium LDL	8e-10	LINC02571	35213538	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31295745	453	rs2524142	Phospholipids to total lipids ratio in medium LDL	1e-08	LINC02571	35213538	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr11:72671011:G>C	chr11	72671011	72671464	453	rs341062	Insomnia	2e-08	PDE2A	35835914	0.99658346	1187.0	MAFK	6.5735e-06	High Impact, Hard to Access	3
chr1:242645492:G>C	chr1	242645492	242645039	453	rs10737883	Skin reflectance (Melanin index)	3e-06	PLD5 - RSL24D1P4	30895295	0.99751866	490.0	FOS	6.6394e-06	Accessible, Low Impact	3
chr19:50002135:C>A	chr19	50002135	50001681	454	rs75732022	1-dihomo-linoleoyl-GPC (20:2) levels	6e-08	VRK3	36357675	0.9799247	768.0	FOS	6.57039e-06	High Impact, Hard to Access	3
chr1:170095016:C>G	chr1	170095016	170095471	455	rs12128116	Venous thromboembolism or plasminogen activator inhibitor 1 levels (pleiotropy)	2e-12	KIFAP3 - SIGLEC30P	35285134	0.9897305	1070.0	ATF7	1.3128e-05	HIGH PRIORITY: Accessible + High Impact	2
chr17:504680:G>C	chr17	504680	504225	455	rs11247554	Waist circumference adjusted for body mass index	2e-11	RFLNB - VPS53	31669095	0.9983231	474.5	FOS	2.6588e-05	Accessible, Low Impact	3
chr9:98831998:C>G	chr9	98831998	98831543	455	rs2295926	joint destruction in rheumatoid arthritis (rapid vs slow)	8e-08	GALNT12	33585033	0.9834347	1251.0	ATF3	6.5735e-06	High Impact, Hard to Access	3
chr9:98831998:C>G	chr9	98831998	98831543	455	rs2295926	Autism spectrum disorder	3e-06	GALNT12	34069769	0.9834347	1251.0	ATF3	6.5735e-06	High Impact, Hard to Access	3
chr3:175703601:G>C	chr3	175703601	175704057	456	rs6773175	Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)	9e-06	NAALADL2	33012170	0.9729977	614.0	BATF	6.57635e-06	High Impact, Hard to Access	3
chr6:12056995:C>A	chr6	12056995	12056538	457	rs12196128	Monocyte count	1e-11	HIVEP1	32888493	0.9702253	644.5	ATF3	6.5786e-06	High Impact, Hard to Access	3
chr11:69359711:G>C	chr11	69359711	69359254	457	rs4343053	Hip index	1e-08	MYEOV - LINC02956	34021172	0.9870033	522.0	BATF	6.57022e-06	Low Priority	3
chr12:117708479:C>G	chr12	117708479	117708937	458	rs895470	Gut microbiome composition (winter)	4e-06	KSR2	26528553	0.9327804	498.0	FOSL2	1.97156e-05	Accessible, Low Impact	2
chr6:32121157:G>C	chr6	32121157	32120698	459	rs144251373	Height (baseline)	1e-14	ATF6B	40374629	0.95348793	658.0	FOSL2	1.31373e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:126697989:C>G	chr9	126697989	126698448	459	rs35632228	Type 2 diabetes	2e-09	LMX1B	38374256	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr15:63108638:G>T	chr15	63108638	63108179	459	rs2729788	Estimated glomerular filtration rate in non-diabetics	8e-09	TPM1 - LACTB	31451708	0.9894933	1795.0	JUNB	6.58467e-06	High Impact, Hard to Access	3
chr4:39802097:C>G	chr4	39802097	39802557	460	rs12511274	Cognitive processing speed	3e-10	UBE2K - PDS5A	39242605	0.94346935	601.5	ATF7	6.64628e-06	HIGH PRIORITY: Accessible + High Impact	3
chr10:20482759:G>C	chr10	20482759	20483219	460	rs34675543	Gut microbial network clusters (Pink (at 1 year) x Any Breastfeeding (3 Months) interaction	2e-09	AMD1P1 - MIR4675	40187613	0.9939092	650.0	FOS	0.0006244	HIGH PRIORITY: Accessible + High Impact	3
chr5:175150033:C>G	chr5	175150033	175150493	460	rs6893566	Glycodeoxycholate sulfate levels in elite athletes	5e-06	LINC01951 - ARL2BPP6	31882771	0.961097	465.5	JUND	2.6255e-05	Accessible, Low Impact	3
chr12:101876114:C>A	chr12	101876114	101876575	461	rs386765820	ARSA protein levels	2e-85	HSPE1P4 - DRAM1	39789286	0.993351	1520.0	FOS	6.57333e-06	High Impact, Hard to Access	3
chr17:47363365:C>A	chr17	47363365	47362903	462	rs62076461	Multi-trait sex score	2e-09	EFCAB13, EFCAB13-DT	37277458	0.9801434	550.0	FOSL2	1.31511e-05	Accessible, Low Impact	3
chr8:16662283:C>G	chr8	16662283	16662745	462	rs1719410	Mortality in COVID-19	5e-06	MSR1 - RN7SL474P	35224516	0.85810196	358.5	FOS	6.578e-06	Low Priority	3
chr15:100149480:C>A	chr15	100149480	100149943	463	rs2035344	Height	3e-21	ADAMTS17	36224396	0.9955867	959.0	FOS	6.58779e-06	High Impact, Hard to Access	3
chr1:72371236:C>A	chr1	72371236	72370773	463	rs1841499	Migraine or type 2 diabetes	3e-08	LINC02796	36292730	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:55033740:C>A	chr1	55033740	55033276	464	rs7523242	Low density lipoprotein cholesterol levels	9.999999999999999e-85	BSND - PCSK9	33462484	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr1:55033740:C>A	chr1	55033740	55033276	464	rs7523242	Apolipoprotein B levels	2.0000000000000002e-72	BSND - PCSK9	33462484	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr1:55033740:C>A	chr1	55033740	55033276	464	rs7523242	Total cholesterol levels	4e-70	BSND - PCSK9	33462484	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr12:65852639:G>T	chr12	65852639	65852175	464	rs118003500	Physical function (baseline)	2e-09	HMGA2, HMGA2-AS1	40374629	0.9782654	599.5	JUND	6.57575e-06	High Impact, Hard to Access	3
chr13:80033845:C>G	chr13	80033845	80033381	464	rs55743972	Motor premotor area	4e-09	LINC01080	35113692	0.9565468	460.0	FOSL2	0.0743839	Accessible, Low Impact	3
chr13:80033845:C>G	chr13	80033845	80033381	464	rs55743972	Motor premotor area (unadjusted for global measures)	7e-09	LINC01080	36893272	0.9565468	460.0	FOSL2	0.0743839	Accessible, Low Impact	3
chr13:80033845:C>G	chr13	80033845	80033381	464	rs55743972	Dorsolateral prefrontal area (unadjusted for global measures)	1e-08	LINC01080	36893272	0.9565468	460.0	FOSL2	0.0743839	Accessible, Low Impact	3
chr11:17064110:C>A	chr11	17064110	17063645	465	rs7949405	Height	6e-15	OR7E14P - RPS13	39134668	0.8712331	473.5	BATF	1.319e-05	Accessible, Low Impact	3
chr15:87778202:G>C	chr15	87778202	87777737	465	rs6496440	Dementia	7e-08	LINC00052 - NTRK3	39046104	0.9953788	572.5	FOS	6.57479e-06	High Impact, Hard to Access	3
chr3:119047483:C>A	chr3	119047483	119047949	466	rs145868254	Estimated glomerular filtration rate (cystatin c)	2e-14	IGSF11	39256582	0.9847427	415.5	BATF2	6.57696e-06	Low Priority	3
chr3:119047483:C>A	chr3	119047483	119047949	466	rs145868254	Estimated glomerular filtration rate (creatinine, cystatin c)	7e-14	IGSF11	39256582	0.9847427	415.5	BATF2	6.57696e-06	Low Priority	3
chr4:91645825:T>A	chr4	91645825	91646291	466	rs10470887	Ease of getting up in the morning	4e-08	CCSER1 - KRT19P6	30804565	0.9756724	478.0	JUND	1.31813e-05	Accessible, Low Impact	2
chr3:119047483:C>A	chr3	119047483	119047949	466	rs145868254	Estimated glomerular filtration rate (creatinine)	2e-06	IGSF11	39256582	0.9847427	415.5	BATF2	6.57696e-06	Low Priority	3
chr6:151279653:G>T	chr6	151279653	151279186	467	rs73615423	Cerebrospinal fluid sTREM-2 levels	4e-06	AKAP12	31708768	0.9470497	619.0	ATF3	6.58146e-06	High Impact, Hard to Access	3
chr3:42866090:C>G	chr3	42866090	42865620	470	rs2228468	Monocyte percentage of white cells	4.0000000000000006e-45	ACKR2, CYP8B1	32888494	0.9584504	501.5	MAFK	6.57748e-06	Low Priority	3
chr15:38393146:T>A	chr15	38393146	38392676	470	rs74843685	Educational attainment	5e-13	SPRED1 - FAM98B	35361970	0.93699247	474.0	JUNB	6.57186e-06	Accessible, Low Impact	2
chr9:27107965:A>C	chr9	27107965	27108435	470	rs10967717	Gut microbial network clusters (Magenta (at 1 year) x Any Formula feeding  (1 Year) interaction	9e-08	IFT74 - TEK	40187613	0.8243095	439.0	FOS	0.0	Low Priority	2
chr3:42866090:C>G	chr3	42866090	42865620	470	rs2228468	Monocyte count	5e-07	ACKR2, CYP8B1	23314186	0.9584504	501.5	MAFK	6.57748e-06	Low Priority	3
chr3:42866090:C>G	chr3	42866090	42865620	470	rs2228468	White blood cell count (monocyte)	1e-06	ACKR2, CYP8B1	28158719	0.9584504	501.5	MAFK	6.57748e-06	Low Priority	3
chr9:113602375:C>G	chr9	113602375	113602846	471	rs568557	Height	3e-11	RGS3 - C14orf119P1	36224396	0.99958974	3792.0	FOSL1	6.56711e-06	High Impact, Hard to Access	3
chr18:43253432:A>C	chr18	43253432	43252961	471	rs9961441	Whole body fat mass (UKB data field 23100)	4e-11	RIT2 - SYT4	38538606	0.92356306	443.0	JUN	6.57644e-06	Accessible, Low Impact	2
chr1:207720600:C>A	chr1	207720600	207721071	471	rs11118475	Brain age gap from white matter microstructure	4e-09	CR1L	38521789	0.9854257	709.0	BATF	6.57393e-06	High Impact, Hard to Access	3
chr6:93990092:A>C	chr6	93990092	93989621	471	rs9363134	Insomnia	4e-08	EPHA7 - MTCYBP36	35835914	0.99840146	5512.0	ATF2	6.57402e-06	High Impact, Hard to Access	3
chr12:9414590:C>A	chr12	9414590	9414118	472	rs28498362	CD160/KLRB1 protein level ratio	2e-53	LINC02367 - DDX12P	38412862	0.92024124	621.0	FOSL2	5.96651e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:54002547:A>C	chr18	54002547	54002075	472	rs72927972	Hoarding symptoms	9e-07	LINC01919 - MBD2	36379924	0.925176	408.0	FOS	6.56858e-06	Low Priority	3
chr15:43761891:T>A	chr15	43761891	43761419	472	rs8040336	Aerodigestive squamous cell cancer (pleiotropy)	4e-06	PDIA3	33667223	0.9892507	617.0	ATF2	6.57307e-06	High Impact, Hard to Access	3
chr17:39423603:G>T	chr17	39423603	39423130	473	rs145835664	Asthma (childhood onset)	8.000000000000001e-23	MED1	31669095	0.9868027	780.0	JUND	6.57575e-06	High Impact, Hard to Access	3
chr9:137000541:C>A	chr9	137000541	137001014	473	rs200644281	Dipeptidyl peptidase 2 levels	5e-16	CLIC3 - ABCA2	34648354	0.9991806	4483.0	ATF2	6.57324e-06	High Impact, Hard to Access	3
chr17:39423603:G>T	chr17	39423603	39423130	473	rs145835664	Atopic asthma	4e-12	MED1	31669095	0.9868027	780.0	JUND	6.57575e-06	High Impact, Hard to Access	3
chr17:39423603:G>T	chr17	39423603	39423130	473	rs145835664	Asthma in any disease	1e-10	MED1	36344522	0.9868027	780.0	JUND	6.57575e-06	High Impact, Hard to Access	3
chr17:39423603:G>T	chr17	39423603	39423130	473	rs145835664	Nonatopic asthma	2e-08	MED1	31669095	0.9868027	780.0	JUND	6.57575e-06	High Impact, Hard to Access	3
chr11:108286220:G>C	chr11	108286220	108285746	474	rs592955	Eosinophill percentage (UKB data field 30210)	2e-21	ATM	39789286	0.96289337	541.0	JUN	6.86069e-06	Accessible, Low Impact	3
chr9:84350248:C>A	chr9	84350248	84349773	475	rs75360147	Diabetic retinopathy (all NPDR and PDR)	2e-07	SLC28A3 - NTRK2	30487263	0.98618805	859.5	ATF7	1.31477e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:19978794:A>C	chr1	19978794	19979270	476	rs11573158	PLA2G2A protein levels	3e-78	PLA2G2A	39789286	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr6:160831261:C>G	chr6	160831261	160831738	477	rs12211977	CXCL9 protein levels	7e-43	PLG - MAP3K4-AS1	39789286	0.9810219	549.0	JUND	2.63033e-05	Accessible, Low Impact	3
chr9:77136735:C>G	chr9	77136735	77137212	477	rs145865882	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (3 Months) interaction	6e-09	RFC5P1 - VPS13A-AS1	40187613	0.9050901	402.0	MAFK	3.31231e-05	Accessible, Low Impact	3
chr10:120546265:C>A	chr10	120546265	120545788	477	rs150044527	Bone mineral density variability	2e-08	PLPP4	37500982	0.9729977	426.5	FOS	1.97259e-05	Accessible, Low Impact	3
chr5:106984401:C>G	chr5	106984401	106983924	477	rs55853362	Alzheimer's disease, proxy Alzheimer's disease or related dementias	8e-06	LINC01950	40708016	0.9912486	967.0	ATF2	6.57168e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:15467675:G>C	chr19	15467675	15467197	478	rs55866012	Serum levels of protein PGLYRP2	2.9999999999999996e-76	RASAL3 - PGLYRP2	35078996	0.9992855	2393.0	FOSL2	6.57367e-06	High Impact, Hard to Access	3
chr19:15467675:G>C	chr19	15467675	15467197	478	rs55866012	Blood protein levels	2e-47	RASAL3 - PGLYRP2	30072576	0.9992855	2393.0	FOSL2	6.57367e-06	High Impact, Hard to Access	3
chr3:41729600:C>A	chr3	41729600	41729122	478	rs117149828	Alcohol-associated liver disease in light drinkers	3e-06	ULK4	34387878	0.9910462	800.0	BATF2	6.56978e-06	High Impact, Hard to Access	3
chr16:268237:C>G	chr16	268237	267758	479	rs140835273	Red blood cell count	0.0	FAM234A	40436827	0.9975805	1037.0	BATF2	6.57117e-06	High Impact, Hard to Access	3
chr1:23908963:T>A	chr1	23908963	23909442	479	rs61778219	Lymphocyte count (UKB data field 30120)	6e-14	CNR2	39789286	0.99570066	2138.0	ATF7	6.57583e-06	High Impact, Hard to Access	3
chr1:23908963:T>A	chr1	23908963	23909442	479	rs61778219	Lymphocyte count	1e-13	CNR2	32888494	0.99570066	2138.0	ATF7	6.57583e-06	High Impact, Hard to Access	3
chr2:121187770:C>G	chr2	121187770	121188249	479	rs11682545	Bicarbonate (mean, inv-norm transformed)	2e-11	Y_RNA - TFCP2L1	39024449	0.95254505	703.0	MAFK	5.2559e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:51918001:A>C	chr6	51918001	51918480	479	rs12199884	Longevity	4e-06	PKHD1	30294719	0.99936336	686.5	FOS	1.31447e-05	HIGH PRIORITY: Accessible + High Impact	2
chr3:120706004:T>A	chr3	120706004	120706484	480	rs13077101	Obesity-related traits	1e-06	RABL3	23251661	0.99658346	1029.0	ATF3	1.31422e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:157835526:C>G	chr6	157835526	157835045	481	rs111731871	platelet count (minimum, inv-norm transformed)	1e-14	SNX9	39024449	0.925176	627.0	FOSL1	1.31834e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:157835526:C>G	chr6	157835526	157835045	481	rs111731871	platelet count (mean, inv-norm transformed)	1e-12	SNX9	39024449	0.925176	627.0	FOSL1	1.31834e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:13447081:G>C	chr18	13447081	13446600	481	rs11660443	COVID-19 (hospitalized vs not hospitalized)	1e-05	LDLRAD4	35224516	0.99840146	902.0	FOSL1	6.57022e-06	High Impact, Hard to Access	3
chr7:81176341:C>G	chr7	81176341	81175859	482	rs1509911	Glucocorticoid-induced osteonecrosis (age 10 years and older)	5e-06	SEMA3C - EIF4EP4	26265699	0.990189	500.5	JUND	6.57886e-06	Low Priority	3
chr5:41050883:A>C	chr5	41050883	41051366	483	rs138832179	DNA methylation variation (age effect)	4e-08	MROH2B	30348214	0.92356306	410.0	ATF3	6.57229e-06	Accessible, Low Impact	2
chr13:52952383:G>T	chr13	52952383	52951899	484	rs12430558	Pneumonia	2e-06	PCDH8 - OLFM4	28928442	0.9008302	478.5	JUN	1.31406e-05	Accessible, Low Impact	3
chr1:86459330:A>C	chr1	86459330	86459814	484	rs149725802	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	7e-06	CLCA2 - CLCA1	29221444	0.85238993	400.0	ATF3	6.57022e-06	Low Priority	3
chr17:39867887:C>G	chr17	39867887	39868373	486	rs11557466	Asthma and cardiovascular disease	1.9999999999999998e-32	ZPBP2	35126453	0.99695456	2415.0	ATF7	6.57194e-06	High Impact, Hard to Access	3
chr11:32802866:C>G	chr11	32802866	32803352	486	rs10835977	Inguinal hernia	2e-14	CCDC73 - PRRG4	34382107	0.93561655	523.5	ATF7	2.63598e-05	Accessible, Low Impact	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Phospholipids in large HDL	8e-22	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in very small VLDL	5e-21	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in IDL	3e-20	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesteryl Esters in Large HDL	2e-18	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in small LDL	2e-17	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesterol in Large HDL	4e-16	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in small VLDL	2e-15	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesterol in Small VLDL	3e-15	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in small LDL	8e-15	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in small VLDL	1e-14	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesteryl Esters in Medium VLDL	1e-14	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Phospholipids in small VLDL	3e-14	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesterol in Medium VLDL	4e-14	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:101765635:C>A	chr12	101765635	101766122	487	rs1209353188	Aspartate levels	1e-13	GNPTAB	35347128	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in medium LDL	1e-13	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in large LDL	2e-13	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in large LDL	3e-13	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in medium VLDL	6e-13	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in medium LDL	8e-13	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides to Total Lipids in Small HDL percentage	1e-12	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in IDL	4e-12	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides in very small VLDL	4e-12	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Free cholesterol in medium VLDL	5e-12	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Omega-6 fatty acids to total fatty acids percentage	1e-11	ASCL1 - C12orf42-AS1	40545721	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:101765635:C>A	chr12	101765635	101766122	487	rs1209353188	N-acetylglucosaminylasparagine levels	3e-11	GNPTAB	35347128	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesteryl Esters in Medium HDL	3e-10	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Triglycerides to Total Lipids in Very Small VLDL percentage	7e-10	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Educational attainment (years of education)	6e-09	ASCL1 - C12orf42-AS1	30038396	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Educational attainment (MTAG)	8e-09	ASCL1 - C12orf42-AS1	30038396	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr3:8510914:G>T	chr3	8510914	8511401	487	rs1873944	Varicose veins	9e-09	LMCD1-AS1, LMCD1	34594039	0.9834347	663.0	FOS	1.31408e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Cholesterol levels in very small VLDL	1e-08	ASCL1 - C12orf42-AS1	41044249	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr17:48713082:G>T	chr17	48713082	48712595	487	rs73985893	Male-pattern baldness	2e-08	LINC02086 - COX6B1P2	30573740	0.95842487	717.0	BATF2	6.57609e-06	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062306	487	rs7958371	Polyunsaturated fatty acids to saturated fatty acids ratio	4e-08	ASCL1 - C12orf42-AS1	40545721	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr15:42413601:C>G	chr15	42413601	42414089	488	rs28364559	DNA methylation GrimAge acceleration	1e-18	ZNF106	34187551	0.9834347	548.5	JUND	6.57134e-06	Accessible, Low Impact	2
chr12:10722840:C>A	chr12	10722840	10723329	489	rs77100210	Age at natural menopause	8e-79	YBX3	34349265	0.99658346	2586.0	JUN	6.57022e-06	High Impact, Hard to Access	3
chr12:10722840:C>A	chr12	10722840	10723329	489	rs77100210	Age at menopause	3e-29	YBX3	30595370	0.99658346	2586.0	JUN	6.57022e-06	High Impact, Hard to Access	3
chr12:10722840:C>A	chr12	10722840	10723329	489	rs77100210	Type 2 diabetes	4e-08	YBX3	38374256	0.99658346	2586.0	JUN	6.57022e-06	High Impact, Hard to Access	3
chr17:7578317:C>G	chr17	7578317	7578807	490	rs3809719	Albumin levels	4e-13	EIF4A1	36329257	0.9987304	1868.0	ATF2	1.31382e-05	HIGH PRIORITY: Accessible + High Impact	3
chr20:36108577:G>T	chr20	36108577	36109068	491	rs148216216	Height (baseline)	9e-13	EPB41L1	40374629	0.94045055	547.5	JUND	6.57687e-06	Low Priority	3
chr20:36108577:G>T	chr20	36108577	36109068	491	rs148216216	Physical function (baseline)	1e-09	EPB41L1	40374629	0.94045055	547.5	JUND	6.57687e-06	Low Priority	3
chr12:121670712:G>T	chr12	121670712	121670221	491	rs561487367	Height (baseline)	2e-08	MORN3	40374629	0.9803781	597.0	MAFK	6.57999e-06	High Impact, Hard to Access	3
chr16:239203:G>T	chr16	239203	239695	492	rs2858010	Glycated haemoglobin HbA1c levels (UKB data field 30750)	2e-33	FAM234A	39789286	0.9875858	699.0	ATF3	0.0	High Impact, Hard to Access	3
chr16:239203:G>T	chr16	239203	239695	492	rs2858010	Hemoglobin A1c levels	1.0000000000000001e-24	FAM234A	34594039	0.9875858	699.0	ATF3	0.0	High Impact, Hard to Access	3
chr3:88347672:T>A	chr3	88347672	88347180	492	rs9861108	Glaucoma	1e-19	CSNK2A2IP	39024449	0.99936336	795.5	JUN	6.57704e-06	High Impact, Hard to Access	3
chr5:34753421:A>C	chr5	34753421	34753913	492	rs563097889	Lowest magnesium plasma levels after treatment with platinum based chemotherapy	5e-07	RAI14	35743677	0.9998405	1820.0	JUND	1.31434e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:77923254:C>A	chr4	77923254	77922761	493	rs35648590	Menstruation quality of life impact (headache)	2e-07	MRPL1	29855537	0.9868027	744.0	FOS	6.58328e-06	High Impact, Hard to Access	3
chr18:79597716:G>T	chr18	79597716	79597223	493	rs532611140	Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass	8e-07	LINC03101 - CTDP1-DT	32239398	0.84946334	694.0	MAFK	0.0	High Impact, Hard to Access	3
chr18:79597716:G>T	chr18	79597716	79597223	493	rs532611140	Femoral neck bone mineral density	1e-06	LINC03101 - CTDP1-DT	32239398	0.84946334	694.0	MAFK	0.0	High Impact, Hard to Access	3
chr7:69179057:C>A	chr7	69179057	69179551	494	rs73154924	Educational attainment	4e-08	RNU6-832P - MTCO2P25	35361970	0.85238993	445.5	FOS	6.57289e-06	Low Priority	3
chr14:68291362:C>A	chr14	68291362	68291858	496	rs10129646	Thyroid peroxidase antibody levels in pregnancy	2e-08	RAD51B	39266554	0.9836582	737.0	MAFG	6.5825e-06	High Impact, Hard to Access	3
chr8:14468544:C>G	chr8	14468544	14468047	497	rs7815726	Body mass index	4e-08	SGCZ	38538606	0.9695515	518.0	FOS	6.57774e-06	Low Priority	3
chr18:79463360:G>C	chr18	79463360	79462862	498	rs11659752	Body size or adipose distribution (multivariate analysis)	1.9999999999999998e-25	NFATC1	40796553	0.99606663	688.0	FOS	0.000143014	HIGH PRIORITY: Accessible + High Impact	3
chr4:119529153:T>A	chr4	119529153	119528655	498	rs1155577	Platelet count	3e-09	PDE5A	27863252	0.95842487	443.0	JUND	6.57471e-06	Accessible, Low Impact	2
chr16:89958995:C>A	chr16	89958995	89959494	499	rs187891579	Hair colour (natural, before greying): Red (UKB data field 1747_2)	3e-13	DEF8	34737426	0.97455275	842.0	ATF3	1.31416e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:69205890:G>T	chr17	69205890	69206390	500	rs1011789	Corneal resistance factor (MTAG)	3e-15	ABCA10	35446358	0.9715297	553.0	JUND	6.57341e-06	Low Priority	3
chr17:69205890:G>T	chr17	69205890	69206390	500	rs1011789	Corneal resistance factor	3e-11	ABCA10	33311554	0.9715297	553.0	JUND	6.57341e-06	Low Priority	3
chr17:69205890:G>T	chr17	69205890	69206390	500	rs1011789	Central corneal thickness (MTAG)	3e-10	ABCA10	35446358	0.9715297	553.0	JUND	6.57341e-06	Low Priority	3
chr9:95707577:G>T	chr9	95707577	95707077	500	rs817156	Dental caries (decayed, missing and filled teeth)	4e-06	PTCH1 - ERCC6L2-AS1	31533690	0.9708846	670.0	MAFG	2.6285e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:33678050:C>G	chr6	33678050	33678551	501	rs2274195	Vitiligo	4e-11	ITPR3	38286188	0.9910462	798.0	JUNB	0.00456564	HIGH PRIORITY: Accessible + High Impact	3
chr5:52693933:C>G	chr5	52693933	52694435	502	rs4865535	Height	2e-33	PELO-AS1	36224396	0.961097	516.5	ATF3	6.57186e-06	Low Priority	3
chr2:66503149:G>T	chr2	66503149	66503651	502	rs62144051	Insomnia	7e-28	MEIS1	35835914	0.993351	1763.0	FOS	6.57194e-06	High Impact, Hard to Access	3
chr2:66503149:G>T	chr2	66503149	66503651	502	rs62144051	Insomnia (standard GWA)	3e-15	MEIS1	37106081	0.993351	1763.0	FOS	6.57194e-06	High Impact, Hard to Access	3
chr14:30924354:C>A	chr14	30924354	30923851	503	rs10138011	Brain shape (segment 237)	3e-09	STRN3	33821002	0.9565468	546.5	ATF3	3.34174e-05	Accessible, Low Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	NPTX1 protein levels	1.0000000000000001e-72	RPL31P13 - PROX1-AS1	39789286	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	Glycated haemoglobin HbA1c levels (UKB data field 30750)	4e-17	RPL31P13 - PROX1-AS1	39789286	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	Mean platelet volume	5e-16	RPL31P13 - PROX1-AS1	32888493	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:41717529:C>G	chr3	41717529	41718033	504	rs9852303	Ascending thoracic aortic diameter	1e-15	ULK4	34837083	0.94931644	458.0	JUND	0.0124877	Accessible, Low Impact	2
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	Reticulocyte count	3e-14	RPL31P13 - PROX1-AS1	32888494	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:98006819:A>C	chr1	98006819	98007323	504	rs1938564	Free cholesterol levels in chylomicrons and extremely large VLDL	1e-13	MIR137HG	41044249	0.98587024	722.0	FOS	1.31693e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:84630160:A>C	chr9	84630160	84629656	504	rs72737614	Drinks per week	4e-12	SLC28A3 - NTRK2	36477530	0.9990792	653.5	FOS	6.56909e-06	High Impact, Hard to Access	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	Total bilirubin levels	6e-12	RPL31P13 - PROX1-AS1	40436827	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	White blood cell count	1e-11	RPL31P13 - PROX1-AS1	30595370	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:98006819:A>C	chr1	98006819	98007323	504	rs1938564	Cholesterol to Total Lipids in Small HDL percentage	1e-11	MIR137HG	41044249	0.98587024	722.0	FOS	1.31693e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	High light scatter reticulocyte count	2e-11	RPL31P13 - PROX1-AS1	32888494	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	Platelet count	3e-11	RPL31P13 - PROX1-AS1	32888493	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:213764543:C>G	chr1	213764543	213764039	504	rs1891058	Reticulocyte fraction of red cells	1e-10	RPL31P13 - PROX1-AS1	32888494	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:15267008:C>A	chr12	15267008	15267512	504	rs7972872	Vaginal microbiome MetaCyc pathway (PWY-5896|superpathway of menaquinol-10 biosynthesis)	9e-06	RERG	34282934	0.8263989	431.75	FOSL2	6.58059e-06	Low Priority	3
chr22:50432230:C>A	chr22	50432230	50432736	506	rs145142446	PLXNB2 protein levels	1e-20	PPP6R2	39789286	0.9996078	1064.0	FOS	1.31449e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:35415756:G>C	chr6	35415756	35415250	506	rs146874451	Waist-to-hip ratio adjusted for BMI	6e-19	PPARD	31669095	0.9989667	5606.0	FOSL2	6.63007e-06	High Impact, Hard to Access	3
chr6:35415756:G>C	chr6	35415756	35415250	506	rs146874451	Waist circumference adjusted for body mass index	4e-17	PPARD	31669095	0.9989667	5606.0	FOSL2	6.63007e-06	High Impact, Hard to Access	3
chr13:53198505:C>G	chr13	53198505	53197998	507	rs138703898	OLFM4 protein levels	2e-14	LINC01065 - PCDH8P1	39789286	0.9810219	645.0	FOSL1	6.57281e-06	High Impact, Hard to Access	3
chr2:55783160:G>T	chr2	55783160	55783668	508	rs4355154	Inguinal hernia	6e-17	PNPT1 - EFEMP1	34382107	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55783668	508	rs4355154	Waist circumference adjusted for body mass index	5e-13	PNPT1 - EFEMP1	34021172	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr5:159488235:T>A	chr5	159488235	159488743	508	rs549310853	IL12B protein levels	3e-12	IL12B-AS1	39789286	0.96195054	456.0	JUND	3.28532e-05	Accessible, Low Impact	3
chr2:55783160:G>T	chr2	55783160	55783668	508	rs4355154	Hip circumference adjusted for BMI	4e-12	PNPT1 - EFEMP1	34021172	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr6:111374174:A>C	chr6	111374174	111374684	510	rs462779	Smoking initiation	7e-82	REV3L, MFSD4B	36477530	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr6:111374174:A>C	chr6	111374174	111374684	510	rs462779	Risk-taking tendency (4-domain principal component model)	1e-11	REV3L, MFSD4B	30643258	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr4:80641314:C>A	chr4	80641314	80641824	510	rs116811165	Protein quantitative trait loci (liver)	9e-09	CFAP299	32778093	0.98289305	684.0	FOSL1	6.57488e-06	High Impact, Hard to Access	3
chr2:119372776:G>T	chr2	119372776	119372265	511	rs8192506	Tyrosine-protein phosphatase non-receptor type 4 levels	3e-33	DBI	39528825	0.9841699	770.5	ATF2	6.57013e-06	High Impact, Hard to Access	3
chr3:20589414:G>C	chr3	20589414	20588903	511	rs62242105	Body mass index	3e-12	SGO1-AS1	40436827	0.9983986	1350.0	FOSL2	6.57462e-06	High Impact, Hard to Access	3
chr21:45254440:G>T	chr21	45254440	45253929	511	rs113664574	Smoking initiation	8e-11	LINC00334	36477530	0.9185313	769.0	ATF7	6.57298e-06	High Impact, Hard to Access	3
chr3:20589414:G>C	chr3	20589414	20588903	511	rs62242105	Osteoarthritis	3e-09	SGO1-AS1	34450027	0.9983986	1350.0	FOSL2	6.57462e-06	High Impact, Hard to Access	3
chr2:30280870:C>A	chr2	30280870	30281381	511	rs12988733	Weight	4e-08	LBH	40436827	0.98058754	552.0	FOS	5.25804e-05	Accessible, Low Impact	3
chr16:78932785:G>C	chr16	78932785	78933297	512	rs7198756	Heart rate in heart failure with reduced ejection fraction	4e-06	WWOX	31113495	0.99969566	2026.0	FOSL2	5.91428e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:30762049:C>A	chr6	30762049	30762562	513	rs9262172	Platelet-to-lymphocyte ratio	9.999999999999999e-27	HCG20	34469753	0.9884112	956.0	FOS	6.56987e-06	High Impact, Hard to Access	3
chr6:30762049:C>A	chr6	30762049	30762562	513	rs150430679	Autism spectrum disorder or schizophrenia	3e-13	HCG20	28540026	0.9884112	956.0	FOS	6.56987e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467999	513	rs112893723	Hip circumference adjusted for BMI	1e-08	LYPLAL1-AS1	34021172	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219467999	513	rs112893723	Hip index	2e-08	LYPLAL1-AS1	34021172	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr17:71239457:T>A	chr17	71239457	71239971	514	rs17178530	Osteoarthritis (with total hip replacement)	2e-13	CASC17 - RNU7-155P	40205036	0.99539393	2590.0	ATF2	6.57713e-06	High Impact, Hard to Access	3
chr7:99517539:G>C	chr7	99517539	99518054	515	rs12533251	X-18601 levels	2e-11	ZKSCAN5	24816252	0.99197406	659.0	MAFK	6.57203e-06	High Impact, Hard to Access	3
chr18:26939709:C>A	chr18	26939709	26940224	515	rs528732638	Severe depressive disorders in coronary artery disease	1e-10	AQP4-AS1, CHST9	30563176	0.95749575	514.0	FOSL2	1.31441e-05	Accessible, Low Impact	3
chr2:220594567:C>A	chr2	220594567	220594052	515	rs1850490	Body surface area	3e-09	MIR4268 - EPHA4	36502284	0.98266596	747.25	MAFG	0.0	High Impact, Hard to Access	3
chr7:99517539:G>C	chr7	99517539	99518054	515	rs12533251	Androsterone sulfate levels in elite athletes	5e-08	ZKSCAN5	31882771	0.99197406	659.0	MAFK	6.57203e-06	High Impact, Hard to Access	3
chr5:180266553:G>C	chr5	180266553	180267068	515	rs13185784	TRAIL levels	4e-06	MAPK9	27989323	0.9644045	587.0	FOSL2	6.58103e-06	High Impact, Hard to Access	3
chr9:69177146:C>G	chr9	69177146	69176631	515	rs1538583	Glomerular filtration rate in type 2 diabetes	4e-06	TJP2	29703844	0.9914465	1305.0	JUNB	6.57272e-06	High Impact, Hard to Access	3
chr7:99517539:G>C	chr7	99517539	99518054	515	rs12533251	5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels in elite athletes	6e-06	ZKSCAN5	31882771	0.99197406	659.0	MAFK	6.57203e-06	High Impact, Hard to Access	3
chr3:69813160:C>A	chr3	69813160	69813676	516	rs111735673	Body mass index (MTAG)	4e-08	MITF	36376304	0.9838064	630.5	JUND	6.5735e-06	High Impact, Hard to Access	3
chr6:56492917:T>A	chr6	56492917	56493434	517	rs143552681	Bone mineral density mean	1e-300	DST	37500982	0.9715297	672.5	JUND	6.58588e-06	High Impact, Hard to Access	3
chr8:97632163:G>C	chr8	97632163	97631646	517	rs5893426	Mean corpuscular volume (UKB data field 30040)	1e-13	SNORD3H - MTDH	39789286	0.9868027	922.0	JUNB	1.97824e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:97632163:G>C	chr8	97632163	97631646	517	rs5893426	Hemoglobin levels	7e-11	SNORD3H - MTDH	40436827	0.9868027	922.0	JUNB	1.97824e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:4298409:A>C	chr9	4298409	4297892	517	rs4258054	Free androgen index	6e-09	GLIS3	36653534	0.98996234	2186.0	JUN	0.000111678	HIGH PRIORITY: Accessible + High Impact	2
chr8:101891286:C>G	chr8	101891286	101890769	517	rs487987	Medication use (beta blocking agents)	1e-08	NCALD	34594039	0.9681593	663.5	ATF3	6.56487e-06	High Impact, Hard to Access	3
chr9:4298409:A>C	chr9	4298409	4297892	517	rs4258054	Type 2 diabetes	6e-08	GLIS3	26818947	0.98996234	2186.0	JUN	0.000111678	HIGH PRIORITY: Accessible + High Impact	2
chr8:135415237:C>A	chr8	135415237	135415756	519	rs881972	Adolescent idiopathic scoliosis	4.0000000000000003e-29	LINC01591 - KHDRBS3	30019117	0.86362827	428.0	JUN	6.57635e-06	Low Priority	3
chr1:93245705:C>G	chr1	93245705	93246225	520	rs3754186	eosinophil (fraction, mean, inv-norm transformed)	5e-16	CCDC18	39024449	0.9855452	805.0	ATF3	6.57393e-06	High Impact, Hard to Access	3
chr13:57976699:G>C	chr13	57976699	57977219	520	rs9537888	Personality traits or cognitive traits (multivariate analysis)	2e-15	PCDH17 - RNA5SP30	37365406	0.972161	532.0	FOS	1.32703e-05	Accessible, Low Impact	3
chr1:93245705:C>G	chr1	93245705	93246225	520	rs3754186	eosinophil (fraction, maximum, inv-norm transformed)	1e-11	CCDC18	39024449	0.9855452	805.0	ATF3	6.57393e-06	High Impact, Hard to Access	3
chr11:78383807:G>C	chr11	78383807	78384327	520	rs10899489	Menarche (age at onset)	8e-09	ZNF75CP, GAB2	21102462	0.99694693	665.5	FOS	6.57583e-06	High Impact, Hard to Access	3
chr11:78383807:G>C	chr11	78383807	78384327	520	rs10899489	Systolic blood pressure	2e-08	ZNF75CP, GAB2	33230300	0.99694693	665.5	FOS	6.57583e-06	High Impact, Hard to Access	3
chr11:78383807:G>C	chr11	78383807	78384327	520	rs10899489	Diastolic blood pressure	5e-08	ZNF75CP, GAB2	33230300	0.99694693	665.5	FOS	6.57583e-06	High Impact, Hard to Access	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Polycythemia vera (PheCode 200.1)	4.0000000000000005e-305	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	platelet count (maximum, inv-norm transformed)	5e-234	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	red cell diameter width (RDW, mean, inv-norm transformed)	5.999999999999999e-206	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	monocyte (fraction, mean, inv-norm transformed)	8.000000000000001e-171	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	monocyte (fraction, minimum, inv-norm transformed)	2e-133	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	neutrophil (fraction, mean, inv-norm transformed)	6e-129	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	lymphocyte (fraction, mean, inv-norm transformed)	3e-122	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	neutrophil (absolute count, mean, inv-norm transformed)	7e-116	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Splenomegaly (PheCode 579.2)	1e-100	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed)	2e-100	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	neutrophil (absolute count, maximum, inv-norm transformed)	2e-94	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Myeloproliferative disease (PheCode 200)	2e-93	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	lymphocyte (fraction, minimum, inv-norm transformed)	5e-92	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	red blood cell count (RBC, maximum, inv-norm transformed)	4.0000000000000003e-88	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	total cholesterol (mean, inv-norm transformed)	9e-80	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Basophil (absolute count, maximum, inv-norm transformed)	3.0000000000000004e-75	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	neutrophil (fraction, minimum, inv-norm transformed)	8.000000000000001e-75	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Basophil (absolute count, mean, inv-norm transformed)	4e-73	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed)	5.9999999999999995e-71	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	total cholesterol (maximum, inv-norm transformed)	4e-70	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Other symptoms involving abdomen and pelvis (PheCode 579)	5.0000000000000005e-68	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	hematocrit (maximum, inv-norm transformed)	1e-65	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	total cholesterol (minimum, inv-norm transformed)	4.9999999999999997e-64	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	lymphocyte (fraction, maximum, inv-norm transformed)	3.9999999999999997e-63	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Diseases of white blood cells (PheCode 288)	4e-53	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Polycythemia, secondary (PheCode 289.8)	9e-53	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Basophil (fraction, maximum, inv-norm transformed)	2e-52	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	neutrophil (absolute count, minimum, inv-norm transformed)	1.9999999999999998e-42	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	potassium (maximum, inv-norm transformed)	9e-38	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed)	3e-37	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Elevated white blood cell count (PheCode 288.2)	7e-36	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	high density lipoprotein cholesterol (HDLC, minimm, inv-norm transformed)	4e-35	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Basophil (fraction, mean, inv-norm transformed)	5e-35	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	high density lipoprotein cholesterol (HDLC, maximum, inv-norm transformed)	2e-33	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	red cell diameter width (RDW, maximum, inv-norm transformed)	1e-31	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	low density lipoprotein cholesterol (LDLC, maximum, inv-norm transformed)	3e-30	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	lymphocyte (absolute count, minimum, inv-norm transformed)	6e-30	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	hemoglobin (maximum, inv-norm transformed)	6e-28	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	low density lipoprotein cholesterol (LDLC, mean, inv-norm transformed)	9e-28	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	monocyte (absolute count, minimum, inv-norm transformed)	8e-27	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	PT international normalized ratio (INR, minimum, inv-norm transformed)	9.999999999999999e-27	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	monocyte (fraction, maximum, inv-norm transformed)	9.999999999999999e-26	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	white blood cell count (WBC, minimum, inv-norm transformed)	3.9999999999999997e-25	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Other diseases of blood and blood-forming organs (PheCode 289)	2.0000000000000002e-24	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	lymphocyte (absolute count, mean, inv-norm transformed)	5e-23	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Takes medication for other cancer?	4e-22	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	potassium (mean, inv-norm transformed)	8e-21	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Glucose (fasting status unknown, minimum, inv-norm transformed)	2e-20	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	PT international normalized ratio (INR, mean, inv-norm transformed)	3e-20	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	low density lipoprotein cholesterol (LDLC, minimum, inv-norm transformed)	7e-20	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	HDL cholesterol	1e-19	JAK2	30275531	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr19:18522424:C>A	chr19	18522424	18522945	521	rs172032	Smoking initiation	2e-19	ELL - FKBP8	36477530	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	white blood cell count (WBC, maximum, inv-norm transformed)	2e-18	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed)	4e-18	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Primary thrombocytopenia (PheCode 287.31)	9e-18	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	PT international normalized ratio (INR, maximum, inv-norm transformed)	1e-17	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Other cancer	8e-17	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr19:18522424:C>A	chr19	18522424	18522945	521	rs172032	Breast cancer	1e-16	ELL - FKBP8	29059683	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	total creatine kinase (mean, inv-norm transformed)	1e-16	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Myeloid leukemia (PheCode 204.2)	4e-16	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Diseases of spleen (PheCode 289.5)	4e-16	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Abnormality of red blood cells (PheCode 289.9)	1e-15	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Disorders of iron metabolism (PheCode 275.1)	1e-15	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Purpura and other hemorrhagic conditions (PheCode 287)	4e-15	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	total creatine kinase (minimum, inv-norm transformed)	4e-15	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Hemoglobin A1c (HbA1c, minimum, inv-norm transformed)	1e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Albumin (maximum, inv-norm transformed)	1e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Secondary thrombocytopenia (PheCode 287.32)	1e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Blood urea nitrogen (BUN, maximum, inv-norm transformed)	2e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Hemoglobin A1c (HbA1c, mean, inv-norm transformed)	3e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	total creatine kinase (maximum, inv-norm transformed)	6e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Total cholesterol levels	7e-14	JAK2	29083408	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	neutrophil (fraction, maximum, inv-norm transformed)	8e-14	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	LDL cholesterol	9e-14	JAK2	30275531	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Hyperlipidemia (PheCode 272.1)	1e-13	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	red cell diameter width (RDW, minimum, inv-norm transformed)	1e-13	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	white blood cell count (WBC, mean, inv-norm transformed)	1e-13	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Disorders of lipid metabolism (PheCode 272)	2e-13	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	creatinine (maximum, inv-norm transformed)	2e-13	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	eosinophil (fraction, minimum, inv-norm transformed)	6e-13	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Bicarbonate (minimum, inv-norm transformed)	1e-12	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Weight (minimum, inv-normal transformed)	2e-12	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Platelet count	3e-12	JAK2	24777453	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Leukemia (PheCode 204)	3e-12	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Other venous embolism and thrombosis (PheCode 452)	7e-12	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Hyperpotassemia (PheCode 276.13)	8e-12	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Basophil (absolute count, minimum, inv-norm transformed)	8e-12	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	hemoglobin (minimum, inv-norm transformed)	1e-11	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Body mass index (BMI, minimum, inv-normal transformed)	1e-11	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Anemia in neoplastic disease (PheCode 285.22)	1e-11	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Thrombocytopenia (PheCode 287.3)	1e-11	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Deep vein thrombosis [DVT] (PheCode 452.2)	1e-11	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	Aplastic anemia (PheCode 284)	2e-11	JAK2	39024449	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr19:18522424:C>A	chr19	18522424	18522945	521	rs172032	Smoking initiation (ever regular vs never regular) (MTAG)	9e-10	ELL - FKBP8	30643251	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr19:18522424:C>A	chr19	18522424	18522945	521	rs172032	Crohn's disease	7e-09	ELL - FKBP8	37156999	0.9996889	7736.0	JUND	6.56996e-06	High Impact, Hard to Access	3
chr9:5074291:C>G	chr9	5074291	5073770	521	rs77375493	High density lipoprotein cholesterol levels	5e-08	JAK2	34887591	0.9715297	504.0	ATF3	7.89328e-05	Accessible, Low Impact	3
chr21:42627705:C>A	chr21	42627705	42627184	521	rs9653814	Verbal learning	3e-06	LINC01671 - PDE9A	35974141	0.96886295	761.5	BATF	1.97195e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:147051586:C>G	chr1	147051586	147052108	522	rs594716	ECM1 protein levels	2e-13	NBPF12 - RNU1-151P	39789286	0.7559361	443.0	FOSL2	6.57082e-06	Low Priority	3
chr1:219467486:C>A	chr1	219467486	219466963	523	rs2605091	Umbilical hernia	2e-15	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219466963	523	rs2605091	Surgical knee osteoarthritis	5e-11	LYPLAL1-AS1	36376028	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr1:219467486:C>A	chr1	219467486	219466963	523	rs2605091	Inguinal hernia	6e-10	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr14:99702283:C>G	chr14	99702283	99701760	523	rs73350415	Oligodendroglioma	2e-09	CYP46A1	36810956	0.990189	1225.0	MAFK	1.97278e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:85685529:G>C	chr16	85685529	85686052	523	rs11117258	Problematic alcohol use (MTAG)	5e-08	GINS2	32451486	0.9950484	1173.0	ATF7	1.3181e-05	HIGH PRIORITY: Accessible + High Impact	3
chr21:38787958:A>C	chr21	38787958	38787434	524	rs117114911	Bone mineral density mean	1e-300	LINC00114 - ETS2	37500982	0.99999	31120.0	FOSL1	6.56953e-06	High Impact, Hard to Access	3
chr12:6745004:C>G	chr12	6745004	6745529	525	rs7307912	Drinks per week	2e-16	COPS7A - MLF2	36477530	0.9695515	875.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr12:6745004:C>G	chr12	6745004	6745529	525	rs7307912	Bitter alcoholic beverage consumption	1e-06	COPS7A - MLF2	31046077	0.9695515	875.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr8:69445867:A>C	chr8	69445867	69446393	526	rs6990149	Nontoxic multinodular goiter (PheCode 241.2)	1e-20	LINC01603	39024449	0.9409573	501.0	FOSL2	6.56858e-06	Accessible, Low Impact	2
chr8:69445867:A>C	chr8	69445867	69446393	526	rs6990149	Nontoxic uninodular goiter (PheCode 241.1)	2e-14	LINC01603	39024449	0.9409573	501.0	FOSL2	6.56858e-06	Accessible, Low Impact	2
chr8:69445867:A>C	chr8	69445867	69446393	526	rs6990149	Nontoxic nodular goiter (PheCode 241)	7e-12	LINC01603	39024449	0.9409573	501.0	FOSL2	6.56858e-06	Accessible, Low Impact	2
chr7:93044656:A>C	chr7	93044656	93044130	526	rs2374602	Body size or adipose distribution (multivariate analysis)	4e-10	RN7SL7P - SAMD9	40796553	0.9999352	5056.0	JUND	6.57549e-06	High Impact, Hard to Access	3
chr8:77805112:C>G	chr8	77805112	77804586	526	rs558258836	Normal body mass index vs. thin	6e-06	HIGD1AP18 - PKIA-AS1	30677029	0.9872979	484.0	MAFK	6.57912e-06	Low Priority	3
chr15:81308454:C>G	chr15	81308454	81308981	527	rs859	Pro-interleukin-16 levels	8e-40	IL16	33067605	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:12677999:C>A	chr9	12677999	12677471	528	rs13297008	Eye color	5e-250	LURAP1L-AS1	33692100	0.83089256	428.0	FOS	3.56014e-05	Accessible, Low Impact	3
chr13:99326026:C>A	chr13	99326026	99325498	528	rs9517686	Eosinophil count	2e-37	UBAC2	32888493	0.99768937	1327.0	ATF2	1.31441e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:208145785:G>T	chr2	208145785	208145256	529	rs71350714	CRYGD protein levels	3e-167	CRYGB	39789286	0.96610916	606.5	MAFG	1.31525e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:78532052:G>C	chr15	78532052	78532582	530	rs12438659	Post bronchodilator FEV1	2e-08	HYKK	26634245	0.9943153	507.0	FOSL2	0.000368159	Accessible, Low Impact	3
chr15:100141111:T>A	chr15	100141111	100141641	530	rs55752727	Waist circumference adjusted for body mass index	3e-08	ADAMTS17	34021172	0.9860784	805.0	FOSL1	0.0	High Impact, Hard to Access	3
chr15:78532052:G>C	chr15	78532052	78532582	530	rs12438659	Post bronchodilator FEV1/FVC ratio	3e-06	HYKK	26634245	0.9943153	507.0	FOSL2	0.000368159	Accessible, Low Impact	3
chr1:55136559:G>T	chr1	55136559	55137090	531	rs4927194	Low density lipoprotein cholesterol levels	5e-19	USP24	33462484	0.9787506	603.0	JUNB	6.57125e-06	High Impact, Hard to Access	3
chr1:55136559:G>T	chr1	55136559	55137090	531	rs4927194	Total cholesterol levels	3e-17	USP24	33462484	0.9787506	603.0	JUNB	6.57125e-06	High Impact, Hard to Access	3
chr1:55136559:G>T	chr1	55136559	55137090	531	rs4927194	Apolipoprotein B levels	5e-15	USP24	33462484	0.9787506	603.0	JUNB	6.57125e-06	High Impact, Hard to Access	3
chr17:7578317:C>G	chr17	7578317	7577786	531	rs8066907	Height	2e-06	EIF4A1, SENP3-EIF4A1	36224396	0.9987304	1868.0	ATF2	1.31382e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:23379022:C>A	chr9	23379022	23378490	532	rs1360380	Height	3.9999999999999995e-42	LINC03142	36224396	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378490	532	rs1360380	Depressed affect	2e-10	LINC03142	29942085	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr2:161367621:T>A	chr2	161367621	161368153	532	rs2303319	Cognitive function	9e-06	PSMD14	25644384	0.9914465	620.0	JUND	6.57142e-06	High Impact, Hard to Access	3
chr19:54343178:C>A	chr19	54343178	54343711	533	rs111558206	LILRB5 protein levels	1.0000000000000001e-23	LILRA4 - LAIR1	39789286	0.98327994	485.0	MAFK	1.31506e-05	Accessible, Low Impact	3
chr3:48490888:T>A	chr3	48490888	48491421	533	rs62264271	Waist circumference adjusted for body mass index	1e-17	SHISA5	34021172	0.9854257	443.75	JUND	6.57194e-06	Accessible, Low Impact	2
chr3:48490888:T>A	chr3	48490888	48491421	533	rs62264271	A body shape index	4e-14	SHISA5	34021172	0.9854257	443.75	JUND	6.57194e-06	Accessible, Low Impact	2
chr6:33156314:A>C	chr6	33156314	33156847	533	rs56313034	KIR2DL2 protein levels	1e-12	HCG24 - COL11A2	39789286	0.9990577	554.0	FOS	0.0	Low Priority	2
chr6:39831406:C>A	chr6	39831406	39831939	533	rs75112004	Appendicular lean mass	2e-11	DAAM2	33097823	0.92356306	511.0	MAFG	6.57376e-06	Low Priority	3
chr17:11533442:G>C	chr17	11533442	11533975	533	rs113941606	Myopia	1e-10	SHISA6	35841873	0.9992518	943.25	FOS	6.58311e-06	High Impact, Hard to Access	3
chr17:11533442:G>C	chr17	11533442	11533975	533	rs113941606	Ocular disease	2e-09	SHISA6	35841873	0.9992518	943.25	FOS	6.58311e-06	High Impact, Hard to Access	3
chr9:113602375:C>G	chr9	113602375	113602908	533	rs567743	Serum total protein levels	3e-09	RGS3 - C14orf119P1	34594039	0.99958974	3792.0	FOSL1	6.56711e-06	High Impact, Hard to Access	3
chr11:2899412:G>T	chr11	2899412	2898878	534	rs76024540	Keloid	3e-18	SLC67A1-AS	40835838	0.9801434	1022.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr11:2899412:G>T	chr11	2899412	2898878	534	rs76024540	Keloid scar (PheCode 701.4)	9e-16	SLC67A1-AS	39024449	0.9801434	1022.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr6:16160660:G>C	chr6	16160660	16161194	534	rs6924995	Response to statins (LDL cholesterol change)	5e-07	PERPP3	22331829	0.95134485	518.0	BATF	6.57358e-06	Low Priority	3
chr20:43887144:G>T	chr20	43887144	43886610	534	rs73609517	Vaginal microbiome MetaCyc pathway (FUC-RHAMCAT-PWY|superpathway of fucose and rhamnose degradation)	4e-06	RNU6-639P - LINC01728	34282934	0.9801434	552.5	ATF3	6.57307e-06	Low Priority	3
chr2:465324:C>A	chr2	465324	464789	535	rs55945295	Triglyceride (60:11) levels	5e-09	LINC01865 - LINC01874	39753034	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr22:17949715:G>C	chr22	17949715	17949180	535	rs139205844	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	3e-06	MICAL3	29221444	0.96204376	668.0	ATF3	1.97075e-05	HIGH PRIORITY: Accessible + High Impact	3
chr22:17949715:G>C	chr22	17949715	17949180	535	rs139205844	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes	7e-06	MICAL3	29221444	0.96204376	668.0	ATF3	1.97075e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:49771266:G>T	chr3	49771266	49770730	536	rs758504714	TDGF1 protein levels	3e-19	IP6K1	39789286	0.98739034	700.5	ATF2	0.0	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196819	536	rs16988381	Invasive breast cancer	3e-09	HORMAD2 - LIF-AS1	32424353	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196819	536	rs16988381	Pulse pressure (BMI unadjusted)	4e-09	HORMAD2 - LIF-AS1	39048560	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr22:30196283:G>C	chr22	30196283	30196819	536	rs16988381	Pulse pressure (BMI adjusted)	2e-08	HORMAD2 - LIF-AS1	39048560	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr2:105524010:G>C	chr2	105524010	105524547	537	rs10164546	Pursuit maintenance gain	9e-06	FHL2 - LINC02946	29064472	0.97898656	427.25	JUND	0.27106	Accessible, Low Impact	3
chr16:79147260:C>G	chr16	79147260	79146722	538	rs56928727	Oligodendroglioma	1e-06	WWOX	36810956	0.96195054	585.0	FOSL2	2.62798e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:225157433:C>A	chr2	225157433	225156894	539	rs10208109	Educational attainment	8e-10	DOCK10 - NYAP2	35361970	0.961097	469.0	ATF3	7.23142e-05	Accessible, Low Impact	3
chr16:58673185:C>G	chr16	58673185	58673724	539	rs59234479	Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer	3e-06	SLC38A7	30648747	0.7921896	510.5	ATF2	6.97866e-06	Accessible, Low Impact	3
chr20:46101494:G>C	chr20	46101494	46100954	540	rs772625275	CD40 protein levels	8e-139	RPL13P2 - CD40	39789286	0.95134485	594.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr5:177066561:A>C	chr5	177066561	177067101	540	rs183686	Noncognitive aspects of educational attainment	1e-08	ZNF346	33414549	0.99843514	792.0	FOS	1.97293e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:234029502:C>G	chr2	234029502	234028961	541	rs60697520	Total bilirubin levels (UKB data field 30840)	9e-185	TRPM8 - SPP2	39789286	0.99901474	1899.0	JUNB	6.57108e-06	High Impact, Hard to Access	3
chr16:82167328:G>C	chr16	82167328	82167869	541	rs4889479	Standing height (UKB data field 50)	9e-34	MPHOSPH6	39789286	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr19:10640945:G>C	chr19	10640945	10640404	541	rs1811376	Familial combined hyperlipidemia defined by Consensus criteria	2.0000000000000002e-23	SLC44A2	34906840	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr2:207691534:A>C	chr2	207691534	207692075	541	rs13033637	CRYGD protein levels	4e-17	Y_RNA - CCNYL1	39789286	0.9984708	653.0	FOS	1.97088e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:143047958:C>G	chr2	143047958	143047417	541	rs75710639	Rab-like protein 3 protein levels (SomaScan ID:4559-64)	2e-13	KYNU	40883583	0.94346935	535.5	ATF3	0.00031504	Accessible, Low Impact	3
chr19:10640945:G>C	chr19	10640945	10640404	541	rs1811376	Saturated fatty acids levels	1e-11	SLC44A2	40545721	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr19:10640945:G>C	chr19	10640945	10640404	541	rs1811376	Total fatty acid levels	6e-11	SLC44A2	40545721	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr19:10640945:G>C	chr19	10640945	10640404	541	rs1811376	Familial combined hyperlipidemia defined by Dutch criteria	1e-09	SLC44A2	34906840	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr19:10640945:G>C	chr19	10640945	10640404	541	rs1811376	Familial combined hyperlipidemia defined by Mexico criteria	8e-06	SLC44A2	34906840	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr15:63858128:C>A	chr15	63858128	63858670	542	rs7180823	Platelet distribution width	3e-25	HERC1 - MIR422A	32888494	0.95749575	609.0	FOS	6.57488e-06	High Impact, Hard to Access	3
chr15:63858128:C>A	chr15	63858128	63858670	542	rs7180823	A body shape index	8e-09	HERC1 - MIR422A	34021172	0.95749575	609.0	FOS	6.57488e-06	High Impact, Hard to Access	3
chr7:26543142:G>C	chr7	26543142	26542599	543	rs2158711	Pulse rate (UKB data field 102)	1e-14	KIAA0087 - LINC03095	39789286	0.9991795	833.0	MAFG	6.57168e-06	High Impact, Hard to Access	3
chr9:4975241:C>A	chr9	4975241	4974697	544	rs141406245	RLN2 protein levels	2.0000000000000002e-29	HNRNPA1P41 - JAK2	39789286	0.9008302	569.0	BATF	6.57583e-06	High Impact, Hard to Access	3
chr2:159633853:C>G	chr2	159633853	159634398	545	rs552558867	LY75 protein levels	3e-26	BAZ2B-AS1 - RPS3AP13	39789286	0.93037623	443.0	ATF3	0.000125457	Accessible, Low Impact	3
chr4:110335306:G>T	chr4	110335306	110334761	545	rs244017	Atrial fibrillation	8e-11	ZBED1P1 - ENPEP	30061737	0.92219406	466.0	ATF2	6.57229e-06	Low Priority	3
chr7:124732785:C>A	chr7	124732785	124733330	545	rs4268071	Lung adenocarcinoma	7e-10	RNU6-102P - GPR37	37236969	0.9729977	366.0	MAFK	1.97138e-05	Accessible, Low Impact	3
chr15:81308454:C>G	chr15	81308454	81308999	545	rs11325	Height	5e-09	IL16	31562340	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:3609576:G>T	chr8	3609576	3610121	545	rs80113388	Aggressiveness in attention deficit hyperactivity disorder	3e-06	CSMD1	27021288	0.9409573	421.5	FOS	1.31683e-05	Accessible, Low Impact	3
chr17:48271524:C>A	chr17	48271524	48272070	546	rs72827805	Systolic blood pressure (MTAG)	2e-17	SKAP1	39537608	0.9855452	816.0	MAFG	6.59074e-06	High Impact, Hard to Access	3
chr16:67889024:C>A	chr16	67889024	67889570	546	rs550548705	Mean corpuscular volume	2e-15	NRN1L - PSKH1	32888494	0.98289305	1251.0	FOSL2	6.56797e-06	High Impact, Hard to Access	3
chr16:67889024:C>A	chr16	67889024	67889570	546	rs550548705	Mean corpuscular hemoglobin	1e-09	NRN1L - PSKH1	27863252	0.98289305	1251.0	FOSL2	6.56797e-06	High Impact, Hard to Access	3
chr16:67889024:C>A	chr16	67889024	67889570	546	rs550548705	Mean reticulocyte volume	3e-09	NRN1L - PSKH1	32888494	0.98289305	1251.0	FOSL2	6.56797e-06	High Impact, Hard to Access	3
chr3:141208916:C>A	chr3	141208916	141208370	546	rs140660179	Intestinal gastric cancer	9e-06	SPSB4 - PXYLP1	39862296	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr2:102131400:A>C	chr2	102131400	102130853	547	rs1024794	Alanine aminotransferase levels	1e-08	IL1R1	33547301	0.99894255	833.5	JUN	9.19673e-05	HIGH PRIORITY: Accessible + High Impact	2
chr14:53883980:G>C	chr14	53883980	53883433	547	rs72678285	Stem cell factor levels	2e-06	DDHD1-DT	27989323	0.9659551	591.875	FOS	1.31588e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:172093032:C>A	chr4	172093032	172092485	547	rs1354631	1-methylimidazoleacetate levels in elite athletes	3e-06	GALNTL6	31882771	0.93910295	422.5	FOSL1	6.58935e-06	Low Priority	3
chr10:132487488:G>C	chr10	132487488	132488037	549	rs7096828	rfMRI amplitudes (ICA100 node 27)	1e-12	LINC02870 - LINC01165	33875891	0.9992518	1191.0	FOS	3.93902e-05	HIGH PRIORITY: Accessible + High Impact	3
chr20:21475434:T>A	chr20	21475434	21475983	549	rs76485293	Aureimonas abundance in stool	4e-08	RN7SKP140 - GSTM3P1	35115689	0.9036088	485.0	JUND	6.58345e-06	Accessible, Low Impact	2
chr4:63456903:A>C	chr4	63456903	63456354	549	rs17628760	Lateral ventricle temporal horn volume	5e-06	LARP1BP1 - TECRL	31530798	0.9992165	784.0	FOSL2	6.58432e-06	HIGH PRIORITY: Accessible + High Impact	2
chr20:8871746:A>C	chr20	8871746	8871195	551	rs4380320	Whole body fat free mass (UKB data field 23101)	1e-09	PLCB1	38538606	0.9990358	669.5	FOSL2	6.56987e-06	High Impact, Hard to Access	3
chr9:94960432:G>T	chr9	94960432	94960984	552	rs7864171	Atrial fibrillation	1e-98	AOPEP	40645996	0.8908594	439.0	ATF3	0.0	Low Priority	3
chr9:94960432:G>T	chr9	94960432	94960984	552	rs7864171	Atrial flutter (PheCode 427.22)	4e-16	AOPEP	39024449	0.8908594	439.0	ATF3	0.0	Low Priority	3
chr13:50765296:A>C	chr13	50765296	50764744	552	rs7334008	Height (baseline)	3e-08	DLEU7, DLEU1	40374629	0.9950484	581.5	FOS	6.56935e-06	High Impact, Hard to Access	3
chr9:94960432:G>T	chr9	94960432	94960984	552	rs7864171	Polycystic ovary syndrome	3e-08	AOPEP	30566500	0.8908594	439.0	ATF3	0.0	Low Priority	3
chr10:79350727:C>A	chr10	79350727	79351280	553	rs876678	Height	2.0000000000000002e-66	PPIF	39134668	0.9964944	1053.0	FOS	6.56978e-06	High Impact, Hard to Access	3
chr10:79350727:C>A	chr10	79350727	79351280	553	rs876678	Hip circumference adjusted for BMI	2e-17	PPIF	34021172	0.9964944	1053.0	FOS	6.56978e-06	High Impact, Hard to Access	3
chr16:89841042:G>C	chr16	89841042	89841595	553	rs1079558	Age of smoking initiation	3e-10	SPIRE2	36477530	0.9759043	646.5	ATF3	6.57825e-06	High Impact, Hard to Access	3
chr16:89841042:G>C	chr16	89841042	89841595	553	rs1079558	White matter microstructure (fractional anisotropy)	3e-08	SPIRE2	31666681	0.9759043	646.5	ATF3	6.57825e-06	High Impact, Hard to Access	3
chr8:102865106:C>G	chr8	102865106	102864552	554	rs2247355	HDL cholesterol levels	6e-17	MAILR, AZIN1	32203549	0.9991002	2196.0	MAFK	1.3166e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:58179033:C>A	chr10	58179033	58178479	554	rs112011926	Monocyte percentage (UKB data field 30190)	3e-14	MRPS35P3 - IPMK	39789286	0.9967285	891.5	FOS	6.57704e-06	High Impact, Hard to Access	3
chr8:102865106:C>G	chr8	102865106	102864552	554	rs2247355	Haematocrit percentage (UKB data field 30030)	1e-13	MAILR, AZIN1	39789286	0.9991002	2196.0	MAFK	1.3166e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:58179033:C>A	chr10	58179033	58178479	554	rs112011926	Monocyte percentage of white cells	2e-12	MRPS35P3 - IPMK	32888494	0.9967285	891.5	FOS	6.57704e-06	High Impact, Hard to Access	3
chr8:102865106:C>G	chr8	102865106	102864552	554	rs2247355	HDL cholesterol	2e-12	MAILR, AZIN1	34594039	0.9991002	2196.0	MAFK	1.3166e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:102865106:C>G	chr8	102865106	102864552	554	rs2247355	Apolipoprotein A1 levels	4e-12	MAILR, AZIN1	32203549	0.9991002	2196.0	MAFK	1.3166e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:38329559:G>C	chr1	38329559	38330113	554	rs2798812	Height	8e-11	LINC01343 - RNU6-753P	36224396	0.9986987	631.5	FOS	5.2608e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:102865106:C>G	chr8	102865106	102864552	554	rs2247355	Phospholipids to total lipids ratio in medium HDL	5e-09	MAILR, AZIN1	35213538	0.9991002	2196.0	MAFK	1.3166e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:53378607:T>A	chr5	53378607	53379161	554	rs62357791	Corneal resistance factor (MTAG)	1e-08	RPL13AP13 - FST	35446358	0.99930274	3188.0	FOS	6.65106e-06	HIGH PRIORITY: Accessible + High Impact	3
chr8:102865106:C>G	chr8	102865106	102864552	554	rs2247355	Medication use (agents acting on the renin-angiotensin system)	4e-08	MAILR, AZIN1	31015401	0.9991002	2196.0	MAFK	1.3166e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:47326247:C>A	chr17	47326247	47325691	556	rs12948299	Brain region volumes	4e-08	EFCAB13-DT, EFCAB13	31676860	0.9267576	477.5	MAFK	6.57644e-06	Low Priority	3
chr2:43196174:C>A	chr2	43196174	43196731	557	rs4952673	Type 2 diabetes	3e-13	LINC02580	38374256	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196731	557	rs4952673	Offspring birth weight	2e-11	LINC02580	31043758	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr8:8431831:C>A	chr8	8431831	8432389	558	rs2976842	Estimated glomerular filtration rate (creatinine)	6e-17	LINC02949 - LINC02950	35710981	0.94346935	446.0	JUND	6.67949e-06	Accessible, Low Impact	3
chr8:8431831:C>A	chr8	8431831	8432389	558	rs2976842	General factor of neuroticism	3e-11	LINC02949 - LINC02950	30867560	0.94346935	446.0	JUND	6.67949e-06	Accessible, Low Impact	3
chr5:117265379:C>A	chr5	117265379	117264820	559	rs12719228	Gut microbial network clusters (Pink (at 1 year) x Any Breastfeeding (3 Months) interaction	4e-08	LINC02214 - RPL35AP15	40187613	0.94045055	477.0	MAFK	6.57315e-06	Low Priority	3
chr9:106857970:T>A	chr9	106857970	106858530	560	rs12343333	Hematocrit	9e-13	RNA5SP292 - ZNF462	32888493	0.9855452	709.0	FOS	1.97112e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:3728917:G>T	chr11	3728917	3728355	562	rs10834966	IGF 1 (UKB data field 30770)	4e-16	NUP98	39789286	0.96744037	539.0	ATF2	6.57324e-05	Accessible, Low Impact	3
chr12:30201604:G>T	chr12	30201604	30201042	562	rs11613048	Major depressive disorder	8e-06	LINC02386	29317602	0.9834347	850.0	ATF3	6.57428e-06	High Impact, Hard to Access	3
chr20:59567706:C>G	chr20	59567706	59568269	563	rs6100502	Bone mineral density mean	1.9999999999999998e-50	PIEZO1P1 - PHACTR3	37500982	0.97922516	713.0	JUNB	6.5678e-06	High Impact, Hard to Access	3
chr11:35267709:C>A	chr11	35267709	35268272	563	rs1570214	Medication use (thyroid preparations)	2e-18	SLC1A2, SLC1A2-AS1	34594039	0.9977934	1401.0	JUND	6.57895e-06	High Impact, Hard to Access	3
chr13:51271906:C>A	chr13	51271906	51272469	563	rs1006064	Cerebrospinal fluid clusterin levels	5e-06	FAM124A	26545630	0.9840279	608.0	FOSL2	6.57281e-06	High Impact, Hard to Access	3
chr12:40156336:C>G	chr12	40156336	40156900	564	rs17442910	Mean platelet thrombocyte volume (UKB data field 30100)	9e-24	LINC02471, LINC02555	39789286	0.9940711	1312.0	ATF2	0.000124836	HIGH PRIORITY: Accessible + High Impact	3
chr12:40156336:C>G	chr12	40156336	40156900	564	rs17442910	Platelet count (UKB data field 30080)	3e-23	LINC02471, LINC02555	39789286	0.9940711	1312.0	ATF2	0.000124836	HIGH PRIORITY: Accessible + High Impact	3
chr12:40156336:C>G	chr12	40156336	40156900	564	rs17442910	Platelet count	5e-23	LINC02471, LINC02555	32888493	0.9940711	1312.0	ATF2	0.000124836	HIGH PRIORITY: Accessible + High Impact	3
chr12:40156336:C>G	chr12	40156336	40156900	564	rs17442910	Platelet distribution width (UKB data field 30110)	7e-14	LINC02471, LINC02555	39789286	0.9940711	1312.0	ATF2	0.000124836	HIGH PRIORITY: Accessible + High Impact	3
chr11:81480510:C>A	chr11	81480510	81481074	564	rs768344148	GLIPR1 protein levels	1e-11	COX6A1P4 - MTND4LP18	39789286	0.95749575	512.0	JUND	2.62892e-05	Accessible, Low Impact	3
chr12:40156336:C>G	chr12	40156336	40156900	564	rs17442910	Mean platelet volume	8e-10	LINC02471, LINC02555	32888494	0.9940711	1312.0	ATF2	0.000124836	HIGH PRIORITY: Accessible + High Impact	3
chr8:8415880:C>G	chr8	8415880	8416445	565	rs17607190	Serum alkaline phosphatase levels	1e-12	LINC02949	33462484	0.90298235	455.5	MAFK	6.59213e-06	Low Priority	3
chr2:82925084:T>A	chr2	82925084	82924517	567	rs4852696	Smoking initiation	7e-14	DHFRP3 - LINC01809	36477530	0.98327994	543.0	JUND	6.57652e-06	Low Priority	3
chr19:49631608:C>G	chr19	49631608	49632177	569	rs11880195	Self-reported math ability	7e-10	PRR12 - RRAS	30038396	0.9855452	1250.0	FOSL2	6.749e-06	HIGH PRIORITY: Accessible + High Impact	3
chr16:8729552:C>G	chr16	8729552	8728983	569	rs4984997	Glycosyl-N-behenoyl-sphingosine (d18:1/22:0) levels in elite athletes	3e-06	ABAT	31882771	0.9185313	653.0	ATF2	0.985772	HIGH PRIORITY: Accessible + High Impact	3
chr2:117634001:A>C	chr2	117634001	117634570	569	rs115262075	Oligodendroglioma	6e-06	RNU7-190P - DDX18	36810956	0.9327804	464.5	FOSL2	1.97246e-05	Accessible, Low Impact	3
chr6:30003382:G>T	chr6	30003382	30002812	570	rs7758512	HIV-1 control	2e-08	POLR1HASP	20041166	0.93131924	527.25	FOS	6.5864e-06	Low Priority	3
chr22:30196283:G>C	chr22	30196283	30196853	570	rs16988383	Behcet's disease	2e-06	HORMAD2 - LIF-AS1	33393726	0.99999	8104.0	JUNB	6.56978e-06	High Impact, Hard to Access	3
chr16:89841042:G>C	chr16	89841042	89840471	571	rs190295257	Skin reflectance	5e-20	SPIRE2	36536295	0.9759043	646.5	ATF3	6.57825e-06	High Impact, Hard to Access	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	Intelligence (MTAG)	4e-17	LINC02796	29326435	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	Body mass index	3e-16	LINC02796	28448500	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	Body mass index (joint analysis main effects and physical activity interaction)	7e-16	LINC02796	28448500	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	High-density lipoprotein levels (MTAG)	5e-11	LINC02796	36376304	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	Triglycerides to Total Lipids in IDL percentage	2e-10	LINC02796	41044249	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	Body mass index in physically active individuals	2e-07	LINC02796	28448500	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr1:72371236:C>A	chr1	72371236	72371807	571	rs11209951	Body mass index in physically inactive individuals	3e-07	LINC02796	28448500	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr10:74248269:G>T	chr10	74248269	74247697	572	rs7895133	Platelet count	2e-10	ADK	32888494	0.9756724	580.0	ATF3	6.5754e-06	High Impact, Hard to Access	3
chr2:170551012:C>G	chr2	170551012	170550440	572	rs148105376	Itch intensity from mosquito bite adjusted by bite size	7e-07	MYO3B	28199695	0.97511876	583.5	ATF2	4.60264e-05	HIGH PRIORITY: Accessible + High Impact	3
chr21:17681236:A>C	chr21	17681236	17681811	575	rs75508270	Gut microbial network clusters (Salmon (at 1 year) x Any Breastfeeding (3 Months) interaction	5e-13	BTG3-AS1 - C21orf91-OT1	40187613	0.963604	557.5	JUN	0.000984588	Accessible, Low Impact	3
chr6:160749247:C>G	chr6	160749247	160749823	576	rs79570361	PLG protein levels	1.9999999999999998e-30	PLG	39789286	0.994591	970.5	JUNB	1.31494e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:160749247:C>G	chr6	160749247	160749823	576	rs79570361	Lipoprotein (a) levels	3e-19	PLG	33462484	0.994591	970.5	JUNB	1.31494e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:160749247:C>G	chr6	160749247	160749823	576	rs79570361	Triglyceride levels	5e-10	PLG	33462484	0.994591	970.5	JUNB	1.31494e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:72228809:C>A	chr13	72228809	72228233	576	rs57355895	Mitral valve prolapse	1e-09	RPS10P21 - RPL18AP17	35245370	0.8908594	462.0	JUN	6.56797e-06	Low Priority	3
chr6:160749247:C>G	chr6	160749247	160749823	576	rs79570361	Coronary heart disease	3e-09	PLG	37947095	0.994591	970.5	JUNB	1.31494e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:160749247:C>G	chr6	160749247	160749823	576	rs79570361	Aging	2e-08	PLG	37550455	0.994591	970.5	JUNB	1.31494e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:111374174:A>C	chr6	111374174	111374751	577	rs61756663	GLIPR1 protein levels	2e-22	REV3L, MFSD4B	39789286	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr6:36633672:C>A	chr6	36633672	36634250	578	rs747844459	Mean corpuscular volume	2e-52	MIR3925 - RNU1-88P	32888494	0.9801434	1083.0	FOS	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:36633672:C>A	chr6	36633672	36634250	578	rs747844459	Mean reticulocyte volume	4e-40	MIR3925 - RNU1-88P	32888494	0.9801434	1083.0	FOS	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:36633672:C>A	chr6	36633672	36634250	578	rs747844459	Mean spheric corpuscular volume	3e-34	MIR3925 - RNU1-88P	32888494	0.9801434	1083.0	FOS	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:36633672:C>A	chr6	36633672	36634250	578	rs747844459	Red blood cell count	9e-31	MIR3925 - RNU1-88P	32888494	0.9801434	1083.0	FOS	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:12780293:C>G	chr16	12780293	12779715	578	rs117751320	CPPED1 protein levels	4.0000000000000003e-29	CPPED1	39789286	0.9185313	697.0	JUNB	6.57428e-06	High Impact, Hard to Access	3
chr6:36633672:C>A	chr6	36633672	36634250	578	rs747844459	Mean corpuscular hemoglobin	2e-18	MIR3925 - RNU1-88P	27863252	0.9801434	1083.0	FOS	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:36633672:C>A	chr6	36633672	36634250	578	rs747844459	Immature fraction of reticulocytes	5e-13	MIR3925 - RNU1-88P	32888494	0.9801434	1083.0	FOS	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:4116495:G>T	chr11	4116495	4117074	579	rs7940013	Telomere length (principal component 1)	2e-08	RRM1	39192095	0.9990591	3953.5	MAFK	1.97246e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:17044393:C>A	chr9	17044393	17044973	580	rs393488	Insomnia	1e-10	BNC2 - RN7SL720P	35835914	0.92191833	533.5	JUNB	2.62947e-05	Accessible, Low Impact	3
chr9:17044393:C>A	chr9	17044393	17044973	580	rs393488	Help-seeking from a GP	2e-10	BNC2 - RN7SL720P	32231276	0.92191833	533.5	JUNB	2.62947e-05	Accessible, Low Impact	3
chr9:17044393:C>A	chr9	17044393	17044973	580	rs393488	Attention deficit hyperactivity disorder (persistent)	3e-06	BNC2 - RN7SL720P	32279069	0.92191833	533.5	JUNB	2.62947e-05	Accessible, Low Impact	3
chr15:56383275:G>C	chr15	56383275	56382694	581	rs2114183	Mean corpuscular volume	3.9999999999999997e-32	TEX9	34594039	0.99961674	1435.5	FOSL1	1.97086e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:104516970:C>A	chr10	104516970	104517551	581	rs6584606	Frailty (Factor 3 - Multimorbidity)	7e-11	LINC02620 - SORCS3	40759756	0.9050901	520.0	JUN	1.31465e-05	Accessible, Low Impact	3
chr1:72371236:C>A	chr1	72371236	72371817	581	rs11209952	Fish- and plant-related diet	1e-08	LINC02796	32066663	0.94931644	545.5	ATF3	6.57376e-06	Low Priority	3
chr2:199434797:C>A	chr2	199434797	199435378	581	rs9646754	Cerebrospinal fluid immune biomarker levels	2e-08	SATB2	32066700	0.9801434	615.0	FOSL1	5.91778e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:43196174:C>A	chr2	43196174	43196756	582	rs4952979	Hemoglobin concentration	2e-21	LINC02580	32888493	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196756	582	rs4952979	Hematocrit	3e-21	LINC02580	32888493	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196756	582	rs4952979	Red blood cell count	3e-19	LINC02580	32888493	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196756	582	rs4952979	Red blood cell erythrocyte count (UKB data field 30010)	4e-15	LINC02580	39789286	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr5:131710724:G>C	chr5	131710724	131710142	582	rs32110	Calcium (mean, inv-norm transformed)	3e-11	FNIP1	39024449	0.9780051	682.0	BATF	6.57203e-06	High Impact, Hard to Access	3
chr20:33869663:G>T	chr20	33869663	33870245	582	rs150618140	Abdominal fat cell number	1e-10	CHMP4B - TPM3P2	35320353	0.8608881	519.5	MAFG	6.56564e-06	Accessible, Low Impact	2
chr2:43196174:C>A	chr2	43196174	43196756	582	rs4952979	Kidney cancer	3e-08	LINC02580	38671320	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr2:43196174:C>A	chr2	43196174	43196756	582	rs4952979	Clear cell renal cell carcinoma	4e-08	LINC02580	38671320	0.99570066	3256.0	MAFG	0.0	High Impact, Hard to Access	3
chr3:108099347:G>T	chr3	108099347	108099930	583	rs7635063	Educational attainment	1e-20	LINC01215	35361970	0.9978391	1369.0	JUND	6.57237e-06	High Impact, Hard to Access	3
chr22:50072422:C>G	chr22	50072422	50073005	583	rs530062647	Femur bone mineral density x serum urate levels interaction	7e-11	MLC1	34046847	0.9036088	753.0	ATF3	6.56901e-06	High Impact, Hard to Access	3
chr15:41745955:C>A	chr15	41745955	41745372	583	rs2577947	Body mass index	7e-10	MGA	30239722	0.9860784	635.0	FOS	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:41745955:C>A	chr15	41745955	41745372	583	rs2577947	Adiposity (multivariate analysis)	2e-08	MGA	40796553	0.9860784	635.0	FOS	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:65364638:C>G	chr1	65364638	65365222	584	rs1570869	Height	1e-16	DNAJC6	36224396	0.9545879	626.0	JUND	0.0	High Impact, Hard to Access	3
chr8:10580191:G>C	chr8	10580191	10580775	584	rs111358281	Bone mineral density mean	5e-14	PRSS55 - RP1L1	37500982	0.99939203	1206.0	FOS	6.57462e-06	High Impact, Hard to Access	3
chr1:206951632:C>G	chr1	206951632	206951048	584	rs12118203	Clear cell renal cell carcinoma	7e-12	PIGR - FCAMR	38671320	0.9991015	2194.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr1:206951632:C>G	chr1	206951632	206951048	584	rs12118203	Kidney cancer	1e-08	PIGR - FCAMR	38671320	0.9991015	2194.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr3:31620846:G>C	chr3	31620846	31620262	584	rs9859349	CD62L- monocyte %monocyte	5e-08	STT3B	32929287	0.99715763	1265.0	ATF2	3.28632e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:67889024:C>A	chr16	67889024	67888439	585	rs10468274	High density lipoprotein cholesterol levels	6e-09	NRN1L	31566214	0.98289305	1251.0	FOSL2	6.56797e-06	High Impact, Hard to Access	3
chr16:31270672:C>A	chr16	31270672	31270085	587	rs775029448	SIGLEC1 protein levels	9e-12	ITGAM	39789286	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr16:31270672:C>A	chr16	31270672	31270085	587	rs775029448	Total concentration of lipoprotein particles	6e-11	ITGAM	41044249	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr16:31270672:C>A	chr16	31270672	31270085	587	rs775029448	Concentration of HDL particles	6e-11	ITGAM	41044249	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr16:31270672:C>A	chr16	31270672	31270085	587	rs775029448	Free cholesterol in medium HDL	2e-10	ITGAM	41044249	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr16:31270672:C>A	chr16	31270672	31270085	587	rs775029448	Free cholesterol to total lipids ratio in very large VLDL	3e-08	ITGAM	35213538	0.8072176	359.0	MAFK	9.45126e-06	Accessible, Low Impact	3
chr21:45254440:G>T	chr21	45254440	45253853	587	rs28715237	Logical memory (immediate recall) in mild cognitive impairment	4e-07	LINC00334	29274321	0.9185313	769.0	ATF7	6.57298e-06	High Impact, Hard to Access	3
chr20:24329954:G>T	chr20	24329954	24330541	587	rs76087671	Binge eating behaviour in bipolar disorder	1e-06	LINC01721 - GAPDHP53	29391396	0.80697334	424.5	JUN	6.57151e-06	Low Priority	3
chr5:123184508:C>A	chr5	123184508	123183919	589	rs9327287	Systolic blood pressure	5e-12	PRDM6	36329257	0.9409573	501.0	FOS	6.57203e-06	Low Priority	3
chr5:123184508:C>A	chr5	123184508	123183919	589	rs9327287	Ascending aorta minimum area	2e-08	PRDM6	35922433	0.9409573	501.0	FOS	6.57203e-06	Low Priority	3
chr9:116741479:C>G	chr9	116741479	116740890	589	rs143417496	Heel bone mineral density x serum urate levels interaction	4e-08	ASTN2	34046847	0.9422262	600.0	MAFK	1.97187e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:9655065:T>A	chr18	9655065	9654476	589	rs558769262	Abdominal fat cell number	7e-08	LINC02856 - KRT18P8	35320353	0.9940711	1085.5	JUN	6.56892e-06	HIGH PRIORITY: Accessible + High Impact	2
chr5:123184508:C>A	chr5	123184508	123183919	589	rs9327287	Electrocardiographic traits (multivariate)	3e-07	PRDM6	32602732	0.9409573	501.0	FOS	6.57203e-06	Low Priority	3
chr17:31823986:G>C	chr17	31823986	31823397	589	rs149802391	Nicotine dependence symptom count	4e-06	GPR160P2 - COPRS	29532581	0.98639375	555.5	ATF3	6.58415e-06	Low Priority	3
chr17:36002761:G>C	chr17	36002761	36002170	591	rs544570071	CCL4 protein levels	1e-11	CCL15-CCL14 - CCL23	39789286	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr9:21810564:A>C	chr9	21810564	21811155	591	rs10811623	Diastolic blood pressure	1e-09	MTAP	39134668	0.9994456	929.0	FOS	6.57246e-06	High Impact, Hard to Access	3
chr12:65852639:G>T	chr12	65852639	65853230	591	rs11834895	Height	5e-08	HMGA2-AS1, HMGA2	35831902	0.9782654	599.5	JUND	6.57575e-06	High Impact, Hard to Access	3
chr1:193863992:T>A	chr1	193863992	193863401	591	rs57219369	Visual disturbances (PheCode 368)	8e-08	RPL23AP22 - EEF1A1P14	40465716	0.95357716	431.0	JUND	1.31472e-05	Accessible, Low Impact	3
chr22:49406024:C>G	chr22	49406024	49406616	592	rs9628005	Memory decline	9e-06	RPL35P8 - MIR3667HG	37984853	0.8791271	468.0	FOS	6.57263e-06	Low Priority	3
chr12:101876114:C>A	chr12	101876114	101876707	593	rs10860806	N-acetylcarnosine levels in elite athletes	6e-06	HSPE1P4 - DRAM1	31882771	0.993351	1520.0	FOS	6.57333e-06	High Impact, Hard to Access	3
chr12:101876114:C>A	chr12	101876114	101876707	593	rs10860806	21-hydroxypregnenolone disulfate levels in elite athletes	1e-05	HSPE1P4 - DRAM1	31882771	0.993351	1520.0	FOS	6.57333e-06	High Impact, Hard to Access	3
chr4:98874906:C>G	chr4	98874906	98874312	594	rs62323189	Self-reported math ability	3e-08	BTF3P13 - EIF4E	30038396	0.9921947	1082.0	ATF2	6.76901e-06	HIGH PRIORITY: Accessible + High Impact	3
chr10:30820485:C>A	chr10	30820485	30819890	595	rs10763839	Height	5e-16	LINC02644 - ZNF438	36224396	0.99987054	2617.0	JUND	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:53802971:G>T	chr5	53802971	53802376	595	rs148906333	Brown vs. black hair color	8e-10	LINC02105	30531825	0.96028686	693.0	JUN	6.57428e-06	High Impact, Hard to Access	3
chr4:164149180:C>G	chr4	164149180	164148585	595	rs17044565	Heart rate response to beta blockers (atenolol add-on therapy)	4e-08	MARCHF1	29478026	0.96518815	460.5	JUND	6.57091e-06	Accessible, Low Impact	2
chr6:100413579:T>A	chr6	100413579	100414175	596	rs17060534	Gait speed in old age	8e-06	SIM1	28077804	0.94819474	516.0	ATF7	0.000137859	Accessible, Low Impact	2
chr5:72421698:C>G	chr5	72421698	72421101	597	rs10515148	Hip geometry	6e-07	YBX1P5 - ZNF366	17903296	0.9644045	520.5	JUND	1.97187e-05	Accessible, Low Impact	3
chr7:77408734:T>A	chr7	77408734	77409332	598	rs59770249	CCL24 protein levels	2e-41	GSAP	39789286	0.9715297	1042.5	JUNB	1.35062e-05	HIGH PRIORITY: Accessible + High Impact	2
chr1:154836057:C>A	chr1	154836057	154835459	598	rs11584630	Height	1e-22	KCNN3	36224396	0.96686935	582.5	FOS	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:154836057:C>A	chr1	154836057	154835459	598	rs11584630	Parkinson disease	5e-06	KCNN3	37842648	0.96686935	582.5	FOS	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:53679482:T>A	chr3	53679482	53678883	599	rs6809164	Chronic obstructive pulmonary disease liability (machine learning-based score)	7.000000000000001e-24	CACNA1D	37069358	0.8908594	390.5	ATF3	6.57929e-06	Low Priority	3
chr3:53679482:T>A	chr3	53679482	53678883	599	rs6809164	Lung function (FEV1/FVC)	6e-19	CACNA1D	30595370	0.8908594	390.5	ATF3	6.57929e-06	Low Priority	3
chr3:53679482:T>A	chr3	53679482	53678883	599	rs6809164	FEV1 FVC ratio Z score (UKB data field 20258)	2e-18	CACNA1D	39789286	0.8908594	390.5	ATF3	6.57929e-06	Low Priority	3
chr7:101326553:G>T	chr7	101326553	101325954	599	rs199889288	PILRB protein levels	4e-15	IFT22 - COL26A1	39789286	0.9939092	497.0	MAFK	6.5838e-06	Accessible, Low Impact	2
chr16:68258818:G>T	chr16	68258818	68259417	599	rs3743739	HDL cholesterol levels	6e-13	PLA2G15	35884923	0.9565468	716.0	FOSL2	6.57929e-06	High Impact, Hard to Access	3
chr7:101326553:G>T	chr7	101326553	101325954	599	rs199889288	PILRA protein levels	7e-12	IFT22 - COL26A1	39789286	0.9939092	497.0	MAFK	6.5838e-06	Accessible, Low Impact	2
chr20:412238:A>C	chr20	412238	411639	599	rs6139113	Eosinophil count	3e-11	RBCK1	32888493	0.9702253	738.0	JUNB	6.56892e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:50665937:G>C	chr7	50665937	50665337	600	rs2715093	Height	1e-15	GRB10	39134668	0.9992518	1299.0	FOS	0.000118182	HIGH PRIORITY: Accessible + High Impact	3
chr7:50665937:G>C	chr7	50665937	50665337	600	rs2715093	Height (baseline)	2e-14	GRB10	40374629	0.9992518	1299.0	FOS	0.000118182	HIGH PRIORITY: Accessible + High Impact	3
chr7:50665937:G>C	chr7	50665937	50665337	600	rs2715093	Waist circumference adjusted for body mass index	3e-12	GRB10	31669095	0.9992518	1299.0	FOS	0.000118182	HIGH PRIORITY: Accessible + High Impact	3
chr13:41528686:G>T	chr13	41528686	41529286	600	rs9315846	Male-pattern baldness	6e-10	RGCC - VWA8	30573740	0.9396624	476.0	JUNB	6.57108e-06	Low Priority	3
chr2:10818322:C>A	chr2	10818322	10817722	600	rs12474895	Educational attainment (years of education)	3e-09	PDIA6	30595370	0.9971508	1641.0	BATF	6.62875e-06	High Impact, Hard to Access	3
chr16:86884468:G>T	chr16	86884468	86885068	600	rs12051139	Interleukin-2 levels	5e-06	LINC02188 - LINC02181	27989323	0.99751866	639.5	JUNB	6.578e-06	High Impact, Hard to Access	3
chr6:37769682:C>A	chr6	37769682	37769082	600	rs35475734	Left unilateral cleft lip	5e-06	MDGA1 - ZFAND3-DT	34130359	0.9917875	587.5	FOS	6.57652e-06	High Impact, Hard to Access	3
chr16:86884468:G>T	chr16	86884468	86885068	600	rs12051139	Interleukin-1-receptor antagonist levels	9e-06	LINC02188 - LINC02181	27989323	0.99751866	639.5	JUNB	6.578e-06	High Impact, Hard to Access	3
chr11:60391777:G>C	chr11	60391777	60391176	601	rs6591578	Monocyte count	8.000000000000001e-24	MS4A6E, MS4A7, MS4A14	32888494	0.94432205	470.0	BATF	0.000446921	Accessible, Low Impact	3
chr8:32482276:G>T	chr8	32482276	32481675	601	rs2347491	Body mass index or colorectal cancer (pleiotropy)	6e-09	NRG1	40874817	0.94468737	441.0	JUN	6.57687e-06	Low Priority	3
chr11:69683102:G>C	chr11	69683102	69682501	601	rs80208956	Major depressive disorder	6e-06	LTO1 - FGF19	29317602	0.9899018	818.0	ATF3	6.56875e-06	High Impact, Hard to Access	3
chr1:190337814:C>A	chr1	190337814	190337212	602	rs1171381	Body mass index (BMI, minimum, inv-normal transformed)	8e-22	BRINP3	39024449	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr1:190337814:C>A	chr1	190337814	190337212	602	rs1171381	Weight (maximum, inv-normal transformed)	3e-13	BRINP3	39024449	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr1:190337814:C>A	chr1	190337814	190337212	602	rs1171381	Body mass index (BMI, mean, inv-normal transformed)	3e-12	BRINP3	39024449	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr1:190337814:C>A	chr1	190337814	190337212	602	rs1171381	Ideal cardiovascular health score (clinical and behavioral)	6e-09	BRINP3	35613103	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr21:42082050:G>C	chr21	42082050	42082652	602	rs220299	Obesity-related traits	4e-07	UMODL1	23251661	0.9991982	1428.0	FOSL2	0.000164107	HIGH PRIORITY: Accessible + High Impact	3
chr10:25580741:T>A	chr10	25580741	25581343	602	rs35600435	Memory decline in impaired cognition	8e-06	GPR158	37984853	0.9283083	393.0	FOS	4.60375e-05	Accessible, Low Impact	3
chr18:23178949:C>A	chr18	23178949	23178346	603	rs34302357	Anthropometric traits	3e-80	CABLES1	30166351	0.98996234	849.5	JUND	0.000105197	HIGH PRIORITY: Accessible + High Impact	3
chr18:23178949:C>A	chr18	23178949	23178346	603	rs34302357	Anthropometric traits (multi-trait analysis)	6e-52	CABLES1	30166351	0.98996234	849.5	JUND	0.000105197	HIGH PRIORITY: Accessible + High Impact	3
chr18:23178949:C>A	chr18	23178949	23178346	603	rs34302357	Waist circumference adjusted for body mass index	4e-22	CABLES1	34021172	0.98996234	849.5	JUND	0.000105197	HIGH PRIORITY: Accessible + High Impact	3
chr18:23178949:C>A	chr18	23178949	23178346	603	rs34302357	Multi-trait sex score	8e-18	CABLES1	37277458	0.98996234	849.5	JUND	0.000105197	HIGH PRIORITY: Accessible + High Impact	3
chr18:23178949:C>A	chr18	23178949	23178346	603	rs34302357	Hip circumference adjusted for BMI	7e-13	CABLES1	34021172	0.98996234	849.5	JUND	0.000105197	HIGH PRIORITY: Accessible + High Impact	3
chr18:23178949:C>A	chr18	23178949	23178346	603	rs34302357	Waist-hip index	4e-08	CABLES1	34021172	0.98996234	849.5	JUND	0.000105197	HIGH PRIORITY: Accessible + High Impact	3
chr8:27950649:C>G	chr8	27950649	27951253	604	rs4395853	Tenascin levels	7.999999999999999e-172	SCARA5	34648354	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27951253	604	rs4395853	Prolargin levels (PRELP.5675.6.3)	3e-43	SCARA5	29875488	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27951253	604	rs4395853	GDP-fucose protein O-fucosyltransferase 2 levels (POFUT2.6042.52.3)	2e-21	SCARA5	29875488	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr8:9305142:C>G	chr8	9305142	9304538	604	rs330068	Impacted cerumen (PheCode 380.4)	4e-18	PPP1R3B-DT	39024449	0.9008302	465.0	MAFK	4.60078e-05	Accessible, Low Impact	3
chr6:127095181:C>G	chr6	127095181	127095785	604	rs2800733	Type 2 diabetes	9e-08	RPS4XP9 - RSPO3	30718926	0.9756724	625.0	FOS	6.59118e-06	High Impact, Hard to Access	3
chr14:57735106:G>T	chr14	57735106	57735711	605	rs1092013	Response to esketamine in treatment resistant depression	9e-06	SLC35F4	32724131	0.9342127	460.0	JUND	7.89027e-05	Accessible, Low Impact	2
chr5:88441123:T>A	chr5	88441123	88440517	606	rs72771835	Educational attainment	5e-14	MIR9-2HG	35361970	0.98058754	511.5	JUND	3.94451e-05	Accessible, Low Impact	2
chr17:71239457:T>A	chr17	71239457	71240064	607	rs17765886	Lung function (FEV1/FVC)	5e-24	CASC17 - RNU7-155P	30595370	0.99539393	2590.0	ATF2	6.57713e-06	High Impact, Hard to Access	3
chr17:71239457:T>A	chr17	71239457	71240064	607	rs17765886	FEV1 FVC ratio Z score (UKB data field 20258)	6e-17	CASC17 - RNU7-155P	39789286	0.99539393	2590.0	ATF2	6.57713e-06	High Impact, Hard to Access	3
chr6:69097209:G>C	chr6	69097209	69096602	607	rs62406773	Femur bone mineral density x serum urate levels interaction	6e-11	ADGRB3	34046847	0.99899024	837.5	FOS	6.56728e-06	High Impact, Hard to Access	3
chr4:36898126:T>A	chr4	36898126	36898733	607	rs555632645	Ceramide (d19:1/20:0) levels	4e-07	LINC02505 - LINC02616	35668104	0.99740165	582.5	FOS	6.57142e-06	High Impact, Hard to Access	3
chr4:36898126:T>A	chr4	36898126	36898733	607	rs555632645	Ceramide (d19:1/22:0) levels	2e-06	LINC02505 - LINC02616	35668104	0.99740165	582.5	FOS	6.57142e-06	High Impact, Hard to Access	3
chr6:69097209:G>C	chr6	69097209	69096602	607	rs62406773	Anxious temperament	2e-06	ADGRB3	34075027	0.99899024	837.5	FOS	6.56728e-06	High Impact, Hard to Access	3
chr6:26670063:C>A	chr6	26670063	26670671	608	rs2498381	Oily fish consumption	4e-10	ZNF322 - GUSBP2	32066663	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:26670063:C>A	chr6	26670063	26670671	608	rs2498381	Pork consumption	4e-10	ZNF322 - GUSBP2	32066663	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr6:26670063:C>A	chr6	26670063	26670671	608	rs2498381	Fish- and plant-related diet	1e-08	ZNF322 - GUSBP2	32066663	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr7:56811651:C>A	chr7	56811651	56812259	608	rs184020470	Glioblastoma	6e-06	CICP28 - MIR4283-1	36810956	0.90298235	216.5	ATF2	6.57999e-06	Low Priority	3
chr9:27185551:C>A	chr9	27185551	27184942	609	rs10967761	Angiopoietin-1 receptor, soluble levels	3e-13	TEK	34814699	0.9879521	752.0	JUN	7.88208e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:65812212:C>A	chr3	65812212	65811602	610	rs182075832	LRIG1 protein levels	3e-17	MAGI1	39789286	0.9979406	1336.0	JUND	6.57445e-06	High Impact, Hard to Access	3
chr11:55978722:C>G	chr11	55978722	55978112	610	rs7931344	Albumin levels	2e-08	OR10AG1 - OR7E5P	40436827	0.9555776	500.5	JUND	1.31522e-05	Accessible, Low Impact	3
chr14:30924354:C>A	chr14	30924354	30924965	611	rs10141421	Node-level brain connectivity (multivariate analysis)	8e-11	STRN3	36800424	0.9565468	546.5	ATF3	3.34174e-05	Accessible, Low Impact	3
chr10:67676848:G>C	chr10	67676848	67676236	612	rs117892132	Thoracic aortic aneurysms	7e-08	CTNNA3	34469433	0.98327994	548.5	FOSL1	6.5716e-06	Low Priority	3
chr1:175455906:T>A	chr1	175455906	175455293	613	rs754245198	TNR protein levels	9.999999999999999e-33	TNR	39789286	0.8791271	563.0	FOSL1	6.57203e-05	Accessible, Low Impact	2
chr9:11446415:G>C	chr9	11446415	11445802	613	rs10959815	Lifetime major depressive disorder (MTAG)	6e-09	LINC03131 - JKAMPP1	37985818	0.9992518	669.0	FOS	3.95726e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:98228267:G>C	chr13	98228267	98227653	614	rs61970167	Bifidobacterium kashiwanohense abundance in stool	4e-08	FARP1	35115689	0.9697459	563.25	FOSL1	6.56944e-06	Low Priority	3
chr13:70382185:A>C	chr13	70382185	70382799	614	rs9542292	Coronary heart disease	8e-06	ATXN8OS - RNU6-54P	36252120	0.97968936	600.0	FOS	1.97291e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:55033740:C>A	chr1	55033740	55033125	615	rs7523141	Low density lipoprotein cholesterol levels	3e-25	BSND - PCSK9	29403010	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr10:89145905:C>A	chr10	89145905	89146520	615	rs188493056	FASLG protein levels	3e-12	MIR4679-2 - CH25H	39789286	0.99347407	490.0	FOSL1	0.0	Low Priority	3
chr19:18276172:G>C	chr19	18276172	18275557	615	rs12983444	Monocyte count	5e-08	IQCN - JUND	34594039	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr11:122180821:A>C	chr11	122180821	122180205	616	rs488062	Height	1e-09	MIR100HG	36224396	0.9999668	4626.0	JUND	1.31453e-05	HIGH PRIORITY: Accessible + High Impact	2
chr17:44373038:C>A	chr17	44373038	44372421	617	rs5910	Platelet count	1e-46	ITGA2B	34469753	0.8072176	510.0	JUND	0.000729438	Accessible, Low Impact	3
chr17:44373038:C>A	chr17	44373038	44372421	617	rs5910	mean platelet volume (MPV, mean, inv-norm transformed)	3.0000000000000003e-31	ITGA2B	39024449	0.8072176	510.0	JUND	0.000729438	Accessible, Low Impact	3
chr17:44373038:C>A	chr17	44373038	44372421	617	rs5910	mean platelet volume (MPV, maximum, inv-norm transformed)	1.0000000000000001e-29	ITGA2B	39024449	0.8072176	510.0	JUND	0.000729438	Accessible, Low Impact	3
chr17:44373038:C>A	chr17	44373038	44372421	617	rs5910	Platelet count at delivery	5e-13	ITGA2B	38064665	0.8072176	510.0	JUND	0.000729438	Accessible, Low Impact	3
chr17:504842:G>C	chr17	504842	504225	617	rs11247554	Waist circumference adjusted for body mass index	2e-11	RFLNB - VPS53	31669095	0.99886686	437.5	FOSL2	1.56331e-05	Accessible, Low Impact	3
chr4:27443565:C>A	chr4	27443565	27442948	617	rs115428819	Baseline memory in normal cognition	4e-07	LINC02261 - IGBP1P5	37984853	0.8791271	404.5	FOS	1.31539e-05	Accessible, Low Impact	3
chr13:31030062:C>G	chr13	31030062	31030679	617	rs4942783	Subjective well-being	6e-07	LINC01066 - WDR95P	27089181	0.9185313	499.0	FOSL1	6.61227e-06	Low Priority	3
chr16:53140497:C>A	chr16	53140497	53139880	617	rs6499308	Pelvic organ prolapse	6e-07	CHD9	39349682	0.9822685	620.5	FOSL2	6.58397e-06	High Impact, Hard to Access	3
chr4:27443565:C>A	chr4	27443565	27442948	617	rs115428819	Baseline memory in normal cognition x sex interaction	7e-07	LINC02261 - IGBP1P5	37984853	0.8791271	404.5	FOS	1.31539e-05	Accessible, Low Impact	3
chr17:44373038:C>A	chr17	44373038	44372421	617	rs5910	Parkinson's disease	4e-06	ITGA2B	28892059	0.8072176	510.0	JUND	0.000729438	Accessible, Low Impact	3
chr20:1312963:G>C	chr20	1312963	1312345	618	rs4814111	Ras-related protein Rab-3D protein levels (SomaScan ID:23028-49)	8e-10	SDCBP2	40883583	0.9990577	788.0	FOS	4.59861e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:136865116:C>A	chr3	136865116	136864497	619	rs28689774	Height	9e-21	NCK1	39134668	0.98942745	750.0	JUND	6.57099e-06	High Impact, Hard to Access	3
chr11:102656969:C>A	chr11	102656969	102657588	619	rs117305614	MMP1 protein levels	1e-17	MMP20-AS1 - MMP27	39789286	0.9422262	401.0	JUND	6.58033e-06	Low Priority	3
chr15:100141111:T>A	chr15	100141111	100140492	619	rs544944870	Height (baseline)	1e-09	ADAMTS17	40374629	0.9860784	805.0	FOSL1	0.0	High Impact, Hard to Access	3
chr8:8681119:C>A	chr8	8681119	8680499	620	rs7012395	Estimated glomerular filtration rate (creatinine)	2e-22	RN7SL178P - CLDN23	35710981	0.86897224	626.5	MAFG	1.31553e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:93659884:C>A	chr9	93659884	93659264	620	rs10761251	Highest math class taken (MTAG)	7e-19	PHF2	30038396	0.9976844	2273.5	FOS	1.97114e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:93659884:C>A	chr9	93659884	93659264	620	rs10761251	Educational attainment (MTAG)	2e-18	PHF2	30038396	0.9976844	2273.5	FOS	1.97114e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:93659884:C>A	chr9	93659884	93659264	620	rs10761251	Educational attainment (years of education)	3e-14	PHF2	30038396	0.9976844	2273.5	FOS	1.97114e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:8681119:C>A	chr8	8681119	8680499	620	rs7012395	General factor of neuroticism	3e-11	RN7SL178P - CLDN23	30867560	0.86897224	626.5	MAFG	1.31553e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:93659884:C>A	chr9	93659884	93659264	620	rs10761251	Highest math class taken	3e-11	PHF2	30038396	0.9976844	2273.5	FOS	1.97114e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:8681119:C>A	chr8	8681119	8680499	620	rs7012395	Waist circumference adjusted for body mass index	8e-11	RN7SL178P - CLDN23	34021172	0.86897224	626.5	MAFG	1.31553e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:46825981:T>A	chr7	46825981	46825360	621	rs201161959	Colorectal polyp (UKB data field 20002_1460)	3e-09	EPS15P1 - MRPL42P4	37965154	0.9981182	506.5	ATF2	6.61349e-06	Accessible, Low Impact	2
chr9:5708285:T>A	chr9	5708285	5707664	621	rs552868666	Smoking x traumatic event in childhood (sexually molested) interaction	2e-08	RIC1	34417442	0.9892507	768.0	ATF2	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	3
chr14:95656692:C>A	chr14	95656692	95656071	621	rs8015016	QT interval	5e-07	TCL6	20031603	0.88394535	437.0	JUNB	1.97751e-05	Accessible, Low Impact	3
chr1:33323176:C>G	chr1	33323176	33322555	621	rs12123240	Memory decline in impaired cognition x sex interaction	8e-06	A3GALT2 - PHC2	37984853	0.996504	1992.0	FOSL2	6.5697e-06	HIGH PRIORITY: Accessible + High Impact	2
chr2:197633632:T>A	chr2	197633632	197633011	621	rs62277866	Pancreatic cancer	8e-06	RFTN2	34290314	0.99658346	1520.0	JUNB	6.56953e-06	HIGH PRIORITY: Accessible + High Impact	2
chr1:219467486:C>A	chr1	219467486	219468108	622	rs2605095	Umbilical hernia	4e-15	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr8:9237764:G>C	chr8	9237764	9238386	622	rs17149592	Serum alkaline phosphatase levels	1e-09	PPP1R3B-DT	33462484	0.9980294	849.0	FOS	9.85753e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:219467486:C>A	chr1	219467486	219468108	622	rs2605095	Inguinal hernia	4e-09	LYPLAL1-AS1	34382107	0.9810219	694.0	JUNB	6.57687e-06	High Impact, Hard to Access	3
chr17:30854825:C>A	chr17	30854825	30854203	622	rs143663961	Invasive epithelial ovarian cancer	1e-07	ATAD5	28346442	0.94346935	636.0	ATF2	6.57462e-06	High Impact, Hard to Access	3
chr9:20553961:G>C	chr9	20553961	20554584	623	rs12377027	Estimated glomerular filtration rate (creatinine)	1e-14	MLLT3	35710981	0.9984708	2046.0	JUN	1.31678e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:20553961:G>C	chr9	20553961	20554584	623	rs12377027	Estimated glomerular filtration rate	7e-13	MLLT3	31152163	0.9984708	2046.0	JUN	1.31678e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:221437260:C>G	chr2	221437260	221436637	623	rs3213844	Body mass index	7e-11	EPHA4	40436827	0.98487294	590.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr2:213064644:C>G	chr2	213064644	213064020	624	rs66531832	Smoking initiation (ever regular vs never regular) (MTAG)	1e-08	IKZF2	30643251	0.99164	541.0	JUND	6.57938e-06	Low Priority	3
chr2:226317592:C>A	chr2	226317592	226316967	625	rs2713552	Drinks per week	7e-19	NYAP2 - MIR5702	36477530	0.9818622	687.5	JUN	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:69683102:G>C	chr11	69683102	69682477	625	rs11386923	Monocyte count	1e-14	LTO1 - FGF19	32888494	0.9899018	818.0	ATF3	6.56875e-06	High Impact, Hard to Access	3
chr15:49024936:C>G	chr15	49024936	49025561	625	rs7164309	Drinks per week	2e-14	SECISBP2L	36477530	0.99784356	1755.0	JUNB	6.57333e-06	High Impact, Hard to Access	3
chr15:49024936:C>G	chr15	49024936	49025561	625	rs7164309	Low density lipoprotein cholesterol levels	3e-09	SECISBP2L	32154731	0.99784356	1755.0	JUNB	6.57333e-06	High Impact, Hard to Access	3
chr22:29775291:C>A	chr22	29775291	29774666	625	rs142682088	Type 2 diabetes	6e-09	UQCR10 - ASCC2	34594039	0.986702	1051.0	MAFG	7.23208e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:150216174:G>C	chr5	150216174	150215547	627	rs17111053	Height	8e-19	SLC6A7	36224396	0.99982905	4564.0	FOSL2	6.57626e-06	High Impact, Hard to Access	3
chr2:68393577:C>G	chr2	68393577	68394206	629	rs17530191	Mean corpuscular volume	2e-12	PLEK	32888494	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr16:9715437:G>C	chr16	9715437	9716066	629	rs1815981	1-arachidonoyl-GPI (20:4) levels in elite athletes	3e-06	LINC02177 - GRIN2A	31882771	0.9840279	494.5	FOS	6.57013e-06	Low Priority	3
chr2:162753033:C>A	chr2	162753033	162753662	629	rs115038670	Post bronchodilator FEV1/FVC ratio	4e-06	KCNH7	26634245	0.88394535	426.5	FOS	0.000210748	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27364857	629	rs1058065	IgG glycosylation	4e-06	EIF2B4, GTF3C2-AS2	23382691	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr6:31295292:A>C	chr6	31295292	31294662	630	rs115971093	Group 10 secretory phospholipase A2 levels	7e-15	LINC02571	34857772	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr12:121534782:A>C	chr12	121534782	121535412	630	rs28520411	Medication use (agents acting on the renin-angiotensin system)	6e-10	KDM2B	31015401	0.99944633	4224.0	ATF7	6.57022e-06	High Impact, Hard to Access	3
chr11:118360238:C>G	chr11	118360238	118360869	631	rs4938507	Height	9e-18	UBE4A	36224396	0.9912486	979.0	ATF3	6.57237e-06	High Impact, Hard to Access	3
chr5:180807871:C>A	chr5	180807871	180808503	632	rs3733750	Height	1.9999999999999998e-54	MGAT1	36224396	0.988674	831.0	FOS	6.56875e-06	High Impact, Hard to Access	3
chr12:65852639:G>T	chr12	65852639	65853271	632	rs11834900	Height	2e-53	HMGA2, HMGA2-AS1	36224396	0.9782654	599.5	JUND	6.57575e-06	High Impact, Hard to Access	3
chr8:7001781:A>C	chr8	7001781	7002414	633	rs575391483	Blood cell traits latent factor 22 (white cell)	1e-11	DEFA1B - DEFT1P2	40220762	0.95134485	67.1875	MAFK	4.71876e-05	Accessible, Low Impact	2
chr8:119349684:C>G	chr8	119349684	119350318	634	rs2470019	Systolic blood pressure (UKB data field 4080)	5e-12	MIR548AZ - CCN3	39789286	0.97922516	595.0	FOS	6.63552e-06	HIGH PRIORITY: Accessible + High Impact	3
chr1:243347568:C>G	chr1	243347568	243348203	635	rs773905848	Drink temperature	2e-14	SDCCAG8	32193382	0.9602251	509.5	JUND	1.31403e-05	Accessible, Low Impact	3
chr17:17641168:G>T	chr17	17641168	17640532	636	rs9891340	Estimated glomerular filtration rate	8e-15	PEMT - SMCR2	31152163	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr19:38234799:G>C	chr19	38234799	38235436	637	rs7253820	Platelet count (UKB data field 30080)	3e-25	DPF1 - SPINT2	39789286	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:141208916:C>A	chr3	141208916	141208279	637	rs143699489	Neutrophill count (UKB data field 30140)	2e-21	SPSB4 - PXYLP1	39789286	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr19:38234799:G>C	chr19	38234799	38235436	637	rs7253820	Platelet crit (UKB data field 30090)	2e-16	DPF1 - SPINT2	39789286	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:38234799:G>C	chr19	38234799	38235436	637	rs7253820	Plateletcrit	2e-15	DPF1 - SPINT2	32888494	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:1216486:G>C	chr19	1216486	1217123	637	rs183640372	Superficial keratitis (PheCode 370.2)	3e-13	STK11	39024449	0.99947065	2266.0	FOSL1	6.58441e-06	High Impact, Hard to Access	3
chr3:141208916:C>A	chr3	141208916	141208279	637	rs143699489	Sum neutrophil eosinophil counts	1e-11	SPSB4 - PXYLP1	27863252	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr3:141208916:C>A	chr3	141208916	141208279	637	rs143699489	Granulocyte count	1e-11	SPSB4 - PXYLP1	27863252	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr3:141208916:C>A	chr3	141208916	141208279	637	rs143699489	Neutrophil percentage of white cells	4e-11	SPSB4 - PXYLP1	32888494	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr3:141208916:C>A	chr3	141208916	141208279	637	rs143699489	White blood cell count	1e-09	SPSB4 - PXYLP1	27863252	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr1:55953221:C>A	chr1	55953221	55953858	637	rs4926705	Height	5e-08	LINC01755	35831902	0.9131995	458.5	JUND	6.57428e-06	Low Priority	3
chr17:16096369:A>C	chr17	16096369	16095731	638	rs143493691	Cholesteryl Esters to Total Lipids in IDL percentage	1e-13	NCOR1	41044249	0.9860784	511.5	FOS	0.0234456	Accessible, Low Impact	2
chr17:16096369:A>C	chr17	16096369	16095731	638	rs143493691	Dorsolateral prefrontal area (unadjusted for global measures)	2e-08	NCOR1	36893272	0.9860784	511.5	FOS	0.0234456	Accessible, Low Impact	2
chr3:8510914:G>T	chr3	8510914	8511552	638	rs9818672	Height (baseline)	2e-08	LMCD1, LMCD1-AS1	40374629	0.9834347	663.0	FOS	1.31408e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:32664823:G>T	chr19	32664823	32665462	639	rs7252621	PDCD5 protein levels	7e-77	ANKRD27	39789286	0.91684973	456.0	MAFF	0.0	Low Priority	3
chr3:187372148:G>C	chr3	187372148	187371509	639	rs9028	Obesity without metabolic disease	3e-07	RTP4	30120429	0.9113531	415.5	ATF3	1.97151e-05	Accessible, Low Impact	3
chr6:32293237:C>A	chr6	32293237	32293876	639	rs4947338	Vaginal microbiome MetaCyc pathway (PWY-5415|catechol degradation I (meta-cleavage pathway))	2e-06	TSBP1-AS1, TSBP1	34282934	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr5:53243426:C>A	chr5	53243426	53242787	639	rs27906	Cardio-cerebrovascular disease in dyslipidemia	3e-06	RPL13AP13 - FST	33632238	0.9782654	542.0	JUND	9.20036e-05	Accessible, Low Impact	3
chr19:51668454:C>G	chr19	51668454	51669094	640	rs34805745	B4GALT1 protein levels	5e-12	RPL7P51 - SPACA6-AS1	39789286	0.97511876	632.0	ATF3	1.31442e-05	HIGH PRIORITY: Accessible + High Impact	2
chr9:126697989:C>G	chr9	126697989	126697349	640	rs10760450	Body mass index	9e-09	LMX1B	36581621	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr5:51941133:C>A	chr5	51941133	51940492	641	rs16879308	Migraine without aura	2e-06	KATNBL1P4 - LINC02118	23793025	0.9637244	459.0	FOS	6.5773e-06	Low Priority	3
chr15:55163671:C>A	chr15	55163671	55164312	641	rs16976033	Neutrophil count	7e-06	UNC13C - RSL24D1	21507922	0.9327804	430.5	JUND	6.56987e-06	Low Priority	3
chr12:15267008:C>A	chr12	15267008	15267649	641	rs78659731	Vaginal microbiome MetaCyc pathway (PWY-5896|superpathway of menaquinol-10 biosynthesis)	9e-06	RERG	34282934	0.8263989	431.75	FOSL2	6.58059e-06	Low Priority	3
chr19:56133984:G>C	chr19	56133984	56133342	642	rs662763	Platelet count	1e-58	ZNF444	40436827	0.9997847	3655.0	FOS	1.31704e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:27460372:G>C	chr1	27460372	27461014	642	rs182184450	CD164L2 protein levels	2e-31	WASF2	39789286	0.99694693	1025.0	BATF	1.31408e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:78382610:T>A	chr17	78382610	78383252	642	rs148101901	LDL cholesterol	1e-12	PGS1	34594039	0.9986684	1528.0	FOSL1	6.58579e-06	High Impact, Hard to Access	3
chr3:150603177:G>C	chr3	150603177	150602535	642	rs2204113	Metabolite levels	6e-06	SERP1	23823483	0.99931777	5380.0	FOS	2.6275e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:8252597:C>A	chr19	8252597	8253240	643	rs59708873	Metabolite levels	6e-10	CERS4	31628463	0.9847427	701.0	BATF	6.5767e-06	High Impact, Hard to Access	3
chr16:83385295:C>G	chr16	83385295	83385938	643	rs889714	Smoking initiation	2e-09	CDH13, CDH13-AS1	36477530	0.8862913	422.0	FOSL2	2.6294e-05	Accessible, Low Impact	3
chr4:79862042:C>G	chr4	79862042	79861398	644	rs1132460	Insomnia	2e-09	PCAT4	35835914	0.9659551	505.5	JUND	1.3177e-05	Accessible, Low Impact	3
chr2:60250562:G>T	chr2	60250562	60249917	645	rs359247	Smoking initiation (ever regular vs never regular) (MTAG)	1e-21	RNA5SP94 - MIR4432HG	30643251	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr2:60250562:G>T	chr2	60250562	60249917	645	rs359247	Insomnia	3e-18	RNA5SP94 - MIR4432HG	35835914	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr2:60250562:G>T	chr2	60250562	60249917	645	rs359247	Smoking initiation (ever regular vs never regular)	1e-16	RNA5SP94 - MIR4432HG	30643251	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr2:60250562:G>T	chr2	60250562	60249917	645	rs359247	Age of smoking initiation (MTAG)	6e-16	RNA5SP94 - MIR4432HG	30643251	0.8626385	390.0	ATF2	0.00013146	Accessible, Low Impact	2
chr2:45527467:G>C	chr2	45527467	45526822	645	rs13023749	Pelvic width	1e-09	SRBD1	40208988	0.9845253	530.0	JUND	6.58692e-06	Low Priority	3
chr9:126697989:C>G	chr9	126697989	126698635	646	rs10733682	Body mass index (MTAG)	6e-20	LMX1B	36376304	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr9:126697989:C>G	chr9	126697989	126698635	646	rs10733682	Body mass index	2e-10	LMX1B	25673413	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr9:126697989:C>G	chr9	126697989	126698635	646	rs10733682	C-reactive protein levels	2e-06	LMX1B	31622379	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr9:126697989:C>G	chr9	126697989	126698635	646	rs10733682	Body mass index (joint analysis main effects and smoking interaction)	5e-06	LMX1B	28443625	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr9:126697989:C>G	chr9	126697989	126698635	646	rs10733682	BMI (adjusted for smoking behaviour)	9e-06	LMX1B	28443625	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Vertex-wise sulcal depth	5e-50	CELSR1	34910505	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr17:39246674:C>A	chr17	39246674	39246027	647	rs2100651	chloride  (mean, inv-norm transformed)	2e-16	STAC2 - FBXL20	39024449	0.973383	969.0	FOSL2	6.5741e-06	High Impact, Hard to Access	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Cortical surface area	1e-15	CELSR1	34560273	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Vertex-wise cortical surface area	2e-14	CELSR1	34910505	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Vertex-wise cortical thickness	8e-14	CELSR1	34910505	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr17:39246674:C>A	chr17	39246674	39246027	647	rs2100651	Mean platelet volume	1e-12	STAC2 - FBXL20	32888493	0.973383	969.0	FOSL2	6.5741e-06	High Impact, Hard to Access	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Cortical thickness	2e-12	CELSR1	34560273	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Brain morphology (MOSTest)	5e-12	CELSR1	35164939	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr11:69359711:G>C	chr11	69359711	69360358	647	rs72932198	Sex hormone-binding globulin levels	3e-10	MYEOV - LINC02956	33462484	0.9870033	522.0	BATF	6.57022e-06	Low Priority	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Brain shape (segment 3)	6e-10	CELSR1	33821002	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr22:46363937:C>A	chr22	46363937	46364584	647	rs9615351	Leftright brain asymmetry	3e-08	CELSR1	33723403	0.9545879	687.0	JUND	6.56927e-06	High Impact, Hard to Access	3
chr7:73563135:C>A	chr7	73563135	73563782	647	rs12539351	Metabolic syndrome	3e-08	BCL7B - TBL2	38201907	0.7805644	453.5	ATF3	8.17154e-06	Accessible, Low Impact	3
chr19:48649457:G>T	chr19	48649457	48650105	648	rs140534128	PRSS27 protein levels	4.999999999999999e-32	SEC1P, SEC1P	39789286	0.9976844	1694.0	ATF3	1.97475e-05	HIGH PRIORITY: Accessible + High Impact	2
chr19:48649457:G>T	chr19	48649457	48650105	648	rs140534128	FAM3D protein levels	9.999999999999999e-27	SEC1P, SEC1P	39789286	0.9976844	1694.0	ATF3	1.97475e-05	HIGH PRIORITY: Accessible + High Impact	2
chr6:31395380:G>T	chr6	31395380	31396028	648	rs28366130	ICAM3/LY9 protein level ratio	2e-18	MICA-AS1	38412862	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr9:16722308:G>C	chr9	16722308	16721660	648	rs7042146	Inguinal hernia	2e-09	BNC2	34382107	0.99746656	2526.0	MAFK	6.56996e-06	High Impact, Hard to Access	3
chr19:48649457:G>T	chr19	48649457	48650105	648	rs140534128	Carbohydrate antigen 19-9 levels	3e-08	SEC1P, SEC1P	38626723	0.9976844	1694.0	ATF3	1.97475e-05	HIGH PRIORITY: Accessible + High Impact	2
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	CREG1/CTSZ protein level ratio	0.0	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	CREG1/PLA2G15 protein level ratio	0.0	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr16:1242245:G>C	chr16	1242245	1241596	649	rs144979264	Tryptase beta-2 levels (TPSB2.3403.1.2)	0.0	TPSAB1	29875488	0.9993018	406.25	FOS	6.59083e-06	Low Priority	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	CTSF/SMPD1 protein level ratio	6e-68	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	DPP7/LGMN protein level ratio	2e-64	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	PLA2G15/PRCP protein level ratio	2e-64	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	DPP7/SIAE protein level ratio	7e-58	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	DPP7/GLB1 protein level ratio	6e-49	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	TPP1 protein levels	2.9999999999999997e-47	GNPTAB	39789286	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	DPP7 protein levels	6e-45	GNPTAB	39789286	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	ARSA/DPP7 protein level ratio	2e-44	GNPTAB	38412862	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr8:101891286:C>G	chr8	101891286	101890637	649	rs512202	Height	1e-43	NCALD	36224396	0.9681593	663.5	ATF3	6.56487e-06	High Impact, Hard to Access	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	PLA2G15 protein levels	4e-38	GNPTAB	39789286	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	FUCA1 protein levels	2e-37	GNPTAB	39789286	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr12:101765635:C>A	chr12	101765635	101764986	649	rs76889468	GGH protein levels	2e-15	GNPTAB	39789286	0.9659551	504.0	FOS	1.31458e-05	Accessible, Low Impact	3
chr4:7435002:C>A	chr4	7435002	7434353	649	rs199512404	PSAPL1 protein levels	2e-12	PSAPL1, SORCS2	39789286	0.99560076	2678.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr18:60053755:T>A	chr18	60053755	60053105	650	rs1573399	Body mass index (MTAG)	1e-21	RNU6-567P - LINC03111	36376304	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr7:145794016:C>A	chr7	145794016	145794666	650	rs144145366	CNTNAP2 protein levels	4e-16	DPY19L4P2 - CNTNAP2	39789286	0.96744037	554.0	JUN	6.5722e-06	Low Priority	3
chr18:60053755:T>A	chr18	60053755	60053105	650	rs1573399	Metabolic syndrome	8e-16	RNU6-567P - LINC03111	39349817	0.99999	15514.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr17:74696575:C>A	chr17	74696575	74697226	651	rs78292629	CD300LF protein levels	1.9999999999999998e-26	CD300LF, RAB37	39789286	0.9978883	638.0	FOSL1	1.97078e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:72421698:C>G	chr5	72421698	72421047	651	rs13175147	Physical function (baseline)	6e-10	YBX1P5 - ZNF366	40374629	0.9644045	520.5	JUND	1.97187e-05	Accessible, Low Impact	3
chr5:65578157:C>G	chr5	65578157	65578808	651	rs10940044	Corneal resistance factor	9e-10	PPWD1	33311554	0.9939336	628.0	JUND	6.57229e-06	High Impact, Hard to Access	3
chr5:72421698:C>G	chr5	72421698	72421047	651	rs13175147	Height (standard GWA)	7e-09	YBX1P5 - ZNF366	37106081	0.9644045	520.5	JUND	1.97187e-05	Accessible, Low Impact	3
chr5:93057081:C>A	chr5	93057081	93056430	651	rs2578492	Cognitive processing speed	2e-08	LINC02058 - POLD2P1	39242605	0.96518815	478.0	JUND	0.0	Low Priority	3
chr11:116850037:C>G	chr11	116850037	116850689	652	rs111894427	Monounsaturated fatty acids to total fatty acids percentage	2e-17	APOA1-AS, SIK3	40545721	0.98618805	622.0	JUNB	6.57117e-06	High Impact, Hard to Access	3
chr11:116850037:C>G	chr11	116850037	116850689	652	rs111894427	Polyunsaturated fatty acids to monounsaturated fatty acids ratio	5e-13	APOA1-AS, SIK3	40545721	0.98618805	622.0	JUNB	6.57117e-06	High Impact, Hard to Access	3
chr15:66693441:C>G	chr15	66693441	66692789	652	rs78850189	Red cell distribution width	2e-10	LINC01169 - SMAD6	32888494	0.93131924	506.5	JUNB	2.63026e-05	Accessible, Low Impact	3
chr6:116398005:G>T	chr6	116398005	116397353	652	rs11406105	Hip circumference adjusted for BMI	1e-09	DSE	34021172	0.9953788	785.0	MAFK	1.97221e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:242645492:G>C	chr1	242645492	242646145	653	rs77039559	Gut microbial network clusters (Salmon (at 1 year) x Household furry pet dog (1 Year) interaction	1e-08	PLD5 - RSL24D1P4	40187613	0.99751866	490.0	FOS	6.6394e-06	Accessible, Low Impact	3
chr1:242645492:G>C	chr1	242645492	242646145	653	rs77039559	Gut microbial network clusters (Salmon (at 1 year) x Household furry pet dog (3 Months) interaction	4e-08	PLD5 - RSL24D1P4	40187613	0.99751866	490.0	FOS	6.6394e-06	Accessible, Low Impact	3
chr5:23353799:T>A	chr5	23353799	23353146	653	rs116220136	Huntington's disease progression	6e-06	PTPN11P4 - PRDM9	28642124	0.9834347	501.0	JUND	6.57056e-06	Accessible, Low Impact	2
chr7:93921789:G>C	chr7	93921789	93921135	654	rs180238	Heart rate variability traits (RMSSD)	8e-19	GNGT1 - GNG11	28613276	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr15:42153356:G>T	chr15	42153356	42154010	654	rs678778	creatinine (maximum, inv-norm transformed)	6e-13	PLA2G4F	39024449	0.9409573	723.0	JUND	0.138197	HIGH PRIORITY: Accessible + High Impact	3
chr7:93921789:G>C	chr7	93921789	93921135	654	rs180238	Heart rate response to recovery post exercise (40 sec)	2e-12	GNGT1 - GNG11	29497042	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93921135	654	rs180238	Heart rate response to recovery post exercise (50 sec)	4e-11	GNGT1 - GNG11	29497042	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr20:12403171:A>C	chr20	12403171	12403825	654	rs2208972	Drinks per week	4e-10	PA2G4P2 - LINC01722	36477530	0.99843514	566.0	FOS	6.56996e-06	Low Priority	3
chr3:185423413:G>T	chr3	185423413	185424069	656	rs7629245	Type 2 diabetes	5e-14	MAP3K13	38374256	0.99977994	6040.0	MAFG	6.57022e-06	High Impact, Hard to Access	3
chr8:120642770:G>C	chr8	120642770	120643426	656	rs528812851	Colorectal cancer	1e-06	SNTB1	38538606	0.98739034	1271.0	FOSL1	5.91529e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:185423413:G>T	chr3	185423413	185424069	656	rs7629245	Airflow obstruction	9e-06	MAP3K13	22837378	0.99977994	6040.0	MAFG	6.57022e-06	High Impact, Hard to Access	3
chr6:152248482:G>T	chr6	152248482	152249139	657	rs17215781	Endometriosis (MTAG)	9e-27	SYNE1	40262193	0.9470497	473.0	ATF3	0.0	Low Priority	3
chr10:93585926:C>A	chr10	93585926	93586583	657	rs11187533	Waist-to-hip ratio adjusted for BMI	8e-15	FFAR4	34021172	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:152248482:G>T	chr6	152248482	152249139	657	rs17215781	Heel bone mineral density	9e-14	SYNE1	30048462	0.9470497	473.0	ATF3	0.0	Low Priority	3
chr10:93585926:C>A	chr10	93585926	93586583	657	rs11187533	Waist circumference adjusted for body mass index	2e-10	FFAR4	34021172	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:4731490:G>T	chr4	4731490	4730833	657	rs34347955	Inguinal hernia	3e-08	STX18-AS1	34382107	0.8791271	473.0	JUND	3.94285e-05	Accessible, Low Impact	3
chr3:8235871:A>C	chr3	8235871	8236528	657	rs6443178	Depression	4e-08	LMCD1-AS1	37464041	0.9185313	421.0	ATF3	0.00716048	Accessible, Low Impact	3
chr11:113049319:C>A	chr11	113049319	113048662	657	rs11214471	Androstenediol (3beta,17beta) disulfate (1) levels in elite athletes	5e-06	NCAM1	31882771	0.99926984	2140.0	FOSL2	6.57333e-06	High Impact, Hard to Access	3
chr2:54673339:C>G	chr2	54673339	54673997	658	rs2971875	Bone mineral density mean	3e-08	SPTBN1-AS2	37500982	0.99746656	2064.0	ATF2	6.57272e-06	High Impact, Hard to Access	3
chr2:128146947:C>A	chr2	128146947	128146288	659	rs35615728	Systolic blood pressure	2e-08	UGGT1	40436827	0.98487294	643.0	JUND	6.57065e-06	High Impact, Hard to Access	3
chr1:210525386:C>G	chr1	210525386	210526045	659	rs6691759	Guanidinoacetate levels in elite athletes	4e-07	HHAT	31882771	0.8815574	470.0	FOSL1	6.5703e-06	Low Priority	3
chr6:31395380:G>T	chr6	31395380	31394720	660	rs72657659	Docosahexaenoic acid levels	5e-10	MICA-AS1	40545721	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr17:27477046:C>G	chr17	27477046	27477706	660	rs550320528	Breast area percent density	3e-06	KSR1	37345113	0.9882237	1067.0	FOS	6.57047e-06	High Impact, Hard to Access	3
chr7:46216695:C>A	chr7	46216695	46217356	661	rs10277096	Forced expiratory volume (baseline)	2e-11	ZNF619P1 - HMGN1P19	40374629	0.94819474	811.0	JUN	1.97037e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:239203:G>T	chr16	239203	238542	661	rs187651195	Mean corpuscular hemoglobin concentration	2e-10	FAM234A	32888494	0.9875858	699.0	ATF3	0.0	High Impact, Hard to Access	3
chr7:154801817:G>T	chr7	154801817	154801156	661	rs71534169	Post-traumatic stress disorder	4e-06	DPP6	24677629	0.92191833	664.0	JUND	1.3155e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:57613793:C>G	chr15	57613793	57614455	662	rs79865155	Gut microbial network clusters (Black) (at 3 months)	3e-08	GCOM1, MYZAP	40187613	0.9787506	679.5	JUN	6.57039e-06	High Impact, Hard to Access	3
chr18:77451097:C>G	chr18	77451097	77451760	663	rs12455724	Type 1 diabetes	9e-07	BDP1P - RNA5SP461	39749473	0.81405944	438.0	FOS	6.5722e-06	Accessible, Low Impact	2
chr9:7681938:C>A	chr9	7681938	7682601	663	rs842304	HIV-1 susceptibility	4e-06	PPIAP33 - DMAC1	21160409	0.9383409	456.0	FOS	6.57376e-05	Accessible, Low Impact	3
chr12:1934452:G>T	chr12	1934452	1933789	663	rs76808809	Pregnancy loss in nulliparas	6e-06	LINC00940	38714721	0.8552694	482.5	MAFK	0.609234	Accessible, Low Impact	3
chr7:82485260:C>A	chr7	82485260	82485924	664	rs10262537	Metabolite levels (Dihydroxy docosatrienoic acid)	7e-06	CACNA2D1 - MTHFD2P5	23934736	0.89951414	402.0	JUND	2.63037e-05	Accessible, Low Impact	3
chr9:118583474:C>G	chr9	118583474	118584139	665	rs1572299	Schizophrenia	4e-06	TPT1P9 - LINC02578	19571808	0.9970238	2593.5	MAFK	6.57618e-06	High Impact, Hard to Access	3
chr3:88339312:C>A	chr3	88339312	88338646	666	rs9879264	Vertical cup-disc ratio	7.000000000000001e-24	CSNK2A2IP	34077760	0.9708846	623.0	JUN	6.58623e-06	High Impact, Hard to Access	3
chr3:88339312:C>A	chr3	88339312	88338646	666	rs9879264	Vertical cup-disc ratio (multi-trait analysis)	1e-13	CSNK2A2IP	31959993	0.9708846	623.0	JUN	6.58623e-06	High Impact, Hard to Access	3
chr3:21388284:C>A	chr3	21388284	21388950	666	rs72625841	Educational attainment	4e-13	SGO1-AS1 - VENTXP7	35361970	0.9470497	420.0	JUND	1.9728e-05	Accessible, Low Impact	3
chr3:23308671:G>C	chr3	23308671	23308005	666	rs4858496	Reaction time	5e-07	UBE2E2	29844566	0.99548393	487.5	FOSL2	1.31484e-05	Accessible, Low Impact	3
chr9:69271480:C>A	chr9	69271480	69270814	666	rs148521708	Fibromuscular dysplasia	1e-05	TJP2	34654805	0.96533185	459.5	BATF	5.27357e-05	Accessible, Low Impact	3
chr14:63697510:C>G	chr14	63697510	63696843	667	rs111406613	Sphingomyelin(32:1)_[M+H]1+ levels	3.0000000000000003e-31	SGPP1	34503513	0.972161	497.0	JUND	3.28735e-05	Accessible, Low Impact	3
chr10:102428314:C>G	chr10	102428314	102427647	667	rs72845696	Educational attainment	1.0000000000000001e-28	CUEDC2	35361970	0.8862913	657.0	JUN	6.57056e-06	High Impact, Hard to Access	3
chr7:2591734:C>G	chr7	2591734	2592402	668	rs10534613	Anxiety disorders	5e-08	IQCE	31906708	0.961175	518.5	JUND	6.58146e-06	Low Priority	3
chr11:5774864:T>A	chr11	5774864	5775532	668	rs7110476	Oropharynx cancer and human papilloma virus 16 negative oropharyngeal cancer	3e-06	TRIM5	34642315	0.9702253	587.0	ATF3	5.01418e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:103816706:C>A	chr2	103816706	103816036	670	rs11889814	Smoking initiation (ever regular vs never regular)	3e-08	CAPZBP1 - LINC01965	30643251	0.9695515	470.5	FOSL2	7.22648e-05	Accessible, Low Impact	3
chr12:132215840:C>A	chr12	132215840	132216510	670	rs11834862	Anti-saccade response	2e-06	GALNT9	29064472	0.90755373	682.0	BATF2	6.57817e-06	High Impact, Hard to Access	3
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Plateletcrit	4e-16	LINC00964	32888494	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Ejection fraction	9e-16	LINC00964	29403010	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Left ventricular internal dimension in systole	2e-13	LINC00964	29403010	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Fractional shortening	2e-13	LINC00964	29403010	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Electrocardiogram morphology (amplitude at temporal datapoints)	2e-11	LINC00964	32916098	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Heart failure (multivariate analysis)	1e-10	LINC00964	36376295	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Left ventricular internal dimension in diastole	2e-09	LINC00964	29403010	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Right ventricular ejection fraction	6e-09	LINC00964	37126556	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Relative wall thickness	1e-08	LINC00964	29403010	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:51586043:C>A	chr8	51586043	51586714	671	rs16916548	Adolescent idiopathic scoliosis	2e-08	PXDNL	30019117	0.9659551	543.0	FOSL2	6.57445e-06	Low Priority	3
chr8:124848279:A>C	chr8	124848279	124847608	671	rs34866937	Left ventricular ejection fraction	1e-07	LINC00964	32382064	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr4:144569879:C>G	chr4	144569879	144569207	672	rs12501071	Post bronchodilator FEV1/FVC ratio	7e-14	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144569207	672	rs12501071	Post bronchodilator FEV1	2e-09	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:36602791:C>A	chr2	36602791	36603463	672	rs13010413	Multi-trait sex score	3e-09	FEZ2	37277458	0.9840279	363.5	FOS	1.31413e-05	Accessible, Low Impact	3
chr4:144569879:C>G	chr4	144569879	144569207	672	rs12501071	Post bronchodilator FEV1/FVC ratio in COPD	1e-06	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:65231804:G>C	chr16	65231804	65232476	672	rs535901290	Breast dense area	1e-05	LINC02126 - LINC00922	37345113	0.99641275	767.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr9:130266490:G>T	chr9	130266490	130265817	673	rs549118533	HMCN2 protein levels	7e-56	HMCN2	39789286	0.9876744	1060.0	JUND	6.5684e-06	High Impact, Hard to Access	3
chr7:92952169:C>A	chr7	92952169	92952842	673	rs117977586	Eosinophil count	2e-11	CDK6-AS1 - RN7SL7P	30595370	0.9872979	440.25	MAFK	0.000145918	Accessible, Low Impact	3
chr1:98006819:A>C	chr1	98006819	98006146	673	rs77177281	PR interval in Tripanosoma cruzi seropositivity	2e-06	MIR137HG	24324551	0.98587024	722.0	FOS	1.31693e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:16722308:G>C	chr9	16722308	16721634	674	rs7042243	height (mean, inv-normal transformed)	7e-13	BNC2	39024449	0.99746656	2526.0	MAFK	6.56996e-06	High Impact, Hard to Access	3
chr7:27913688:C>G	chr7	27913688	27914362	674	rs10275982	Waist circumference adjusted for body mass index	5e-10	JAZF1	31669095	0.996504	2340.0	BATF	6.57125e-06	High Impact, Hard to Access	3
chr9:130266490:G>T	chr9	130266490	130265816	674	rs10988663	Aggressive periodontitis	6e-08	HMCN2	38140892	0.9876744	1060.0	JUND	6.5684e-06	High Impact, Hard to Access	3
chr3:134270211:G>T	chr3	134270211	134270887	676	rs12488908	systolic blood pressure (SBP, maximum, inv-normal transformed)	6e-13	RYK - LINC02004	39024449	0.86897224	520.0	JUNB	0.0	Low Priority	2
chr3:134270211:G>T	chr3	134270211	134270887	676	rs12488908	systolic blood pressure (SBP, mean, inv-normal transformed)	3e-11	RYK - LINC02004	39024449	0.86897224	520.0	JUNB	0.0	Low Priority	2
chr7:44778806:G>C	chr7	44778806	44778129	677	rs55935340	Citrate levels	2e-16	ZMIZ2 - PPIA	41044249	0.9963292	812.0	FOS	3.94514e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:58527851:C>A	chr3	58527851	58527173	678	rs13434020	Aspartate aminotransferase levels	2e-15	ACOX2	33462484	0.9814467	2174.0	JUN	7.08265e-06	HIGH PRIORITY: Accessible + High Impact	3
chr3:58527851:C>A	chr3	58527851	58527173	678	rs13434020	Height	2e-13	ACOX2	36224396	0.9814467	2174.0	JUN	7.08265e-06	HIGH PRIORITY: Accessible + High Impact	3
chr20:43810820:G>C	chr20	43810820	43811498	678	rs1974107	Facial morphology (factor 21, depth of nasal alae)	4e-06	RNU6-639P - LINC01728	28441456	0.9602251	453.0	FOSL2	3.2845e-05	Accessible, Low Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Body mass index	4e-51	LINC01865 - LINC01874	31453325	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Hip circumference	6e-45	LINC01865 - LINC01874	31453325	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Waist circumference	4e-44	LINC01865 - LINC01874	31453325	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Alcohol consumption (drinks per week) (MTAG)	9e-15	LINC01865 - LINC01874	30643251	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Body fat percentage	3e-14	LINC01865 - LINC01874	30593698	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Waist circumference variance	4e-14	LINC01865 - LINC01874	31453325	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:65231804:G>C	chr16	65231804	65231125	679	rs28802661	Systolic blood pressure	5e-14	LINC02126 - LINC00922	40436827	0.99641275	767.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	C-reactive protein levels (MTAG)	4e-12	LINC01865 - LINC01874	36376304	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Body mass index variance	1e-11	LINC01865 - LINC01874	31453325	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Sex hormone-binding globulin levels and heel estimated bone mineral density	2e-11	LINC01865 - LINC01874	37615194	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:55399223:C>G	chr11	55399223	55398544	679	rs117273915	Hemoglobin A1c levels	9e-10	OR4A9P - OR4X7P	34594039	0.946766	404.0	MAFK	1.31643e-05	Accessible, Low Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Hip circumference variance	2e-09	LINC01865 - LINC01874	31453325	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	C-reactive protein	4e-09	LINC01865 - LINC01874	34594039	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:465324:C>A	chr2	465324	466003	679	rs62104180	Coffee consumption	5e-09	LINC01865 - LINC01874	31046077	0.9727787	606.0	ATF3	1.97104e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:49236402:C>G	chr4	49236402	49237081	679	rs4235169	Monocyte count	3e-08	SNX18P23 - MTCO3P39	34594039	0.48588192	331.0	FOS	6.56659e-06	Low Priority	3
chr6:35583210:C>G	chr6	35583210	35583891	681	rs180923765	SEMA3G protein levels	2e-31	LINC03135, FKBP5	39789286	0.95254505	535.5	ATF3	6.57298e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31295974	682	rs2894207	Nasopharyngeal carcinoma	3e-33	LINC02571	20512145	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr2:36964670:T>A	chr2	36964670	36965352	682	rs3770774	Subcortical volume (min-P)	1e-14	STRN	32665545	0.973383	722.0	JUNB	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:36964670:T>A	chr2	36964670	36965352	682	rs3770774	Brain morphology (min-P)	3e-14	STRN	32665545	0.973383	722.0	JUNB	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:36964670:T>A	chr2	36964670	36965352	682	rs3770774	TPE interval (resting)	8e-10	STRN	32386560	0.973383	722.0	JUNB	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:36964670:T>A	chr2	36964670	36965352	682	rs3770774	Brain region volumes	2e-09	STRN	31676860	0.973383	722.0	JUNB	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr20:6999306:C>G	chr20	6999306	6999988	682	rs6085820	Alzheimer's disease (late onset)	9e-06	BMP2 - LINC01428	22881374	0.95254505	419.0	JUND	1.31546e-05	Accessible, Low Impact	3
chr10:30820485:C>A	chr10	30820485	30819802	683	rs10826873	Height	9e-37	LINC02644 - ZNF438	40436827	0.99987054	2617.0	JUND	1.31496e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:31395380:G>T	chr6	31395380	31396063	683	rs2596484	Inferior parietal area (unadjusted for global measures)	4e-11	MICA-AS1	36893272	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr17:45446089:G>C	chr17	45446089	45446772	683	rs184359167	Posterolateral temporal area (unadjusted for global measures)	6e-10	PLEKHM1	36893272	0.99994355	6616.0	FOS	1.31297e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:45446089:G>C	chr17	45446089	45446772	683	rs184359167	Anteromedial temporal area (unadjusted for global measures)	3e-09	PLEKHM1	36893272	0.99994355	6616.0	FOS	1.31297e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:45446089:G>C	chr17	45446089	45446772	683	rs184359167	Dorsomedial frontal area (unadjusted for global measures)	2e-08	PLEKHM1	36893272	0.99994355	6616.0	FOS	1.31297e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:42705202:A>C	chr11	42705202	42704519	683	rs147206860	Monocyte chemoattractant protein-3 levels	4e-06	LINC02740 - HNRNPKP3	27989323	0.99641275	433.0	FOS	6.57281e-06	Accessible, Low Impact	2
chr4:7435002:C>A	chr4	7435002	7435686	684	rs28613646	PSAPL1 protein levels	1.9999999999999998e-50	SORCS2	39789286	0.99560076	2678.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr1:216483233:G>T	chr1	216483233	216483917	684	rs4240923	Height	2e-11	USH2A - ESRRG	36224396	0.9470497	450.5	ATF3	3.94389e-05	Accessible, Low Impact	3
chr9:16846412:T>A	chr9	16846412	16845728	684	rs10810645	Free cholesterol to total lipids ratio in medium LDL	3e-10	BNC2	38448586	0.9185313	434.5	JUND	6.56452e-06	Low Priority	3
chr2:117525339:G>C	chr2	117525339	117524654	685	rs1996277	Severe influenza A (H1N1) infection	2e-19	RNU7-190P - DDX18	26379185	0.83706266	435.5	FOSL2	1.31425e-05	Accessible, Low Impact	3
chr3:16824069:A>C	chr3	16824069	16824754	685	rs9867227	Neuroticism	5e-10	PLCL2	29942085	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr15:87893755:G>T	chr15	87893755	87894440	685	rs73452628	Protein quantitative trait loci (liver)	2e-08	NTRK3	32778093	0.9727787	526.0	JUN	6.5672e-06	Accessible, Low Impact	2
chr6:80512292:G>C	chr6	80512292	80512977	685	rs61669709	Waist circumference adjusted for body mass index	2e-08	RPSAP72 - TENT5A	31669095	0.98639375	494.5	MAFK	0.000289314	Accessible, Low Impact	3
chr3:16824069:A>C	chr3	16824069	16824754	685	rs9867227	Feeling fed-up	5e-08	PLCL2	29500382	0.997742	2513.0	ATF2	6.57004e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93921103	686	rs180239	heart rate (HR, minimum, inv-normal transformed)	5e-28	GNGT1 - GNG11	39024449	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr7:93921789:G>C	chr7	93921789	93921103	686	rs180239	Resting heart rate	5e-21	GNGT1 - GNG11	27798624	0.9991002	2656.0	JUNB	6.57047e-06	High Impact, Hard to Access	3
chr7:55983519:T>A	chr7	55983519	55982832	687	rs35844144	Height	1.9999999999999998e-42	NIPSNAP2	40436827	0.99164	657.0	JUND	6.57013e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:55983519:T>A	chr7	55983519	55982832	687	rs35844144	Glycine levels	5e-11	NIPSNAP2	36357675	0.99164	657.0	JUND	6.57013e-06	HIGH PRIORITY: Accessible + High Impact	2
chr17:36597047:G>T	chr17	36597047	36596360	687	rs35258073	Cognitive performance	6e-11	DHRS11	30038396	0.9514912	631.5	MAFF	7.23151e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:36597047:G>T	chr17	36597047	36596360	687	rs35258073	Cognitive aspects of educational attainment	8e-11	DHRS11	33414549	0.9514912	631.5	MAFF	7.23151e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:55983519:T>A	chr7	55983519	55982832	687	rs35844144	White blood cell count	9e-11	NIPSNAP2	34594039	0.99164	657.0	JUND	6.57013e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:55983519:T>A	chr7	55983519	55982832	687	rs35844144	Neutrophil count	1e-08	NIPSNAP2	34594039	0.99164	657.0	JUND	6.57013e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:55983519:T>A	chr7	55983519	55982832	687	rs35844144	Systolic blood pressure	2e-08	NIPSNAP2	30595370	0.99164	657.0	JUND	6.57013e-06	HIGH PRIORITY: Accessible + High Impact	2
chr15:78579150:C>G	chr15	78579150	78578461	689	rs576982	Post bronchodilator FEV1	2e-09	CHRNA5	26634245	0.9396624	482.5	ATF3	0.000902669	Accessible, Low Impact	3
chr2:102637534:A>C	chr2	102637534	102638223	689	rs12712165	Forced expiratory volume (baseline)	3e-08	SLC9A2	40374629	0.99998	5796.0	FOS	6.57117e-06	HIGH PRIORITY: Accessible + High Impact	2
chr15:78579150:C>G	chr15	78579150	78578461	689	rs576982	Post bronchodilator FEV1/FVC ratio	1e-07	CHRNA5	26634245	0.9396624	482.5	ATF3	0.000902669	Accessible, Low Impact	3
chr15:78579150:C>G	chr15	78579150	78578461	689	rs576982	Lung cancer in ever smokers	9e-07	CHRNA5	40829600	0.9396624	482.5	ATF3	0.000902669	Accessible, Low Impact	3
chr7:84528582:A>C	chr7	84528582	84529272	690	rs1014498	Brain region volumes	9e-10	LINC03017	31676860	0.9970238	3591.5	ATF2	6.58501e-06	HIGH PRIORITY: Accessible + High Impact	2
chr3:49771266:G>T	chr3	49771266	49770574	692	rs115506546	Noncognitive aspects of educational attainment	2e-10	IP6K1	33414549	0.98739034	700.5	ATF2	0.0	High Impact, Hard to Access	3
chr19:4938902:C>A	chr19	4938902	4939594	692	rs118000845	Height (baseline)	4e-10	UHRF1	40374629	0.97174054	641.0	MAFG	6.65345e-06	HIGH PRIORITY: Accessible + High Impact	3
chr3:49771266:G>T	chr3	49771266	49770574	692	rs115506546	Pain intensity (NRS pain scale 0-11)	2e-09	IP6K1	38429522	0.98739034	700.5	ATF2	0.0	High Impact, Hard to Access	3
chr2:53505460:G>T	chr2	53505460	53504768	692	rs7559951	Height	3e-09	MIR4431 - ASB3	36224396	0.98521286	1008.5	MAFK	1.31477e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:49771266:G>T	chr3	49771266	49770574	692	rs115506546	Pain intensity (without opioid use disorder)	9e-09	IP6K1	38429522	0.98739034	700.5	ATF2	0.0	High Impact, Hard to Access	3
chr1:100338473:G>T	chr1	100338473	100337781	692	rs11577884	Height (baseline)	4e-08	CDC14A	40374629	0.96886295	716.0	FOSL1	6.5722e-06	High Impact, Hard to Access	3
chr20:63597943:G>C	chr20	63597943	63598636	693	rs381331	Prostate cancer	1e-12	GMEB2	33398198	0.9845253	842.0	BATF2	6.56953e-06	High Impact, Hard to Access	3
chr19:660487:C>A	chr19	660487	661180	693	rs150250908	Vaginal microbiome MetaCyc pathway (PWY-181|photorespiration)	1e-06	RNF126	34282934	0.9957853	2462.0	FOS	6.57272e-06	High Impact, Hard to Access	3
chr7:1140185:G>C	chr7	1140185	1140879	694	rs10227709	Apolipoprotein A-I levels	4e-11	CHLSN - ZFAND2A	38448586	0.99945825	1789.0	FOSL1	6.61971e-06	High Impact, Hard to Access	3
chr9:6669605:C>A	chr9	6669605	6668911	694	rs11789414	Platelet count	2e-08	LINC02851	34594039	0.9921947	1380.5	MAFK	1.31633e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:28718588:T>A	chr11	28718588	28717893	695	rs580377	Adiposity (multivariate analysis)	6e-12	LINC02742	40796553	0.9702253	521.5	FOS	2.6284e-05	Accessible, Low Impact	2
chr4:69085897:T>A	chr4	69085897	69086592	695	rs13135225	Enterococcus abundance in stool	5e-08	UGT2B7	35115689	0.97621405	561.5	FOS	3.29229e-05	Accessible, Low Impact	3
chr12:104394520:C>G	chr12	104394520	104395216	696	rs149817299	GLIPR1 protein levels	6e-12	TXNRD1 - CHST11	39789286	0.9892507	1226.75	ATF2	6.57168e-06	High Impact, Hard to Access	3
chr22:48837753:C>A	chr22	48837753	48837057	696	rs28695882	Educational attainment	2e-08	TAFA5	35361970	0.99875736	2909.0	FOSL2	2.62695e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:41901852:A>C	chr12	41901852	41901156	696	rs570788995	Postmenopausal breast cancer	1e-06	LINC02400 - GXYLT1	38538606	0.94346935	435.5	FOS	6.56892e-06	Low Priority	3
chr2:139557112:C>G	chr2	139557112	139557809	697	rs838041	Educational attainment	6e-14	SNORA72 - MRPS18BP2	35361970	0.95348793	405.0	BATF	6.68592e-06	Accessible, Low Impact	3
chr12:114715336:G>T	chr12	114715336	114714639	697	rs1910046	R begin-to-T end interval in lead aVR	3e-10	TBX3-AS1	38507016	0.98575574	543.0	ATF2	1.32116e-05	Accessible, Low Impact	3
chr12:114715336:G>T	chr12	114715336	114714639	697	rs1910046	S amplitude of combined wave in lead V4	3e-10	TBX3-AS1	38507016	0.98575574	543.0	ATF2	1.32116e-05	Accessible, Low Impact	3
chr12:114715336:G>T	chr12	114715336	114714639	697	rs1910046	S begin-to-T end interval in lead aVR	3e-10	TBX3-AS1	38507016	0.98575574	543.0	ATF2	1.32116e-05	Accessible, Low Impact	3
chr12:114715336:G>T	chr12	114715336	114714639	697	rs1910046	R start and S end in voltage difference in lead II	3e-10	TBX3-AS1	38507016	0.98575574	543.0	ATF2	1.32116e-05	Accessible, Low Impact	3
chr12:114715336:G>T	chr12	114715336	114714639	697	rs1910046	R start and S end in voltage difference in lead V5	3e-10	TBX3-AS1	38507016	0.98575574	543.0	ATF2	1.32116e-05	Accessible, Low Impact	3
chr19:5288926:G>C	chr19	5288926	5289624	698	rs78771822	PTPRS protein levels	3e-60	PTPRS	39789286	0.9979365	728.0	FOS	6.56858e-06	High Impact, Hard to Access	3
chr22:40338471:C>A	chr22	40338471	40337773	698	rs9611310	Body mass index	2e-08	TNRC6B - ADSL	31669095	0.9834347	1174.0	FOSL2	6.57929e-06	High Impact, Hard to Access	3
chr20:3697788:C>A	chr20	3697788	3697089	699	rs673114	Sialoadhesin levels	4e-15	SIGLEC1	34648354	0.994571	850.0	FOS	3.93846e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:23379022:C>A	chr9	23379022	23379721	699	rs1360382	Restless legs syndrome	1e-07	LINC03142	38839884	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr3:31475345:G>T	chr3	31475345	31476044	699	rs80000774	Chronic graft-versus-host disease (donor effect)	2e-07	THRAP3P1 - STT3B	34996099	0.96744037	513.5	JUND	6.57367e-06	Accessible, Low Impact	2
chr9:23379022:C>A	chr9	23379022	23379721	699	rs1360382	Educational attainment	3e-07	LINC03142	25201988	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr2:102620582:C>A	chr2	102620582	102621282	700	rs528044082	IL18R1 protein levels	9.999999999999999e-26	SLC9A2	39789286	0.9868027	840.0	MAFK	1.3147e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:112064026:C>G	chr1	112064026	112064726	700	rs550856031	Systolic blood pressure	2e-07	LINC02884	35652341	0.9961673	1229.5	MAFK	6.57229e-06	High Impact, Hard to Access	3
chr1:21283964:C>G	chr1	21283964	21283264	700	rs200199208	Interleukin-5 levels	9e-06	ECE1	27989323	0.98327994	641.0	FOSL1	6.57272e-06	High Impact, Hard to Access	3
chr10:93585926:C>A	chr10	93585926	93585225	701	rs374246406	Weight	5e-08	FFAR4	40436827	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:75700141:C>A	chr2	75700141	75699439	702	rs2298948	Hippocampal atrophy	5e-08	GCFC2	22745009	0.973383	620.0	MAFG	6.57471e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	TEK protein levels	9e-18	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr6:135348662:G>T	chr6	135348662	135347959	703	rs2746427	Myeloid white cell count	2e-15	AHI1	27863252	0.97674394	720.0	JUND	6.57618e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	Height	5e-15	MMP14	30595370	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	Diastolic blood pressure	6e-13	MMP14	30224653	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	Height (baseline)	7e-12	MMP14	40374629	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr2:134054389:G>T	chr2	134054389	134055092	703	rs16830012	Educational attainment	7e-12	RN7SKP93 - MGAT5	35361970	0.925176	411.0	JUND	6.57626e-06	Low Priority	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	Standing height (UKB data field 50)	8e-12	MMP14	39789286	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	Diastolic blood pressure (MTAG)	8e-11	MMP14	39537608	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr14:22843721:G>C	chr14	22843721	22844424	703	rs17880989	Systolic blood pressure	3e-08	MMP14	33230300	0.99250877	701.0	FOS	6.57523e-06	High Impact, Hard to Access	3
chr3:164415508:C>A	chr3	164415508	164414805	703	rs113578996	Gut microbiota (bacterial taxa, hurdle binary method)	1e-06	MIR1263 - LINC01324	32572223	0.91499144	371.5	ATF2	3.30718e-05	Accessible, Low Impact	3
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Atrial fibrillation	1e-18	LINC00964	40645996	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Hypertrophic cardiomyopathy (MTAG)	2e-18	LINC00964	39966646	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Primary/intrinsic cardiomyopathies (PheCode 425.1)	2e-13	LINC00964	39024449	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Cardiomyopathy (PheCode 425)	2e-13	LINC00964	39024449	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	PR interval	2e-12	LINC00964	32439900	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Myocardial fractal dimension (slice 5)	3e-11	LINC00964	32814899	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Myocardial fractal dimension (slice 6)	6e-09	LINC00964	32814899	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124847575	704	rs35006907	Myocardial fractal dimension (slice 4)	2e-07	LINC00964	32814899	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:47695333:G>C	chr11	47695333	47696038	705	rs377691617	GAS6 protein levels	2e-12	AGBL2	39789286	0.95842487	664.0	ATF7	6.58302e-06	High Impact, Hard to Access	3
chr1:237333908:A>C	chr1	237333908	237333203	705	rs75310728	Color vision defects (Tritan)	8e-06	RYR2	37359372	0.9984708	710.5	FOS	6.56961e-06	High Impact, Hard to Access	3
chr16:89368764:G>C	chr16	89368764	89369470	706	rs141216394	CDH15 protein levels	8e-12	ANKRD11	39789286	0.9984708	797.5	FOS	2.63071e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:19604159:G>T	chr13	19604159	19603453	706	rs9579517	Colorectal cancer	9e-06	TPTE2-AS1 - MPHOSPH8	34062886	0.97621405	1410.5	ATF2	6.57289e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:2709449:C>A	chr7	2709449	2710156	707	rs10257934	Hip circumference adjusted for BMI	3e-18	AMZ1	34021172	0.9978883	1251.0	JUNB	4.29332e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:2709449:C>A	chr7	2709449	2710156	707	rs10257934	Multi-trait sex score	1e-14	AMZ1	37277458	0.9978883	1251.0	JUNB	4.29332e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:2709449:C>A	chr7	2709449	2710156	707	rs10257934	Waist circumference adjusted for body mass index	7e-11	AMZ1	34021172	0.9978883	1251.0	JUNB	4.29332e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:16792452:C>A	chr9	16792452	16791745	707	rs10962594	Aseptic loosening in total joint arthroplasty	7e-06	BNC2	31791832	0.9777694	481.0	JUND	6.57168e-06	Low Priority	3
chr3:136789874:G>T	chr3	136789874	136789166	708	rs1280622	Irritable bowel syndrome or schizophrenia (pleiotropy)	2e-10	STAG1-DT	36753304	0.9890026	1287.0	FOS	6.57315e-06	High Impact, Hard to Access	3
chr8:75679725:G>T	chr8	75679725	75679017	708	rs12235100	Body mass index (MTAG)	1e-09	HNF4G - RNU2-54P	36376304	0.98266596	646.0	FOS	6.59953e-06	High Impact, Hard to Access	3
chr3:136789874:G>T	chr3	136789874	136789166	708	rs1280622	Feeling nervous	2e-08	STAG1-DT	29500382	0.9890026	1287.0	FOS	6.57315e-06	High Impact, Hard to Access	3
chr2:150497383:C>A	chr2	150497383	150498091	708	rs544436097	Platelet count	4e-08	RND3	31217584	0.98521286	936.75	MAFK	6.57938e-06	High Impact, Hard to Access	3
chr8:75679725:G>T	chr8	75679725	75679017	708	rs12235100	Body mass index	5e-08	HNF4G - RNU2-54P	31669095	0.98266596	646.0	FOS	6.59953e-06	High Impact, Hard to Access	3
chr16:48557018:T>A	chr16	48557018	48557727	709	rs7187513	Eosinophil count	9.999999999999999e-27	N4BP1	32888493	0.99972916	6238.0	BATF	4.59661e-05	HIGH PRIORITY: Accessible + High Impact	2
chr6:127095181:C>G	chr6	127095181	127095890	709	rs2800734	Random glucose levels	6e-10	RPS4XP9 - RSPO3	37679419	0.9756724	625.0	FOS	6.59118e-06	High Impact, Hard to Access	3
chr2:217112151:C>G	chr2	217112151	217112860	709	rs10164944	Ischemic stroke (cardioembolic)	2e-06	TESHL	34031191	0.9383409	487.0	JUNB	6.5716e-06	Low Priority	3
chr18:54554270:C>A	chr18	54554270	54554979	709	rs77175632	Oligodendroglioma	6e-06	DYNAPP1 - DYNAPP2	36810956	0.72030014	376.5	FOS	0.595039	Accessible, Low Impact	3
chr8:53484526:C>G	chr8	53484526	53483816	710	rs1585634	Age at first sexual intercourse	1e-08	LINC02984	34211149	0.94819474	625.5	MAFK	3.94254e-05	HIGH PRIORITY: Accessible + High Impact	2
chr20:10842147:C>A	chr20	10842147	10842858	711	rs6134049	Height	3e-12	LINC01752	30595370	0.99709153	2085.0	MAFK	6.57004e-06	High Impact, Hard to Access	3
chr20:10842147:C>A	chr20	10842147	10842858	711	rs6134049	Physical function (baseline)	8e-10	LINC01752	40374629	0.99709153	2085.0	MAFK	6.57004e-06	High Impact, Hard to Access	3
chr20:10842147:C>A	chr20	10842147	10842858	711	rs6134049	Height (baseline)	1e-08	LINC01752	40374629	0.99709153	2085.0	MAFK	6.57004e-06	High Impact, Hard to Access	3
chr5:96904266:G>C	chr5	96904266	96903554	712	rs17408150	Endoplasmic reticulum aminopeptidase 2 levels (ERAP2.8960.3.3)	3.9999999999999997e-230	ERAP2	29875488	0.9953788	672.0	ATF2	6.57358e-06	High Impact, Hard to Access	3
chr6:33678050:C>G	chr6	33678050	33677338	712	rs2274197	Blood cell traits latent factor 10 (platelet)	1e-11	ITPR3	40220762	0.9910462	798.0	JUNB	0.00456564	HIGH PRIORITY: Accessible + High Impact	3
chr2:69944272:A>C	chr2	69944272	69944984	712	rs11686934	High light scatter reticulocyte count	7e-09	MXD1 - ASPRV1	27863252	0.96886295	906.0	JUND	6.56754e-06	HIGH PRIORITY: Accessible + High Impact	2
chr6:33678050:C>G	chr6	33678050	33677338	712	rs2274197	HDL cholesterol	2e-08	ITPR3	34594039	0.9910462	798.0	JUNB	0.00456564	HIGH PRIORITY: Accessible + High Impact	3
chr6:160156692:C>A	chr6	160156692	160155979	713	rs41267797	Lipoprotein (a) levels	1e-19	SLC22A1	33462484	0.9808213	649.5	FOS	6.56504e-06	High Impact, Hard to Access	3
chr2:172448011:G>C	chr2	172448011	172448725	714	rs1574259	Prostate cancer	2e-77	ITGA6	37945903	0.9978391	1586.5	FOS	6.57073e-06	High Impact, Hard to Access	3
chr6:111374174:A>C	chr6	111374174	111374888	714	rs458017	Psoriasis	2e-16	REV3L, MFSD4B	20953190	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr9:17044393:C>A	chr9	17044393	17045107	714	rs416529	Impedance of arm right (UKB data field 23109)	8e-14	BNC2 - RN7SL720P	39789286	0.92191833	533.5	JUNB	2.62947e-05	Accessible, Low Impact	3
chr9:17044393:C>A	chr9	17044393	17045107	714	rs416529	Impedance of arm left (UKB data field 23110)	3e-12	BNC2 - RN7SL720P	39789286	0.92191833	533.5	JUNB	2.62947e-05	Accessible, Low Impact	3
chr6:111374174:A>C	chr6	111374174	111374888	714	rs458017	Psoriatic arthritis	3e-11	REV3L, MFSD4B	30552173	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:102574928:T>A	chr11	102574928	102575643	715	rs11607749	MMP7 protein levels	2e-21	MMP7 - MMP20	39789286	0.9267576	444.5	FOSL1	1.31475e-05	Accessible, Low Impact	2
chr11:83621561:A>C	chr11	83621561	83620846	715	rs1233917	Subcortical volume (MOSTest)	1e-16	DLG2	32665545	0.9992518	717.0	FOS	1.31423e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:102574928:T>A	chr11	102574928	102575643	715	rs11607749	Matrix metalloproteinase-7 levels	1e-13	MMP7 - MMP20	33067605	0.9267576	444.5	FOSL1	1.31475e-05	Accessible, Low Impact	2
chr17:27423236:C>G	chr17	27423236	27422521	715	rs112437747	Lactococcus lactis abundance in stool	2e-08	TBC1D3P5, TBC1D3P5	35115689	0.99057394	1332.0	ATF3	1.97704e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:217246958:C>A	chr1	217246958	217247673	715	rs12058987	Intracranial aneurysm	1e-06	ESRRG - GPATCH2	29531279	0.9708846	524.0	FOS	2.63279e-05	Accessible, Low Impact	3
chr5:170253852:C>G	chr5	170253852	170253135	717	rs34192428	GRB2-related adapter protein levels	5e-33	LCP2	34648354	0.996737	919.5	JUND	6.57341e-06	High Impact, Hard to Access	3
chr1:218938404:A>C	chr1	218938404	218937686	718	rs73103335	Intraocular pressure	3e-15	LYPLAL1-DT	29785010	0.99695456	714.5	JUND	1.31411e-05	HIGH PRIORITY: Accessible + High Impact	2
chr1:154836057:C>A	chr1	154836057	154836777	720	rs11264273	Atrial fibrillation (MTAG)	7e-37	KCNN3	39537608	0.96686935	582.5	FOS	1.31428e-05	HIGH PRIORITY: Accessible + High Impact	3
chr20:2102821:G>T	chr20	2102821	2103541	720	rs2211325	Body mass index (MTAG)	2e-08	STK35	36376304	0.9999497	7041.75	JUND	1.31377e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:119701011:G>C	chr11	119701011	119701731	720	rs885430	3-hydroxysebacate levels in elite athletes	2e-07	NECTIN1	31882771	0.9998168	5210.0	JUNB	6.57168e-06	High Impact, Hard to Access	3
chr3:124328919:A>C	chr3	124328919	124329639	720	rs72976591	Stroke	9e-07	KALRN	32693751	0.9993485	717.5	FOS	3.28576e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:8722870:G>C	chr19	8722870	8723591	721	rs564421774	Sulfate levels	7e-07	OR2Z1	36357675	0.92557216	478.0	FOSL2	2.63023e-05	Accessible, Low Impact	3
chr13:59312845:G>C	chr13	59312845	59313567	722	rs9563710	Smoking initiation	8e-16	RPP40P2 - RNU7-88P	36477530	0.97922516	876.0	MAFK	6.56918e-06	High Impact, Hard to Access	3
chr17:49651922:G>T	chr17	49651922	49652644	722	rs12937072	Height	1e-14	SPOP	36224396	0.9479486	679.0	FOSL1	6.57117e-06	High Impact, Hard to Access	3
chr6:30025206:T>A	chr6	30025206	30024484	722	rs1150743	BTN1A1 protein levels	5e-14	POLR1HASP	39789286	0.9855452	619.0	ATF3	6.57013e-06	HIGH PRIORITY: Accessible + High Impact	2
chr13:59312845:G>C	chr13	59312845	59313567	722	rs9563710	Smoking initiation (ever regular vs never regular) (MTAG)	2e-09	RPP40P2 - RNU7-88P	30643251	0.97922516	876.0	MAFK	6.56918e-06	High Impact, Hard to Access	3
chr14:53883980:G>C	chr14	53883980	53883258	722	rs11625034	Waist-to-hip ratio adjusted for body mass index	6e-06	DDHD1-DT	27195708	0.9659551	591.875	FOS	1.31588e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:112519698:C>G	chr10	112519698	112518975	723	rs4554811	Colorectal cancer	8e-14	VTI1A	31826910	0.9957983	1411.0	JUND	0.0101025	HIGH PRIORITY: Accessible + High Impact	3
chr8:141294943:G>C	chr8	141294943	141295667	724	rs7014099	Height	3e-10	SLC45A4	30595370	0.99641275	785.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr20:46101494:G>C	chr20	46101494	46100770	724	rs6104460	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)	2e-06	RPL13P2 - CD40	28441456	0.95134485	594.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr16:8491453:C>G	chr16	8491453	8490729	724	rs12929740	Longevity	8e-06	LINC02152 - TMEM114	31484785	0.9396624	514.0	FOSL1	6.57272e-06	Low Priority	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Lysophosphatidylethanolamine_22:4_[M-H]1- levels	9e-60	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Lysophosphatidylcholine_20:4_[M+H]1+ levels	2e-59	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Fatty acid(20:4)_[M-H]1- levels	3e-35	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Cholesteryl ester_20:5_[M+NH4]1+ levels	4e-33	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_38:4_[M-H]1- levels	5.0000000000000004e-29	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels	8.999999999999998e-25	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_37:4_[M+H]1+/Phosphatidylethanolamine_40:4_[M+H]1+/Phosphatidate_42:5_[M+NH4]1+ levels	1.0000000000000001e-24	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylinositol_36:3_[M-H]1- levels	2e-22	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr16:17090510:C>A	chr16	17090510	17089784	726	rs4533273	Height	3e-22	SPRING1P3 - TCERG1P2	36224396	0.93631864	462.0	MAFK	0.0	Low Priority	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_39:4_[M-H]1- levels	1e-21	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_35:4_[M+H]1+/Phosphatidylethanolamine_38:4_[M+H]1+/Phosphatidate_40:5_[M+NH4]1+ levels	2e-21	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Diacylglycerol_38:3_[M+H-H2O]1+ levels	1e-20	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels	2e-20	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_31:2_[M+H]1+/Phosphatidylethanolamine_34:2_[M+H]1+/Phosphatidate_36:3_[M+NH4]1+ levels	2e-20	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_34:2_[M-H]1- levels	4e-20	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Diacylglycerol_38:4_[M+H-H2O]1+ levels	6e-20	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_36:3_[M+H]1+/Phosphatidylethanolamine_39:3_[M+H]1+/Phosphatidate_41:4_[M+NH4]1+ levels	2e-18	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_34:2_[M+OAc]1-/Phosphatidylserine_38:1_[M-H]1- levels	2e-18	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_38:3_[M-H]1- levels	2e-18	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_35:3_[M+H]1+/Phosphatidylethanolamine_38:3_[M+H]1+/Phosphatidate_40:4_[M+NH4]1+ levels	3e-18	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Diacylglycerol_38:5_[M+H-H2O]1+ levels	4e-17	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_36:3_[M-H]1- levels	5e-17	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine-O_40:5_[M-H]1-/Phosphatidylethanolamine-P_40:4_[M-H]1- levels	3e-16	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Triacylglycerol_58:10_[M+NH4]1+ levels	3e-16	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Triacylglycerol_56:6_[M+NH4]1+ levels	2e-15	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine-O_36:4_[M+H]1+/Phosphatidylcholine-P_36:3_[M+H]1+ levels	6e-15	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_40:5_[M+H]1+ levels	8e-15	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_36:2_[M-H]1- levels	8e-15	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Cholesteryl ester_20:3_[M+NH4]1+ levels	1e-14	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Lysophosphatidylethanolamine_20:4_[M-H]1- levels	3e-14	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Lysophosphatidylethanolamine_18:2_[M-H]1- levels	7e-13	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_42:4_[M+OAc]1- levels	1e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine_38:5_[M-H]1- levels	2e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylinositol_36:2_[M-H]1- levels	2e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels	3e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine-O_38:5_[M+H]1+/Phosphatidylcholine-P_38:4_[M+H]1+ levels	4e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylethanolamine-O_38:5_[M-H]1-/Phosphatidylethanolamine-P_38:4_[M-H]1- levels	6e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Triacylglycerol_58:9_[M+NH4]1+ levels	2e-11	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Cholesteryl ester_22:6_[M+NH4]1+ levels	6e-11	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_32:2_[M+H]1+/Phosphatidylethanolamine_35:2_[M+H]1+/Phosphatidate_37:3_[M+NH4]1+ levels	8e-11	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_36:2_[M+OAc]1-/Phosphatidylserine_40:1_[M-H]1- levels	9e-11	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylcholine_40:7_[M+H]1+ levels	1e-10	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Fatty acid(22:5)_[M-H]1- levels	2e-10	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Triacylglycerol_56:7_[M+NH4]1+ levels	3e-10	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902565	726	rs174471	Phosphatidylinositol_34:0_[M+H]1+ levels	4e-10	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr2:128376444:C>A	chr2	128376444	128375718	726	rs79341575	Proportion of activated microglia (inferior temporal cortex)	3e-06	Y_RNA - RNA5SP103	30679421	0.994183	746.0	FOS	6.57056e-06	High Impact, Hard to Access	3
chr3:111164205:T>A	chr3	111164205	111163479	726	rs6414248	Ischemic stroke	5e-06	NECTIN3	38317187	0.972161	556.0	FOS	6.57307e-06	Accessible, Low Impact	2
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Saturated fatty acids levels	2e-31	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Total fatty acid levels	3e-26	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr12:119825926:G>C	chr12	119825926	119825199	727	rs55707601	CIT protein levels	5e-16	CIT	39789286	0.97419965	546.0	ATF3	6.57445e-06	Low Priority	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Polyunsaturated fatty acid levels	1e-14	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Monounsaturated fatty acid levels	1e-12	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Polyunsaturated fatty acids to total fatty acids percentage	1e-12	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Saturated fatty acids to total fatty acids percentage	5e-12	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Linoleic acid to total fatty acids percentage	3e-11	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Omega-3 fatty acid levels	5e-11	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Monounsaturated fatty acids to total fatty acids percentage	9e-11	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Polyunsaturated fatty acids to monounsaturated fatty acids ratio	2e-10	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Linoleic acid levels	5e-10	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Polyunsaturated fatty acids to saturated fatty acids ratio	7e-10	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Omega-6 fatty acid levels	8e-10	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr12:119825926:G>C	chr12	119825926	119825199	727	rs55707601	Red cell distribution width	9e-10	CIT	32888493	0.97419965	546.0	ATF3	6.57445e-06	Low Priority	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Omega-3 fatty acids to Omega-6 fatty acids ratio	1e-08	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Omega-6 fatty acids to total fatty acids percentage	2e-08	GTF3C2-AS2, EIF2B4	40545721	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr2:27365486:C>A	chr2	27365486	27366213	727	rs142398019	Body fat percentage (adjusted for testosterone and SHBG)	3e-08	GTF3C2-AS2, EIF2B4	37867527	0.96686935	564.0	FOS	6.64055e-06	Accessible, Low Impact	3
chr4:98874906:C>G	chr4	98874906	98875633	727	rs7665590	Primary biliary cholangitis	1e-07	BTF3P13 - EIF4E	23000144	0.9921947	1082.0	ATF2	6.76901e-06	HIGH PRIORITY: Accessible + High Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Pleckstrin levels	3e-21	PLEK	34648354	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr7:50665937:G>C	chr7	50665937	50666665	728	rs2237468	Birth size (multivariate analysis)	2e-10	GRB10	40796553	0.9992518	1299.0	FOS	0.000118182	HIGH PRIORITY: Accessible + High Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism	3e-10	PLEK	31420334	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or factor VII levels (pleiotropy)	3e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or fibrinogen levels (pleiotropy)	4e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or plasminogen activator inhibitor 1 levels (pleiotropy)	6e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or tissue plasminogen activator levels (pleiotropy)	6e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or factor XI levels (pleiotropy)	6e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or von Willebrand factor levels (pleiotropy)	6e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr2:68393577:C>G	chr2	68393577	68392849	728	rs1867312	Venous thromboembolism or factor VIII levels (pleiotropy)	6e-10	PLEK	35285134	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr13:24170470:G>T	chr13	24170470	24169742	728	rs116424804	Alzheimer's disease, proxy Alzheimer's disease or related dementias	6e-06	SPATA13	40708016	0.95041513	479.5	ATF3	0.000571406	Accessible, Low Impact	3
chr2:201209074:C>A	chr2	201209074	201209805	731	rs7576306	CASP10 protein levels	8e-173	CASP10	39789286	0.99961716	3764.0	ATF2	0.0	High Impact, Hard to Access	3
chr1:8931417:A>C	chr1	8931417	8930686	731	rs12750976	CA6 protein levels	9e-26	HMGN2P17 - CA6	39789286	0.9727787	684.0	ATF7	9.84665e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:27950649:C>G	chr8	27950649	27949917	732	rs2685417	Tenascin levels	5.0000000000000005e-158	SCARA5	34648354	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27949917	732	rs2685417	Serum levels of protein SFTPC	1.9999999999999998e-42	SCARA5	35078996	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27949917	732	rs2685417	Serum levels of protein TNC	3.9999999999999997e-32	SCARA5	35078996	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27949917	732	rs2685417	Serum levels of protein EVA1C	3e-23	SCARA5	35078996	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr6:31295292:A>C	chr6	31295292	31296024	732	rs114583506	Major depressive episode treated with electroconvulsive therapy	4e-08	LINC02571	33483693	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31296024	732	rs114583506	Major depressive disorder and major depressive episode treated with electroconvulsive therapy	1e-07	LINC02571	33483693	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr11:49694009:C>G	chr11	49694009	49694742	733	rs771968342	Other venous embolism and thrombosis (PheCode 452)	2e-11	GRM5P1, GRM5P1	39024449	0.6242398	333.5	FOS	6.77654e-06	Accessible, Low Impact	3
chr11:49694009:C>G	chr11	49694009	49694742	733	rs771968342	Deep vein thrombosis [DVT] (PheCode 452.2)	4e-11	GRM5P1, GRM5P1	39024449	0.6242398	333.5	FOS	6.77654e-06	Accessible, Low Impact	3
chr13:31330579:C>A	chr13	31330579	31331312	733	rs876540	Height	4e-08	B3GLCT	36224396	0.97922516	593.0	FOS	0.0	High Impact, Hard to Access	3
chr9:94960432:G>T	chr9	94960432	94961167	735	rs7865239	Atrial fibrillation and flutter (PheCode 427.2)	5e-31	AOPEP	39024449	0.8908594	439.0	ATF3	0.0	Low Priority	3
chr9:94960432:G>T	chr9	94960432	94961167	735	rs7865239	Atrial fibrillation (PheCode 427.21)	6e-30	AOPEP	39024449	0.8908594	439.0	ATF3	0.0	Low Priority	3
chr9:94960432:G>T	chr9	94960432	94961167	735	rs7865239	QT interval	4e-09	AOPEP	36271874	0.8908594	439.0	ATF3	0.0	Low Priority	3
chr4:139213684:C>G	chr4	139213684	139214419	735	rs13134168	COVID-19 (severe vs non-severe with positive test)	9e-06	Y_RNA - RNU6-506P	35224516	0.9830546	827.0	JUNB	1.3195e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:126153411:G>T	chr11	126153411	126154147	736	rs61898819	Neutrophil count	2e-11	NAP1L1P1 - RPUSD4	32888494	0.98739034	724.5	FOS	6.56961e-06	High Impact, Hard to Access	3
chr11:126153411:G>T	chr11	126153411	126154147	736	rs61898819	White blood cell count	8e-11	NAP1L1P1 - RPUSD4	30595370	0.98739034	724.5	FOS	6.56961e-06	High Impact, Hard to Access	3
chr17:36497698:C>G	chr17	36497698	36498436	738	rs2306590	Body mass index	2e-18	MYO19, ZNHIT3	29273807	0.96670574	695.0	JUND	6.57367e-06	High Impact, Hard to Access	3
chr11:72615423:C>A	chr11	72615423	72616161	738	rs3781931	Testosterone levels	1e-10	PDE2A	33462484	0.94555736	681.0	JUN	1.31418e-05	HIGH PRIORITY: Accessible + High Impact	3
chr20:46101494:G>C	chr20	46101494	46102233	739	rs75950643	CD40 protein levels	5.999999999999999e-44	RPL13P2 - CD40	39789286	0.95134485	594.0	JUN	6.57341e-06	High Impact, Hard to Access	3
chr11:59830395:C>A	chr11	59830395	59831134	739	rs17596862	Height (baseline)	2e-11	CBLIF	40374629	0.98575574	466.0	FOSL1	6.58267e-06	Low Priority	3
chr6:37093371:G>T	chr6	37093371	37092631	740	rs9357237	MDGA1 protein levels	1e-13	RPL12P2 - PIM1	39789286	0.99746656	2804.0	BATF	6.57022e-06	HIGH PRIORITY: Accessible + High Impact	2
chr1:201910432:C>A	chr1	201910432	201911172	740	rs2820322	Leiomodin-1 levels	5e-08	LMOD1	39528825	0.9094714	556.0	FOS	6.57436e-06	Low Priority	3
chr11:69359711:G>C	chr11	69359711	69360452	741	rs72932201	Waist-hip index	2e-10	MYEOV - LINC02956	34021172	0.9870033	522.0	BATF	6.57022e-06	Low Priority	3
chr1:29543200:C>A	chr1	29543200	29543942	742	rs7418865	Adolescent idiopathic scoliosis	4.999999999999999e-32	LINC01756 - LINC01648	30019117	0.80697334	526.5	JUND	6.56659e-06	Low Priority	3
chr1:33323176:C>G	chr1	33323176	33323919	743	rs5861	Adiposity (multivariate analysis)	6e-10	PHC2	40796553	0.996504	1992.0	FOSL2	6.5697e-06	HIGH PRIORITY: Accessible + High Impact	2
chr15:39018357:C>G	chr15	39018357	39017614	743	rs1380939	Kidney medulla volume	5e-09	LINC02694	41077127	0.972161	568.5	JUND	6.57194e-06	High Impact, Hard to Access	3
chr1:206527095:C>A	chr1	206527095	206526352	743	rs150269952	Late-onset Alzheimer's disease	6e-06	RASSF5	27770636	0.9267576	541.0	MAFK	6.57367e-06	Low Priority	3
chr6:33897104:A>C	chr6	33897104	33896360	744	rs6903171	Idiopathic knee osteoarthritis	1e-08	LINC01016	37247657	0.99995816	4210.0	FOSL2	6.56953e-06	High Impact, Hard to Access	3
chr10:93585926:C>A	chr10	93585926	93586671	745	rs12241416	A body shape index	7e-13	FFAR4	34021172	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:93585926:C>A	chr10	93585926	93586671	745	rs12241416	Waist-to-hip ratio adjusted for BMI	2e-12	FFAR4	31669095	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:93585926:C>A	chr10	93585926	93586671	745	rs12241416	Waist-hip ratio	8e-11	FFAR4	30595370	0.88394535	695.0	BATF2	1.96941e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:36457034:C>A	chr15	36457034	36456289	745	rs193032689	1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels	9e-06	LINC02853 - COX6CP4	40360795	0.95242816	443.0	FOS	7.2458e-05	Accessible, Low Impact	3
chr16:79890757:G>C	chr16	79890757	79891503	746	rs28384289	Urate levels (UKB data field 30880)	3e-30	LINC01228 - DYNLRB2-AS1	39789286	0.95348793	440.0	FOS	1.31482e-05	Accessible, Low Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides to total lipids in large HDL percentage (UKB data field 23638)	7e-16	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides to total lipids in medium HDL percentage (UKB data field 23643)	8e-16	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesteryl esters to total lipids in medium HDL percentage (UKB data field 23641)	3e-15	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides to total lipids in small HDL percentage (UKB data field 23648)	5e-15	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesteryl esters to total lipids in large HDL percentage (UKB data field 23636)	2e-14	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesterol to total lipids in large HDL percentage (UKB data field 23635)	1e-13	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622)	2e-13	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides to total lipids in very large HDL percentage (UKB data field 23633)	2e-13	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides to phosphoglycerides ratio (UKB data field 23435)	6e-13	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Total triglycerides levels (UKB data field 23407)	2e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in HDL (UKB data field 23410)	2e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in very small VLDL (UKB data field 23522)	2e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452)	3e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Free cholesterol to total lipids in small LDL percentage (UKB data field 23627)	4e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in small LDL (UKB data field 23550)	1e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesterol to total lipids in small HDL percentage (UKB data field 23645)	3e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Phospholipids to total lipids in large VLDL percentage (UKB data field 23589)	4e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485)	6e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484)	7e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Free cholesterol in very large VLDL (UKB data field 23493)	8e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in IDL (UKB data field 23529)	9e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646)	1e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in LDL (UKB data field 23409)	3e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in medium LDL (UKB data field 23543)	3e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Total lipids in VLDL (UKB data field 23424)	5e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Omega-3 fatty acid levels	5e-10	TRIB1AL - LINC02964	40545721	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:122586600:G>T	chr4	122586600	122587346	746	rs12642902	Systemic lupus erythematosus (MTAG)	1e-09	IL2 - IL21	36750564	0.84946334	453.5	JUND	2.62671e-05	Accessible, Low Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Triglycerides in medium VLDL (UKB data field 23508)	1e-09	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619443	746	rs3860846	Omega-3 fatty acids to Omega-6 fatty acids ratio	3e-08	TRIB1AL - LINC02964	40545721	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:49813686:C>A	chr12	49813686	49812940	746	rs10875969	Body mass index	8e-06	NCKAP5L	31888951	0.996803	759.5	BATF	6.5735e-06	High Impact, Hard to Access	3
chr5:54589582:G>C	chr5	54589582	54590329	747	rs2565010	Sleep disturbance (changes in sleep) in depressive disorders	1e-06	SNX18 - CSPG4BP	32399468	0.95357716	511.5	FOS	1.31397e-05	Accessible, Low Impact	3
chr10:13494456:C>G	chr10	13494456	13495204	748	rs12770479	Glucose (fasting status unknown, maximum, inv-norm transformed)	9e-12	BEND7	39024449	0.8885958	610.5	ATF7	0.000111758	HIGH PRIORITY: Accessible + High Impact	3
chr4:138207123:C>G	chr4	138207123	138207871	748	rs182651559	Sleep duration (> 10 hours)	1e-08	SLC7A11	33075057	0.9968112	3448.0	ATF2	1.32024e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:13494456:C>G	chr10	13494456	13495204	748	rs12770479	Smoking status	2e-08	BEND7	30595370	0.8885958	610.5	ATF7	0.000111758	HIGH PRIORITY: Accessible + High Impact	3
chr3:169838051:C>G	chr3	169838051	169837302	749	rs185473131	Ocular sarcoidosis	2e-06	LRRIQ4	32141793	0.91499144	426.25	MAFK	6.57263e-06	Low Priority	3
chr8:141294943:G>C	chr8	141294943	141295693	750	rs6999890	platelet count (mean, inv-norm transformed)	2e-13	SLC45A4	39024449	0.99641275	785.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr8:141294943:G>C	chr8	141294943	141295693	750	rs6999890	platelet count (maximum, inv-norm transformed)	2e-12	SLC45A4	39024449	0.99641275	785.0	FOS	6.56892e-06	High Impact, Hard to Access	3
chr20:25507531:C>G	chr20	25507531	25506781	750	rs376742	Alkaline phosphatase levels	4e-10	NINL	39414775	0.9644045	1012.0	JUN	6.56401e-06	HIGH PRIORITY: Accessible + High Impact	2
chr11:4116495:G>T	chr11	4116495	4115744	751	rs1662161	Mean corpuscular volume	4e-08	RRM1	40436827	0.9990591	3953.5	MAFK	1.97246e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:7570052:C>A	chr19	7570052	7570803	751	rs7260296	Stable warfarin dose	5e-06	PNPLA6 - CAMSAP3	39163621	0.9910462	1219.5	JUNB	1.31731e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:20759258:G>C	chr1	20759258	20758506	752	rs2985313	Height	9.999999999999999e-26	HP1BP3	34594039	0.96610916	607.0	ATF3	1.31413e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:20759258:G>C	chr1	20759258	20758506	752	rs2985313	What is your height? (cm, inv-normal transformed)	1e-15	HP1BP3	39024449	0.96610916	607.0	ATF3	1.31413e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:20759258:G>C	chr1	20759258	20758506	752	rs2985313	Height (maximum, inv-normal transformed)	2e-15	HP1BP3	39024449	0.96610916	607.0	ATF3	1.31413e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:20759258:G>C	chr1	20759258	20758506	752	rs2985313	height (mean, inv-normal transformed)	2e-15	HP1BP3	39024449	0.96610916	607.0	ATF3	1.31413e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:20759258:G>C	chr1	20759258	20758506	752	rs2985313	height (minimum, inv-normal transformed)	9e-14	HP1BP3	39024449	0.96610916	607.0	ATF3	1.31413e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:132794020:C>G	chr11	132794020	132794772	752	rs10791250	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (3 Months) interaction	3e-10	OPCML	40187613	0.93131924	530.5	JUNB	6.56953e-06	Accessible, Low Impact	2
chr11:132794020:C>G	chr11	132794020	132794772	752	rs10791250	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (1 Year) interaction	2e-08	OPCML	40187613	0.93131924	530.5	JUNB	6.56953e-06	Accessible, Low Impact	2
chr13:104187109:A>G	chr13	104187109	104187861	752	rs16964289	RBC levels of Nonanoic acid (pelargonate)	3e-08	ATP6V1G1P7 - RPL7P45	36395887	0.96518815	482.5	JUND	3.93887e-05	Accessible, Low Impact	3
chr7:95375182:T>A	chr7	95375182	95374429	753	rs578141133	PON2 protein levels	3e-16	PON3	39789286	0.8885958	376.25	ATF3	6.59126e-06	Low Priority	3
chr7:95375182:T>A	chr7	95375182	95374429	753	rs578141133	PON1 protein levels	6e-15	PON3	39789286	0.8885958	376.25	ATF3	6.59126e-06	Low Priority	3
chr4:182244563:C>G	chr4	182244563	182245316	753	rs7696796	Personality traits or cognitive traits (multivariate analysis)	6e-10	TENM3	37365406	0.9940711	610.0	FOS	5.25797e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:182244563:C>G	chr4	182244563	182245316	753	rs7696796	General factor of neuroticism	4e-09	TENM3	30867560	0.9940711	610.0	FOS	5.25797e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:182244563:C>G	chr4	182244563	182245316	753	rs7696796	Neuroticism	5e-09	TENM3	32231276	0.9940711	610.0	FOS	5.25797e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:140259427:G>C	chr6	140259427	140258674	753	rs9403164	Triglyceride levels in non-type 2 diabetes	1e-08	MIR3668 - MIR4465	36269708	0.99013096	331.5	MAFK	6.61498e-06	Low Priority	3
chr6:127060091:C>A	chr6	127060091	127059337	754	rs6902885	Bone mineral density mean	8e-11	RPS4XP9 - RSPO3	37500982	0.86897224	323.75	FOS	0.0	Low Priority	3
chr18:49036414:G>T	chr18	49036414	49035660	754	rs181553	Hip circumference adjusted for BMI	3e-10	DYM-AS1	25673412	0.95041513	488.5	ATF3	2.65146e-05	Accessible, Low Impact	3
chr19:5288926:G>C	chr19	5288926	5288171	755	rs740058	Thyroid stimulating hormone levels	2e-17	PTPRS	37872160	0.9979365	728.0	FOS	6.56858e-06	High Impact, Hard to Access	3
chr18:52472192:A>C	chr18	52472192	52471437	755	rs1372626	Smoking behaviour (cigarettes smoked per day)	3e-06	DCC	27393504	0.9939092	941.5	FOS	6.57246e-06	HIGH PRIORITY: Accessible + High Impact	2
chr10:61471959:A>C	chr10	61471959	61471203	756	rs78238196	Bone mineral density mean	7e-35	TMEM26-AS1	37500982	0.99947065	1417.0	FOS	0.0	High Impact, Hard to Access	3
chr6:150416156:A>C	chr6	150416156	150415400	756	rs546044924	GLIPR1 protein levels	1e-17	IYD - PLEKHG1	39789286	0.97674394	690.5	JUN	3.28407e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:54673339:C>G	chr2	54673339	54672583	756	rs4671966	height (minimum, inv-normal transformed)	5e-17	SPTBN1-AS2	39024449	0.99746656	2064.0	ATF2	6.57272e-06	High Impact, Hard to Access	3
chr7:33465301:G>T	chr7	33465301	33466057	756	rs202162020	Disease progression in age-related macular degeneration	1e-06	BBS9	29346644	0.9787506	584.75	JUND	0.0	High Impact, Hard to Access	3
chr11:113027735:C>A	chr11	113027735	113028492	757	rs1892983	Smoking initiation	2e-179	NCAM1	36477530	0.97621405	822.0	MAFK	3.28554e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:83287708:G>C	chr15	83287708	83288465	757	rs8033380	Blond vs. brown/black hair color	1e-14	BNC1 - SH3GL3	30531825	0.99999	4466.0	FOSL2	1.31461e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:26591073:C>A	chr8	26591073	26590314	759	rs68019818	Node-level brain connectivity (multivariate analysis)	1e-11	DPYSL2	36800424	0.988674	1132.0	FOS	6.57151e-06	High Impact, Hard to Access	3
chr10:100289645:G>C	chr10	100289645	100288886	759	rs117260820	Parental extreme longevity (95 years and older)	2e-06	PKD2L1	27015805	0.9840279	1636.625	FOS	6.5703e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17640408	760	rs12936587	Waist-to-hip ratio adjusted for BMI	8.000000000000001e-29	PEMT - SMCR2	30575882	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:77354372:G>C	chr17	77354372	77355132	760	rs567689672	Ulcerative colitis (chronic) (PheCode 555.21)	2e-11	SEPTIN9	39024449	0.9973411	1599.0	FOSL2	6.57151e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:17641168:G>T	chr17	17641168	17640408	760	rs12936587	Coronary artery disease or large artery stroke	2e-10	PEMT - SMCR2	24262325	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17640408	760	rs12936587	Coronary heart disease	4e-10	PEMT - SMCR2	21378990	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17640408	760	rs12936587	Hip circumference	3e-08	PEMT - SMCR2	25673412	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17640408	760	rs12936587	Waist-hip ratio	5e-08	PEMT - SMCR2	30575882	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr17:17641168:G>T	chr17	17641168	17640408	760	rs12936587	Coronary artery disease	2e-07	PEMT - SMCR2	24262325	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr9:91902138:C>A	chr9	91902138	91901378	760	rs140005165	Alzheimer's disease in non-APOE e4 carriers	6e-06	ROR2	35694926	0.990189	713.0	FOS	1.31475e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Heel bone mineral density	0.0	CPED1 - WNT16	30048462	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Fracture of forearm	1.9999999999999998e-174	CPED1 - WNT16	37919453	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Bone stiffness index	7.0000000000000005e-99	CPED1 - WNT16	36329257	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Bone ultrasound measurement (velocity of sound)	2e-48	CPED1 - WNT16	28472463	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Fractures	2.0000000000000002e-39	CPED1 - WNT16	30158200	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Bone properties (heel)	4e-35	CPED1 - WNT16	24430505	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Fracture of ankle and foot (PheCode 801)	8e-33	CPED1 - WNT16	39024449	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Bone ultrasound measurement (broadband ultrasound attenuation)	1e-27	CPED1 - WNT16	28472463	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Fracture of radius and ulna (PheCode 803.2)	2e-22	CPED1 - WNT16	39024449	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:121322871:C>G	chr7	121322871	121322110	761	rs2908007	Fracture of hand or wrist (PheCode 804)	1e-18	CPED1 - WNT16	39024449	0.99539393	2086.0	MAFK	1.97003e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:8246922:C>A	chr16	8246922	8247683	761	rs982855	Body mass index	4e-08	RBFOX1 - LINC02152	34594039	0.9930392	1187.0	MAFG	7.92466e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:8246922:C>A	chr16	8246922	8247683	761	rs982855	Intracranial aneurysm	2e-06	RBFOX1 - LINC02152	29531279	0.9930392	1187.0	MAFG	7.92466e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:43957354:C>A	chr15	43957354	43958115	761	rs2929278	Schizophrenia	6e-06	FRMD5	26198764	0.96761274	530.5	MAFF	2.62943e-05	Accessible, Low Impact	3
chr17:52394617:A>C	chr17	52394617	52393855	762	rs72837734	Educational attainment	1e-09	LINC01982	35361970	0.95749575	450.0	FOSL2	0.000124806	Accessible, Low Impact	2
chr17:36002761:G>C	chr17	36002761	36001998	763	rs41508645	Serum levels of protein CCL15	3e-293	CCL15-CCL14 - CCL23	35078996	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr17:36002761:G>C	chr17	36002761	36001998	763	rs41508645	C-C motif chemokine 15 (analyte X14109.15) levels	1e-105	CCL15-CCL14 - CCL23	39528825	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr17:36002761:G>C	chr17	36002761	36001998	763	rs41508645	C-C motif chemokine 15 (analyte X18289.16) levels	2.9999999999999997e-96	CCL15-CCL14 - CCL23	39528825	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr17:36002761:G>C	chr17	36002761	36001998	763	rs41508645	C-C motif chemokine 15 (analyte X3509.1) levels	6e-66	CCL15-CCL14 - CCL23	39528825	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr7:96207003:C>G	chr7	96207003	96207766	763	rs28579874	Osteoarthritis	2e-21	SLC25A13	40205036	0.9868027	581.0	JUND	6.57212e-06	High Impact, Hard to Access	3
chr6:63505481:G>T	chr6	63505481	63506244	763	rs10943832	Body mass index (BMI, maximum, inv-normal transformed)	4e-12	EEF1B2P5 - PTP4A1	39024449	0.9921947	1490.0	JUNB	0.0	High Impact, Hard to Access	3
chr7:96207003:C>G	chr7	96207003	96207766	763	rs28579874	Osteoarthritis of the hip or knee	1e-11	SLC25A13	40205036	0.9868027	581.0	JUND	6.57212e-06	High Impact, Hard to Access	3
chr6:63505481:G>T	chr6	63505481	63506244	763	rs10943832	Body mass index (BMI, mean, inv-normal transformed)	4e-11	EEF1B2P5 - PTP4A1	39024449	0.9921947	1490.0	JUNB	0.0	High Impact, Hard to Access	3
chr6:132509041:C>G	chr6	132509041	132509805	764	rs9493341	Red cell distribution width	5e-13	STX7	27863252	0.84946334	507.5	ATF3	6.57601e-06	Low Priority	3
chr4:162299945:C>A	chr4	162299945	162300710	765	rs188452950	REST UKBBICA NET100 1044	7e-09	FSTL5 - MTHFD2P4	38811844	0.9928454	541.5	FOS	6.57134e-06	Low Priority	3
chr10:14584226:G>C	chr10	14584226	14584991	765	rs77108059	Insomnia in migraine with aura	6e-07	FAM107B	35698589	0.99527115	916.0	FOS	0.00033494	HIGH PRIORITY: Accessible + High Impact	3
chr18:23822876:G>T	chr18	23822876	23822111	765	rs62094793	Pulmonary tuberculosis	2e-06	LAMA3	37009413	0.994591	2111.5	ATF2	1.97135e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:23822876:G>T	chr18	23822876	23822111	765	rs62094793	Tuberculosis	4e-06	LAMA3	37009413	0.994591	2111.5	ATF2	1.97135e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:22485266:C>G	chr11	22485266	22486031	765	rs141055993	Sphingosine levels	5e-06	LINC01495	40360795	0.629636	323.875	FOS	1.31461e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378256	766	rs12345352	Educational attainment	3e-33	LINC03142	35361970	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr12:66030789:A>C	chr12	66030789	66031555	766	rs11176010	Waist-hip ratio	4e-19	LINC02425	30595370	0.9989667	913.75	FOS	1.97125e-05	HIGH PRIORITY: Accessible + High Impact	2
chr4:88280621:G>C	chr4	88280621	88279855	766	rs7661312	Serum metabolite levels (CMS)	2e-17	PPM1K	31636271	0.9887488	1240.0	BATF	1.97143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:76184786:C>A	chr15	76184786	76184020	766	rs17456573	N-acetyl-2-aminooctanoate levels	5e-14	TMEM266	35347128	0.98438936	627.0	FOS	6.56918e-06	High Impact, Hard to Access	3
chr15:76184786:C>A	chr15	76184786	76184020	766	rs17456573	2-ketocaprylate levels	2e-13	TMEM266	35347128	0.98438936	627.0	FOS	6.56918e-06	High Impact, Hard to Access	3
chr4:88280621:G>C	chr4	88280621	88279855	766	rs7661312	Serum metabolite levels	4e-13	PPM1K	31636271	0.9887488	1240.0	BATF	1.97143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:76184786:C>A	chr15	76184786	76184020	766	rs17456573	2-aminooctanoate levels	6e-11	TMEM266	35347128	0.98438936	627.0	FOS	6.56918e-06	High Impact, Hard to Access	3
chr22:46049409:C>G	chr22	46049409	46048643	766	rs150318280	Concentration of apixaban (at 12h)	9e-09	MIRLET7BHG	36867504	0.8791271	433.5	ATF3	4.61145e-05	Accessible, Low Impact	3
chr12:93918348:G>T	chr12	93918348	93919115	767	rs7312795	Height (baseline)	4e-21	CRADD - RN7SKP263	40374629	0.9963395	1309.0	FOSL2	1.31465e-05	HIGH PRIORITY: Accessible + High Impact	3
chr22:43910461:T>A	chr22	43910461	43909694	767	rs149157446	Post bronchodilator FEV1/FVC ratio	3e-06	PNPLA5 - PNPLA3	26634245	0.99891955	6194.0	ATF2	6.57203e-06	High Impact, Hard to Access	3
chr1:219604005:G>T	chr1	219604005	219604773	768	rs11118358	Umbilical hernia	1e-09	LYPLAL1-AS1 - ZC3H11B	34382107	0.8072176	291.75	FOSL2	6.57212e-06	Low Priority	3
chr11:7422720:C>A	chr11	7422720	7421952	768	rs11601238	Adiposity (multivariate analysis)	1e-08	SYT9, SYT9-AS1	40796553	0.95023745	465.0	BATF	6.58423e-06	Low Priority	3
chr9:12413912:A>C	chr9	12413912	12414681	769	rs7864694	Body mass index	2e-08	RNU2-47P - LURAP1L-AS1	36581621	0.9992343	735.5	FOS	6.56651e-06	High Impact, Hard to Access	3
chr1:40693763:C>A	chr1	40693763	40694532	769	rs7519348	Airway obstruction (FEV1/FVC<70%) in never smokers	1e-06	NFYC	30845926	0.9772623	821.0	ATF3	0.000630401	HIGH PRIORITY: Accessible + High Impact	3
chr1:40693763:C>A	chr1	40693763	40694532	769	rs7519348	Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers	2e-06	NFYC	30845926	0.9772623	821.0	ATF3	0.000630401	HIGH PRIORITY: Accessible + High Impact	3
chr6:135348662:G>T	chr6	135348662	135347893	769	rs17064440	Peripheral arterial disease (traffic-related air pollution interaction)	6e-06	AHI1	27082954	0.97674394	720.0	JUND	6.57618e-06	High Impact, Hard to Access	3
chr10:50980819:C>A	chr10	50980819	50980049	770	rs10995225	Height	1.9999999999999998e-25	MIX23P2 - PRKG1	30595370	0.7883657	320.25	FOS	0.0	Low Priority	3
chr4:132983828:T>A	chr4	132983828	132984598	770	rs79630021	Gut microbial network clusters (BlueViolet (at 3 months) x Older Siblings interaction	2e-08	LINC01256 - PCDH10-DT	40187613	0.98786724	523.5	FOS	6.56892e-06	Accessible, Low Impact	2
chr4:132983828:T>A	chr4	132983828	132984598	770	rs79630021	Word spelling	8e-06	LINC01256 - PCDH10-DT	30741946	0.98786724	523.5	FOS	6.56892e-06	Accessible, Low Impact	2
chr15:43208009:C>G	chr15	43208009	43207238	771	rs45594632	Mean spheric corpuscular volume	8e-14	EPB42	32888494	0.86897224	688.0	MAFK	6.57039e-06	High Impact, Hard to Access	3
chr15:43208009:C>G	chr15	43208009	43207238	771	rs45594632	Mean sphered cell volume	3e-11	EPB42	34226706	0.86897224	688.0	MAFK	6.57039e-06	High Impact, Hard to Access	3
chr15:43208009:C>G	chr15	43208009	43207238	771	rs45594632	Reticulocyte count	3e-08	EPB42	34226706	0.86897224	688.0	MAFK	6.57039e-06	High Impact, Hard to Access	3
chr1:68175375:C>A	chr1	68175375	68174603	772	rs878548	Bone mineral density (spine)	5e-17	GNG12-AS1, WLS	34673960	0.9964227	1523.0	FOS	5.25783e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:90265400:T>A	chr11	90265400	90264628	772	rs10741329	Metabolic syndrome	4e-11	DISC1FP1	39349817	0.7385101	331.0	ATF3	1.31404e-05	Accessible, Low Impact	3
chr11:119989144:C>G	chr11	119989144	119989916	772	rs583606	Metabolic syndrome	4e-09	LINC02744	39349817	0.9113531	601.5	FOS	0.00315147	HIGH PRIORITY: Accessible + High Impact	2
chr11:90265400:T>A	chr11	90265400	90264628	772	rs10741329	Body mass index	2e-08	DISC1FP1	31669095	0.7385101	331.0	ATF3	1.31404e-05	Accessible, Low Impact	3
chr17:17641168:G>T	chr17	17641168	17641940	772	rs4925057	Monounsaturated fatty acid levels	2e-08	PEMT - SMCR2	40545721	0.8791271	587.0	ATF3	6.5851e-06	High Impact, Hard to Access	3
chr6:30120601:A>C	chr6	30120601	30119828	773	rs115254023	High light scatter reticulocyte count	8.000000000000001e-29	TRIM31-AS1 - TRIM40	32888494	0.99968857	3390.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr3:178503682:C>A	chr3	178503682	178502909	773	rs187722945	Cutaneous lupus erythematosus (PheCode 695.41)	1e-12	KCNMB2	39024449	0.95041513	449.0	JUNB	6.70367e-06	Accessible, Low Impact	3
chr11:15980978:C>G	chr11	15980978	15981751	773	rs4237711	Height	1e-11	SOX6	36224396	0.97968936	533.0	JUND	1.3151e-05	Accessible, Low Impact	3
chr11:126134953:C>G	chr11	126134953	126134180	773	rs7930128	Height	3e-10	NAP1L1P1 - RPUSD4	36224396	0.99658346	657.0	FOS	1.31581e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:120367664:C>A	chr12	120367664	120366891	773	rs61945847	Hip circumference adjusted for BMI	2e-08	MSI1	34021172	0.99751866	1334.0	FOS	6.57912e-06	High Impact, Hard to Access	3
chr6:169049918:C>A	chr6	169049918	169049144	774	rs12207730	Seropositivity for euarchontoglires peptide (agilent_7767)	1e-08	SMOC2 - LINC01615	37164013	0.9584504	360.0	FOSL1	6.95565e-06	Accessible, Low Impact	3
chr2:72125670:C>G	chr2	72125670	72126444	774	rs2041666	Sib-shared facial trait 545; Facial segment 21; 3D morphology of the nose sides	3e-08	RPS20P10 - CYP26B1	33983923	0.9868027	1030.0	ATF2	0.00093922	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81307679	775	rs7166271	Blood protein levels	6.999999999999999e-83	IL16	30072576	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:105108328:C>A	chr9	105108328	105107553	775	rs4743805	Behavioral disturbance or psychiatric symptoms in prion disease	6e-06	RN7SKP191 - SLC44A1	25897833	0.8741373	398.5	ATF3	0.0	Low Priority	3
chr2:33227185:C>A	chr2	33227185	33227961	776	rs11693247	Waist circumference adjusted for body mass index	6e-12	LTBP1	31669095	0.92024124	570.5	ATF2	6.5884e-06	High Impact, Hard to Access	3
chr4:19392738:G>T	chr4	19392738	19393514	776	rs968264	Alzheimers disease polygenic risk score (upper quantile vs lower quantile)	2e-08	LINC02438	35589863	0.9602251	533.5	JUN	6.58207e-06	Low Priority	3
chr11:113027735:C>A	chr11	113027735	113028514	779	rs142861910	Smoking initiation	9.999999999999999e-55	NCAM1	36477530	0.97621405	822.0	MAFK	3.28554e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:113027735:C>A	chr11	113027735	113028514	779	rs781914294	Brussel sprout liking	2e-09	NCAM1	35585065	0.97621405	822.0	MAFK	3.28554e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:101650995:G>C	chr9	101650995	101651774	779	rs10760799	Body mass index	9e-08	GRIN3A	30595370	0.9896673	449.0	FOS	0.00751083	Accessible, Low Impact	3
chr8:131486482:C>A	chr8	131486482	131485703	779	rs12114496	Clostridium difficile infection in multiple myeloma	3e-06	SNORA72 - EFR3A	29594489	0.9882237	1117.0	ATF2	6.57921e-06	High Impact, Hard to Access	3
chr3:3980535:C>A	chr3	3980535	3981315	780	rs60385470	Neurofilament light chain levels	3e-07	SUMF1	39251807	0.98167825	435.0	FOS	1.32584e-05	Accessible, Low Impact	3
chr1:173038025:G>T	chr1	173038025	173037245	780	rs541022691	Height	1e-06	AIMP1P2 - TNFSF18	28552196	0.9645371	503.5	ATF2	1.31731e-05	Accessible, Low Impact	3
chr1:158613839:G>C	chr1	158613839	158614620	781	rs72698798	red cell diameter width (RDW, minimum, inv-norm transformed)	1e-16	SPTA1	39024449	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158614620	781	rs72698798	red cell diameter width (RDW, mean, inv-norm transformed)	4e-13	SPTA1	39024449	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:74819819:C>A	chr13	74819819	74819038	781	rs1074634	Vaginal microbiome MetaCyc pathway (PWY-7187|pyrimidine deoxyribonucleotides de novo biosynthesis II)	4e-06	LINC00347 - RIOK3P1	34282934	0.97534883	436.0	FOS	6.57618e-06	Low Priority	3
chr13:95265027:C>A	chr13	95265027	95265809	782	rs870004	N-acetylcarnosine levels	1e-43	ABCC4	35050183	0.9872979	610.5	BATF	3.94856e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:131462890:G>T	chr7	131462890	131462108	782	rs1648441	Red blood cell count	2e-11	MKLN1	40436827	0.9887488	634.0	JUND	6.57177e-06	High Impact, Hard to Access	3
chr9:8357322:C>G	chr9	8357322	8356540	782	rs7022162	Heel bone mineral density	4e-09	PTPRD	30598549	0.94468737	491.0	JUND	0.00323733	Accessible, Low Impact	3
chr2:124683854:C>A	chr2	124683854	124684636	782	rs17011865	Post bronchodilator FEV1/FVC ratio	2e-06	CNTNAP5	26634245	0.9928779	1324.5	MAFK	2.62978e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:12835144:A>C	chr8	12835144	12834362	782	rs17120471	IgG glycosylation	6e-06	LINC00681 - TRMT9B	23382691	0.92356306	476.0	JUNB	1.31396e-05	Accessible, Low Impact	3
chr12:105865755:G>C	chr12	105865755	105864971	784	rs7963923	Height	9e-18	CASC18 - ST13P3	36224396	0.97174054	455.5	JUND	5.92706e-05	Accessible, Low Impact	3
chr7:50665937:G>C	chr7	50665937	50666721	784	rs17449280	Eosinophil count	9e-15	GRB10	32888494	0.9992518	1299.0	FOS	0.000118182	HIGH PRIORITY: Accessible + High Impact	3
chr21:39950100:C>A	chr21	39950100	39950885	785	rs2837314	Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0) levels in elite athletes	9e-06	PCP4 - DSCAM	31882771	0.8552694	462.0	MAFK	6.57315e-06	Low Priority	3
chr17:74696575:C>A	chr17	74696575	74695789	786	rs2034310	CD300E/CD300LF protein level ratio	0.0	CD300LF, RAB37	38412862	0.9978883	638.0	FOSL1	1.97078e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:74696575:C>A	chr17	74696575	74695789	786	rs2034310	Lymphocyte count	4e-09	CD300LF, RAB37	27863252	0.9978883	638.0	FOSL1	1.97078e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:56900995:G>C	chr17	56900995	56900209	786	rs139560285	Type 2 diabetes in cholesterol intake above Dietary Reference Intake	4e-08	TRIM25	40400704	0.93488073	598.0	FOS	3.28235e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:25572255:T>A	chr7	25572255	25573041	786	rs975369	Preeclampsia	8e-06	LINC03007	23551011	0.94931644	452.5	JUND	6.56452e-06	Low Priority	3
chr6:2913924:G>T	chr6	2913924	2914711	787	rs199890456	ghrelin levels in overweight individuals	9e-12	SERPINB9 - SERPINB6	34620218	0.9659551	1134.0	JUN	6.56573e-06	High Impact, Hard to Access	3
chr6:2913924:G>T	chr6	2913924	2914711	787	rs199890456	Adipsin levels in overweight individuals	4e-09	SERPINB9 - SERPINB6	34620218	0.9659551	1134.0	JUN	6.56573e-06	High Impact, Hard to Access	3
chr6:2913924:G>T	chr6	2913924	2914711	787	rs199890456	Adipsin levels	3e-08	SERPINB9 - SERPINB6	34620218	0.9659551	1134.0	JUN	6.56573e-06	High Impact, Hard to Access	3
chr6:2913924:G>T	chr6	2913924	2914711	787	rs199890456	Adipsin levels in type 2 diabetes	5e-08	SERPINB9 - SERPINB6	34620218	0.9659551	1134.0	JUN	6.56573e-06	High Impact, Hard to Access	3
chr5:81824832:C>G	chr5	81824832	81824044	788	rs114926827	Arm fat ratio or breast cancer (pleiotropy)	2e-09	SSBP2 - SEM1P1	40874817	0.9939092	1346.0	JUND	6.60432e-06	High Impact, Hard to Access	3
chr6:149891655:G>T	chr6	149891655	149890867	788	rs9383583	Autism spectrum disorder	2e-07	RAET1E-AS1, RAET1E	35215271	0.9417692	448.5	JUND	6.57229e-06	Low Priority	3
chr3:187880928:T>A	chr3	187880928	187880139	789	rs149049329	Type 2 diabetes	2e-06	BCL6-AS1 - LINC01991	25760438	0.99254405	1204.0	FOSL1	6.57229e-06	HIGH PRIORITY: Accessible + High Impact	2
chr20:25507531:C>G	chr20	25507531	25506741	790	rs6115200	Height	9e-09	NINL	36224396	0.9644045	1012.0	JUN	6.56401e-06	HIGH PRIORITY: Accessible + High Impact	2
chr9:126697989:C>G	chr9	126697989	126697199	790	rs10987414	Brain shape (segment 133)	1e-08	LMX1B	33821002	0.9584504	534.0	ATF3	0.00719146	Accessible, Low Impact	3
chr4:27443565:C>A	chr4	27443565	27444355	790	rs28681428	Baseline memory in normal cognition	4e-07	LINC02261 - IGBP1P5	37984853	0.8791271	404.5	FOS	1.31539e-05	Accessible, Low Impact	3
chr4:27443565:C>A	chr4	27443565	27444355	790	rs28681428	Baseline memory in normal cognition x sex interaction	7e-07	LINC02261 - IGBP1P5	37984853	0.8791271	404.5	FOS	1.31539e-05	Accessible, Low Impact	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Mean spheric corpuscular volume	4e-59	SPTA1	32888494	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Lymphocyte count (UKB data field 30120)	2.9999999999999998e-40	SPTA1	39789286	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:15997927:A>C	chr19	15997927	15997136	791	rs182155403	PGLYRP2 protein levels	9.999999999999999e-26	CYP4F9P	39789286	0.99947065	1115.0	FOS	6.57168e-06	High Impact, Hard to Access	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Lymphocyte percentage (UKB data field 30180)	1e-19	SPTA1	39789286	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Lymphocyte percentage of white cells	3e-18	SPTA1	32888494	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Neutrophil percentage of white cells	3e-17	SPTA1	32888494	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Lymphocyte count	9e-16	SPTA1	27863252	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:72661005:C>A	chr4	72661005	72661796	791	rs9995997	Height	3e-11	ADAMTS3 - HNRNPA1P67	31562340	0.97621405	433.0	JUND	2.62978e-05	Accessible, Low Impact	3
chr1:158613839:G>C	chr1	158613839	158613048	791	rs2157691	Glycated haemoglobin HbA1c levels adjusted for BMI	1e-09	SPTA1	34951656	0.98575574	725.0	FOSL1	1.31536e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:64659709:C>A	chr15	64659709	64660500	791	rs76064345	Neuroticism	3e-07	ZNF609	29255261	0.9983231	1420.0	JUNB	6.57454e-06	High Impact, Hard to Access	3
chr19:14154374:C>G	chr19	14154374	14153583	791	rs34163270	Cerebrospinal fluid progranulin levels	5e-06	ADGRL1, ADGRL1-AS1	33087363	0.961097	935.0	JUND	6.57004e-06	High Impact, Hard to Access	3
chr9:3832777:T>A	chr9	3832777	3833570	793	rs62521410	Prostate-associated microseminoprotein levels	5e-25	GLIS3	34648354	0.9545879	491.5	JUND	6.57039e-06	Low Priority	3
chr19:45359127:C>A	chr19	45359127	45358334	793	rs3916847	Apolipoprotein B levels	4e-14	ERCC2	33462484	0.9695515	685.0	JUNB	6.58432e-06	High Impact, Hard to Access	3
chr9:136521181:C>A	chr9	136521181	136520387	794	rs3124607	Height	1.0000000000000001e-24	NOTCH1	36224396	0.9850881	843.0	BATF	6.57246e-06	High Impact, Hard to Access	3
chr2:36964670:T>A	chr2	36964670	36965464	794	rs3770772	Platelet count (UKB data field 30080)	1e-14	STRN	39789286	0.973383	722.0	JUNB	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr2:36964670:T>A	chr2	36964670	36965464	794	rs3770772	Educational attainment	5e-10	STRN	35361970	0.973383	722.0	JUNB	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr15:77508109:C>A	chr15	77508109	77507315	794	rs4886869	Body mass index	9e-10	HMG20A - LINGO1	36581621	0.99376744	2454.0	FOS	6.56556e-06	High Impact, Hard to Access	3
chr1:60065102:C>A	chr1	60065102	60064308	794	rs11578492	Migraine	6e-09	C1orf87	35115687	0.9575012	377.15625	FOS	0.0	Low Priority	3
chr15:77508109:C>A	chr15	77508109	77507315	794	rs4886869	Hemoglobin A1c levels	1e-08	HMG20A - LINGO1	29403010	0.99376744	2454.0	FOS	6.56556e-06	High Impact, Hard to Access	3
chr15:77508109:C>A	chr15	77508109	77507315	794	rs4886869	Hand grip strength	3e-08	HMG20A - LINGO1	29691431	0.99376744	2454.0	FOS	6.56556e-06	High Impact, Hard to Access	3
chr15:77508109:C>A	chr15	77508109	77507315	794	rs4886869	Adiposity (multivariate analysis)	4e-08	HMG20A - LINGO1	40796553	0.99376744	2454.0	FOS	6.56556e-06	High Impact, Hard to Access	3
chr7:100965110:G>T	chr7	100965110	100965904	794	rs80040741	Non-small cell lung cancer	9e-08	MUC3A	37689528	0.9921947	1451.0	MAFK	0.0	High Impact, Hard to Access	3
chr3:101704819:C>A	chr3	101704819	101705614	795	rs11919389	SARS-CoV-2 infection	3e-15	RPL24 - PDCL3P4	34237774	0.9923346	731.5	FOS	2.62722e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:130779272:A>C	chr9	130779272	130780067	795	rs34224906	Macrophage colony stimulating factor levels	6e-06	ABL1	27989323	0.9994059	1113.0	JUND	2.63279e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:113032961:G>C	chr11	113032961	113033757	796	rs7127528	Smoking initiation	3e-179	NCAM1	36477530	0.961097	567.0	FOSL1	6.5697e-06	Low Priority	3
chrX:145036529:C>G	chrX	145036529	145035733	796	rs5920419	Neuroticism	4e-06	HNRNPCP10 - RN7SKP189	30842574	0.94588065	431.0	FOS	8.99815e-06	Accessible, Low Impact	3
chr14:63697510:C>G	chr14	63697510	63698308	798	rs3742622	Dihexosylceramide (d16:1/16:0) levels	3e-29	SGPP1	35668104	0.972161	497.0	JUND	3.28735e-05	Accessible, Low Impact	3
chr14:63697510:C>G	chr14	63697510	63698308	798	rs3742622	Monohexosylceramide (d16:1/22:0) levels	3e-12	SGPP1	35668104	0.972161	497.0	JUND	3.28735e-05	Accessible, Low Impact	3
chr14:63697510:C>G	chr14	63697510	63698308	798	rs3742622	Sphingomyelin(32:1)_[M+H]1+ levels	5e-12	SGPP1	34503513	0.972161	497.0	JUND	3.28735e-05	Accessible, Low Impact	3
chr6:78716672:C>A	chr6	78716672	78715874	798	rs10455352	Multi-trait sex score	9e-09	MEI4 - IRAK1BP1	37277458	0.9185313	401.5	JUNB	0.208484	Accessible, Low Impact	3
chr1:12555617:C>G	chr1	12555617	12554818	799	rs3924048	Optic cup area	1e-10	LINC02766 - DHRS3	25631615	0.96744037	804.0	FOS	6.57022e-06	HIGH PRIORITY: Accessible + High Impact	2
chr14:51957989:C>A	chr14	51957989	51958788	799	rs17124780	Triglyceride levels	6e-08	GNG2	31170924	0.9960782	1333.0	JUN	6.57333e-06	High Impact, Hard to Access	3
chr12:132215840:C>A	chr12	132215840	132216639	799	rs11247009	Body mass index	3e-06	GALNT9	25673413	0.90755373	682.0	BATF2	6.57817e-06	High Impact, Hard to Access	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Educational attainment	4.0000000000000004e-72	LINC03142	35361970	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr20:50138880:C>A	chr20	50138880	50139680	800	rs74172983	Monocyte percentage (UKB data field 30190)	1.0000000000000001e-29	PEDS1-UBE2V1, PEDS1	39789286	0.9971508	2876.0	FOSL2	6.5653e-06	High Impact, Hard to Access	3
chr20:50138880:C>A	chr20	50138880	50139680	800	rs74172983	Monocyte count (UKB data field 30130)	4e-20	PEDS1-UBE2V1, PEDS1	39789286	0.9971508	2876.0	FOSL2	6.5653e-06	High Impact, Hard to Access	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Attention deficit hyperactivity disorder or autism spectrum disorder or intelligence (pleiotropy)	6e-18	LINC03142	35764056	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr20:50138880:C>A	chr20	50138880	50139680	800	rs558811955	Granulocyte percentage of myeloid white cells	3e-16	PEDS1-UBE2V1, PEDS1	27863252	0.9971508	2876.0	FOSL2	6.5653e-06	High Impact, Hard to Access	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Intelligence	6e-16	LINC03142	29942086	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr3:49348784:G>C	chr3	49348784	49347984	800	rs13086611	BMI (standard GWA)	1e-14	USP4 - GPX1	37106081	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr3:49348784:G>C	chr3	49348784	49347984	800	rs13086611	Educational attainment	2e-14	USP4 - GPX1	27046643	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Household income (MTAG)	7e-14	LINC03142	31844048	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Intelligence (MTAG)	1e-13	LINC03142	29326435	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)	3e-12	LINC03142	33349686	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr3:49348784:G>C	chr3	49348784	49347984	800	rs13086611	Common executive function	1e-11	USP4 - GPX1	36150907	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis)	2e-11	LINC03142	33349686	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis)	3e-11	LINC03142	33349686	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr1:88996065:C>G	chr1	88996065	88995265	800	rs7525985	Height (baseline)	4e-11	RBMXL1 - GBP3	40374629	0.9342127	489.5	ATF3	2.62954e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)	4e-11	LINC03142	33349686	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	General cognitive ability	6e-09	LINC03142	29844566	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Household income	2e-08	LINC03142	31844048	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr9:4975241:C>A	chr9	4975241	4974441	800	rs1327495	Gestational thrombocytopenia	7e-08	HNRNPA1P41 - JAK2	38064665	0.9008302	569.0	BATF	6.57583e-06	High Impact, Hard to Access	3
chr9:23379022:C>A	chr9	23379022	23378222	800	rs10733389	Neuroticism	8e-08	LINC03142	27089181	0.98327994	540.0	FOS	1.31501e-05	Accessible, Low Impact	3
chr19:45206397:C>A	chr19	45206397	45207198	801	rs111435864	C-reactive protein levels	2e-14	BLOC1S3, MARK4	31900758	0.90755373	530.5	FOSL1	0.0	Low Priority	3
chr4:117451479:G>C	chr4	117451479	117452280	801	rs11932518	Delta-5 desaturase activity response to n3-polyunsaturated fat supplement	1e-09	LINC01378	29246731	0.93772584	436.0	FOSL2	0.000434502	Accessible, Low Impact	3
chr11:77965172:C>A	chr11	77965172	77965973	801	rs6592753	Mean reticulocyte volume	2e-09	INTS4	32888494	0.99035496	501.25	BATF	1.97228e-05	Accessible, Low Impact	3
chr2:69440054:C>A	chr2	69440054	69440855	801	rs6758228	White blood cell count	2e-07	NFU1 - AAK1	30595370	0.95357716	588.5	MAFK	6.56745e-06	High Impact, Hard to Access	3
chr11:119261026:C>G	chr11	119261026	119260224	802	rs68034047	Reticulocyte count	2.0000000000000002e-24	CBL	32888494	0.993008	1034.0	MAFK	6.92367e-06	HIGH PRIORITY: Accessible + High Impact	3
chr11:119261026:C>G	chr11	119261026	119260224	802	rs68034047	Reticulocyte fraction of red cells	4e-22	CBL	32888494	0.993008	1034.0	MAFK	6.92367e-06	HIGH PRIORITY: Accessible + High Impact	3
chr2:60749358:G>C	chr2	60749358	60750160	802	rs113746525	Educational attainment	6e-18	ATP1B3P1 - PAPOLG	35361970	0.9907879	560.0	FOS	6.57263e-06	Low Priority	3
chr11:119261026:C>G	chr11	119261026	119260224	802	rs68034047	Mean spheric corpuscular volume	1e-17	CBL	32888494	0.993008	1034.0	MAFK	6.92367e-06	HIGH PRIORITY: Accessible + High Impact	3
chr11:119261026:C>G	chr11	119261026	119260224	802	rs68034047	High light scatter reticulocyte count	2e-11	CBL	27863252	0.993008	1034.0	MAFK	6.92367e-06	HIGH PRIORITY: Accessible + High Impact	3
chr11:119261026:C>G	chr11	119261026	119260224	802	rs68034047	High light scatter reticulocyte percentage of red cells	4e-10	CBL	27863252	0.993008	1034.0	MAFK	6.92367e-06	HIGH PRIORITY: Accessible + High Impact	3
chr19:38768139:G>C	chr19	38768139	38767337	802	rs7248248	Estimated glomerular filtration rate (creatinine)	4e-09	CAPN12	34272381	0.97360545	681.0	FOS	6.57324e-06	High Impact, Hard to Access	3
chr8:101835776:C>A	chr8	101835776	101834974	802	rs2155939	Coronary artery disease (MTAG)	1e-08	NCALD	41022758	0.9644045	541.0	JUNB	6.5838e-06	Low Priority	3
chr2:60749358:G>C	chr2	60749358	60750160	802	rs113746525	Smoking initiation (MTAG)	3e-08	ATP1B3P1 - PAPOLG	37156939	0.9907879	560.0	FOS	6.57263e-06	Low Priority	3
chr7:115486790:C>A	chr7	115486790	115487593	803	rs76346899	Insomnia	3e-11	LINC01392 - POLR2DP2	35835914	0.9777694	554.0	JUND	8.55736e-05	Accessible, Low Impact	3
chr13:24931326:C>G	chr13	24931326	24932131	805	rs190474871	C1QTNF9 protein levels	5e-21	CPAP - SLC25A15P3	39789286	0.95254505	528.0	ATF2	5.84659e-05	Accessible, Low Impact	3
chr16:69891735:C>A	chr16	69891735	69890930	805	rs7184995	Blood urea nitrogen levels	7e-13	WWP2	38116116	0.9627861	667.0	FOS	0.00101765	HIGH PRIORITY: Accessible + High Impact	3
chr7:158818761:C>A	chr7	158818761	158817956	805	rs35513757	Mild influenza (H1N1) infection	2e-08	ESYT2	26379185	0.9999041	15280.0	FOSL2	0.000551319	HIGH PRIORITY: Accessible + High Impact	3
chr11:49552393:G>T	chr11	49552393	49551587	806	rs11040423	Monounsaturated fatty acid levels	3e-08	TYRL - GRM5P1	40545721	0.84346706	358.5	FOS	6.5786e-06	Low Priority	3
chr5:125318062:C>G	chr5	125318062	125318869	807	rs62374660	Gut microbiome abundance (class Clostridium sensu stricto sp. 17 (at 1 year) x Exclusive Breastfeeding (6 Months) interaction	5e-09	LINC02240	40187613	0.99919933	5914.5	ATF2	0.190768	HIGH PRIORITY: Accessible + High Impact	3
chr19:38234799:G>C	chr19	38234799	38233990	809	rs8100697	Kunitz-type protease inhibitor 2 levels	1e-18	DPF1 - SPINT2	36168886	0.998203	775.0	FOS	1.31522e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:193863992:T>A	chr1	193863992	193864801	809	rs72734655	Tuberculosis	8e-07	RPL23AP22 - EEF1A1P14	28928442	0.95357716	431.0	JUND	1.31472e-05	Accessible, Low Impact	3
chr7:4458507:C>A	chr7	4458507	4459316	809	rs55869773	Disease progression in age-related macular degeneration	4e-06	SDK1 - CYP3A54P	29346644	0.9383409	566.0	JUND	6.58198e-05	Accessible, Low Impact	3
chr7:28354594:C>A	chr7	28354594	28353784	810	rs7805378	Vertical cup-disc ratio	1e-11	CREB5	34077760	0.99919933	2567.5	FOSL2	6.57471e-06	High Impact, Hard to Access	3
chr7:28354594:C>A	chr7	28354594	28353784	810	rs7805378	Vertical cup-disc ratio (multi-trait analysis)	2e-11	CREB5	31959993	0.99919933	2567.5	FOSL2	6.57471e-06	High Impact, Hard to Access	3
chr7:28354594:C>A	chr7	28354594	28353784	810	rs7805378	Vertical cup-disc ratio (adjusted for vertical disc diameter)	3e-09	CREB5	31959993	0.99919933	2567.5	FOSL2	6.57471e-06	High Impact, Hard to Access	3
chr12:22293566:C>A	chr12	22293566	22292756	810	rs2541303	Weight	7e-09	ST8SIA1	40436827	0.9814467	576.0	JUND	6.57289e-06	High Impact, Hard to Access	3
chr12:22293566:C>A	chr12	22293566	22292756	810	rs2541303	Height	1e-08	ST8SIA1	35653334	0.9814467	576.0	JUND	6.57289e-06	High Impact, Hard to Access	3
chr12:123224048:C>G	chr12	123224048	123224859	811	rs56104963	Forced expiratory volume (baseline)	2e-09	MPHOSPH9	40374629	0.9785014	388.5	FOSL1	6.62901e-06	Low Priority	3
chr13:97922778:C>G	chr13	97922778	97923589	811	rs9517132	Sleep duration	3e-06	RPL7AP61 - IPO5	25469926	0.8869387	536.0	MAFF	6.5825e-06	Low Priority	3
chr13:97922778:C>G	chr13	97922778	97923589	811	rs9517132	Colorectal cancer x tea intake interaction	5e-06	RPL7AP61 - IPO5	38411962	0.8869387	536.0	MAFF	6.5825e-06	Low Priority	3
chr12:130998623:C>A	chr12	130998623	130999435	812	rs12823753	Adhesion G-protein coupled receptor D1 levels	6e-294	ADGRD1	39528825	0.94555736	611.0	ATF3	1.31465e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:55783160:G>T	chr2	55783160	55783972	812	rs7574127	Inguinal hernia	1.9999999999999998e-30	PNPT1 - EFEMP1	34382107	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55783972	812	rs7574127	Multi-trait sex score	8e-17	PNPT1 - EFEMP1	37277458	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr15:63004708:G>C	chr15	63004708	63005520	812	rs28514429	Cortical surface area	2e-07	TPM1-AS	32193296	0.91499144	465.0	FOSL2	6.56892e-06	Low Priority	3
chr6:160926824:C>A	chr6	160926824	160927637	813	rs79135559	Lipoprotein (a) levels	6e-195	PLG - MAP3K4-AS1	33462484	0.993351	1727.0	ATF3	1.97327e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:151617233:G>T	chr6	151617233	151618046	813	rs3734804	Bone mineral density mean	2e-18	CCDC170	37500982	0.9814467	564.5	ATF3	6.57505e-06	Low Priority	3
chr3:3224653:C>A	chr3	3224653	3225466	813	rs559221773	IL5RA protein levels	9e-12	CRBN - SUMF1	39789286	0.8917613	313.75	BATF	7.39382e-06	Accessible, Low Impact	3
chr5:78771621:C>A	chr5	78771621	78770808	813	rs4704521	Upper eyelid sagging severity	3e-06	LHFPL2 - ARSB	24869959	0.9997094	2812.0	JUNB	6.5678e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:37851822:C>G	chr1	37851822	37852636	814	rs35724646	Total bilirubin levels	3e-09	MTF1	34594039	0.99560076	1749.0	MAFK	6.59005e-06	High Impact, Hard to Access	3
chr3:136865116:C>A	chr3	136865116	136865930	814	rs6797509	Pain intensity (NRS pain scale 0-11)	4e-08	NCK1	38429522	0.98942745	750.0	JUND	6.57099e-06	High Impact, Hard to Access	3
chr13:74819819:C>A	chr13	74819819	74819005	814	rs1074633	Vaginal microbiome MetaCyc pathway (PWY-7187|pyrimidine deoxyribonucleotides de novo biosynthesis II)	6e-06	LINC00347 - RIOK3P1	34282934	0.97534883	436.0	FOS	6.57618e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55782345	815	rs62167689	Inguinal hernia	5e-33	PNPT1 - EFEMP1	34382107	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr7:93044656:A>C	chr7	93044656	93043840	816	rs6960056	Educational attainment	4.0000000000000006e-34	RN7SL7P - SAMD9	35361970	0.9999352	5056.0	JUND	6.57549e-06	High Impact, Hard to Access	3
chr8:70250698:A>C	chr8	70250698	70249882	816	rs2977976	Serum alkaline phosphatase levels	5e-18	NCOA2	33547301	0.93131924	477.5	FOS	6.59692e-06	Low Priority	3
chr16:19907808:G>T	chr16	19907808	19908624	816	rs11640942	Body mass index z-score	7e-15	GPRC5B - GPR139	39885687	0.9972855	2187.0	ATF2	6.57125e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31394564	816	rs3094588	Hunner-type interstitial cystitis or rheumatoid arthritis (MTAG)	1e-10	MICA-AS1	39620209	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr2:12969712:C>A	chr2	12969712	12968896	816	rs779348	Hip index	3e-09	TRIB2 - LINC00276	34021172	0.93772584	475.5	MAFK	6.57099e-06	Low Priority	3
chr16:19907808:G>T	chr16	19907808	19908624	816	rs11640942	Total cholesterol levels	5e-09	GPRC5B - GPR139	34887591	0.9972855	2187.0	ATF2	6.57125e-06	High Impact, Hard to Access	3
chr7:93044656:A>C	chr7	93044656	93043840	816	rs6960056	Dorsomedial frontal area	1e-08	RN7SL7P - SAMD9	35113692	0.9999352	5056.0	JUND	6.57549e-06	High Impact, Hard to Access	3
chr21:42082050:G>C	chr21	42082050	42081234	816	rs75957543	Male infertility	3e-08	UMODL1	40229599	0.9991982	1428.0	FOSL2	0.000164107	HIGH PRIORITY: Accessible + High Impact	3
chr7:93044656:A>C	chr7	93044656	93043840	816	rs6960056	Self-reported math ability	4e-08	RN7SL7P - SAMD9	30038396	0.9999352	5056.0	JUND	6.57549e-06	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902474	817	rs3815045	Lysophosphatidylethanolamine_22:4_[M-H]1- levels	2e-12	RAB3IL1	34503513	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902474	817	rs3815045	Polyunsaturated fatty acids to total fatty acids percentage	5e-10	RAB3IL1	40545721	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr9:11446415:G>C	chr9	11446415	11445598	817	rs10959813	Experiencing mood swings	2e-09	LINC03131 - JKAMPP1	29500382	0.9992518	669.0	FOS	3.95726e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:61903291:C>G	chr11	61903291	61902474	817	rs3815045	Height	4e-08	RAB3IL1	40436827	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:61903291:C>G	chr11	61903291	61902474	817	rs3815045	Dehydrocholesteryl ester (20:4) levels	9e-07	RAB3IL1	35668104	0.9818622	820.0	ATF2	0.0	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806790	818	rs11039405	Body mass index (BMI, minimum, inv-normal transformed)	5.9999999999999996e-55	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806790	818	rs11039405	Body mass index (BMI, mean, inv-normal transformed)	3e-27	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806790	818	rs11039405	Body mass index (BMI, maximum, inv-normal transformed)	4e-27	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806790	818	rs11039405	Obesity (PheCode 278.1)	6e-24	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806790	818	rs11039405	Overweight, obesity and other hyperalimentation (PheCode 278)	1e-20	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806790	818	rs11039405	total cholesterol (minimum, inv-norm transformed)	3e-14	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr13:44132950:C>A	chr13	44132950	44132132	818	rs9595066	Schizophrenia	4e-06	SMIM2-AS1, LINC00390	26198764	0.9997097	4186.0	FOS	3.28498e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:10277845:C>A	chr16	10277845	10278663	818	rs147774538	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	4e-06	RN7SL493P - ATF7IP2	26053186	0.9999395	14906.0	MAFK	0.100125	HIGH PRIORITY: Accessible + High Impact	3
chr5:43336287:C>A	chr5	43336287	43335468	819	rs56206275	Self-reported math ability (MTAG)	1e-12	HMGCS1 - CCL28	30038396	0.99999	8045.0	FOSL1	1.97182e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:43336287:C>A	chr5	43336287	43335468	819	rs56206275	Self-reported math ability	9e-11	HMGCS1 - CCL28	30038396	0.99999	8045.0	FOSL1	1.97182e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:62133669:G>C	chr12	62133669	62134488	819	rs1245441	interferon-related traits	2e-06	TAFA2	33104735	0.9996424	1530.0	FOSL2	6.57808e-06	High Impact, Hard to Access	3
chr11:47805972:C>A	chr11	47805972	47806792	820	rs11039406	Weight (minimum, inv-normal transformed)	2e-15	NUP160	39024449	0.97360545	659.0	BATF	6.58458e-06	High Impact, Hard to Access	3
chr3:187739936:A>C	chr3	187739936	187739116	820	rs3821817	Pulse pressure	5e-09	BCL6	38689001	0.99971604	6552.0	FOSL2	1.31406e-05	HIGH PRIORITY: Accessible + High Impact	2
chr16:20683566:C>G	chr16	20683566	20682745	821	rs7498905	Standing height (UKB data field 50)	3e-13	ACSM1, ACSM3	39789286	0.9627861	572.0	JUNB	4.60848e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:34616812:G>T	chr1	34616812	34617633	821	rs11589940	Nausea incidence in varenicline-treated smokers	4e-06	C1orf94 - MIR552	33713409	0.9644045	587.0	ATF2	6.57013e-06	High Impact, Hard to Access	3
chr2:199434797:C>A	chr2	199434797	199435619	822	rs137887406	Bioavailable testosterone levels	3e-17	SATB2	34321204	0.9801434	615.0	FOSL1	5.91778e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:199434797:C>A	chr2	199434797	199435619	822	rs137887406	Total testosterone levels	8e-14	SATB2	34321204	0.9801434	615.0	FOSL1	5.91778e-05	HIGH PRIORITY: Accessible + High Impact	3
chr12:130998623:C>A	chr12	130998623	130999445	822	rs7135850	Height	2e-10	ADGRD1	36224396	0.94555736	611.0	ATF3	1.31465e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:127060091:C>A	chr6	127060091	127060915	824	rs2875971	Bone mineral density mean	1e-11	RPS4XP9 - RSPO3	37500982	0.86897224	323.75	FOS	0.0	Low Priority	3
chr1:155959658:C>G	chr1	155959658	155960483	825	rs200915920	Body fat percentage (adjusted for testosterone and SHBG)	3e-08	ARHGEF2	37867527	0.9708846	747.0	FOSL1	1.31444e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:49523670:G>C	chr18	49523670	49522844	826	rs11873669	Polyunsaturated fatty acid levels	8e-10	LINC02837	40545721	0.9875858	496.0	JUN	6.58215e-06	Low Priority	3
chr18:49523670:G>C	chr18	49523670	49522844	826	rs11873669	Omega-6 fatty acid levels	4e-09	LINC02837	40545721	0.9875858	496.0	JUN	6.58215e-06	Low Priority	3
chr18:49523670:G>C	chr18	49523670	49522844	826	rs11873669	Total fatty acid levels	3e-08	LINC02837	40545721	0.9875858	496.0	JUN	6.58215e-06	Low Priority	3
chr6:151588114:G>C	chr6	151588114	151587288	826	rs79797664	Go reaction time variability	8e-07	CCDC170	37500827	0.9981182	656.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr17:55383730:G>C	chr17	55383730	55384556	826	rs190581871	Phosphoethanolamine levels	4e-06	HLF - MMD	36357675	0.9967285	785.0	FOSL2	1.31489e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:36002761:G>C	chr17	36002761	36001934	827	rs184763496	C-C motif chemokine 14 levels	1e-11	CCL15-CCL14 - CCL23	36168886	0.99843514	3424.5	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr8:10086241:G>T	chr8	10086241	10085414	827	rs814424	Bipolar disorder or inflammatory bowel disease (MTAG)	2e-10	MSRA	38154582	0.9545879	446.0	JUN	3.94166e-05	Accessible, Low Impact	2
chr4:7435002:C>A	chr4	7435002	7434174	828	rs56269914	PSAPL1 protein levels	3e-303	PSAPL1, SORCS2	39789286	0.99560076	2678.0	FOSL2	6.57022e-06	High Impact, Hard to Access	3
chr8:27950649:C>G	chr8	27950649	27951477	828	rs10866867	Scavenger receptor class A member 5 levels (SCARA5.10419.1.3)	8e-21	SCARA5	29875488	0.8815574	666.5	FOS	6.57022e-06	High Impact, Hard to Access	3
chr17:10284148:C>A	chr17	10284148	10284976	828	rs4791972	Height	2e-09	RPS27AP1 - MYHAS	36224396	0.9267576	424.0	JUND	6.57687e-06	Low Priority	3
chr10:52652420:G>C	chr10	52652420	52651592	828	rs201760907	Bone mineral density mean	4e-09	LNCAROD	37500982	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr5:159488235:T>A	chr5	159488235	159487405	830	rs10515796	IL12B protein levels	7e-22	IL12B-AS1	39789286	0.96195054	456.0	JUND	3.28532e-05	Accessible, Low Impact	3
chr5:159488235:T>A	chr5	159488235	159487405	830	rs10515796	IL12A or IL12B protein levels	7e-20	IL12B-AS1	39789286	0.96195054	456.0	JUND	3.28532e-05	Accessible, Low Impact	3
chr16:82167328:G>C	chr16	82167328	82166498	830	rs2967355	Telomere length	4e-19	MPHOSPH6	35530816	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr5:27518605:G>C	chr5	27518605	27519435	830	rs553963535	GLIPR1 protein levels	4e-15	PURPL - LINC02103	39789286	0.85351515	407.5	JUN	6.57203e-06	Low Priority	3
chr9:123417755:C>A	chr9	123417755	123416925	830	rs7851052	Type 2 diabetes	2e-12	DENND1A	38374256	0.9422262	636.0	ATF2	6.56564e-06	High Impact, Hard to Access	3
chr16:82167328:G>C	chr16	82167328	82166498	830	rs2967355	Height	4e-09	MPHOSPH6	40436827	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr16:82167328:G>C	chr16	82167328	82166498	830	rs2967355	Leukocyte telomere length	4e-08	MPHOSPH6	37216007	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr3:15165249:C>A	chr3	15165249	15164419	830	rs1287456	Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers	3e-06	COL6A4P1	40708016	0.9962544	1652.0	MAFG	1.97156e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:52318852:C>G	chr6	52318852	52318022	830	rs143650968	Color vision defects (Tritan)	8e-06	MCM3 - PAQR8	37359372	0.9808213	937.0	ATF3	6.5799e-06	High Impact, Hard to Access	3
chr3:99540189:C>A	chr3	99540189	99539358	831	rs4928200	Height	1.9999999999999998e-192	ARHGEF28P1 - COL8A1	36224396	0.9055997	456.0	JUND	2.63116e-05	Accessible, Low Impact	3
chr3:99540189:C>A	chr3	99540189	99539358	831	rs4928200	Waist circumference adjusted for body mass index	6e-13	ARHGEF28P1 - COL8A1	34021172	0.9055997	456.0	JUND	2.63116e-05	Accessible, Low Impact	3
chr4:11012367:C>G	chr4	11012367	11013198	831	rs4504245	Late-onset Alzheimer's disease	5e-12	LINC02498 - MIR572	34493870	0.94588065	440.0	JUND	6.5697e-06	Low Priority	3
chr3:99540189:C>A	chr3	99540189	99539358	831	rs4928200	A body shape index	3e-08	ARHGEF28P1 - COL8A1	34021172	0.9055997	456.0	JUND	2.63116e-05	Accessible, Low Impact	3
chr4:11012367:C>G	chr4	11012367	11013198	831	rs4504245	Reaction time	3e-06	LINC02498 - MIR572	29844566	0.94588065	440.0	JUND	6.5697e-06	Low Priority	3
chr18:79463360:G>C	chr18	79463360	79464192	832	rs9958919	Waist circumference adjusted for body mass index	2e-16	NFATC1	31669095	0.99606663	688.0	FOS	0.000143014	HIGH PRIORITY: Accessible + High Impact	3
chr19:54952994:G>C	chr19	54952994	54953826	832	rs1213132600	Alzheimer's disease or family history of Alzheimer's disease	6e-10	NLRP2, NLRP7	39998322	0.99364895	1523.0	FOSL1	0.0705017	HIGH PRIORITY: Accessible + High Impact	3
chr3:73499437:C>A	chr3	73499437	73498605	832	rs13082924	Lung function (FEV1/FVC)	6e-10	PDZRN3	30595370	0.9975752	2595.0	JUNB	1.31432e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:120845176:G>T	chr2	120845176	120846009	833	rs4848641	Height	4e-22	GLI2	36224396	0.95023745	566.5	JUND	6.57393e-06	Low Priority	3
chr3:3980535:C>A	chr3	3980535	3981369	834	rs9827298	Fractures (paediatric)	1e-07	SUMF1	32742401	0.98167825	435.0	FOS	1.32584e-05	Accessible, Low Impact	3
chr16:75122374:G>C	chr16	75122374	75123209	835	rs185231544	CTRB1 protein levels	6e-15	LDHD - ZFP1	39789286	0.99941945	4975.0	FOS	0.000190389	HIGH PRIORITY: Accessible + High Impact	3
chr7:44778806:G>C	chr7	44778806	44779641	835	rs112942650	Apolipoprotein A1 levels	2e-09	ZMIZ2 - PPIA	32203549	0.9963292	812.0	FOS	3.94514e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:68847971:C>A	chr6	68847971	68848806	835	rs513357	Body mass index	8e-09	ADGRB3	30108127	0.9756724	587.5	ATF2	9.94247e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:93682031:G>C	chr9	93682031	93681194	837	rs10120798	CAMSIS occupational score (MTAG)	3e-12	PHF2 - MIR4291	39715877	0.9727787	1047.0	JUND	6.56866e-06	High Impact, Hard to Access	3
chr9:93682031:G>C	chr9	93682031	93681194	837	rs10120798	SIOPS occupational score (MTAG)	3e-12	PHF2 - MIR4291	39715877	0.9727787	1047.0	JUND	6.56866e-06	High Impact, Hard to Access	3
chr9:93682031:G>C	chr9	93682031	93681194	837	rs10120798	ISEI occupational score (MTAG)	4e-12	PHF2 - MIR4291	39715877	0.9727787	1047.0	JUND	6.56866e-06	High Impact, Hard to Access	3
chr6:33156314:A>C	chr6	33156314	33157152	838	rs9277914	Hip circumference adjusted for BMI	8e-09	HCG24 - COL11A2	34021172	0.9990577	554.0	FOS	0.0	Low Priority	2
chr13:59468115:C>A	chr13	59468115	59467276	839	rs9317080	Smoking initiation	1e-20	RPP40P2 - RNU7-88P	36477530	0.9708846	532.5	FOS	5.25997e-05	Accessible, Low Impact	3
chr3:61992473:C>G	chr3	61992473	61993312	839	rs251035	Height	2e-10	PTPRG	39134668	0.7921896	490.25	FOSL2	1.97174e-05	Accessible, Low Impact	3
chr1:59450266:C>G	chr1	59450266	59449426	840	rs12060527	White matter microstructure (radial diusivities)	2e-09	FGGY	31666681	0.973383	613.0	ATF3	6.57592e-06	High Impact, Hard to Access	3
chr4:30826599:C>G	chr4	30826599	30825758	841	rs12513276	Attention deficit hyperactivity disorder	2e-06	PCDH7	40962958	0.95041513	468.5	JUND	0.0	Low Priority	2
chr11:110065668:C>A	chr11	110065668	110064827	841	rs12419121	Computer vision syndrome	4e-06	RDX, LINC02715	33941792	0.9896673	659.0	BATF	6.56849e-06	High Impact, Hard to Access	3
chr2:103816706:C>A	chr2	103816706	103817547	841	rs2570498	Attention deficit hyperactivity disorder	9e-06	CAPZBP1 - LINC01965	40962958	0.9695515	470.5	FOSL2	7.22648e-05	Accessible, Low Impact	3
chr6:37691964:C>A	chr6	37691964	37691122	842	rs79879161	MDGA1 protein levels	1e-87	MDGA1	39789286	0.9921947	1598.5	FOSL1	6.56875e-06	High Impact, Hard to Access	3
chr7:8918901:G>T	chr7	8918901	8919743	842	rs10247578	Lung adenocarcinoma (survival time) in never smokers	8e-08	NXPH1 - GAPDHP68	32699080	0.98587024	845.5	JUND	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:31295292:A>C	chr6	31295292	31296134	842	rs2394966	Ulcerative colitis	1e-07	LINC02571	37262302	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr6:31295292:A>C	chr6	31295292	31296134	842	rs2394966	Ulcerative colitis x sex interaction (2df)	2e-07	LINC02571	37262302	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr12:40300451:C>A	chr12	40300451	40301293	842	rs10878340	Daytime sleep phenotypes	8e-07	LRRK2	27126917	0.9923714	990.0	FOS	6.5735e-06	High Impact, Hard to Access	3
chr18:74506902:G>T	chr18	74506902	74507745	843	rs3829640	Serum metabolite levels	2e-21	CNDP2	33031748	0.9808213	644.0	FOSL1	6.57065e-06	High Impact, Hard to Access	3
chr18:74506902:G>T	chr18	74506902	74507745	843	rs3829640	Spherical equivalent	1e-10	CNDP2	32352494	0.9808213	644.0	FOSL1	6.57065e-06	High Impact, Hard to Access	3
chr9:117901948:T>A	chr9	117901948	117901105	843	rs12552443	Body mass index	3e-09	TLR4 - TPT1P9	31669095	0.93699247	414.5	JUN	5.91545e-05	Accessible, Low Impact	2
chr9:117901948:T>A	chr9	117901948	117901105	843	rs12552443	Adiposity (multivariate analysis)	3e-09	TLR4 - TPT1P9	40796553	0.93699247	414.5	JUN	5.91545e-05	Accessible, Low Impact	2
chr16:268237:C>G	chr16	268237	267394	843	rs72765821	Vaginal microbiome MetaCyc pathway (FUCCAT-PWY|fucose degradation)	2e-06	FAM234A	34282934	0.9975805	1037.0	BATF2	6.57117e-06	High Impact, Hard to Access	3
chr2:10277204:G>T	chr2	10277204	10278047	843	rs10178726	Asthma exacerbations in inhaled corticosteroid treatment	7e-06	RRM2 - RN7SL66P	35501119	0.96518815	871.0	ATF7	6.57609e-06	High Impact, Hard to Access	3
chr2:54246753:A>C	chr2	54246753	54245909	844	rs965109	Telomere length (principal component 1)	9.999999999999999e-85	ACYP2	39192095	0.96195054	534.0	ATF3	2.62854e-05	Accessible, Low Impact	3
chr6:26670063:C>A	chr6	26670063	26670907	844	rs9461288	Waist circumference adjusted for body mass index	6e-13	ZNF322 - GUSBP2	34021172	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr8:10086241:G>T	chr8	10086241	10085397	844	rs12545826	Omega-6 fatty acid levels	4e-12	MSRA	40545721	0.9545879	446.0	JUN	3.94166e-05	Accessible, Low Impact	2
chr8:10086241:G>T	chr8	10086241	10085397	844	rs12545826	Linoleic acid levels	5e-12	MSRA	40545721	0.9545879	446.0	JUN	3.94166e-05	Accessible, Low Impact	2
chr8:10086241:G>T	chr8	10086241	10085397	844	rs12545826	General factor of neuroticism	3e-10	MSRA	30867560	0.9545879	446.0	JUN	3.94166e-05	Accessible, Low Impact	2
chr8:10086241:G>T	chr8	10086241	10085397	844	rs12545826	Polyunsaturated fatty acid levels	5e-10	MSRA	40545721	0.9545879	446.0	JUN	3.94166e-05	Accessible, Low Impact	2
chr8:10086241:G>T	chr8	10086241	10085397	844	rs12545826	Saturated fatty acids levels	7e-09	MSRA	40545721	0.9545879	446.0	JUN	3.94166e-05	Accessible, Low Impact	2
chr6:26670063:C>A	chr6	26670063	26670907	844	rs9461288	A body shape index	3e-08	ZNF322 - GUSBP2	34021172	0.9555776	497.0	JUNB	6.58103e-06	Low Priority	3
chr10:120273851:G>C	chr10	120273851	120274695	844	rs7900717	Mercury levels in pregnancy	6e-06	NACAP2 - RPL21P16	38136945	0.95348793	466.0	FOSL2	1.31463e-05	Accessible, Low Impact	3
chr11:24874400:G>T	chr11	24874400	24875245	845	rs12290161	Resistance to COVID-19 infection (Exposed negative vs positive)	5e-10	LUZP2	36662838	0.90755373	503.5	JUND	0.47488	Accessible, Low Impact	3
chr8:24538595:G>C	chr8	24538595	24537750	845	rs113414285	Post bronchodilator FEV1/FVC ratio	6e-07	ADAM7-AS1	26634245	0.95357716	461.5	JUND	6.5722e-06	Low Priority	3
chr4:21454479:C>A	chr4	21454479	21453634	845	rs11942476	IgG glycosylation	6e-06	KCNIP4	23382691	0.9955867	558.5	FOSL1	6.57523e-06	Low Priority	3
chr20:53948556:C>A	chr20	53948556	53947711	845	rs10485442	R-warfarin levels	1e-05	BCAS1	36210801	0.99740165	785.5	BATF	1.31389e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:16096369:A>C	chr17	16096369	16095523	846	rs8080378	Lymphocyte count	4e-14	NCOR1	32888494	0.9860784	511.5	FOS	0.0234456	Accessible, Low Impact	2
chr17:16096369:A>C	chr17	16096369	16095523	846	rs8080378	Citrate levels	8e-11	NCOR1	41044249	0.9860784	511.5	FOS	0.0234456	Accessible, Low Impact	2
chr7:53831584:C>A	chr7	53831584	53832430	846	rs138896312	Post bronchodilator FEV1 in COPD	1e-06	LINC01446 - HAUS6P3	26634245	0.9756724	464.0	JUND	6.57004e-06	Low Priority	3
chr17:30854825:C>A	chr17	30854825	30853978	847	rs62070645	Weight	9e-26	ATAD5	34594039	0.94346935	636.0	ATF2	6.57462e-06	High Impact, Hard to Access	3
chr17:30854825:C>A	chr17	30854825	30853978	847	rs62070645	Prostate-specific antigen levels	1e-14	ATAD5	39930085	0.94346935	636.0	ATF2	6.57462e-06	High Impact, Hard to Access	3
chr6:29031722:C>G	chr6	29031722	29030875	847	rs16894554	Hypothyroidism or rheumatoid arthritis (pleiotropy)	1e-14	OR2AD1P - OR2W1-AS1	38368726	0.97511876	560.0	JUND	6.57791e-06	Low Priority	3
chr8:74814891:T>A	chr8	74814891	74815738	847	rs16938963	Pulse pressure	5e-12	MIR2052HG	38689001	0.92024124	421.5	JUND	2.63407e-05	Accessible, Low Impact	3
chr3:157775316:C>G	chr3	157775316	157776163	847	rs4585149	Neuroticism	2e-09	SLC66A1LP - RN7SKP46	29255261	0.925176	481.0	JUND	0.0	Low Priority	3
chr3:157775316:C>G	chr3	157775316	157776163	847	rs4585149	Neurociticism	7e-09	SLC66A1LP - RN7SKP46	29500382	0.925176	481.0	JUND	0.0	Low Priority	3
chr15:81604018:G>C	chr15	81604018	81603171	847	rs10540764	Basophil count	1e-08	TMC3-AS1	34594039	0.92191833	512.5	ATF3	6.58458e-06	Low Priority	3
chr6:31395380:G>T	chr6	31395380	31394533	847	rs16899524	Beta-2 microglubulin plasma levels	1e-08	MICA-AS1	23417110	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr3:157775316:C>G	chr3	157775316	157776163	847	rs4585149	Neuroticism general factor	9e-08	SLC66A1LP - RN7SKP46	37783279	0.925176	481.0	JUND	0.0	Low Priority	3
chr5:82680137:A>C	chr5	82680137	82679289	848	rs1827396	Corpus callosum fractional anisotropy (genu)	1e-08	ATP6AP1L - RPL5P16	37164063	0.9845253	690.0	FOS	6.57272e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:46202136:C>A	chr7	46202136	46202985	849	rs6964415	Sudden cardiac arrest	5e-07	ZNF619P1 - HMGN1P19	21658281	0.96670574	477.5	JUN	1.31465e-05	Accessible, Low Impact	3
chr1:213764543:C>G	chr1	213764543	213763694	849	rs2359934	Branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1) levels	8e-06	RPL31P13 - PROX1-AS1	40360795	0.9131995	677.0	FOSL2	1.31425e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:32664823:G>T	chr19	32664823	32663973	850	rs373828598	PDCD5 protein levels	9.999999999999999e-26	ANKRD27	39789286	0.91684973	456.0	MAFF	0.0	Low Priority	3
chr11:86141865:A>C	chr11	86141865	86141015	850	rs75992634	Memory decline	3e-06	PICALM - RNU6-560P	37984853	0.9999272	2078.0	FOS	1.31351e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:219604005:G>T	chr1	219604005	219603154	851	rs12033783	Umbilical hernia	3e-09	LYPLAL1-AS1 - ZC3H11B	34382107	0.8072176	291.75	FOSL2	6.57212e-06	Low Priority	3
chr12:71062071:T>A	chr12	71062071	71061219	852	rs1512988	Type 2 diabetes	5e-16	PTPRR - TSPAN8	38685053	0.97511876	526.5	JUND	6.57315e-06	Accessible, Low Impact	2
chr10:38643996:C>A	chr10	38643996	38643144	852	rs1297852527	Aromatic antiseizure medication-induced Stevens-Johnson syndrome or toxic epidermal necrolysis	9e-09	SLC9B1P3	35170024	0.91309357	240.5	MAFK	0.000118577	Accessible, Low Impact	3
chr1:4834919:G>C	chr1	4834919	4835771	852	rs1462387588	Nonsyndromic cleft palate	1e-06	AJAP1 - LINC02781	39500877	0.9847427	349.5	FOS	0.00689706	Accessible, Low Impact	3
chr18:77926919:T>G	chr18	77926919	77926067	852	rs12455580	IgG glycosylation	7e-06	LINC01029	23382691	0.9799247	142.625	JUND	0.0	Low Priority	3
chr8:124848279:A>C	chr8	124848279	124849132	853	rs7461129	Spatial QRS-T angle	2e-11	LINC00964	36918541	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124849132	853	rs7461129	Hypertrophic cardiomyopathy	8e-11	LINC00964	39966646	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124849132	853	rs7461129	Dilated cardiomyopathy	2e-09	LINC00964	39572784	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr8:124848279:A>C	chr8	124848279	124849132	853	rs7461129	Dilated cardiomyopathy (MTAG)	2e-09	LINC00964	39572784	0.99997365	10428.0	FOSL1	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	2
chr16:239203:G>T	chr16	239203	238349	854	rs182103652	Heel bone mineral density	8e-10	FAM234A	30598549	0.9875858	699.0	ATF3	0.0	High Impact, Hard to Access	3
chr3:53446722:C>G	chr3	53446722	53445868	854	rs537160726	Height (baseline)	5e-09	CACNA1D	40374629	0.9715297	847.0	BATF2	6.57108e-06	High Impact, Hard to Access	3
chr7:44778806:G>C	chr7	44778806	44779661	855	rs540755175	GLIPR1 protein levels	2e-14	ZMIZ2 - PPIA	39789286	0.9963292	812.0	FOS	3.94514e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:68993954:G>T	chr11	68993954	68994812	858	rs12420399	Height	2e-16	MRGPRD - MRGPRF	36224396	0.9383409	614.0	MAFK	0.453935	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Triglycerides in small HDL (UKB data field 23578)	1e-13	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Triglycerides in medium HDL (UKB data field 23571)	3e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Triglycerides in small VLDL (UKB data field 23515)	4e-12	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Triglycerides in VLDL (UKB data field 23408)	2e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486)	2e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Triglycerides in very large VLDL (UKB data field 23494)	2e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483)	3e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Total lipids in very large VLDL (UKB data field 23489)	3e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Concentration of very large VLDL particles (UKB data field 23488)	3e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Phospholipids in very large VLDL (UKB data field 23490)	4e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481)	4e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Phospholipids in large VLDL (UKB data field 23497)	7e-11	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Concentration of large VLDL particles (UKB data field 23495)	1e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482)	3e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Free cholesterol in large VLDL (UKB data field 23500)	4e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Total lipids in large VLDL (UKB data field 23496)	5e-10	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:125618697:C>A	chr8	125618697	125619555	858	rs3860847	Triglycerides in large VLDL (UKB data field 23501)	1e-09	TRIB1AL - LINC02964	36764567	0.995975	856.0	FOS	3.44732e-05	HIGH PRIORITY: Accessible + High Impact	3
chr14:82499768:C>A	chr14	82499768	82500626	858	rs1911223	Height	1e-08	Metazoa_SRP - LINC02301	36224396	0.95041513	444.0	FOS	6.57921e-06	Low Priority	3
chr11:116578433:C>G	chr11	116578433	116577575	858	rs568054852	Polyunsaturated fatty acid levels	4e-08	LINC02151 - LINC02702	40545721	0.7156284	458.75	FOSL1	6.57039e-06	Low Priority	3
chr7:45576134:A>C	chr7	45576134	45575276	858	rs73318930	alpha-Aminoadipic acid levels	2e-06	ADCY1	35621206	0.99863726	601.0	FOS	5.25148e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	Group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP	0.0	PLA2G2A	31070471	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	Phospholipase A2, membrane associated levels (PLA2G2A.2692.74.2)	0.0	PLA2G2A	29875488	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	Serum levels of protein PLA2G2A	9.999999999999999e-293	PLA2G2A	35078996	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	Phospholipase A2, membrane associated levels	1e-38	PLA2G2A	28240269	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	Brevican core protein protein levels (SomaScan ID:2692-74)	4.0000000000000004e-23	PLA2G2A	40883583	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	CXCL14 protein levels	3e-17	PLA2G2A	39789286	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr1:19978794:A>C	chr1	19978794	19979653	859	rs11573156	LECT2 protein levels	4e-16	PLA2G2A	39789286	0.84346706	687.0	JUNB	6.57281e-06	High Impact, Hard to Access	3
chr18:74506902:G>T	chr18	74506902	74506043	859	rs34780792	Metabolite levels (valylleucine)	4e-14	CNDP2	37253714	0.9808213	644.0	FOSL1	6.57065e-06	High Impact, Hard to Access	3
chr8:11590002:C>G	chr8	11590002	11589143	859	rs13255662	Alanine levels	2e-11	LINC00208 - GATA4	41044249	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr8:5003828:C>G	chr8	5003828	5002969	859	rs12547604	Morning vs. evening chronotype	3e-07	CSMD1 - SNORA70	26835600	0.9884892	1161.5	MAFK	1.97143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:136671019:G>T	chr9	136671019	136671878	859	rs529509344	Lean body mass	8e-06	EGFL7	28552196	0.9787506	952.0	JUN	0.0	High Impact, Hard to Access	3
chr10:38643996:C>A	chr10	38643996	38643136	860	rs879656274	Aromatic antiseizure medication-induced Stevens-Johnson syndrome or toxic epidermal necrolysis	4e-08	SLC9B1P3	35170024	0.91309357	240.5	MAFK	0.000118577	Accessible, Low Impact	3
chr17:81596655:C>G	chr17	81596655	81597516	861	rs11656126	Visual acuity	2e-08	NPLOC4	37491545	0.973383	702.5	FOSL2	1.31397e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:89145905:C>A	chr10	89145905	89146767	862	rs11203002	Ulcerative colitis	3e-12	MIR4679-2 - CH25H	37156999	0.99347407	490.0	FOSL1	0.0	Low Priority	3
chr10:89145905:C>A	chr10	89145905	89146767	862	rs11203002	Inflammatory bowel disease	3e-10	MIR4679-2 - CH25H	37156999	0.99347407	490.0	FOSL1	0.0	Low Priority	3
chr20:33869663:G>T	chr20	33869663	33870526	863	rs73096872	Height (baseline)	4e-10	CHMP4B - TPM3P2	40374629	0.8608881	519.5	MAFG	6.56564e-06	Accessible, Low Impact	2
chr20:33869663:G>T	chr20	33869663	33870526	863	rs73096872	Colorectal cancer x alcohol intake interaction	6e-06	CHMP4B - TPM3P2	38411962	0.8608881	519.5	MAFG	6.56564e-06	Accessible, Low Impact	2
chr2:102637534:A>C	chr2	102637534	102636669	865	rs7567133	Plateletcrit	7e-10	SLC9A2	32888494	0.99998	5796.0	FOS	6.57117e-06	HIGH PRIORITY: Accessible + High Impact	2
chr16:24679462:C>A	chr16	24679462	24680327	865	rs77989568	Height (baseline)	2e-09	TNRC6A	40374629	0.9417692	689.0	FOS	3.29047e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:24679462:C>A	chr16	24679462	24680327	865	rs77989568	Self-reported math ability (MTAG)	1e-08	TNRC6A	30038396	0.9417692	689.0	FOS	3.29047e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:95008284:T>A	chr4	95008284	95007419	865	rs7662504	Hematocrit	3e-08	BMPR1B	40436827	0.9937929	559.5	JUND	6.57229e-06	Low Priority	3
chr3:49348784:G>C	chr3	49348784	49347918	866	rs533904333	Body mass index	3e-17	USP4 - GPX1	38538606	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr3:49348784:G>C	chr3	49348784	49347918	866	rs71077794	Scientific occupational creativity	5e-13	USP4 - GPX1	39237691	0.97898656	1140.0	FOS	6.58605e-06	High Impact, Hard to Access	3
chr15:32709797:C>G	chr15	32709797	32710663	866	rs148375239	Facial morphology (segment 53)	5e-10	SCG5 - GREM1	33288918	0.9940711	902.5	ATF3	1.31435e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:87543532:G>C	chr9	87543532	87544398	866	rs1421001	Cognitive function	4e-06	DAPK1	24684796	0.998573	2396.0	JUN	6.57488e-06	High Impact, Hard to Access	3
chr10:118983916:C>A	chr10	118983916	118984783	867	rs10886358	Post bronchodilator FEV1/FVC ratio in COPD	3e-06	LINC03036	26634245	0.85810196	503.5	ATF7	8.69127e-06	Accessible, Low Impact	3
chr9:81404987:C>A	chr9	81404987	81404119	868	rs147684499	Bone mineral density mean	1e-300	RPS19P6 - RPS20P25	37500982	0.97511876	554.0	FOS	2.63006e-05	Accessible, Low Impact	3
chr9:113627109:T>A	chr9	113627109	113627979	870	rs10981847	Glycosphingolipids (d40:1) levels	9e-10	RGS3 - C14orf119P1	35393526	0.9814467	719.0	FOS	6.57108e-06	HIGH PRIORITY: Accessible + High Impact	2
chr2:19073802:G>C	chr2	19073802	19072932	870	rs4380183	Vertical cup-disc ratio	9e-09	LINC01376	34077760	0.9996589	6096.0	JUND	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr19:4069294:C>A	chr19	4069294	4070165	871	rs59394312	Red blood cell count	6e-43	ZBTB7A - MAP2K2	34594039	0.9814467	1143.0	MAFK	4.60399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:119557317:G>C	chr6	119557317	119556446	871	rs79149498	CBLIF protein levels	2.0000000000000002e-23	MAN1A1 - MIR3144	39789286	0.99376744	614.5	FOSL1	6.57281e-06	High Impact, Hard to Access	3
chr2:47545530:C>G	chr2	47545530	47546401	871	rs6708696	EPCAM/GPA33 protein level ratio	3e-16	KCNK12, MSH2	38412862	0.9036088	535.0	JUND	6.57004e-06	Low Priority	3
chr4:144569879:C>G	chr4	144569879	144570750	871	rs79670895	Forced expiratory volume (baseline)	2e-09	GUSBP5 - KRT18P51	40374629	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:22498530:C>G	chr10	22498530	22497658	872	rs139160329	Bone mineral density mean	1e-92	SPAG6 - PIP4K2A	37500982	0.85238993	541.0	JUNB	1.31427e-05	Accessible, Low Impact	3
chr10:52652420:G>C	chr10	52652420	52651548	872	rs10762857	Bone mineral density mean	6e-09	LNCAROD	37500982	0.99694693	923.0	FOS	6.57367e-06	High Impact, Hard to Access	3
chr1:170095016:C>G	chr1	170095016	170095888	872	rs76134841	Waist circumference adjusted for body mass index	1e-08	KIFAP3 - SIGLEC30P	34021172	0.9897305	1070.0	ATF7	1.3128e-05	HIGH PRIORITY: Accessible + High Impact	2
chr3:116239725:G>C	chr3	116239725	116238853	872	rs5852001	Insomnia	4e-08	LSAMP	35835914	0.99159664	603.0	FOSL2	6.57678e-06	High Impact, Hard to Access	3
chr11:68993954:G>T	chr11	68993954	68993081	873	rs12283870	Elevated alanine aminotransferase and aspartate aminotransferase levels in acute lymphoblastic leukemia	9e-10	MRGPRD - MRGPRF	36580335	0.9383409	614.0	MAFK	0.453935	HIGH PRIORITY: Accessible + High Impact	3
chr10:42518790:G>C	chr10	42518790	42519663	873	rs182246327	R-warfarin levels	6e-06	ZNF37BP, ZNF37BP	36210801	0.9914013	447.5	ATF3	6.58579e-06	Low Priority	3
chr12:102735234:G>T	chr12	102735234	102736108	874	rs61940837	Bone mineral density mean	1e-300	IGF1 - LINC00485	37500982	0.9972223	1952.0	ATF2	6.57445e-06	High Impact, Hard to Access	3
chr8:11590002:C>G	chr8	11590002	11589128	874	rs11250150	X-12739 levels	2e-08	LINC00208 - GATA4	36357675	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr20:15289850:A>C	chr20	15289850	15290724	874	rs16995508	Color vision defects (Tritan)	4e-06	MACROD2	37359372	0.999634	1216.0	FOS	6.57168e-06	High Impact, Hard to Access	3
chr9:11446415:G>C	chr9	11446415	11445540	875	rs10959812	Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)	5e-13	LINC03131 - JKAMPP1	33349686	0.9992518	669.0	FOS	3.95726e-05	HIGH PRIORITY: Accessible + High Impact	3
chr5:104407155:G>T	chr5	104407155	104408031	876	rs55649128	Major depressive disorder	2e-22	NIHCOLE	34045744	0.973383	626.0	ATF3	0.0	High Impact, Hard to Access	3
chr5:104407155:G>T	chr5	104407155	104408031	876	rs55649128	Major depressive disorder or stress-related disorder	9e-09	NIHCOLE	34634379	0.973383	626.0	ATF3	0.0	High Impact, Hard to Access	3
chr6:151588114:G>C	chr6	151588114	151588991	877	rs6557155	Total body bone mineral density	3e-34	CCDC170	29304378	0.9981182	656.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr6:151588114:G>C	chr6	151588114	151588991	877	rs6557155	Total body bone mineral density (age over 60)	5e-22	CCDC170	29304378	0.9981182	656.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr6:151588114:G>C	chr6	151588114	151588991	877	rs6557155	Total body bone mineral density (age 45-60)	1e-18	CCDC170	29304378	0.9981182	656.0	FOS	6.57065e-06	High Impact, Hard to Access	3
chr12:103061819:G>T	chr12	103061819	103062696	877	rs10860937	Sex hormone-binding globulin levels	6e-16	ASCL1 - C12orf42-AS1	34321204	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr1:47482946:T>A	chr1	47482946	47482069	877	rs6683032	Male-pattern baldness	2e-13	FOXD2 - RPL21P24	28196072	0.98786724	497.5	FOS	0.314869	Accessible, Low Impact	3
chr12:103061819:G>T	chr12	103061819	103062696	877	rs10860937	XPNPEP2 protein levels	2e-11	ASCL1 - C12orf42-AS1	39789286	0.9787506	616.5	ATF2	0.0	High Impact, Hard to Access	3
chr9:21810564:A>C	chr9	21810564	21811442	878	rs7859886	Lung adenocarcinoma (conditioned on cigarettes per day)	9e-19	MTAP	39366959	0.9994456	929.0	FOS	6.57246e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31396258	878	rs11757660	Hip circumference adjusted for BMI	9e-13	MICA-AS1	34021172	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr10:34001512:G>C	chr10	34001512	34000634	878	rs224697	Educational attainment	8e-09	LINC02629 - PARD3	35361970	0.9999272	4803.0	JUN	6.5716e-06	High Impact, Hard to Access	3
chr8:5512321:G>C	chr8	5512321	5513199	878	rs184075442	Prostate cancer	9e-07	RPL23AP54 - RN7SKP159	38538606	0.9975752	499.5	ATF3	0.000893479	Accessible, Low Impact	3
chr4:64444839:C>A	chr4	64444839	64443960	879	rs1842955	Formate levels	3e-07	DPP3P1 - MTCO3P27	38239409	0.98125464	613.5	BATF	0.0	High Impact, Hard to Access	3
chr4:64444839:C>A	chr4	64444839	64443960	879	rs1842955	Valine levels	6e-07	DPP3P1 - MTCO3P27	38239409	0.98125464	613.5	BATF	0.0	High Impact, Hard to Access	3
chr4:64444839:C>A	chr4	64444839	64443960	879	rs1842955	Leucine levels	2e-06	DPP3P1 - MTCO3P27	38239409	0.98125464	613.5	BATF	0.0	High Impact, Hard to Access	3
chr4:64444839:C>A	chr4	64444839	64443960	879	rs1842955	Creatinine levels	3e-06	DPP3P1 - MTCO3P27	38239409	0.98125464	613.5	BATF	0.0	High Impact, Hard to Access	3
chr4:64444839:C>A	chr4	64444839	64443960	879	rs1842955	Tyrosine levels	6e-06	DPP3P1 - MTCO3P27	38239409	0.98125464	613.5	BATF	0.0	High Impact, Hard to Access	3
chr6:111374174:A>C	chr6	111374174	111375054	880	rs461646	Smoking initiation	2e-74	REV3L, MFSD4B	36477530	0.9942056	720.0	JUND	3.28537e-05	HIGH PRIORITY: Accessible + High Impact	2
chr11:113049319:C>A	chr11	113049319	113050199	880	rs10891496	Neuroticism	3e-09	NCAM1	29942085	0.99926984	2140.0	FOSL2	6.57333e-06	High Impact, Hard to Access	3
chr6:33156314:A>C	chr6	33156314	33157195	881	rs3130160	Platelet crit (UKB data field 30090)	9e-27	HCG24 - COL11A2	39789286	0.9990577	554.0	FOS	0.0	Low Priority	2
chr3:41089795:C>A	chr3	41089795	41088914	881	rs5848586	Bone density T-score	2e-14	RPS27P4 - MRPS31P1	38116116	0.9602251	518.0	FOS	6.57099e-06	Low Priority	3
chr3:41089795:C>A	chr3	41089795	41088914	881	rs5848586	Bone density Z-score	6e-14	RPS27P4 - MRPS31P1	38116116	0.9602251	518.0	FOS	6.57099e-06	Low Priority	3
chr6:33156314:A>C	chr6	33156314	33157195	881	rs3130160	Atopic asthma	9e-11	HCG24 - COL11A2	31669095	0.9990577	554.0	FOS	0.0	Low Priority	2
chr13:46715259:C>A	chr13	46715259	46714378	881	rs35283972	TNFB levels	4e-06	LRCH1	38326779	0.95254505	470.0	JUND	1.97272e-05	Accessible, Low Impact	3
chr19:35259541:G>T	chr19	35259541	35258660	881	rs2073898	Cognitive function	4e-06	LSR	36973338	0.9659551	810.0	JUND	2.63064e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:31330579:C>A	chr13	31330579	31329697	882	rs1060709	Highest math class taken (MTAG)	3e-13	B3GLCT	30038396	0.97922516	593.0	FOS	0.0	High Impact, Hard to Access	3
chr1:44286920:G>C	chr1	44286920	44286038	882	rs325163	Anxiety	9e-08	ERI3	33859377	0.99740165	681.5	FOSL1	6.57307e-06	High Impact, Hard to Access	3
chr16:89368764:G>C	chr16	89368764	89369647	883	rs11865298	Hair colour (natural, before greying): Red (UKB data field 1747_2)	1.0000000000000001e-24	ANKRD11	34737426	0.9984708	797.5	FOS	2.63071e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:66980130:C>G	chr1	66980130	66981013	883	rs115064659	Inflammatory bowel disease (MTAG)	7e-17	MIER1	39792054	0.95254505	597.5	JUND	0.000118157	HIGH PRIORITY: Accessible + High Impact	3
chr13:50765296:A>C	chr13	50765296	50766179	883	rs592333	Snoring	1e-16	DLEU1, DLEU7	30804565	0.9950484	581.5	FOS	6.56935e-06	High Impact, Hard to Access	3
chr13:50765296:A>C	chr13	50765296	50766179	883	rs592333	Sleep apnea (MTAG)	2e-14	DLEU1, DLEU7	36525587	0.9950484	581.5	FOS	6.56935e-06	High Impact, Hard to Access	3
chr19:10640945:G>C	chr19	10640945	10640062	883	rs1560707	Osteoarthritis	1e-13	SLC44A2	30664745	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr19:10640945:G>C	chr19	10640945	10640062	883	rs1560707	Osteoarthritis (MTAG)	7e-13	SLC44A2	40262193	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr13:50765296:A>C	chr13	50765296	50766179	883	rs592333	Obstructive sleep apnea (BMI adjusted)	1e-09	DLEU1, DLEU7	36989840	0.9950484	581.5	FOS	6.56935e-06	High Impact, Hard to Access	3
chr19:10640945:G>C	chr19	10640945	10641828	883	rs12461470	LDL cholesterol levels	2e-08	SLC44A2	35884923	0.9637244	866.0	ATF7	6.57964e-06	High Impact, Hard to Access	3
chr9:136521181:C>A	chr9	136521181	136522064	883	rs7036298	Telomere length (principal component 1)	3e-08	NOTCH1	39192095	0.9850881	843.0	BATF	6.57246e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31394497	883	rs28366122	Pallidum volume change rate x age interaction (1df)	8e-07	MICA-AS1	35383335	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr1:91633478:G>C	chr1	91633478	91632595	883	rs12137034	Facial phenotypes (right palpebral fissure length)	6e-06	WDR82P2 - HSP90B3P	35970861	0.973383	548.5	MAFK	6.57117e-06	Low Priority	3
chr19:45206397:C>A	chr19	45206397	45207281	884	rs7249570	C-reactive protein levels (MTAG)	3e-14	BLOC1S3, MARK4	36376304	0.90755373	530.5	FOSL1	0.0	Low Priority	3
chr19:51668454:C>G	chr19	51668454	51669340	886	rs12461881	Sialic acid-binding Ig-like lectin 14 levels	1.0000000000000001e-34	RPL7P51 - SPACA6-AS1	36168886	0.97511876	632.0	ATF3	1.31442e-05	HIGH PRIORITY: Accessible + High Impact	2
chr7:38027054:C>A	chr7	38027054	38026168	886	rs1721397	Bone mineral density mean	6e-16	SFRP4 - STARD3NL	37500982	0.988674	411.0	BATF	3.28934e-05	Accessible, Low Impact	3
chr7:38027054:C>A	chr7	38027054	38026168	886	rs1721397	Apparent treatment-resistant hypertension	3e-06	SFRP4 - STARD3NL	38162683	0.988674	411.0	BATF	3.28934e-05	Accessible, Low Impact	3
chr12:120620795:G>C	chr12	120620795	120621682	887	rs188188782	Gamma glutamyltransferase levels (UKB data field 30730)	1e-11	RPL11P5 - CABP1-DT	39789286	0.99931777	2015.0	FOS	6.5722e-06	High Impact, Hard to Access	3
chr3:141884816:C>A	chr3	141884816	141883928	888	rs11721024	QT interval	5e-10	ATP1B3	36050321	0.9845253	904.5	ATF2	0.000374409	HIGH PRIORITY: Accessible + High Impact	3
chr19:38917441:G>T	chr19	38917441	38916553	888	rs59785584	Height (baseline)	2e-08	SARS2	40374629	0.92191833	712.0	JUND	1.31391e-05	HIGH PRIORITY: Accessible + High Impact	3
chr18:70474290:G>C	chr18	70474290	70475178	888	rs8092443	Response to antipsychotic treatment	1e-06	RPS2P6 - RN7SL795P	20195266	0.99968857	969.0	FOS	1.9706e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:45019742:C>G	chr2	45019742	45020631	889	rs2921996	Height	1e-15	SIX2 - LINC01121	36224396	0.9383409	498.0	ATF7	6.58675e-06	Low Priority	3
chr15:28315754:G>T	chr15	28315754	28314864	890	rs11324616	Eye color	1.9999999999999998e-86	HERC2	36672889	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr2:238679356:A>C	chr2	238679356	238680246	890	rs11693678	Height	4e-52	LINC01937	36224396	0.9644045	480.0	JUND	6.57065e-06	Low Priority	3
chr15:28315754:G>T	chr15	28315754	28314864	890	rs11324616	Skin phototype score	1.9999999999999998e-30	HERC2	36672889	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr15:28315754:G>T	chr15	28315754	28314864	890	rs11324616	Skin color (Fitzpatrick scale)	1.0000000000000001e-23	HERC2	36672889	0.94555736	389.5	FOSL1	2.62795e-05	Accessible, Low Impact	3
chr5:104407155:G>T	chr5	104407155	104406265	890	rs13166408	Major depressive disorder or stress-related disorder	2e-09	NIHCOLE	34634379	0.973383	626.0	ATF3	0.0	High Impact, Hard to Access	3
chr17:45315733:G>T	chr17	45315733	45314842	891	rs7216796	Eosinophil count	3e-09	MAP3K14	30595370	0.9834347	1085.0	ATF7	6.57523e-06	High Impact, Hard to Access	3
chr17:45315733:G>T	chr17	45315733	45314842	891	rs7216796	Multiple sclerosis (MTAG)	4e-08	MAP3K14	40262193	0.9834347	1085.0	ATF7	6.57523e-06	High Impact, Hard to Access	3
chr13:19346349:C>A	chr13	19346349	19347240	891	rs2485016	Hypertensive renal disease	2e-06	LINC00421 - PARP4P2	34067580	0.7844907	489.25	MAFK	6.57065e-06	Low Priority	3
chr6:133542221:C>A	chr6	133542221	133543112	891	rs4895970	Developmental language disorder (linguistic errors)	5e-06	TARID	27016271	0.99985784	3106.0	JUNB	6.58744e-06	High Impact, Hard to Access	3
chr17:45315733:G>T	chr17	45315733	45314842	891	rs7216796	Joint damage in rheumatoid arthritis	6e-06	MAP3K14	26498133	0.9834347	1085.0	ATF7	6.57523e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31394488	892	rs28366119	Keratinocyte cancer (MTAG)	4e-11	MICA-AS1	31174203	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:27857190:G>C	chr6	27857190	27858082	892	rs9461416	HTLV-1 associated myelopathy	2e-06	H2BC15 - H2BC16P	33649182	0.9989667	723.0	FOSL2	6.57272e-06	High Impact, Hard to Access	3
chr7:140157827:G>C	chr7	140157827	140158720	893	rs6943811	Height	8.999999999999999e-121	KDM7A	36224396	0.9872979	541.75	ATF3	2.64131e-05	Accessible, Low Impact	3
chr1:83446997:G>T	chr1	83446997	83446104	893	rs12137652	Memory decline in impaired cognition	7e-06	LINC01725, LINC01712	37984853	0.9185313	454.5	ATF2	6.57047e-06	Low Priority	3
chr7:137863948:A>C	chr7	137863948	137863054	894	rs7795163	Height	4e-108	DGKI - CREB3L2	36224396	0.9991982	805.5	FOSL2	0.0	High Impact, Hard to Access	2
chr7:77408734:T>A	chr7	77408734	77409628	894	rs2190097	Eczema	7e-15	GSAP	30595370	0.9715297	1042.5	JUNB	1.35062e-05	HIGH PRIORITY: Accessible + High Impact	2
chr7:77408734:T>A	chr7	77408734	77409628	894	rs2190097	Allergic disease (asthma, hay fever or eczema)	3e-11	GSAP	31361310	0.9715297	1042.5	JUNB	1.35062e-05	HIGH PRIORITY: Accessible + High Impact	2
chr7:77408734:T>A	chr7	77408734	77409628	894	rs2190097	Hay fever and/or eczema	2e-10	GSAP	31361310	0.9715297	1042.5	JUNB	1.35062e-05	HIGH PRIORITY: Accessible + High Impact	2
chr7:77408734:T>A	chr7	77408734	77409628	894	rs2190097	Asthma	1e-08	GSAP	32296059	0.9715297	1042.5	JUNB	1.35062e-05	HIGH PRIORITY: Accessible + High Impact	2
chrX:35494282:G>C	chrX	35494282	35493387	895	rs12833114	Serum levels of protein TENM3	5e-17	FAM47B - RNU6-1087P	35078996	0.8908594	436.0	ATF2	8.99159e-06	Accessible, Low Impact	3
chr3:50693649:C>G	chr3	50693649	50694546	897	rs544108035	N-acetylmethionine levels	1e-44	DOCK3	35347128	0.9584504	428.5	FOSL1	1.32564e-05	Accessible, Low Impact	3
chr1:206951632:C>G	chr1	206951632	206950735	897	rs34639880	CST5 protein levels	9e-34	PIGR - FCAMR	39789286	0.9991015	2194.0	JUND	6.57082e-06	High Impact, Hard to Access	3
chr7:46208336:C>A	chr7	46208336	46207439	897	rs112558930	Insulin-like growth factor 1 levels	4e-13	ZNF619P1 - HMGN1P19	33462484	0.99164	886.0	ATF3	6.57108e-06	High Impact, Hard to Access	3
chr3:138042212:C>A	chr3	138042212	138041314	898	rs329129	ALPP protein levels	1e-16	CLDN18 - DZIP1L	39789286	0.99894416	2026.0	FOSL2	6.56737e-06	High Impact, Hard to Access	3
chr13:27775807:G>C	chr13	27775807	27774909	898	rs1891953	Sialolithiasis (PheCode 528.7)	1e-11	POLR1D - GSX1	39024449	0.9972157	736.0	FOS	6.57549e-06	High Impact, Hard to Access	3
chr12:122123188:C>A	chr12	122123188	122122290	898	rs11059094	Osteoarthritis (hip)	7e-11	MLXIP	30664745	0.9923714	2062.0	ATF3	1.3143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:65623291:G>T	chr15	65623291	65624189	898	rs3743171	Body mass index	1e-09	SLC24A1	36581621	0.9383409	521.0	FOSL1	5.91545e-05	Accessible, Low Impact	3
chr15:65623291:G>T	chr15	65623291	65624189	898	rs3743171	Iron status biomarkers (ferritin levels)	3e-08	SLC24A1	33536631	0.9383409	521.0	FOSL1	5.91545e-05	Accessible, Low Impact	3
chr11:63774982:C>A	chr11	63774982	63775881	899	rs588523	Systolic blood pressure	4e-09	ZFTA - RN7SL596P	38689001	0.925176	499.5	FOSL2	6.57393e-06	Low Priority	3
chr11:63774982:C>A	chr11	63774982	63775881	899	rs588523	Pulse pressure	2e-07	ZFTA - RN7SL596P	38689001	0.925176	499.5	FOSL2	6.57393e-06	Low Priority	3
chr4:39802097:C>G	chr4	39802097	39802996	899	rs113769228	Pediatric bone mineral content (spine)	7e-06	UBE2K - PDS5A	28181694	0.94346935	601.5	ATF7	6.64628e-06	HIGH PRIORITY: Accessible + High Impact	3
chr20:56234334:G>T	chr20	56234334	56233434	900	rs111651827	Bone mineral density mean	9e-77	RNA5SP487 - MC3R	37500982	0.998284	907.0	MAFK	0.000532013	HIGH PRIORITY: Accessible + High Impact	3
chr17:17467556:G>C	chr17	17467556	17466656	900	rs1242511	Waist-to-hip ratio adjusted for BMI	2e-15	Y_RNA - MED9	34021172	0.9983986	803.5	FOS	1.97161e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:17467556:G>C	chr17	17467556	17466656	900	rs1242511	Waist-hip index	5e-15	Y_RNA - MED9	34021172	0.9983986	803.5	FOS	1.97161e-05	HIGH PRIORITY: Accessible + High Impact	3
chr21:38787958:A>C	chr21	38787958	38787058	900	rs1209930	Creatinine levels	2e-09	LINC00114 - ETS2	40436827	0.99999	31120.0	FOSL1	6.56953e-06	High Impact, Hard to Access	3
chr17:17467556:G>C	chr17	17467556	17466656	900	rs1242511	A body shape index	3e-09	Y_RNA - MED9	34021172	0.9983986	803.5	FOS	1.97161e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:17467556:G>C	chr17	17467556	17466656	900	rs1242511	Waist circumference adjusted for body mass index	1e-08	Y_RNA - MED9	34021172	0.9983986	803.5	FOS	1.97161e-05	HIGH PRIORITY: Accessible + High Impact	3
chr17:17467556:G>C	chr17	17467556	17466656	900	rs1242511	Height	3e-08	Y_RNA - MED9	40436827	0.9983986	803.5	FOS	1.97161e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:31295292:A>C	chr6	31295292	31294392	900	rs3873379	Phosphatidylcholine (O-16:0_18:1) levels	4e-06	LINC02571	36193934	0.9383409	430.5	FOSL1	6.56996e-06	Low Priority	3
chr11:28718588:T>A	chr11	28718588	28719489	901	rs512619	Body mass index (BMI, mean, inv-normal transformed)	2e-13	LINC02742	39024449	0.9702253	521.5	FOS	2.6284e-05	Accessible, Low Impact	2
chr16:58108930:C>A	chr16	58108930	58108029	901	rs74019792	Facial morphology (factor 14, intercanthal width)	9e-07	TIPINP2 - CFAP20	28441456	0.9840279	591.0	MAFK	0.0318738	HIGH PRIORITY: Accessible + High Impact	3
chr7:3462673:C>G	chr7	3462673	3463575	902	rs13237637	Smoking initiation	1e-59	SDK1	36477530	0.9830546	714.0	JUNB	0.000184024	HIGH PRIORITY: Accessible + High Impact	2
chr7:3462673:C>G	chr7	3462673	3463575	902	rs13237637	Smoking initiation (ever regular vs never regular) (MTAG)	1e-27	SDK1	30643251	0.9830546	714.0	JUNB	0.000184024	HIGH PRIORITY: Accessible + High Impact	2
chr7:3462673:C>G	chr7	3462673	3463575	902	rs13237637	Smoking initiation (ever regular vs never regular)	2e-20	SDK1	30643251	0.9830546	714.0	JUNB	0.000184024	HIGH PRIORITY: Accessible + High Impact	2
chr7:3462673:C>G	chr7	3462673	3463575	902	rs13237637	Age of smoking initiation (MTAG)	8e-18	SDK1	30643251	0.9830546	714.0	JUNB	0.000184024	HIGH PRIORITY: Accessible + High Impact	2
chr7:3462673:C>G	chr7	3462673	3463575	902	rs13237637	Smoking status (ever vs never smokers)	1e-08	SDK1	32231276	0.9830546	714.0	JUNB	0.000184024	HIGH PRIORITY: Accessible + High Impact	2
chr9:36387124:G>T	chr9	36387124	36386221	903	rs16933266	Color vision defects (Tritan)	3e-06	RNF38	37359372	0.9756724	647.0	JUNB	0.00233212	HIGH PRIORITY: Accessible + High Impact	3
chr6:24615518:G>C	chr6	24615518	24616424	906	rs150183996	Alkaline phosphatase (UKB data field 30610)	6e-28	KIAA0319	39789286	0.99250877	667.0	ATF3	6.57652e-06	High Impact, Hard to Access	3
chr1:241890646:A>C	chr1	241890646	241889740	906	rs851797	Age at natural menopause	2e-13	EXO1	34349265	0.99947065	1145.0	FOS	6.56832e-06	High Impact, Hard to Access	3
chr13:61658976:T>A	chr13	61658976	61659883	907	rs4886357	Restless legs syndrome	4e-10	LINC02339 - RAC1P8	38839884	0.95254505	472.5	ATF3	6.57212e-06	Accessible, Low Impact	2
chr5:81824832:C>G	chr5	81824832	81823925	907	rs145836687	Educational attainment	4e-10	SSBP2 - SEM1P1	35361970	0.9939092	1346.0	JUND	6.60432e-06	High Impact, Hard to Access	3
chr13:61658976:T>A	chr13	61658976	61659883	907	rs4886357	Verbal short term memory (paragraph recall test)	2e-07	LINC02339 - RAC1P8	35974141	0.95254505	472.5	ATF3	6.57212e-06	Accessible, Low Impact	2
chr7:117939716:C>G	chr7	117939716	117938808	908	rs2158050	Height	5e-15	CTTNBP2 - LSM8	36224396	0.9342127	446.0	JUND	5.25693e-05	Accessible, Low Impact	3
chr12:106066096:C>G	chr12	106066096	106067004	908	rs141618950	Median measurement of hepatic fat	9e-06	NUAK1	36513072	0.9914465	628.5	FOS	6.56521e-06	High Impact, Hard to Access	3
chr20:4726019:C>A	chr20	4726019	4725110	909	rs2756263	Liver injury in anti-tuberculosis drug treatment	7e-06	PRND	31109976	0.94910556	524.5	JUN	7.37844e-06	Accessible, Low Impact	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	sMRI-derived phenotypes (MOSTest) (pleiotropy)	4e-85	ADAMTS19-AS1	38531894	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Brain shape (segment 1)	1e-77	ADAMTS19-AS1	33821002	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Brain morphology (MOSTest)	7e-77	ADAMTS19-AS1	35164939	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Whole brain restricted directional diffusion (multivariate analysis)	5.0000000000000005e-39	ADAMTS19-AS1	35505052	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Whole brain restricted isotropic diffusion (multivariate analysis)	1.9999999999999998e-25	ADAMTS19-AS1	35505052	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Whole brain free water diffusion (multivariate analysis)	3e-24	ADAMTS19-AS1	35505052	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Edge-level brain connectivity (multivariate analysis)	4e-22	ADAMTS19-AS1	36800424	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-DKTatlas lh volume parsopercularis	1e-18	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-Desikan lh volume parsopercularis	3e-18	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Cortical volume	4e-18	ADAMTS19-AS1	32963231	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Cortical surface area	1e-17	ADAMTS19-AS1	34560273	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Cortical thickness	1e-17	ADAMTS19-AS1	34560273	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-DKTatlas rh volume parsopercularis	6e-16	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-Desikan rh volume parstriangularis	7e-14	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Vertex-wise cortical surface area	7e-14	ADAMTS19-AS1	34910505	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-Desikan rh volume parsopercularis	8e-14	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Vertex-wise sulcal depth	3e-13	ADAMTS19-AS1	34910505	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	BA-exvivo rh volume BA45	4e-12	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Vertex-wise cortical thickness	4e-12	ADAMTS19-AS1	34910505	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-a2009s lh volume G-front-inf-Opercular	5e-12	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr4:144443332:C>G	chr4	144443332	144442422	910	rs12499125	Post bronchodilator FEV1/FVC ratio	1e-11	GUSBP5 - KRT18P51	26634245	0.99798346	825.0	FOSL2	0.000321746	HIGH PRIORITY: Accessible + High Impact	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-Desikan rh area parstriangularis	1e-11	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Regional cortical thickness (parsopercularis)	6e-11	ADAMTS19-AS1	38890310	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	IDP T1 FAST ROIs R inf front gyrus parstri	1e-10	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-DKTatlas rh volume parstriangularis	3e-10	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-pial rh area parstriangularis	3e-10	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Node-level brain connectivity (multivariate analysis)	4e-10	ADAMTS19-AS1	36800424	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-Desikan lh volume parstriangularis	6e-10	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Height (baseline)	8e-10	ADAMTS19-AS1	40374629	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr4:144443332:C>G	chr4	144443332	144442422	910	rs12499125	Post bronchodilator FEV1	4e-09	GUSBP5 - KRT18P51	26634245	0.99798346	825.0	FOSL2	0.000321746	HIGH PRIORITY: Accessible + High Impact	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-a2009s rh volume G-front-inf-Triangul	4e-09	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	aparc-DKTatlas rh area parstriangularis	5e-09	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	BA-exvivo rh area BA45	2e-08	ADAMTS19-AS1	33875891	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr5:129397405:T>A	chr5	129397405	129398315	910	rs12187568	Regional cortical thickness (parstriangularis)	4e-08	ADAMTS19-AS1	38890310	0.9298287	487.5	JUND	6.58224e-06	Low Priority	3
chr11:50172737:G>T	chr11	50172737	50173648	911	rs74513743	N-acetyl-aspartyl-glutamate (naag) levels	2e-12	GTF2IP11 - PHKG1P3	36635386	0.9917875	354.0	ATF3	6.56832e-06	Low Priority	3
chr1:53121911:T>A	chr1	53121911	53122822	911	rs1679977	Body size or adipose distribution (multivariate analysis)	2e-08	SLC1A7	40796553	0.999858	15456.0	FOSL2	6.57557e-06	HIGH PRIORITY: Accessible + High Impact	2
chr11:59830395:C>A	chr11	59830395	59831308	913	rs149310286	Bone mineral density mean	4e-44	CBLIF	37500982	0.98575574	466.0	FOSL1	6.58267e-06	Low Priority	3
chr2:55783160:G>T	chr2	55783160	55782247	913	rs62167688	Inguinal hernia	3.9999999999999997e-32	PNPT1 - EFEMP1	34382107	0.9681593	566.0	JUNB	6.57168e-06	Low Priority	3
chr3:48490888:T>A	chr3	48490888	48489975	913	rs12491849	Educational attainment	2e-09	SHISA5	35361970	0.9854257	443.75	JUND	6.57194e-06	Accessible, Low Impact	2
chr1:227856710:G>C	chr1	227856710	227855795	915	rs7541048	Height	8e-22	PRSS38 - WNT9A	36224396	0.99773717	592.0	FOS	1.31427e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:117812119:G>C	chr3	117812119	117813035	916	rs533166440	Insomnia	2e-19	LSAMP, LINC03051	35835914	0.973383	607.0	FOSL1	1.3447e-05	HIGH PRIORITY: Accessible + High Impact	3
chr7:80200558:A>C	chr7	80200558	80199642	916	rs4489243	Educational attainment	3e-10	GNAI1	35361970	0.9575012	482.0	FOSL2	1.31492e-05	Accessible, Low Impact	2
chr9:559160:T>A	chr9	559160	560077	917	rs4742094	Eye morphology	2e-06	KANK1	29921221	0.95041513	445.0	FOS	1.31378e-05	Accessible, Low Impact	3
chr9:4395530:C>A	chr9	4395530	4394612	918	rs10758619	DNA methylation variation (age effect)	5e-08	RNU6-694P - SLC1A1	30348214	0.9983231	1494.0	BATF	6.57419e-06	High Impact, Hard to Access	3
chr3:5812530:G>C	chr3	5812530	5811612	918	rs6781156	Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome	1e-06	RN7SL553P - MTARC2P1	31991592	0.998284	1640.0	MAFG	1.31394e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:15778444:C>A	chr8	15778444	15777526	918	rs201581573	Response to paliperidone in schizophrenia (PANSS score)	2e-06	TUSC3 - PPM1AP1	27846195	0.9830546	511.5	JUND	1.31489e-05	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	Hip circumference adjusted for BMI	6e-18	MICA-AS1	34021172	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr19:18276172:G>C	chr19	18276172	18275253	919	rs10416600	Posterior thigh muscle fat infiltration percentage	2e-13	IQCN - JUND	36402844	0.9868027	1138.0	ATF2	6.5767e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	Basal ganglia structure	2e-11	MICA-AS1	39353893	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	Epigenetic age acceleration (Hannum) in childhood cancer survivors	4e-11	MICA-AS1	35313970	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	A body shape index	5e-10	MICA-AS1	34021172	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	Waist-to-hip ratio adjusted for BMI	7e-10	MICA-AS1	34021172	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	Waist-hip index	6e-09	MICA-AS1	34021172	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31396299	919	rs28366133	Conotruncal heart defects (maternal effects)	4e-06	MICA-AS1	28468790	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr1:169486691:C>A	chr1	169486691	169485770	921	rs2072757	Pyruvate levels	7e-13	SLC19A2	41044249	0.9968837	2208.0	FOS	6.57298e-06	High Impact, Hard to Access	3
chr11:47026781:G>T	chr11	47026781	47025859	922	rs74318746	Bone mineral density mean	1e-300	CSTPP1	37500982	0.95134485	568.0	MAFK	0.000322207	Accessible, Low Impact	3
chr13:40763089:G>C	chr13	40763089	40764011	922	rs77473576	Mean corpuscular volume	3e-25	MRPS31	40436827	0.9995283	1593.0	FOSL2	2.62895e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:75893968:C>A	chr3	75893968	75894891	923	rs573930449	GLIPR1 protein levels	8e-13	ZNF717 - ROBO2	39789286	0.972161	768.5	MAFK	6.57886e-06	High Impact, Hard to Access	3
chr18:15045683:C>A	chr18	15045683	15046606	923	rs71365296	Night sleep phenotypes	9e-06	LINC01444 - BNIP3P3	27126917	0.7817188	202.75	JUND	6.5937e-06	Low Priority	3
chr9:137040579:G>C	chr9	137040579	137039655	924	rs6604	White blood cell count	5e-14	NPDC1	30595370	0.9704257	682.0	FOS	1.31456e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:83287708:G>C	chr15	83287708	83286784	924	rs55893521	Hip circumference adjusted for BMI	9e-09	BNC1 - SH3GL3	34021172	0.99999	4466.0	FOSL2	1.31461e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:34126430:C>A	chr2	34126430	34125506	924	rs1477506	Acceptance of an invitation to participate in a mental health questionnaire	1e-08	LINC01320	33563987	0.9923714	1461.0	JUNB	7.88747e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32294163	926	rs146647793	Bone mineral density mean	1.0000000000000001e-145	TSBP1-AS1, TSBP1	37500982	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr11:102700157:C>A	chr11	102700157	102701083	926	rs2846701	Serum levels of protein MMP8	6e-15	MMP27	35078996	0.9756724	647.5	JUN	1.31463e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:32293237:C>A	chr6	32293237	32294163	926	rs146647793	Polyunsaturated fatty acids to monounsaturated fatty acids ratio	9e-09	TSBP1-AS1, TSBP1	40545721	0.9879521	802.0	JUNB	0.0462107	HIGH PRIORITY: Accessible + High Impact	3
chr1:239552619:C>A	chr1	239552619	239553545	926	rs76759221	Post bronchodilator FEV1	7e-07	CHRM3	26634245	0.8209431	384.125	FOS	3.21383e-05	Accessible, Low Impact	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Basal metabolic rate (UKB data field 23105)	1e-14	SKAP1	39789286	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr5:124949890:G>T	chr5	124949890	124948963	927	rs4279337	Educational attainment	4e-13	LINC02240	35361970	0.994337	549.5	JUND	0.0	Low Priority	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Whole body water mass (UKB data field 23102)	6e-13	SKAP1	39789286	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Body surface area	2e-12	SKAP1	36502284	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Hip circumference (UKB data field 49)	6e-12	SKAP1	39789286	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Total fatty acid levels	8e-12	SKAP1	40545721	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Monounsaturated fatty acid levels	1e-11	SKAP1	40545721	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Saturated fatty acids levels	2e-10	SKAP1	40545721	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr17:48210360:G>T	chr17	48210360	48211287	927	rs56161855	Polyunsaturated fatty acid levels	2e-10	SKAP1	40545721	0.9545879	702.0	FOSL1	6.57237e-06	High Impact, Hard to Access	3
chr11:128319074:G>C	chr11	128319074	128318147	927	rs10893846	Rheumatoid arthritis	3e-09	LINC02098 - ETS1	36333501	0.999976	9980.0	JUNB	6.57479e-06	High Impact, Hard to Access	3
chr13:21793685:G>C	chr13	21793685	21794612	927	rs781386326	Prostate cancer	1e-06	RN7SL766P - LINC00424	38538606	0.97946095	303.0	JUND	6.63517e-06	Low Priority	3
chr20:33869663:G>T	chr20	33869663	33870592	929	rs149389676	Hair color	2.9999999999999995e-54	CHMP4B - TPM3P2	30595370	0.8608881	519.5	MAFG	6.56564e-06	Accessible, Low Impact	2
chr12:101674766:G>T	chr12	101674766	101675695	929	rs112241865	SMPD1 protein levels	6e-14	MYBPC1	39789286	0.96670574	715.0	MAFK	0.000540101	HIGH PRIORITY: Accessible + High Impact	3
chr12:101674766:G>T	chr12	101674766	101675695	929	rs112241865	CREG1 protein levels	2e-12	MYBPC1	39789286	0.96670574	715.0	MAFK	0.000540101	HIGH PRIORITY: Accessible + High Impact	3
chr12:101674766:G>T	chr12	101674766	101675695	929	rs112241865	CTSF protein levels	4e-12	MYBPC1	39789286	0.96670574	715.0	MAFK	0.000540101	HIGH PRIORITY: Accessible + High Impact	3
chr19:4938902:C>A	chr19	4938902	4939831	929	rs149372897	Height (baseline)	4e-09	UHRF1	40374629	0.97174054	641.0	MAFG	6.65345e-06	HIGH PRIORITY: Accessible + High Impact	3
chr8:5003828:C>G	chr8	5003828	5002898	930	rs139136076	GLIPR1 protein levels	6e-16	CSMD1 - SNORA70	39789286	0.9884892	1161.5	MAFK	1.97143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:67530477:G>C	chr11	67530477	67531408	931	rs35297589	Metabolite levels (N-acetyltryptophan)	2e-14	CABP2 - GSTP1	37253714	0.99889266	1259.0	FOS	6.56418e-06	High Impact, Hard to Access	3
chr15:88612667:C>A	chr15	88612667	88611735	932	rs7170666	Cystatin C plasma levels	1.9999999999999998e-138	MIR1179 - MIR7-2	34899825	0.9879521	1108.5	ATF2	1.31685e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:80033845:C>G	chr13	80033845	80034777	932	rs3902568	Height	1e-20	LINC01080	36224396	0.9565468	460.0	FOSL2	0.0743839	Accessible, Low Impact	3
chr15:88612667:C>A	chr15	88612667	88611735	932	rs7170666	Endometriosis (MTAG)	4e-06	MIR1179 - MIR7-2	31488892	0.9879521	1108.5	ATF2	1.31685e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:28858575:G>C	chr16	28858575	28857641	934	rs62037365	Body size at age 10	1e-21	SH2B1	32376654	0.9997094	2075.0	FOS	6.57661e-06	High Impact, Hard to Access	3
chr16:1864647:C>A	chr16	1864647	1865582	935	rs391543	Mean corpuscular volume	6e-11	LINC02124, MEIOB	32888493	0.96833974	681.0	MAFG	5.92729e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:54882432:C>A	chr13	54882432	54883367	935	rs75104126	Major depression and alcohol dependence	3e-06	RPL13AP25 - LINC02335	29071344	0.99332225	709.5	FOS	6.58077e-06	High Impact, Hard to Access	3
chr2:124683854:C>A	chr2	124683854	124682918	936	rs1454139	Post bronchodilator FEV1/FVC ratio	2e-06	CNTNAP5	26634245	0.9928779	1324.5	MAFK	2.62978e-05	HIGH PRIORITY: Accessible + High Impact	3
chr22:28359657:C>A	chr22	28359657	28360593	936	rs738199	Reaction time	4e-06	TTC28	29844566	0.9818622	551.0	JUND	6.57652e-06	Low Priority	3
chr16:30124295:G>T	chr16	30124295	30123358	937	rs61764202	BMI (standard GWA)	9e-12	MAPK3	37106081	0.99539393	2034.0	FOSL2	6.58597e-06	High Impact, Hard to Access	3
chr16:1864647:C>A	chr16	1864647	1865584	937	rs2917521	Height (baseline)	4e-09	MEIOB, LINC02124	40374629	0.96833974	681.0	MAFG	5.92729e-05	HIGH PRIORITY: Accessible + High Impact	3
chr16:69891735:C>A	chr16	69891735	69892673	938	rs1039952245	High density lipoprotein cholesterol levels	5e-23	WWP2	34887591	0.9627861	667.0	FOS	0.00101765	HIGH PRIORITY: Accessible + High Impact	3
chr13:80238930:G>C	chr13	80238930	80239869	939	rs348055	Height	4e-14	LINC01080 - SPRY2	39134668	0.97360545	490.5	FOS	1.97117e-05	Accessible, Low Impact	3
chr13:80238930:G>C	chr13	80238930	80239869	939	rs348055	height (mean, inv-normal transformed)	3e-12	LINC01080 - SPRY2	39024449	0.97360545	490.5	FOS	1.97117e-05	Accessible, Low Impact	3
chr13:80238930:G>C	chr13	80238930	80239869	939	rs348055	height (minimum, inv-normal transformed)	2e-11	LINC01080 - SPRY2	39024449	0.97360545	490.5	FOS	1.97117e-05	Accessible, Low Impact	3
chr6:6170596:C>G	chr6	6170596	6169657	939	rs6934608	Antibody status in Tripanosoma cruzi seropositivity	1e-06	F13A1	24324551	0.90755373	454.5	JUND	6.5672e-06	Low Priority	3
chr16:6885392:A>C	chr16	6885392	6884453	939	rs1492376	Educational attainment	6e-06	RBFOX1	35361970	0.99894255	600.5	FOS	1.31315e-05	HIGH PRIORITY: Accessible + High Impact	2
chr6:140402523:T>A	chr6	140402523	140401583	940	rs560431188	Insomnia	8e-09	MIR3668 - MIR4465	35835914	0.9830546	571.0	JUND	6.57315e-06	HIGH PRIORITY: Accessible + High Impact	2
chr17:53388828:C>A	chr17	53388828	53389769	941	rs6504822	Life satisfaction	7e-06	MTCO1P40 - RPS2P48	27089181	0.9645371	394.0	FOSL1	1.97397e-05	Accessible, Low Impact	3
chr5:165946374:G>C	chr5	165946374	165947316	942	rs26443	Self-reported math ability (MTAG)	1e-12	RPL21P59 - RPL7P20	30038396	0.99035496	355.0	FOSL2	6.58918e-06	Low Priority	3
chr5:165946374:G>C	chr5	165946374	165947316	942	rs26443	Cognitive performance (MTAG)	2e-12	RPL21P59 - RPL7P20	30038396	0.99035496	355.0	FOSL2	6.58918e-06	Low Priority	3
chr7:17972728:C>A	chr7	17972728	17973670	942	rs12699931	Free Cholesterol to Total Lipids in Medium VLDL percentage	2e-12	MRM3P2 - PRPS1L1	41044249	0.8908594	415.5	JUNB	6.57298e-06	Low Priority	3
chr5:165946374:G>C	chr5	165946374	165947316	942	rs26443	Highest math class taken (MTAG)	1e-09	RPL21P59 - RPL7P20	30038396	0.99035496	355.0	FOSL2	6.58918e-06	Low Priority	3
chr3:192948938:C>A	chr3	192948938	192947996	942	rs2133868	Retinal arteriolar tortuosity	1e-08	MB21D2 - VEZF1P1	36757925	0.98639375	411.5	BATF	0.0	Low Priority	3
chr5:165946374:G>C	chr5	165946374	165947316	942	rs26443	Intelligence	3e-08	RPL21P59 - RPL7P20	36378351	0.99035496	355.0	FOSL2	6.58918e-06	Low Priority	3
chr16:84721052:C>A	chr16	84721052	84721994	942	rs75556715	Vaginal microbiome MetaCyc pathway (PWY0-321|phenylacetate degradation I (aerobic))	3e-07	USP10	34282934	0.98167825	664.0	MAFG	0.0781495	HIGH PRIORITY: Accessible + High Impact	3
chr16:84721052:C>A	chr16	84721052	84721994	942	rs75556715	Vaginal microbiome MetaCyc pathway (NAD-BIOSYNTHESIS-II|NAD salvage pathway II)	3e-06	USP10	34282934	0.98167825	664.0	MAFG	0.0781495	HIGH PRIORITY: Accessible + High Impact	3
chr3:169851271:G>C	chr3	169851271	169850328	943	rs16847897	Telomere length	2e-38	LRRC31	35530816	0.96533185	557.5	ATF3	6.57687e-06	Low Priority	3
chr6:161690472:C>A	chr6	161690472	161689529	943	rs140594067	Post bronchodilator FEV1/FVC ratio	3e-07	PRKN	26634245	0.9739743	686.5	ATF2	6.5703e-06	High Impact, Hard to Access	3
chr7:23434618:C>G	chr7	23434618	23433673	945	rs6971100	Multi-trait sex score	8e-10	IGF2BP3	37277458	0.9884892	793.0	JUND	6.57004e-06	High Impact, Hard to Access	3
chr7:2709449:C>A	chr7	2709449	2710394	945	rs10229817	Hip circumference adjusted for BMI	3e-08	AMZ1	34021172	0.9978883	1251.0	JUNB	4.29332e-05	HIGH PRIORITY: Accessible + High Impact	3
chr11:77133278:C>A	chr11	77133278	77134224	946	rs7122842	AAMDC protein levels	4e-22	MYO7A	39789286	0.93910295	595.0	BATF	1.31359e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:62318135:C>G	chr1	62318135	62317189	946	rs79742895	Fuchs' dystrophy (PheCode 364.51)	1e-18	KANK4	39024449	0.9602251	983.0	ATF2	6.56513e-06	High Impact, Hard to Access	3
chr1:62318135:C>G	chr1	62318135	62317189	946	rs79742895	Fuchs's corneal dystrophy	1e-14	KANK4	28358029	0.9602251	983.0	ATF2	6.56513e-06	High Impact, Hard to Access	3
chr1:62318135:C>G	chr1	62318135	62317189	946	rs79742895	Corneal dystrophy (PheCode 364.5)	1e-13	KANK4	39024449	0.9602251	983.0	ATF2	6.56513e-06	High Impact, Hard to Access	3
chr20:4726019:C>A	chr20	4726019	4725072	947	rs2245220	Palmitoleoyl-protein carboxylesterase NOTUM levels	4e-33	PRND	39528825	0.94910556	524.5	JUN	7.37844e-06	Accessible, Low Impact	3
chr20:4726019:C>A	chr20	4726019	4725072	947	rs2245220	Calcium-dependent phospholipase A2 levels	1.9999999999999998e-26	PRND	39528825	0.94910556	524.5	JUN	7.37844e-06	Accessible, Low Impact	3
chr20:4726019:C>A	chr20	4726019	4725072	947	rs2245220	Annexin A11 levels	3e-19	PRND	39528825	0.94910556	524.5	JUN	7.37844e-06	Accessible, Low Impact	3
chr8:11590002:C>G	chr8	11590002	11589055	947	rs112961583	Carotid intima-media thickness (MTAG)	5e-10	LINC00208 - GATA4	39537608	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr8:11590002:C>G	chr8	11590002	11589055	947	rs112961583	Alzheimer's disease (MTAG)	2e-08	LINC00208 - GATA4	39537608	0.9702253	830.0	FOS	0.000111642	HIGH PRIORITY: Accessible + High Impact	3
chr5:170253852:C>G	chr5	170253852	170254800	948	rs72830349	Bone mineral density mean	1e-300	LCP2	37500982	0.996737	919.5	JUND	6.57341e-06	High Impact, Hard to Access	3
chr6:31395380:G>T	chr6	31395380	31396328	948	rs28366135	Response to BNT162b2 vaccine (anti-SARS-CoV-2 Spike antibody levels after second dose)	4e-08	MICA-AS1	38575714	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr15:74953866:C>A	chr15	74953866	74954815	949	rs34063670	Systolic blood pressure x alcohol consumption interaction (2df test)	2e-12	RPP25	29912962	0.99350166	1750.0	ATF3	0.000144857	HIGH PRIORITY: Accessible + High Impact	3
chr5:53374195:A>C	chr5	53374195	53375144	949	rs12514897	Refractive error	6e-12	RPL13AP13 - FST	32231278	0.9979406	2144.0	FOS	6.58146e-06	HIGH PRIORITY: Accessible + High Impact	2
chr19:38498292:C>A	chr19	38498292	38499241	949	rs147213895	Creatinine levels	6e-11	RYR1	34226706	0.9814467	720.5	JUNB	1.97306e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:31395380:G>T	chr6	31395380	31394430	950	rs1052409	Height (baseline)	2e-40	MICA-AS1	40374629	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr15:81308454:C>G	chr15	81308454	81309404	950	rs17875585	IL16/NADK protein level ratio	1.0000000000000001e-39	IL16, STARD5	38412862	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr15:81308454:C>G	chr15	81308454	81309404	950	rs17875585	IL16 protein levels	3e-29	IL16, STARD5	39789286	0.9834347	807.5	FOSL2	3.94228e-05	HIGH PRIORITY: Accessible + High Impact	3
chr6:31395380:G>T	chr6	31395380	31394430	950	rs1052409	THBS2 protein levels	5e-12	MICA-AS1	39789286	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr6:31395380:G>T	chr6	31395380	31394430	950	rs1052409	Monounsaturated fatty acid levels	2e-11	MICA-AS1	40545721	0.8793248	515.0	JUN	6.90007e-06	Accessible, Low Impact	3
chr10:122711004:C>A	chr10	122711004	122711954	950	rs78939407	Protein quantitative trait loci (liver)	5e-10	C10orf120 - DMBT1L1	32778093	0.9983613	772.0	FOS	0.000124842	HIGH PRIORITY: Accessible + High Impact	3
chr4:58935575:C>A	chr4	58935575	58934625	950	rs13118804	Chromosomal aberration frequency (chromatid type) in genotoxic compound exposure	4e-06	LINC02494 - LINC02619	31586183	0.9884892	685.0	FOSL2	6.59317e-06	High Impact, Hard to Access	3
chr1:204605402:C>A	chr1	204605402	204606353	951	rs4950953	Chronic obstructive pulmonary disease or colon polyp (MTAG)	1e-09	RNA5SP74 - LRRN2	40155373	0.9575012	582.0	FOSL1	6.57704e-06	High Impact, Hard to Access	3
chr17:50228511:C>A	chr17	50228511	50229463	952	rs76002987	Kynurenine levels	8e-07	TILAM - SUMO2P7	40360795	0.91678804	454.0	FOSL1	4.59921e-05	Accessible, Low Impact	3
chr18:42274059:C>A	chr18	42274059	42273107	952	rs8085753	IL12B levels	5e-06	LINC00907	38326779	0.98575574	425.0	FOS	0.0	Low Priority	3
chr17:50228511:C>A	chr17	50228511	50229463	952	rs76002987	Quinolinate levels	8e-06	TILAM - SUMO2P7	40360795	0.91678804	454.0	FOSL1	4.59921e-05	Accessible, Low Impact	3
chr16:82167328:G>C	chr16	82167328	82166375	953	rs7194734	Height	2.0000000000000002e-23	MPHOSPH6	34594039	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr16:82167328:G>C	chr16	82167328	82166375	953	rs7194734	Telomere length	3e-13	MPHOSPH6	35530816	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr4:83576557:C>G	chr4	83576557	83575604	953	rs1335344166	Alzheimer's disease or family history of Alzheimer's disease	6e-13	GPAT3	39998322	0.9417692	451.0	ATF3	6.58146e-06	Low Priority	3
chr17:28882282:C>A	chr17	28882282	28883235	953	rs6505095	Alanine aminotransferase levels	6e-12	FLOT2	40436827	0.9912015	775.0	FOS	6.57203e-06	High Impact, Hard to Access	3
chr16:82167328:G>C	chr16	82167328	82166375	953	rs7194734	Leukocyte telomere length	7e-10	MPHOSPH6	32109421	0.9575012	553.5	JUN	6.57324e-06	Low Priority	3
chr17:28882282:C>A	chr17	28882282	28883235	953	rs6505095	Highest math class taken (MTAG)	3e-09	FLOT2	30038396	0.9912015	775.0	FOS	6.57203e-06	High Impact, Hard to Access	3
chr17:28882282:C>A	chr17	28882282	28883235	953	rs6505095	Gamma glutamyl transferase levels	9e-09	FLOT2	40436827	0.9912015	775.0	FOS	6.57203e-06	High Impact, Hard to Access	3
chr17:28882282:C>A	chr17	28882282	28883235	953	rs6505095	Cognitive performance (MTAG)	3e-08	FLOT2	30038396	0.9912015	775.0	FOS	6.57203e-06	High Impact, Hard to Access	3
chr17:28882282:C>A	chr17	28882282	28883235	953	rs6505095	Self-reported math ability (MTAG)	3e-08	FLOT2	30038396	0.9912015	775.0	FOS	6.57203e-06	High Impact, Hard to Access	3
chr8:129714733:T>A	chr8	129714733	129713779	954	rs7461495	Height	5.0000000000000004e-77	CCDC26	36224396	0.9727787	611.0	ATF3	6.62366e-06	High Impact, Hard to Access	3
chr11:101709047:G>C	chr11	101709047	101708093	954	rs73590248	Prostate-specific antigen levels	2e-11	TRPC6	39930085	0.9637244	414.0	JUN	6.57229e-06	Low Priority	3
chr21:17681236:A>C	chr21	17681236	17682190	954	rs62241784	Human milk oligosaccharide concentration (lacto-N-fucopentaose III) in non-secretors	7e-10	BTG3-AS1 - C21orf91-OT1	33831438	0.963604	557.5	JUN	0.000984588	Accessible, Low Impact	3
chr14:30924354:C>A	chr14	30924354	30923400	954	rs7153028	Biological sex	3e-09	STRN3	33888908	0.9565468	546.5	ATF3	3.34174e-05	Accessible, Low Impact	3
chr6:165714196:C>G	chr6	165714196	165715150	954	rs9364813	Economic and political preferences (immigration/crime)	8e-06	PDE10A	22566634	0.9814467	974.5	BATF	1.31392e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:55402561:C>G	chr4	55402561	55403516	955	rs28433072	Metabolic biomarkers (multivariate analysis)	4e-19	TMEM165	33980691	0.87668186	587.375	MAFK	0.0	High Impact, Hard to Access	3
chr4:55402561:C>G	chr4	55402561	55403516	955	rs28433072	Body fat percentage	1e-14	TMEM165	33980691	0.87668186	587.375	MAFK	0.0	High Impact, Hard to Access	3
chr7:38027054:C>A	chr7	38027054	38028009	955	rs1524073	Height (baseline)	1e-11	SFRP4 - STARD3NL	40374629	0.988674	411.0	BATF	3.28934e-05	Accessible, Low Impact	3
chr7:38027054:C>A	chr7	38027054	38028009	955	rs1524073	Bone mineral density mean	6e-10	SFRP4 - STARD3NL	37500982	0.988674	411.0	BATF	3.28934e-05	Accessible, Low Impact	3
chr9:126157236:C>G	chr9	126157236	126158191	955	rs4838353	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (3 Months) interaction	7e-09	PBX3 - MVB12B	40187613	0.9894933	679.0	JUNB	6.57108e-06	HIGH PRIORITY: Accessible + High Impact	2
chr9:126157236:C>G	chr9	126157236	126158191	955	rs4838353	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (1 Year) interaction	6e-08	PBX3 - MVB12B	40187613	0.9894933	679.0	JUNB	6.57108e-06	HIGH PRIORITY: Accessible + High Impact	2
chr7:135679043:G>C	chr7	135679043	135680000	957	rs56411048	Platelet count	3e-26	STMP1	32888493	0.9998084	2776.0	JUND	6.5735e-06	High Impact, Hard to Access	3
chr20:33928164:C>G	chr20	33928164	33929121	957	rs6087545	Multi-trait sex score	5e-08	TPM3P2 - PIGPP3	37277458	0.98058754	790.0	FOS	1.97096e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:4173786:A>C	chr8	4173786	4172829	957	rs4875297	Plasma amyloid beta 42 to 40 ratio	1e-07	CSMD1	35623891	0.99548393	522.5	FOSL2	6.57531e-06	Low Priority	3
chr8:4173786:A>C	chr8	4173786	4172829	957	rs4875297	Plasma amyloid beta 40 levels	3e-06	CSMD1	35623891	0.99548393	522.5	FOSL2	6.57531e-06	Low Priority	3
chr1:66980130:C>G	chr1	66980130	66981088	958	rs58842463	Monocyte count (UKB data field 30130)	3e-19	MIER1	39789286	0.95254505	597.5	JUND	0.000118157	HIGH PRIORITY: Accessible + High Impact	3
chr1:66980130:C>G	chr1	66980130	66981088	958	rs58842463	Monocyte count	4e-16	MIER1	32888494	0.95254505	597.5	JUND	0.000118157	HIGH PRIORITY: Accessible + High Impact	3
chr2:68393577:C>G	chr2	68393577	68394535	958	rs35287888	Mean corpuscular volume	4e-12	PLEK	32888493	0.9695515	524.0	ATF2	5.25963e-05	Accessible, Low Impact	3
chr5:162679415:T>A	chr5	162679415	162680373	958	rs6874604	3-hydroxypropylmercapturic acid levels in smokers	2e-07	RNU6-164P - ARL2BPP5	26053186	0.9383409	428.0	FOS	7.04533e-06	Accessible, Low Impact	3
chr5:162679415:T>A	chr5	162679415	162680373	958	rs6874604	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	3e-07	RNU6-164P - ARL2BPP5	26053186	0.9383409	428.0	FOS	7.04533e-06	Accessible, Low Impact	3
chr3:110478565:T>A	chr3	110478565	110479524	959	rs12629785	Smoking initiation	2e-21	NECTIN3-AS1	36477530	0.99641275	1943.0	JUN	6.59248e-06	High Impact, Hard to Access	3
chr20:30254660:G>C	chr20	30254660	30253701	959	rs6119190	Cystatin C levels in bottom 99% of individuals by creatinine levels	2e-20	CFTRP3 - LINC01597	39927731	0.95452464	341.0	ATF2	6.74928e-06	Accessible, Low Impact	3
chr12:120367664:C>A	chr12	120367664	120366705	959	rs2238161	Diastolic blood pressure	3e-11	MSI1	40436827	0.99751866	1334.0	FOS	6.57912e-06	High Impact, Hard to Access	3
chr12:120367664:C>A	chr12	120367664	120366705	959	rs2238161	Systolic blood pressure	2e-10	MSI1	40436827	0.99751866	1334.0	FOS	6.57912e-06	High Impact, Hard to Access	3
chr16:30124295:G>T	chr16	30124295	30123335	960	rs28529403	hematocrit (minimum, inv-norm transformed)	6e-13	MAPK3	39024449	0.99539393	2034.0	FOSL2	6.58597e-06	High Impact, Hard to Access	3
chr16:30124295:G>T	chr16	30124295	30123335	960	rs28529403	Overweight, obesity and other hyperalimentation (PheCode 278)	2e-11	MAPK3	39024449	0.99539393	2034.0	FOSL2	6.58597e-06	High Impact, Hard to Access	3
chr16:30124295:G>T	chr16	30124295	30123335	960	rs28529403	Docosahexaenoic acid to total fatty acids percentage	2e-10	MAPK3	41044249	0.99539393	2034.0	FOSL2	6.58597e-06	High Impact, Hard to Access	3
chr16:30124295:G>T	chr16	30124295	30123335	960	rs28529403	Volume of right anterior amygdaloid area	3e-09	MAPK3	40097784	0.99539393	2034.0	FOSL2	6.58597e-06	High Impact, Hard to Access	3
chr16:30124295:G>T	chr16	30124295	30123335	960	rs28529403	Blood protein levels	5e-06	MAPK3	30072576	0.99539393	2034.0	FOSL2	6.58597e-06	High Impact, Hard to Access	3
chr7:6068077:G>C	chr7	6068077	6069039	962	rs631423	1-oleoyl-GPC (18:1) levels	9e-06	EIF2AK1 - USP42	40360795	0.99159664	578.5	FOS	6.5812e-06	High Impact, Hard to Access	3
chr2:19073802:G>C	chr2	19073802	19072839	963	rs34587059	prostate-specific antigen (PSA, maximum, inv-norm transformed)	7e-12	LINC01376	39024449	0.9996589	6096.0	JUND	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:19073802:G>C	chr2	19073802	19072839	963	rs34587059	prostate-specific antigen (PSA, minimum, inv-norm transformed)	2e-11	LINC01376	39024449	0.9996589	6096.0	JUND	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:86869866:C>G	chr4	86869866	86870829	963	rs11722905	Educational attainment	1e-08	RPL6P13	35361970	0.8791271	428.25	FOSL1	6.56996e-06	Low Priority	3
chr15:97490607:C>G	chr15	97490607	97489644	963	rs75625056	Glioblastoma	9e-06	LINC00923, LINC02253	36810956	0.963604	546.5	JUND	0.0	Low Priority	3
chr2:102637534:A>C	chr2	102637534	102636570	964	rs67768228	Atopic asthma	3e-11	SLC9A2	31669095	0.99998	5796.0	FOS	6.57117e-06	HIGH PRIORITY: Accessible + High Impact	2
chr5:121915956:T>A	chr5	121915956	121916921	965	rs9637910	Height	4.0000000000000005e-49	FTMT - SRFBP1	36224396	0.96886295	506.0	JUND	0.0667665	Accessible, Low Impact	3
chr22:30606117:G>T	chr22	30606117	30607082	965	rs5753231	Transcobalamin-2 levels (TCN2.5584.21.3)	8e-13	PES1, TCN2	29875488	0.9838064	1132.0	FOSL1	6.56668e-06	High Impact, Hard to Access	3
chr22:30606117:G>T	chr22	30606117	30607082	965	rs5753231	Serum levels of protein TCN2	3e-07	PES1, TCN2	35078996	0.9838064	1132.0	FOSL1	6.56668e-06	High Impact, Hard to Access	3
chr7:26543142:G>C	chr7	26543142	26542177	965	rs2391285	Post bronchodilator FEV1/FVC ratio	3e-06	KIAA0087 - LINC03095	26634245	0.9991795	833.0	MAFG	6.57168e-06	High Impact, Hard to Access	3
chr22:30606117:G>T	chr22	30606117	30607082	965	rs5753231	Gut microbiota relative abundance (Blautia)	4e-06	PES1, TCN2	33208821	0.9838064	1132.0	FOSL1	6.56668e-06	High Impact, Hard to Access	3
chr8:98453299:G>C	chr8	98453299	98454264	965	rs78390113	Creatine levels	4e-06	STK3	40360795	0.9986055	583.5	BATF	6.60371e-06	High Impact, Hard to Access	3
chr3:117875603:C>A	chr3	117875603	117874636	967	rs7433864	Menarche (age at onset)	7e-33	LINC03051, LSAMP	30595370	0.9981611	1021.0	JUND	1.31527e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:141208916:C>A	chr3	141208916	141207949	967	rs113799399	Neutrophil count	2e-22	SPSB4 - PXYLP1	32888494	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr3:117875603:C>A	chr3	117875603	117874636	967	rs7433864	Height	7e-21	LINC03051, LSAMP	40436827	0.9981611	1021.0	JUND	1.31527e-05	HIGH PRIORITY: Accessible + High Impact	3
chr3:141208916:C>A	chr3	141208916	141207949	967	rs113799399	White blood cell count	3e-18	SPSB4 - PXYLP1	30595370	0.9470497	488.0	JUNB	1.97135e-05	Accessible, Low Impact	3
chr9:75107277:C>G	chr9	75107277	75108245	968	rs12376344	Resting-state electroencephalogram vigilance	7e-06	OSTF1	29703947	0.98487294	644.0	ATF3	0.00119572	HIGH PRIORITY: Accessible + High Impact	3
chr17:77354372:G>C	chr17	77354372	77355341	969	rs453370	Fasting glucose change (long-term)	9e-07	SEPTIN9	31263163	0.9973411	1599.0	FOSL2	6.57151e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:12395965:G>C	chr1	12395965	12396934	969	rs79937613	Hospitalization rate in serious mental illnesses	2e-06	VPS13D	38469033	0.92557216	402.75	JUN	7.85781e-06	Accessible, Low Impact	3
chr7:94392616:C>A	chr7	94392616	94391644	972	rs11765563	PON1 protein levels	1.9999999999999999e-63	BET1-AS1 - COL1A2	39789286	0.9992343	1133.0	BATF	6.57402e-06	High Impact, Hard to Access	3
chr4:144569879:C>G	chr4	144569879	144570851	972	rs6817273	Chronic obstructive pulmonary disease	4e-21	GUSBP5 - KRT18P51	35308900	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144570851	972	rs6817273	Post bronchodilator FEV1/FVC ratio	5e-17	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144570851	972	rs6817273	Post bronchodilator FEV1	2e-12	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:144569879:C>G	chr4	144569879	144570851	972	rs6817273	Post bronchodilator FEV1/FVC ratio in COPD	1e-06	GUSBP5 - KRT18P51	26634245	0.9937929	955.0	JUND	8.53399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:143128930:G>C	chr8	143128930	143127957	973	rs62525116	LY6D protein levels	8.000000000000001e-28	LY6L - LY6H	39789286	0.9990358	761.0	JUN	6.56858e-06	High Impact, Hard to Access	3
chr8:143128930:G>C	chr8	143128930	143127957	973	rs62525116	SLURP1 protein levels	1e-12	LY6L - LY6H	39789286	0.9990358	761.0	JUN	6.56858e-06	High Impact, Hard to Access	3
chr8:5003828:C>G	chr8	5003828	5002855	973	rs188621405	Fasting blood glucose	3e-08	CSMD1 - SNORA70	40436827	0.9884892	1161.5	MAFK	1.97143e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:22574553:T>A	chr13	22574553	22575527	974	rs374462308	Exostosis of jaw (PheCode 526.8)	3e-12	LINC00540 - FTH1P7	39024449	0.9727787	608.5	ATF3	6.56513e-06	HIGH PRIORITY: Accessible + High Impact	2
chr22:29775291:C>A	chr22	29775291	29776265	974	rs737721	Pulse pressure	2e-11	UQCR10 - ASCC2	30224653	0.986702	1051.0	MAFG	7.23208e-05	HIGH PRIORITY: Accessible + High Impact	3
chr4:163959158:C>A	chr4	163959158	163958184	974	rs13124397	Smoking initiation	7e-11	MARCHF1	36477530	0.95933455	523.0	JUND	6.58744e-06	Low Priority	3
chr11:101598064:C>A	chr11	101598064	101597090	974	rs59739823	General risk tolerance (MTAG)	9e-09	TRPC6	30643258	0.9772623	694.5	JUN	6.57497e-06	High Impact, Hard to Access	3
chr22:29775291:C>A	chr22	29775291	29776265	974	rs737721	Systolic blood pressure	1e-08	UQCR10 - ASCC2	38689001	0.986702	1051.0	MAFG	7.23208e-05	HIGH PRIORITY: Accessible + High Impact	3
chr13:109868747:G>C	chr13	109868747	109869722	975	rs78366942	Protein quantitative trait loci (liver)	2e-09	IRS2 - RN7SKP10	32778093	0.9990358	1025.5	FOSL2	1.31399e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:84630160:A>C	chr9	84630160	84631136	976	rs17087472	Drinks per week	2e-12	SLC28A3 - NTRK2	36477530	0.9990792	653.5	FOS	6.56909e-06	High Impact, Hard to Access	3
chr4:164149180:C>G	chr4	164149180	164148204	976	rs6822628	Heart rate response to beta blockers (atenolol add-on therapy)	4e-08	MARCHF1	29478026	0.96518815	460.5	JUND	6.57091e-06	Accessible, Low Impact	2
chr7:73491457:G>C	chr7	73491457	73490480	977	rs17145713	BTN2A1/EPHA1 protein level ratio	1e-17	BAZ1B	38412862	0.97674394	763.0	JUNB	6.57678e-06	High Impact, Hard to Access	3
chr9:84634925:G>T	chr9	84634925	84635902	977	rs1332894	Educational attainment	8e-15	SLC28A3 - NTRK2	35361970	0.994337	1682.0	MAFK	6.57903e-06	High Impact, Hard to Access	3
chr1:190337814:C>A	chr1	190337814	190336837	977	rs35571580	Insomnia	1e-11	BRINP3	35835914	0.95041513	451.5	JUND	6.58103e-06	Low Priority	3
chr7:73491457:G>C	chr7	73491457	73490480	977	rs17145713	Protein C levels	3e-08	BAZ1B	20802025	0.97674394	763.0	JUNB	6.57678e-06	High Impact, Hard to Access	3
chr8:94977131:C>A	chr8	94977131	94976153	978	rs6984240	Diastolic blood pressure (MTAG)	2e-09	NDUFAF6	39537608	0.9881423	753.0	FOSL2	0.0	High Impact, Hard to Access	3
chr14:30924354:C>A	chr14	30924354	30925332	978	rs17447314	Colorectal cancer x tea intake interaction	8e-06	STRN3	38411962	0.9565468	546.5	ATF3	3.34174e-05	Accessible, Low Impact	3
chr14:23371803:G>T	chr14	23371803	23370824	979	rs10137082	Embryonal Fyn-associated substrate levels	2e-12	EFS - IL25	34648354	0.8791271	613.0	MAFK	0.0436716	HIGH PRIORITY: Accessible + High Impact	3
chr1:171347040:G>C	chr1	171347040	171348019	979	rs7519001	S-carboxyethylcysteine levels	5e-10	SRP14P4 - GM2AP2	36635386	0.99975276	2860.0	JUNB	6.57151e-06	High Impact, Hard to Access	3
chr14:23371803:G>T	chr14	23371803	23370824	979	rs10137082	Type 1 diabetes	6e-06	EFS - IL25	21980299	0.8791271	613.0	MAFK	0.0436716	HIGH PRIORITY: Accessible + High Impact	3
chr2:198839555:A>C	chr2	198839555	198840535	980	rs34360613	Height (baseline)	7e-09	PLCL1 - RNU7-147P	40374629	0.9981611	483.0	JUND	6.57454e-06	Low Priority	3
chr16:89785605:G>C	chr16	89785605	89784625	980	rs16966142	Caffeine consumption	6e-06	FANCA	21490707	0.9545879	690.5	FOSL1	6.5716e-06	High Impact, Hard to Access	3
chr1:112721472:C>A	chr1	112721472	112720490	982	rs6688050	Creatinine levels (UKB data field 23478)	2e-10	TAFA3	36764567	0.96289337	427.25	MAFG	6.56927e-06	Low Priority	3
chr4:2637936:C>G	chr4	2637936	2636954	982	rs75144206	Educational attainment	1e-08	FAM193A	35361970	0.9565468	678.0	BATF2	1.31372e-05	HIGH PRIORITY: Accessible + High Impact	3
chr8:27629291:C>A	chr8	27629291	27630273	982	rs569214	Alzheimer's disease	4e-08	CLU - SCARA3	21627779	0.9834347	575.5	JUND	6.57921e-06	High Impact, Hard to Access	3
chr6:151617233:G>T	chr6	151617233	151618215	982	rs3734805	Breast cancer	1e-07	CCDC170	21263130	0.9814467	564.5	ATF3	6.57505e-06	Low Priority	3
chr15:63849139:G>C	chr15	63849139	63850122	983	rs4776455	Red cell distribution width	2e-17	HERC1 - MIR422A	32888494	0.9931669	745.0	FOS	6.56883e-06	High Impact, Hard to Access	3
chr15:63849139:G>C	chr15	63849139	63850122	983	rs4776455	Red blood cell erythrocyte distribution width (UKB data field 30070)	9e-14	HERC1 - MIR422A	39789286	0.9931669	745.0	FOS	6.56883e-06	High Impact, Hard to Access	3
chr9:136210910:C>G	chr9	136210910	136209926	984	rs7031621	Sulfhydryl oxidase 2 levels	2e-18	QSOX2	39528825	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr9:136210910:C>G	chr9	136210910	136209926	984	rs7031621	Alkaline phosphatase (UKB data field 30610)	7e-12	QSOX2	39789286	0.9409573	528.0	FOSL1	6.57255e-06	Low Priority	3
chr15:54306458:G>T	chr15	54306458	54307442	984	rs12915790	Gut microbiome abundance (class Parasutterella sp. 1 (at 1 year) x Exclusive Breastfeeding (6 Months) interaction	5e-09	UNC13C	40187613	0.97968936	468.5	JUND	0.0	Low Priority	3
chr6:105069121:G>T	chr6	105069121	105070105	984	rs75086931	Perinatal depression	7e-06	LIN28B	34985809	0.9575012	614.0	MAFK	1.31468e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:55033740:C>A	chr1	55033740	55032755	985	rs2495491	High cholesterol	8e-21	BSND - PCSK9	39789286	0.9602251	919.0	JUN	6.56823e-06	High Impact, Hard to Access	3
chr17:39246674:C>A	chr17	39246674	39247659	985	rs76327840	Varicose veins	2e-13	STAC2 - FBXL20	36653477	0.973383	969.0	FOSL2	6.5741e-06	High Impact, Hard to Access	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Vertex-wise sulcal depth	4.0000000000000006e-45	ADAMTS18	34910505	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Vertex-wise cortical surface area	1e-27	ADAMTS18	34910505	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Vertex-wise cortical thickness	2.0000000000000002e-24	ADAMTS18	34910505	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Whole brain restricted directional diffusion (multivariate analysis)	4e-21	ADAMTS18	35505052	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Cortical surface area	1e-17	ADAMTS18	34560273	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Cortical thickness	1e-17	ADAMTS18	34560273	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Brain morphology (MOSTest)	1e-16	ADAMTS18	35164939	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Brain shape (segment 21)	9e-15	ADAMTS18	33821002	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr9:84630160:A>C	chr9	84630160	84629174	986	rs112154757	Drinks per week	3e-12	SLC28A3 - NTRK2	36477530	0.9990792	653.5	FOS	6.56909e-06	High Impact, Hard to Access	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Whole brain free water diffusion (multivariate analysis)	3e-09	ADAMTS18	35505052	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Volume of left basal nucleus	5e-09	ADAMTS18	40097784	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	BA-exvivo rh area entorhinal	7e-09	ADAMTS18	33875891	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr16:77285722:G>C	chr16	77285722	77286708	986	rs12921392	Cortical surface area (min-P)	3e-08	ADAMTS18	32665545	0.9992343	627.5	JUND	0.000203698	HIGH PRIORITY: Accessible + High Impact	3
chr1:204083300:G>C	chr1	204083300	204082313	987	rs16852778	Diastolic blood pressure (MTAG)	2e-10	SOX13	39537608	0.946766	670.0	FOS	6.57358e-06	High Impact, Hard to Access	3
chr1:204083300:G>C	chr1	204083300	204082313	987	rs16852778	Diastolic blood pressure	2e-10	SOX13	38689001	0.946766	670.0	FOS	6.57358e-06	High Impact, Hard to Access	3
chr3:187632427:C>G	chr3	187632427	187631440	987	rs35471107	Acute pancreatitis	8e-09	LINC02041 - SST	38491158	0.9627861	527.0	MAFK	6.56978e-06	Low Priority	3
chr1:204083300:G>C	chr1	204083300	204082313	987	rs16852778	Systolic blood pressure	9e-07	SOX13	38689001	0.946766	670.0	FOS	6.57358e-06	High Impact, Hard to Access	3
chr8:69445867:A>C	chr8	69445867	69444879	988	rs144235404	Chronic obstructive pulmonary disease liability (machine learning-based score)	4e-15	LINC01603	37069358	0.9409573	501.0	FOSL2	6.56858e-06	Accessible, Low Impact	2
chr2:22952996:A>C	chr2	22952996	22953984	988	rs112033525	Left colon cancer	5e-06	RN7SKP27 - LINC02923	36077729	0.99957967	970.0	FOS	6.5703e-06	HIGH PRIORITY: Accessible + High Impact	2
chr18:59648564:G>C	chr18	59648564	59647575	989	rs11152166	Gut microbial network clusters (Pink (at 1 year) x Household furry pet dog (3 Months) interaction	1e-08	CCBE1	40187613	0.9239011	625.5	FOS	1.97101e-05	HIGH PRIORITY: Accessible + High Impact	3
chr14:56498057:G>C	chr14	56498057	56499046	989	rs10133284	Resistance to COVID-19 infection (Exposed negative vs positive)	2e-06	TMEM260	36662838	0.96686935	490.0	FOS	1.31738e-05	Accessible, Low Impact	3
chr18:59648564:G>C	chr18	59648564	59647575	989	rs11152166	Major depressive disorder	3e-06	CCBE1	23857890	0.9239011	625.5	FOS	1.97101e-05	HIGH PRIORITY: Accessible + High Impact	3
chr20:24893907:C>A	chr20	24893907	24892917	990	rs6050091	Cystatin-F levels	7e-12	SYNDIG1 - LINC02967	28240269	0.9824973	578.0	FOS	6.57168e-06	High Impact, Hard to Access	3
chr6:161513894:A>C	chr6	161513894	161512903	991	rs16892673	Aging	5e-06	PRKN	22773346	0.94931644	458.0	JUND	6.56978e-06	Low Priority	3
chr16:11122559:C>G	chr16	11122559	11121567	992	rs35032408	Eosinophill count (UKB data field 30150)	3e-99	CLEC16A	39789286	0.9963395	1504.0	JUND	6.57289e-06	HIGH PRIORITY: Accessible + High Impact	2
chr6:152021444:C>A	chr6	152021444	152020452	992	rs9340985	Pulse pressure	1e-41	ESR1	34594039	0.9185313	443.0	JUND	6.57678e-06	Low Priority	3
chr16:11122559:C>G	chr16	11122559	11121567	992	rs35032408	Asthma (childhood onset)	5e-14	CLEC16A	31036433	0.9963395	1504.0	JUND	6.57289e-06	HIGH PRIORITY: Accessible + High Impact	2
chr16:11122559:C>G	chr16	11122559	11121567	992	rs35032408	Eosinophil count	6e-14	CLEC16A	32888494	0.9963395	1504.0	JUND	6.57289e-06	HIGH PRIORITY: Accessible + High Impact	2
chr16:11122559:C>G	chr16	11122559	11121567	992	rs35032408	Eosinophil percentage of white cells	2e-13	CLEC16A	32888494	0.9963395	1504.0	JUND	6.57289e-06	HIGH PRIORITY: Accessible + High Impact	2
chr4:8612291:C>G	chr4	8612291	8611299	992	rs3796727	Sporadic neuroblastoma	1e-12	GPR78, CPZ	28545128	0.61335564	422.25	FOSL1	6.57281e-06	Low Priority	3
chr6:152021444:C>A	chr6	152021444	152020452	992	rs9340985	Systolic blood pressure	6e-09	ESR1	34594039	0.9185313	443.0	JUND	6.57678e-06	Low Priority	3
chr16:11122559:C>G	chr16	11122559	11121567	992	rs35032408	Asthma (adult onset)	1e-08	CLEC16A	31036433	0.9963395	1504.0	JUND	6.57289e-06	HIGH PRIORITY: Accessible + High Impact	2
chr15:79607145:C>G	chr15	79607145	79606153	992	rs79311347	Bone mineral density mean	4e-08	TFDP1P3 - RPL7L1P15	37500982	0.9715297	660.0	JUNB	6.56401e-06	High Impact, Hard to Access	3
chr13:51220492:C>G	chr13	51220492	51219500	992	rs76819924	Oligodendroglioma	8e-06	C13orf42 - FAM124A	36810956	0.84648913	547.0	ATF3	0.00894677	Accessible, Low Impact	3
chr10:21559242:C>A	chr10	21559242	21558249	993	rs10828250	Cholelithiasis (UKB data field 20002_1162)	8e-13	MLLT10	37965154	0.9782654	680.0	JUND	1.97018e-05	HIGH PRIORITY: Accessible + High Impact	3
chr10:21559242:C>A	chr10	21559242	21558249	993	rs10828250	Degree of unsaturation	1e-08	MLLT10	40545721	0.9782654	680.0	JUND	1.97018e-05	HIGH PRIORITY: Accessible + High Impact	3
chr9:121724223:G>C	chr9	121724223	121725216	993	rs13290547	Vaginal microbiome MetaCyc pathway (P221-PWY|octane oxidation)	7e-06	DAB2IP	34282934	0.9990577	1142.0	FOS	6.57851e-06	High Impact, Hard to Access	3
chr3:192947002:C>A	chr3	192947002	192947996	994	rs2133868	Retinal arteriolar tortuosity	1e-08	MB21D2 - VEZF1P1	36757925	0.992679	675.0	ATF3	6.57246e-06	High Impact, Hard to Access	3
chr15:55163671:C>A	chr15	55163671	55164665	994	rs149426181	Metabolonic lactone sulfate levels	2e-08	UNC13C - RSL24D1	34563731	0.9327804	430.5	JUND	6.56987e-06	Low Priority	3
chr21:35081316:T>A	chr21	35081316	35080321	995	rs8126516	Asthma	4e-12	RUNX1	31361310	0.8862913	472.5	FOS	0.000289295	Accessible, Low Impact	2
chr21:35081316:T>A	chr21	35081316	35080321	995	rs8126516	Respiratory diseases	2e-11	RUNX1	30595370	0.8862913	472.5	FOS	0.000289295	Accessible, Low Impact	2
chr3:14067641:C>G	chr3	14067641	14066646	995	rs114176875	Protein quantitative trait loci (liver)	1e-10	TPRXL	32778093	0.9644045	511.5	JUND	6.57134e-06	Low Priority	3
chr9:117901948:T>A	chr9	117901948	117902943	995	rs10435879	Body mass index (MTAG)	2e-10	TLR4 - TPT1P9	36376304	0.93699247	414.5	JUN	5.91545e-05	Accessible, Low Impact	2
chr21:35081316:T>A	chr21	35081316	35080321	995	rs8126516	Allergic disease (asthma, hay fever or eczema)	1e-09	RUNX1	31361310	0.8862913	472.5	FOS	0.000289295	Accessible, Low Impact	2
chr11:125944331:C>A	chr11	125944331	125943335	996	rs113881594	RBC levels of 11-HETE.1	2e-09	DDX25	36395887	0.9830546	1000.0	MAFK	4.60127e-05	HIGH PRIORITY: Accessible + High Impact	3
chr1:35448713:C>A	chr1	35448713	35449710	997	rs141113839	Bone mineral density mean	1e-300	KIAA0319L	37500982	0.996737	2184.0	FOS	6.57004e-06	High Impact, Hard to Access	3
chr22:30606117:G>T	chr22	30606117	30605119	998	rs5753228	Dementia	7e-06	PES1-AS1, PES1	39046104	0.9838064	1132.0	FOSL1	6.56668e-06	High Impact, Hard to Access	3
chr6:1908875:C>A	chr6	1908875	1909874	999	rs10484693	Height	9e-31	GMDS	36224396	0.9949509	1265.0	FOS	6.57194e-06	High Impact, Hard to Access	3
chr14:24225017:G>C	chr14	24225017	24224018	999	rs34655126	Platelet count	5e-15	NEDD8, NEDD8-MDP1	32888493	0.99919933	2820.0	JUN	1.31595e-05	HIGH PRIORITY: Accessible + High Impact	3
chr2:45549855:C>A	chr2	45549855	45548856	999	rs728327	Haemorrhoidal disease	3e-10	SRBD1	33888516	0.98125464	551.0	FOS	6.58979e-06	Low Priority	3
chr8:344471:C>G	chr8	344471	345470	999	rs7009731	Gut microbial network clusters (Salmon (at 1 year) x Any Breastfeeding (3 Months) interaction	3e-08	ZNF596 - FAM87A	40187613	0.91678804	520.0	ATF3	2.62881e-05	Accessible, Low Impact	3
chr9:129701959:G>C	chr9	129701959	129702958	999	rs3844046	Phosphatidylcholine diacyl C36:5 levels	3e-08	PRRX2	27073872	0.9836582	606.5	FOS	6.57324e-06	High Impact, Hard to Access	3
chrX:109351743:G>T	chrX	109351743	109350743	1000	rs12833418	Basal cell carcinoma	1e-10	GAPDHP77 - GUCY2F	38182794	0.9396624	672.0	JUND	8.97175e-06	HIGH PRIORITY: Accessible + High Impact	3
chrX:109351743:G>T	chrX	109351743	109350743	1000	rs12833418	Non-melanoma skin cancer	1e-06	GAPDHP77 - GUCY2F	34290314	0.9396624	672.0	JUND	8.97175e-06	HIGH PRIORITY: Accessible + High Impact	3
chr8:69767748:G>C	chr8	69767748	69768748	1000	rs10090896	Metabolite levels  (X-11787)	2e-06	SLCO5A1	23934736	0.9981611	874.0	ATF2	6.58727e-06	High Impact, Hard to Access	3
